id	name	citation	first_author	year	pmid	doi	status	status_reason	rationale	repository	repository_ids	source_files	method	method_source	beads	lot	instrument	instrument_detail	instrument_source	cell_or_tissue	sample_scope	accession_columns	filters	sample_groups	n_total_ids	n_in_reference	reference_overlap	overlap_cutoff	target_species	species_note	n_species_excluded	n_species_unresolved	n_proteins
george-aml-2026	Acute-leukemia surfaceome atlas	George et al. 2026	George BM	2026		10.64898/2026.09.16.752145	core		Intact-cell Sulfo-NHS-SS-biotin capture across 25 acute-leukemia lines, full surface identification list (no surface-annotation selection). Restored in sweep-v13: wired only into calibrated-v1 and dropped from every snapshot from morning-v1 on.	none_deposited		surface_mean_abundance.tsv	Live leukemia cell lines (15 million viable cells per reaction; viability >96% confirmed before labeling) surface-labeled with membrane-impermeable Sulfo-NHS-SS-biotin (Pierce Cell Surface Protein Isolation Kit, Thermo 89881), quenched, lysed in the kit's mild detergent buffer; biotinylated proteins captured on NeutrAvidin agarose, eluted under reducing conditions, methanol/chloroform precipitated, LysC + trypsin digest; Orbitrap Fusion Lumos or Eclipse DDA; Proteome Discoverer 2.5, Swiss-Prot human (Jan 2021); proteins kept with >=2 unique peptides in >=2 replicates; paired whole-cell proteome per line.	Method as described in the preprint's Methods 'Cell surface protein enrichment' (bioRxiv 10.64898/2026.09.16.752145v1).	NeutrAvidin agarose from the Pierce Cell Surface Protein Isolation Kit (Thermo 89881); no separate catalog or lot number given	not reported	Orbitrap Fusion Lumos			25 acute-leukemia cell lines (lymphoid + myeloid)	bioRxiv supplementary S4 (surface compiled): mean surface abundance per line, 0 = not detected (2,669 proteins). Membership = detected (> 0) in at least one of the 25 lines; the SPC column is a surface-prediction annotation, not a filter.	surface_mean_abundance.tsv: Accession		697 / Sulfo-NHS-SS-biotin surface capture: 697 (min_observed 1; floor 0) | CMS / Sulfo-NHS-SS-biotin surface capture: CMS (min_observed 1; floor 0) | EOL1 / Sulfo-NHS-SS-biotin surface capture: EOL1 (min_observed 1; floor 0) | HEL9217 / Sulfo-NHS-SS-biotin surface capture: HEL9217 (min_observed 1; floor 0) | HL60 / Sulfo-NHS-SS-biotin surface capture: HL60 (min_observed 1; floor 0) | K562 / Sulfo-NHS-SS-biotin surface capture: K562 (min_observed 1; floor 0) | KASUMI1 / Sulfo-NHS-SS-biotin surface capture: KASUMI1 (min_observed 1; floor 0) | KG1 / Sulfo-NHS-SS-biotin surface capture: KG1 (min_observed 1; floor 0) | M07E / Sulfo-NHS-SS-biotin surface capture: M07E (min_observed 1; floor 0) | ML2 / Sulfo-NHS-SS-biotin surface capture: ML2 (min_observed 1; floor 0) | MOLM13 / Sulfo-NHS-SS-biotin surface capture: MOLM13 (min_observed 1; floor 0) | MOLT4 / Sulfo-NHS-SS-biotin surface capture: MOLT4 (min_observed 1; floor 0) | MONOMAC6 / Sulfo-NHS-SS-biotin surface capture: MONOMAC6 (min_observed 1; floor 0) | MV411 / Sulfo-NHS-SS-biotin surface capture: MV411 (min_observed 1; floor 0) | NALM6 / Sulfo-NHS-SS-biotin surface capture: NALM6 (min_observed 1; floor 0) | NOMO1 / Sulfo-NHS-SS-biotin surface capture: NOMO1 (min_observed 1; floor 0) | OCIAML2 / Sulfo-NHS-SS-biotin surface capture: OCIAML2 (min_observed 1; floor 0) | OCIAML3 / Sulfo-NHS-SS-biotin surface capture: OCIAML3 (min_observed 1; floor 0) | REH / Sulfo-NHS-SS-biotin surface capture: REH (min_observed 1; floor 0) | RS411 / Sulfo-NHS-SS-biotin surface capture: RS411 (min_observed 1; floor 0) | SET2 / Sulfo-NHS-SS-biotin surface capture: SET2 (min_observed 1; floor 0) | THP1 / Sulfo-NHS-SS-biotin surface capture: THP1 (min_observed 1; floor 0) | U937 / Sulfo-NHS-SS-biotin surface capture: U937 (min_observed 1; floor 0) | UKE1 / Sulfo-NHS-SS-biotin surface capture: UKE1 (min_observed 1; floor 0) | WSU / Sulfo-NHS-SS-biotin surface capture: WSU (min_observed 1; floor 0)	2666	806	0.3023255813953488	0.2	Homo sapiens		0	0	2666
salmela-cscc-2026--c1s-sirna-knockdown	Cutaneous SCC UT-SCC-59A sulfo-NHS-SS-biotin surfaceome · C1s siRNA knockdown	Salmela et al. 2026	Salmela M	2026	41792108	10.1038/s41389-026-00606-4	perturbed	genetic perturbation: C1s siRNA knockdown	genetic perturbation arm of salmela-cscc-2026; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD065511	proteinGroups.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/03/PXD065511/proteinGroups.txt>	EZ-Link sulfo-NHS-SS-biotin on intact cells, streptavidin capture, DTT elution; Q Exactive HF DDA, MaxQuant 1.6.10.43 MaxLFQ against reviewed human SwissProt 2022_04 (full proteome).	Method summarized from the paper (PMC12982766) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive HF			UT-SCC-59A	UT-SCC-59A, C1s siRNA knockdown: a non-baseline state of salmela-cscc-2026, listed when observed in at least 2 of its 9 samples				2156	298	0.13821892393320964		Homo sapiens		0	0	2156
salmela-cscc-2026	Cutaneous SCC UT-SCC-59A sulfo-NHS-SS-biotin surfaceome · control siRNA (120 nM, 72 h) (baseline)	Salmela et al. 2026	Salmela M	2026	41792108	10.1038/s41389-026-00606-4	core		Live-cell sulfo-NHS-SS-biotin capture with a full MaxQuant protein-group table; membership restricted to the control-siRNA arm. No no-label control was run.	PRIDE	PXD065511	proteinGroups.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/03/PXD065511/proteinGroups.txt>	EZ-Link sulfo-NHS-SS-biotin on intact cells, streptavidin capture, DTT elution; Q Exactive HF DDA, MaxQuant 1.6.10.43 MaxLFQ against reviewed human SwissProt 2022_04 (full proteome).	Method summarized from the paper (PMC12982766) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive HF			Cutaneous squamous cell carcinoma line UT-SCC-59A (control siRNA)	MaxQuant proteinGroups.txt; drop Reverse / Potential contaminant / Only identified by site; authors' detection rule of >= 2 razor+unique peptides (column pooled over all 18 runs); membership = MaxQuant intensity > 0 in >= 2 of the 9 control-siRNA runs (3 biological samples x 3 repeated injections). siC1s knockdown runs kept as measurements only.	proteinGroups.txt: Protein IDs	Razor + unique peptides ≥ 2 | Q-value ≤ 0.01 | drop rows flagged Reverse, Potential contaminant, Only identified by site	UT-SCC-59A / control siRNA (120 nM, 72 h), intact-cell sulfo-NHS-SS-biotin capture: Intensity 180828_Pekka_Ctrl_C1s_1_nr1, Intensity 180828_Pekka_Ctrl_C1s_1_nr2, Intensity 180828_Pekka_Ctrl_C1s_1_nr3, Intensity 180828_Pekka_Ctrl_C1s_2_nr1, Intensity 180828_Pekka_Ctrl_C1s_2_nr2, Intensity 180828_Pekka_Ctrl_C1s_2_nr3, Intensity 180828_Pekka_Ctrl_C1s_3_nr1, Intensity 180828_Pekka_Ctrl_C1s_3_nr2, Intensity 180828_Pekka_Ctrl_C1s_3_nr3 (min_observed 2) | UT-SCC-59A / C1s siRNA knockdown (not used for membership): Intensity 180828_Pekka_C1s_4_nr1, Intensity 180828_Pekka_C1s_4_nr2, Intensity 180828_Pekka_C1s_4_nr3, Intensity 180828_Pekka_C1s_5_nr1, Intensity 180828_Pekka_C1s_5_nr2, Intensity 180828_Pekka_C1s_5_nr3, Intensity 180828_Pekka_C1s_6_nr1, Intensity 180828_Pekka_C1s_6_nr2, Intensity 180828_Pekka_C1s_6_nr3 (min_observed 2)	2270	305	0.1343612334801762	0.2	Homo sapiens		0	0	2270
dusailly-ec-2026	Endothelial, pericyte and astrocyte Qproteome membrane fractions	Dusailly et al. 2026	Dusailly O	2026	42883398	10.3390/biology15191724	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Qproteome kit membrane fraction; no surface label. Lists are per cell type without replicate detection columns.	none found		Table S2.xlsx sheet ECs - F2 in supplementaryFiles › biology-15-01724-s001.zip <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC13663365/supplementaryFiles> | Table S3.xlsx sheet BPs - F2 in supplementaryFiles › biology-15-01724-s001.zip <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC13663365/supplementaryFiles> | Table S4.xlsx sheet ACs - F2 in supplementaryFiles › biology-15-01724-s001.zip <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC13663365/supplementaryFiles>	Qiagen Qproteome Cell Compartment kit (37502), fraction F2 = membranes; DDA, ProteinPilot (Peptides (95%) reported).	Method summarized from the paper (PMC13663365) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	AB Sciex TripleTOF 5600+	LC-MS/MS DDA, library samples	Instrument as named in the paper's Methods (full text PMC13663365).	Cord-blood CD34+-derived endothelial cells, brain pericytes and astrocytes	Tables S2-S4, membrane fraction (F2) sheets: every protein listed for that cell type	Table S2.xlsx: Accession | Table S3.xlsx: Accession | Table S4.xlsx: Accession			3020	343	0.11357615894039735	0.2	Homo sapiens		0	0	3020
govindarajan-fte-csc-2026	Fallopian tube epithelial cell lines cell surface N-glycoproteomics	Govindarajan et al. 2026	Govindarajan M	2026		10.1186/s13059-026-04294-6	core		Intact-cell glycan labeling (CSC) on untreated cultured cells; every line is a baseline. Processed table of all CSC identifications, not annotation-selected. Published in Genome Biology after the 2025 preprint, whose table was not retrievable (sweep lead); Methods text not yet online, method taken from the abstract and Table S4.	MassIVE	MSV000099007	13059_2026_4294_MOESM2_ESM.xlsx sheet CSC_MEDIAN_NORM_LOG2_FOR_SUPP <https://static-content.springer.com/esm/art%3A10.1186%2Fs13059-026-04294-6/MediaObjects/13059_2026_4294_MOESM2_ESM.xlsx>	Cell-surface N-glycoproteomics (CSC) on intact untreated cells: surface glycans periodate-oxidized and labeled with biocytin hydrazide, streptavidin capture of glycopeptides, PNGase F release of formerly N-glycosylated peptides (Kislinger laboratory CSC). Full Methods not yet online for the accepted Genome Biology version; method from its abstract ('cell surface N-glycoproteomics') and Table S4A, and the lab's published CSC protocol (Govindarajan et al. 2026, Cell Rep Med).	Method read from: Genome Biol 2026, doi:10.1186/s13059-026-04294-6: abstract and Additional file 5 (Table S4A, LC-MS/MS parameters).	streptavidin (per the lab's CSC protocol; not restated in available text)	not stated	Orbitrap Q-Exactive	Easy-nLC 1000, 50 cm EasySpray column, DDA top-20, HCD 27%	Where we looked for the instrument: Additional file 5, Table S4A.	Immortalized fallopian tube epithelium FT194, FT237 (normal comparison for HGSC)	Table S1 (13059_2026_4294_MOESM2_ESM.xlsx, sheet 'CSC_MEDIAN_NORM_LOG2_FOR_SUPP'; 855 proteins x 9 cell types x 3 CSC replicates, median-normalized log2 intensities, blank = not detected). This arm: the fallopian tube epithelium (FT194, FT237). Membership = a value in >= 2 of 3 replicates of a line, any line. The other cell groups of the paper are separate arms. No annotation filter: Table S2 (274 HGSC-enriched surface proteins) is the authors' selection and is not used.	13059_2026_4294_MOESM2_ESM.xlsx: protein		FT194 / untreated, cell surface capture: CSC_FT194_1, CSC_FT194_2, CSC_FT194_3 (min_observed 2) | FT237 / untreated, cell surface capture: CSC_FT237_1, CSC_FT237_2, CSC_FT237_3 (min_observed 2)	484	389	0.8037190082644629	0.2	Homo sapiens		0	0	484
porter-gbm-2026	Glioblastoma invasive-margin kit membrane fraction	Porter et al. 2026	Porter H	2026	42534387	10.1093/noajnl/vdag181	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Kit-based (Abcam ab65400) membrane fraction, the first detergent/kit extraction in the family; no surface label. Paired total-proteome runs allow a direct check of how much the kit fraction enriches surface proteins over whole cells.	PRIDE	PXD058999	report.pg_matrix.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/09/PXD058999/240610_RumanRahmanPheobeShay_24Lysates_report.pg_matrix.tsv> | sdrf.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/09/PXD058999/PXD058999_community_annotated.sdrf.tsv>	Abcam plasma-membrane protein extraction buffer (ab65400) with differential centrifugation to a membrane pellet; SWATH/DIA on a SCIEX 7600, DIA-NN. Paired total-proteome runs of the same lines.	Method summarized from the paper (PMC13420503) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Exploris 480		Instrument as listed in the ProteomeXchange record PXD058999.	3 patient-derived glioblastoma invasive-margin lines (GIN8, GIN28, GIN31) and normal human astrocytes	DIA-NN protein-group matrix; membership = observed in >= 2 of 3 membrane-fraction (MP) runs of a line; total-proteome (TP) runs kept as measurements only	report.pg_matrix.tsv: Protein.Group		GIN8 / baseline membrane fraction (Abcam ab65400): zSWATH_4_GIN8_MP_n1, zSWATH_5_GIN8_MP_n2, zSWATH_6_GIN8_MP_n3 (min_observed 2) | GIN28 / baseline membrane fraction (Abcam ab65400): zSWATH_10_GIN28_MP_n1, zSWATH_11_GIN28_MP_n2, zSWATH_12_GIN28_MP_n3 (min_observed 2) | GIN31 / baseline membrane fraction (Abcam ab65400): zSWATH_16_GIN31_MP_n1, zSWATH_17_GIN31_MP_n2, zSWATH_18_GIN31_MP_n3 (min_observed 2) | primary astrocytes (normal) / baseline membrane fraction (Abcam ab65400): zSWATH_22_HA_MP_n1, zSWATH_23_HA_MP_n2, zSWATH_24_HA_MP_n3 (min_observed 2) | GIN8 / total proteome (not used for membership): zSWATH_1_GIN8_TP_n1, zSWATH_2_GIN8_TP_n2, zSWATH_3_GIN8_TP_n3 (min_observed 2) | GIN28 / total proteome (not used for membership): zSWATH_7_GIN28_TP_n1, zSWATH_8_GIN28_TP_n2, zSWATH_9_GIN28_TP_n3 (min_observed 2) | GIN31 / total proteome (not used for membership): zSWATH_13_GIN31_TP_n1, zSWATH_14_GIN31_TP_n2, zSWATH_15_GIN31_TP_n3 (min_observed 2) | primary astrocytes (normal) / total proteome (not used for membership): zSWATH_19_HA_TP_n1, zSWATH_20_HA_TP_n2, zSWATH_21_HA_TP_n3 (min_observed 2)	4665	518	0.11103965702036442	0.2	Homo sapiens		0	0	4665
glyco-pdx-csc-2026	Glyco-PDXplorer intact-cell CSC panel	Govindarajan et al. 2026	Govindarajan M	2026	41579862	10.1016/j.xcrm.2025.102578	core		Original identification and specimen caveats retained in previous_reason.			mmc4.xlsx sheet S3a <https://pubmed.ncbi.nlm.nih.gov/41579862/>	Genuine cell-surface capture on intact cells: nine HNSC/squamous lines (NOE, KYSE-70, MGH7, Detroit-562, FaDu, SCC4, SCC8, SCC25, SCC42a) in triplicate 150 mm plates at 90% confluency; on ice, washed, mildly oxidized with 1 mM NaIO4 (15 min, 4 C, dark), labeled with 5 mM biocytin hydrazide (Biotium) 1 h at 4 C, washed, scraped and lysed in SP3 buffer; 2 mg protein, SP3 trypsin/Lys-C digest; biotinylated glycopeptides bound to Streptavidin Sepharose High Performance (100 uL, 1 h RT), stringent washes (invitrosol, 5 M NaCl, Na2CO3 pH 11, 80% isopropanol), PNGase F release of formerly N-glycosylated peptides; same LC-MS/MS and MaxQuant pipeline as the PDX arm.	Method as described in the paper's STAR Methods 'Cell surface capture (CSC)' and Key Resources Table (Cell Rep Med 2026; full text PMC12923961).	Streptavidin Sepharose High Performance (GE HealthCare/Cytiva, Cat# 17-5113-01); biocytin hydrazide (Biotium, Cat# 90060); PNGase F (Roche 06538355103)	not reported	Orbitrap Eclipse Tribrid; Orbitrap Q-Exactive; Q-Exactive HF	Eclipse Tribrid for PDX samples; Q-Exactive for HNSC patient tumors; Q-Exactive HF for CSC (cell surface capture) samples	Instrument as named in the paper's Methods, MS-based proteomics (full text PMC12923961).	Squamous-carcinoma cell panel: Detroit, FaDU, KYSE70, MGH7, NOE, SCC25, SCC4, SCC42a and SCC8	Nine human cell lines, >=2/3 observed log2 intensities within a cell line; FAT2 perturbation sheets excluded	mmc4.xlsx: Protein		Detroit / baseline: Detroit_1, Detroit_2, Detroit_3 (min_observed 2) | FaDU / baseline: FaDU_1, FaDU_2, FaDU_3 (min_observed 2) | KYSE70 / baseline: KYSE70_1, KYSE70_2, KYSE70_3 (min_observed 2) | MGH7 / baseline: MGH7_1, MGH7_2, MGH7_3 (min_observed 2) | NOE / baseline: NOE_1, NOE_2, NOE_3 (min_observed 2) | SCC25 / baseline: SCC25_1, SCC25_2, SCC25_3 (min_observed 2) | SCC4 / baseline: SCC4_1, SCC4_2, SCC4_3 (min_observed 2) | SCC42a / baseline: SCC42a_1, SCC42a_2, SCC42a_3 (min_observed 2) | SCC8 / baseline: SCC8_1, SCC8_2, SCC8_3 (min_observed 2)	844	603	0.7144549763033176	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			833
slezak-hct116apex-2026	HCT116 exogenous APEX2 surface proximity labeling	Slezak et al. 2026	Slezak T	2026	41875162	10.1073/pnas.2529493123	held	no background control in the deposit	Exogenous peroxidase labeling of intact cells is surface-restricted in principle, but there is no no-H2O2/no-enzyme background control in the deposit, cells were trypsinised before labeling, and the study targets intracellular 'inside-out' proteins; hold until background can be judged.	PRIDE	PXD069264	EX1_02142025_P00019_Anthony_Kossiakoff_APEX_1_S1_Proteins.xlsx sheet EX1_02142025_P00019_Anthony_Kos <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/03/PXD069264/EX1_02142025_P00019_Anthony_Kossiakoff_APEX_1_S1_Proteins.xlsx>	Soluble recombinant APEX2 (200 nM) added to trypsinised intact HCT116 cells in suspension with biotin-PEG4-phenol and H2O2 for 60 s, quenched, NeutrAvidin capture; Exploris 480 DDA, Proteome Discoverer 3.0 Sequest HT against a human protein database.	Method summarized from the paper (PMC13037926) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Exploris 480			Colorectal carcinoma line HCT116	PRIDE Proteins.xlsx (PD export, 709 master proteins); Master == IsMasterProtein, Contaminant == False, q <= 0.01; membership = abundance in >= 2 of 4 APEX-labeled replicates with buffer-only post-incubation. Heparinase II and proteinase K post-labeling arms kept as measurements only. No no-H2O2 or no-enzyme control is in the deposited table.	EX1_02142025_P00019_Anthony_Kossiakoff_APEX_1_S1_Proteins.xlsx: Accession	Master = IsMasterProtein | Contaminant = false | Exp. q-value: Combined ≤ 0.01	HCT116 / exogenous APEX2 labeling, buffer-only post-incubation: Abundance: F1: Sample, APEX, 1, Abundance: F2: Sample, APEX, 2, Abundance: F3: Sample, APEX, 3, Abundance: F4: Sample, APEX, 4 (min_observed 2) | HCT116 / APEX2 labeling then heparinase II (not used for membership): Abundance: F5: Sample, HepII, 1, Abundance: F6: Sample, HepII, 2, Abundance: F7: Sample, HepII, 3, Abundance: F8: Sample, HepII, 4 (min_observed 2) | HCT116 / APEX2 labeling then proteinase K shaving (not used for membership): Abundance: F9: Sample, PK, 1, Abundance: F10: Sample, PK, 2, Abundance: F11: Sample, PK, 3, Abundance: F12: Sample, PK, 4 (min_observed 2)	656	85	0.12957317073170732	0.2	Homo sapiens		0	0	656
rethore-huvec-2026	HUVEC crude membrane pellet under static and flow conditions	Réthoré et al. 2026	Réthoré L	2026	42405863	10.1021/acs.jproteome.5c01254	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Crude total membrane, not a plasma-membrane prep; low weight, complementary only. Gene symbols only.	PRIDE	PXD072355	Raw_data_mb.transposed.tsv | Raw_data_mb.transposed.uniprot_mapped.tsv	Crude total-membrane pellet (high-speed centrifugation) from HUVECs under static culture, laminar or oscillatory shear stress; timsTOF PASEF, Spectronaut.	Method summarized from the paper (PMC13460056) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	timsTOF			Human umbilical vein endothelial cells (HUVEC)	PRIDE Raw_data_mb.xlsx (2,930 protein groups as gene symbols, runs as rows), transposed; membership = intensity in >= 2 of 3 static membrane runs (mb1, mb2, mb4); laminar and oscillatory shear runs kept as measurements only. Gene symbols mapped through the pipeline's symbol_only step (first symbol of a ';' group).	Raw_data_mb.transposed.uniprot_mapped.tsv: uniprot_mapped		HUVEC / static culture crude membrane fraction: [9] Static mb1, [10] Static mb2, [11] Static mb4 (min_observed 2) | HUVEC / laminar shear stress crude membrane fraction: [1] LS mb1, [2] LS mb2, [3] LS mb4, [4] LSmb3 (min_observed 2) | HUVEC / oscillatory shear stress crude membrane fraction: [5] OS mb1, [6] OS mb2, [7] OS mb4, [8] OSmb3 (min_observed 2)	2915	311	0.10668953687821613	0.2	Homo sapiens		0	0	2915
cohenyaron-hela-2026--mgat1-knockout-sulfo-nhs-biotin-labelled	HeLa sulfo-NHS surfaceome with no-biotin controls · MGAT1 knockout	Cohen Yaron et al. 2026	Cohen Yaron K	2026	42814570	10.1016/j.celrep.2026.118043	perturbed	genetic perturbation: MGAT1 knockout	genetic perturbation arm of cohenyaron-hela-2026; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD083032	91073-82_proteinGroups-perseus.xlsx sheet 91073-82 proteinGroups-perseus <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/09/PXD083032/91073-82_proteinGroups-perseus.xlsx>	sulfo-NHS-(SS)-biotin on ice, PBS negative control	Method read from: PRIDE PXD083032 sample processing protocol.	streptavidin agarose	not stated	Q Exactive HF		Instrument as listed in the ProteomeXchange record PXD083032.	HeLa MGAT1 KO	HeLa MGAT1 KO, MGAT1 knockout, sulfo-NHS-biotin labeled: a non-baseline state of cohenyaron-hela-2026, listed when observed in at least 2 of its 4 samples				1142	219	0.19176882661996497		Homo sapiens		0	0	1142
cohenyaron-hela-2026	HeLa sulfo-NHS surfaceome with no-biotin controls · wild-type (baseline)	Cohen Yaron et al. 2026	Cohen Yaron K	2026	42814570	10.1016/j.celrep.2026.118043	core		Intact-cell sulfo-NHS capture of unperturbed WT HeLa with a matched no-biotin control; the deposit is a Perseus export whose row set was already reduced (1,706 groups) by an unstated valid-value filter, but not by surface annotation (GO columns are annotations only).	PRIDE	PXD083032	91073-82_proteinGroups-perseus.xlsx sheet 91073-82 proteinGroups-perseus <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/09/PXD083032/91073-82_proteinGroups-perseus.xlsx>	sulfo-NHS-(SS)-biotin on ice, PBS negative control	Method read from: PRIDE PXD083032 sample processing protocol.	streptavidin agarose	not stated	Q Exactive HF		Instrument as listed in the ProteomeXchange record PXD083032.	HeLa cervical carcinoma cell line (WT) and an MGAT1-knockout derivative	Deposited Perseus export of MaxQuant proteinGroups (1,706 groups; Perseus replaced missing Intensity values with 1e6, so the raw iBAQ columns, 0 = not detected, are used). Only-identified-by-site rows dropped. Membership = iBAQ > 0 in >= 2 of 4 WT HeLa biotin replicates (H1-H4); the WT no-biotin control (H NC) and the MGAT1-KO arm (M1-M4, M NC) are measurements only.	91073-82_proteinGroups-perseus.xlsx: Protein IDs	drop rows flagged Only identified by site	HeLa / baseline sulfo-NHS-biotin labeled: iBAQ H1, iBAQ H2, iBAQ H3, iBAQ H4 (min_observed 2) | HeLa / no-biotin control (not used for membership): iBAQ H NC (min_observed 1) | HeLa MGAT1 KO / MGAT1 knockout, sulfo-NHS-biotin labeled (not used for membership): iBAQ M1, iBAQ M2, iBAQ M3, iBAQ M4 (min_observed 2) | HeLa MGAT1 KO / MGAT1 knockout no-biotin control (not used for membership): iBAQ M NC (min_observed 1)	1261	241	0.19111816019032513	0.2	Homo sapiens		0	0	1261
zhou-pbmc-2026	Healthy-donor PBMC HRP/biotin-XX-phenol cell-surface labeling	Zhou et al. 2026	Zhou Y	2026	41126722	10.1002/advs.202511573	core		Intact-cell HRP/biotin-XX-phenol labeling with matched untreated pulldown controls. Supplemental Dataset 1 is the full Perseus table (>= 2 unique peptides, reverse and contaminant hits removed) for every protein quantified in a labeled sample, with unimputed log2 LFQ values; the paper's imputed significance analysis is not used. No surface annotation selects rows. Whether the PBMC columns are separate donors is not stated.	iProX / ProteomeXchange (not yet released at ingestion)	PXD058892	ADVS-13-e11573-s005.xlsx sheet PBMC(batch1) vs NC <https://pmc.ncbi.nlm.nih.gov/articles/PMC12849903/> | ADVS-13-e11573-s005.xlsx sheet PBMC(batch2) vs NC <https://pmc.ncbi.nlm.nih.gov/articles/PMC12849903/>	Intact MV4-11, MOLM-13, RS4;11 cells and healthy-donor PBMCs labeled with biotin-XX-phenol (BxxP) and H2O2 with horseradish peroxidase (HRP) catalysis; streptavidin capture; untreated pulldowns (no BxxP/H2O2) as background controls; MaxQuant 2.4.9 LFQ with match-between-runs, Perseus (reverse and contaminant hits removed, >= 2 unique peptides)	Method read from: PMC12849903 full text (Results 2.1, Methods 'LC-MS Analysis' and 'MS Data Processing'); Supplemental Dataset 1 (ADVS-13-e11573-s005.xlsx).	streptavidin beads (vendor not stated)	not stated	Orbitrap Exploris 480	DDA, 120-min gradient	Instrument as named in the paper's Methods, 'LC-MS Analysis' (full text PMC12849903).	Peripheral blood mononuclear cells from healthy donors, two batches	Supplemental Dataset 1 sheets 'PBMC(batch1) vs NC' (3 labeled, 3 untreated) and 'PBMC(batch2) vs NC' (12 labeled, 8 untreated). Membership = log2 LFQ quantified in >= 2 labeled samples of a batch; untreated no-label pulldowns are measurements only.	ADVS-13-e11573-s005.xlsx: Unnamed: 8 | ADVS-13-e11573-s005.xlsx: Unnamed: 22		PBMC / BxxP/H2O2 HRP surface labeling: PBMC1, PBMC2, PBMC3 (min_observed 2) | PBMC / untreated no-label pulldown control (not used for membership): PBMCNC1, PBMCNC2, PBMCNC3 (min_observed 1) | PBMC / BxxP/H2O2 HRP surface labeling: PBMC4, PBMC5, PBMC6, PBMC7, PBMC8, PBMC9, PBMC10, PBMC11, PBMC12, PBMC13, PBMC14, PBMC15 (min_observed 2) | PBMC / untreated no-label pulldown control (not used for membership): PBMCNC4, PBMCNC5, PBMCNC6, PBMCNC7, PBMCNC8, PBMCNC9, PBMCNC10, PBMCNC11 (min_observed 1)	973	189	0.19424460431654678	0.2	Homo sapiens		0	0	973
govindarajan-hgsc-csc-2026	High-grade serous ovarian cancer cell lines cell surface N-glycoproteomics	Govindarajan et al. 2026	Govindarajan M	2026		10.1186/s13059-026-04294-6	core		Intact-cell glycan labeling (CSC) on untreated cultured cells; every line is a baseline. Processed table of all CSC identifications, not annotation-selected. Published in Genome Biology after the 2025 preprint, whose table was not retrievable (sweep lead); Methods text not yet online, method taken from the abstract and Table S4.	MassIVE	MSV000099007	13059_2026_4294_MOESM2_ESM.xlsx sheet CSC_MEDIAN_NORM_LOG2_FOR_SUPP <https://static-content.springer.com/esm/art%3A10.1186%2Fs13059-026-04294-6/MediaObjects/13059_2026_4294_MOESM2_ESM.xlsx>	Cell-surface N-glycoproteomics (CSC) on intact untreated cells: surface glycans periodate-oxidized and labeled with biocytin hydrazide, streptavidin capture of glycopeptides, PNGase F release of formerly N-glycosylated peptides (Kislinger laboratory CSC). Full Methods not yet online for the accepted Genome Biology version; method from its abstract ('cell surface N-glycoproteomics') and Table S4A, and the lab's published CSC protocol (Govindarajan et al. 2026, Cell Rep Med).	Method read from: Genome Biol 2026, doi:10.1186/s13059-026-04294-6: abstract and Additional file 5 (Table S4A, LC-MS/MS parameters).	streptavidin (per the lab's CSC protocol; not restated in available text)	not stated	Orbitrap Q-Exactive	Easy-nLC 1000, 50 cm EasySpray column, DDA top-20, HCD 27%	Where we looked for the instrument: Additional file 5, Table S4A.	HGSC lines ES2, Kuramochi, OVCAR8, PEO4	Table S1 (13059_2026_4294_MOESM2_ESM.xlsx, sheet 'CSC_MEDIAN_NORM_LOG2_FOR_SUPP'; 855 proteins x 9 cell types x 3 CSC replicates, median-normalized log2 intensities, blank = not detected). This arm: the HGSC cancer lines (ES2, KURAMOCHI, OVCAR8, PEO4). Membership = a value in >= 2 of 3 replicates of a line, any line. The other cell groups of the paper are separate arms. No annotation filter: Table S2 (274 HGSC-enriched surface proteins) is the authors' selection and is not used.	13059_2026_4294_MOESM2_ESM.xlsx: protein		ES2 / untreated, cell surface capture: CSC_ES2_1, CSC_ES2_2, CSC_ES2_3 (min_observed 2) | Kuramochi / untreated, cell surface capture: CSC_KURAMOCHI_1, CSC_KURAMOCHI_2, CSC_KURAMOCHI_3 (min_observed 2) | OVCAR8 / untreated, cell surface capture: CSC_OVCAR8_1, CSC_OVCAR8_2, CSC_OVCAR8_3 (min_observed 2) | PEO4 / untreated, cell surface capture: CSC_PEO4_1, CSC_PEO4_2, CSC_PEO4_3 (min_observed 2)	481	423	0.8794178794178794	0.2	Homo sapiens		0	0	481
mesidor-cf-s1-2026	Human cardiac fibroblast CSC surfaceome, Substudy I, Veneer High/Medium surface proteins	Mesidor et al. 2026	Mesidor R	2026		10.64898/2026.11.09.765497	annotation_selected	author pre-filtered to annotated surface proteins	Intact-cell CSC on adherent primary cardiac fibroblasts, but the public matrix is restricted to High or Medium confidence cell surface proteins classified by Veneer (an annotation-based selection), so it cannot vote; held like tyleckova-npc-2016 and xiao-mcf7-2017. The unfiltered protein table is requested from the authors; the MassIVE deposit (MSV000103688) was private when ingested.	MassIVE (private at ingestion; reviewer access only)	MSV000103688	substudy-I.csv <https://cfxplorer.net/data/surfaceome/substudy-I.csv?v=cf-culture-methods-aligned-2026-11-09>	microscale Cell Surface Capture (µCSC) on cardiac fibroblasts adherent to the plate, on ice: 1 mM sodium metaperiodate (pH 6.0, 15 min), sulfite quench, 10 mM biocytin hydrazide with 50 mM (1H-imidazol-2-yl)methanamine catalyst (60 min); lysis, trypsin digestion, streptavidin capture of labeled glycopeptides, PNGase F release of N-glycopeptides; DDA and DIA, Spectronaut 21 directDIA+ against human Swiss-Prot with isoforms; MaxLFQ (iq); surfaceome restricted to Veneer High/Medium confidence cell surface proteins	Method read from: bioRxiv 10.64898/2026.11.09.765497v1: Supplementary Methods (media-1.pdf) 'Microscale Cell Surface Capture (µCSC)' and 'Nanoscale Cell Surface Capture (nanoCSC)'; main Methods 2.5 (Spectronaut 21 directDIA+, MaxLFQ via iq, surfaceome restricted to Veneer High/Medium); Supplementary Table 4 (instruments).	GenScript Streptavidin MagBeads (L00424)	not stated	Orbitrap Exploris 480	DDA and DIA	Instrument as listed in the paper's Supplementary Table 4 (MS acquisition settings by substudy).	Primary cardiac fibroblasts isolated from non-failing human hearts (3 donors), cultured P0 to P2	CFxplorer Substudy I surfaceome matrix (cfxplorer.net/data/surfaceome/substudy-I.csv, data version cf-culture-methods-aligned-2026-11-09; 627 proteins, all classified High or Medium confidence cell surface by Veneer). Membership = quantified in at least one passage 0 sample (614 proteins); later conditions kept as measurements only.	substudy-I.csv: Protein		cardiac fibroblast / passage 0: P0_D14083, P0_D14118, P0_D14150 (min_observed 1) | cardiac fibroblast / passage 1: P1_D14083, P1_D14118, P1_D14150 (min_observed 1) | cardiac fibroblast / passage 2: P2_D14083, P2_D14118, P2_D14150 (min_observed 1)	610	448	0.7344262295081967	0.2	Homo sapiens		0	0	610
mesidor-cf-s2-2026	Human cardiac fibroblast CSC surfaceome, Substudy II, Veneer High/Medium surface proteins	Mesidor et al. 2026	Mesidor R	2026		10.64898/2026.11.09.765497	annotation_selected	author pre-filtered to annotated surface proteins	Intact-cell CSC on adherent primary cardiac fibroblasts, but the public matrix is restricted to High or Medium confidence cell surface proteins classified by Veneer (an annotation-based selection), so it cannot vote; held like tyleckova-npc-2016 and xiao-mcf7-2017. The unfiltered protein table is requested from the authors; the MassIVE deposit (MSV000103688) was private when ingested.	MassIVE (private at ingestion; reviewer access only)	MSV000103688	substudy-II.csv <https://cfxplorer.net/data/surfaceome/substudy-II.csv?v=cf-culture-methods-aligned-2026-11-09>	microscale Cell Surface Capture (µCSC) on cardiac fibroblasts adherent to the plate, on ice: 1 mM sodium metaperiodate (pH 6.0, 15 min), sulfite quench, 10 mM biocytin hydrazide with 50 mM (1H-imidazol-2-yl)methanamine catalyst (60 min); lysis, trypsin digestion, streptavidin capture of labeled glycopeptides, PNGase F release of N-glycopeptides; DDA and DIA, Spectronaut 21 directDIA+ against human Swiss-Prot with isoforms; MaxLFQ (iq); surfaceome restricted to Veneer High/Medium confidence cell surface proteins	Method read from: bioRxiv 10.64898/2026.11.09.765497v1: Supplementary Methods (media-1.pdf) 'Microscale Cell Surface Capture (µCSC)' and 'Nanoscale Cell Surface Capture (nanoCSC)'; main Methods 2.5 (Spectronaut 21 directDIA+, MaxLFQ via iq, surfaceome restricted to Veneer High/Medium); Supplementary Table 4 (instruments).	GenScript Streptavidin MagBeads (L00424)	not stated	Orbitrap Exploris 480	DDA and DIA	Instrument as listed in the paper's Supplementary Table 4 (MS acquisition settings by substudy).	Primary cardiac fibroblasts from non-failing (3) and failing (3) human hearts, passage 0	CFxplorer Substudy II surfaceome matrix (cfxplorer.net/data/surfaceome/substudy-II.csv, data version cf-culture-methods-aligned-2026-11-09; 605 proteins, all classified High or Medium confidence cell surface by Veneer). Membership = quantified in at least one non-failing heart, passage 0 or failing heart, passage 0 sample (605 proteins); later conditions kept as measurements only.	substudy-II.csv: Protein		cardiac fibroblast / non-failing heart, passage 0: Control_D13354, Control_D14118, Control_D14150 (min_observed 1) | cardiac fibroblast / failing heart, passage 0: HF_D350, HF_D376, HF_D381 (min_observed 1)	603	436	0.7230514096185738	0.2	Homo sapiens		0	0	603
mesidor-cf-s3-2026	Human cardiac fibroblast CSC surfaceome, Substudy III, Veneer High/Medium surface proteins	Mesidor et al. 2026	Mesidor R	2026		10.64898/2026.11.09.765497	annotation_selected	author pre-filtered to annotated surface proteins	Intact-cell CSC on adherent primary cardiac fibroblasts, but the public matrix is restricted to High or Medium confidence cell surface proteins classified by Veneer (an annotation-based selection), so it cannot vote; held like tyleckova-npc-2016 and xiao-mcf7-2017. The unfiltered protein table is requested from the authors; the MassIVE deposit (MSV000103688) was private when ingested.	MassIVE (private at ingestion; reviewer access only)	MSV000103688	substudy-III.csv <https://cfxplorer.net/data/surfaceome/substudy-III.csv?v=cf-culture-methods-aligned-2026-11-09>	nanoscale Cell Surface Capture (nanoCSC) on cardiac fibroblasts adherent to the plate, on ice: 1.6 mM sodium metaperiodate (pH 6.5, 15 min), 0.5 mM alkoxyamine-PEG4-biotin with 5 mM 5-methoxyanthranilic acid catalyst; lysis, trypsin digestion, streptavidin capture of labeled glycopeptides on an Opentrons OT-2, PNGase F release; DIA, Spectronaut 21 directDIA+ against human Swiss-Prot with isoforms; MaxLFQ (iq); surfaceome restricted to Veneer High/Medium confidence cell surface proteins	Method read from: bioRxiv 10.64898/2026.11.09.765497v1: Supplementary Methods (media-1.pdf) 'Microscale Cell Surface Capture (µCSC)' and 'Nanoscale Cell Surface Capture (nanoCSC)'; main Methods 2.5 (Spectronaut 21 directDIA+, MaxLFQ via iq, surfaceome restricted to Veneer High/Medium); Supplementary Table 4 (instruments).	GenScript Streptavidin MagBeads (L00936)	not stated	Orbitrap Exploris 480	DIA	Instrument as listed in the paper's Supplementary Table 4 (MS acquisition settings by substudy).	Primary cardiac fibroblasts (7 donors), plated 24 h or 48 h before the first wash	CFxplorer Substudy III surfaceome matrix (cfxplorer.net/data/surfaceome/substudy-III.csv, data version cf-culture-methods-aligned-2026-11-09; 858 proteins, all classified High or Medium confidence cell surface by Veneer). Membership = quantified in at least one 24 h initial adhesion sample (849 proteins); later conditions kept as measurements only.	substudy-III.csv: Protein		cardiac fibroblast / 24 h initial adhesion: X24_413R, X24_686R, X24_710R, X24_769R, X24_832R, X24_907R, X24_957R (min_observed 1) | cardiac fibroblast / 48 h initial adhesion: X48_413R, X48_686R, X48_710R, X48_769R, X48_832R, X48_907R, X48_957R (min_observed 1)	843	569	0.67497034400949	0.2	Homo sapiens		0	0	843
mesidor-cf-s4-2026	Human cardiac fibroblast CSC surfaceome, Substudy IV, Veneer High/Medium surface proteins	Mesidor et al. 2026	Mesidor R	2026		10.64898/2026.11.09.765497	annotation_selected	author pre-filtered to annotated surface proteins	Intact-cell CSC on adherent primary cardiac fibroblasts, but the public matrix is restricted to High or Medium confidence cell surface proteins classified by Veneer (an annotation-based selection), so it cannot vote; held like tyleckova-npc-2016 and xiao-mcf7-2017. The unfiltered protein table is requested from the authors; the MassIVE deposit (MSV000103688) was private when ingested.	MassIVE (private at ingestion; reviewer access only)	MSV000103688	substudy-IV.csv <https://cfxplorer.net/data/surfaceome/substudy-IV.csv?v=cf-culture-methods-aligned-2026-11-09>	nanoscale Cell Surface Capture (nanoCSC) on cardiac fibroblasts adherent to the plate, on ice: 1.6 mM sodium metaperiodate (pH 6.5, 15 min), 0.5 mM alkoxyamine-PEG4-biotin with 5 mM 5-methoxyanthranilic acid catalyst; lysis, trypsin digestion, streptavidin capture of labeled glycopeptides on an Opentrons OT-2, PNGase F release; DIA, Spectronaut 21 directDIA+ against human Swiss-Prot with isoforms; MaxLFQ (iq); surfaceome restricted to Veneer High/Medium confidence cell surface proteins	Method read from: bioRxiv 10.64898/2026.11.09.765497v1: Supplementary Methods (media-1.pdf) 'Microscale Cell Surface Capture (µCSC)' and 'Nanoscale Cell Surface Capture (nanoCSC)'; main Methods 2.5 (Spectronaut 21 directDIA+, MaxLFQ via iq, surfaceome restricted to Veneer High/Medium); Supplementary Table 4 (instruments).	GenScript Streptavidin MagBeads (L00936)	not stated	Orbitrap Astral	DIA	Instrument as listed in the paper's Supplementary Table 4 (MS acquisition settings by substudy).	Primary cardiac fibroblasts from failing left-ventricular tissue (5 donors), fresh or cryopreserved tissue, cultured P0 to P2	CFxplorer Substudy IV surfaceome matrix (cfxplorer.net/data/surfaceome/substudy-IV.csv, data version cf-culture-methods-aligned-2026-11-09; 1486 proteins, all classified High or Medium confidence cell surface by Veneer). Membership = quantified in at least one fresh tissue, passage 0 or cryopreserved tissue, passage 0 sample (1477 proteins); later conditions kept as measurements only.	substudy-IV.csv: Protein		cardiac fibroblast / cryopreserved tissue, passage 0: P0Cryo_1157R, P0Cryo_1187R, P0Cryo_1376R, P0Cryo_1384R, P0Cryo_778R (min_observed 1) | cardiac fibroblast / fresh tissue, passage 0: P0Fresh_1157R, P0Fresh_1187R, P0Fresh_1376R, P0Fresh_1384R, P0Fresh_778R (min_observed 1) | cardiac fibroblast / cryopreserved tissue, passage 1: P1Cryo_1157R, P1Cryo_1187R, P1Cryo_1376R, P1Cryo_1384R, P1Cryo_778R (min_observed 1) | cardiac fibroblast / fresh tissue, passage 1: P1Fresh_1157R, P1Fresh_1187R, P1Fresh_1376R, P1Fresh_1384R, P1Fresh_778R (min_observed 1) | cardiac fibroblast / cryopreserved tissue, passage 2: P2Cryo_1157R, P2Cryo_1187R, P2Cryo_1376R, P2Cryo_1384R, P2Cryo_778R (min_observed 1) | cardiac fibroblast / fresh tissue, passage 2: P2Fresh_1157R, P2Fresh_1187R, P2Fresh_1376R, P2Fresh_1384R, P2Fresh_778R (min_observed 1)	1470	871	0.5925170068027211	0.2	Homo sapiens		0	0	1470
mesidor-cf-s5-2026	Human cardiac fibroblast CSC surfaceome, Substudy V, Veneer High/Medium surface proteins	Mesidor et al. 2026	Mesidor R	2026		10.64898/2026.11.09.765497	annotation_selected	author pre-filtered to annotated surface proteins	Intact-cell CSC on adherent primary cardiac fibroblasts, but the public matrix is restricted to High or Medium confidence cell surface proteins classified by Veneer (an annotation-based selection), so it cannot vote; held like tyleckova-npc-2016 and xiao-mcf7-2017. The unfiltered protein table is requested from the authors; the MassIVE deposit (MSV000103688) was private when ingested.	MassIVE (private at ingestion; reviewer access only)	MSV000103688	substudy-V.csv <https://cfxplorer.net/data/surfaceome/substudy-V.csv?v=cf-culture-methods-aligned-2026-11-09>	nanoscale Cell Surface Capture (nanoCSC) on cardiac fibroblasts adherent to the plate, on ice: 1.6 mM sodium metaperiodate (pH 6.5, 15 min), 0.5 mM alkoxyamine-PEG4-biotin with 5 mM 5-methoxyanthranilic acid catalyst; lysis, trypsin digestion, streptavidin capture of labeled glycopeptides on an Opentrons OT-2, PNGase F release; DIA, Spectronaut 21 directDIA+ against human Swiss-Prot with isoforms; MaxLFQ (iq); surfaceome restricted to Veneer High/Medium confidence cell surface proteins	Method read from: bioRxiv 10.64898/2026.11.09.765497v1: Supplementary Methods (media-1.pdf) 'Microscale Cell Surface Capture (µCSC)' and 'Nanoscale Cell Surface Capture (nanoCSC)'; main Methods 2.5 (Spectronaut 21 directDIA+, MaxLFQ via iq, surfaceome restricted to Veneer High/Medium); Supplementary Table 4 (instruments).	GenScript Streptavidin MagBeads (L00936)	not stated	Orbitrap Astral	DIA	Instrument as listed in the paper's Supplementary Table 4 (MS acquisition settings by substudy).	Commercial human cardiac fibroblasts (Lonza CC-2904, 5 lots), passages 3 to 5	CFxplorer Substudy V surfaceome matrix (cfxplorer.net/data/surfaceome/substudy-V.csv, data version cf-culture-methods-aligned-2026-11-09; 903 proteins, all classified High or Medium confidence cell surface by Veneer). Membership = quantified in at least one passage 3 sample (896 proteins); later conditions kept as measurements only.	substudy-V.csv: Protein		cardiac fibroblast / passage 3: P3_L2676, P3_L3460, P3_L5828, P3_L8534, P3_L9965 (min_observed 1) | cardiac fibroblast / passage 4: P4_L2676, P4_L3460, P4_L5828, P4_L8534, P4_L9965 (min_observed 1) | cardiac fibroblast / passage 5: P5_L2676, P5_L3460, P5_L5828, P5_L8534, P5_L9965 (min_observed 1)	891	626	0.7025813692480359	0.2	Homo sapiens		0	0	891
sanchez-jurkat-2026	Jurkat sulfo-NHS-biotin surfaceome after dead-cell depletion	Sánchez et al. 2026	Sánchez CD	2026	41453615	10.1016/j.mcpro.2025.101503	core		Published version (MCP) of the bioRxiv preprint 10.1101/2025.09.30.679609. Live-cell sulfo-NHS-biotin with dead cells removed first; one representative biological replicate, so membership is a single-run identification.	PRIDE	PXD068422	mmc1.xlsx sheet DCD in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC12859484/supplementaryFiles> | mmc1.xlsx sheet Control in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC12859484/supplementaryFiles>	Annexin V-based dead-cell depletion before live-cell sulfo-NHS-biotin labeling, streptavidin enrichment, DDA on Orbitrap Fusion Lumos (technical duplicate injections), MaxQuant 2.1.3.0 against human SwissProt.	Method summarized from the paper (PMC12859484) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion Lumos			Jurkat acute T-cell leukemia line	Supplemental Table S1 (mmc1.xlsx) MaxQuant proteinGroups for the representative replicate. Membership = 'DCD' sheet (dead-cell-depleted) protein groups with Intensity > 0, excluding only-identified-by-site groups (no reverse or contaminant groups present). 'Control' sheet (labeled without dead-cell depletion) kept as non-membership measurements because its intracellular contamination from dead cells is the paper's subject.	mmc1.xlsx: Majority protein IDs | mmc1.xlsx: Majority protein IDs	drop rows flagged Reverse, Potential contaminant, Only identified by site | drop rows flagged Reverse, Potential contaminant, Only identified by site	Jurkat / baseline untreated, dead-cell-depleted then sulfo-NHS-biotin labeled: Intensity DCD (min_observed 1) | Jurkat / untreated, labeled without dead-cell depletion (not used for membership): Intensity Control (min_observed 1)	1543	337	0.21840570317563188	0.2	Homo sapiens		0	0	1543
ho-k562-csc-2026	K562 Cell surface capture (periodate/biocytin hydrazide) (Ho et al. 2026, Wells lab)	Ho et al. 2026	Ho WW	2026	42905542	10.1073/pnas.2623700123	core		One arm of a same-cell comparison of eight intact-cell surface chemistries with matched whole-cell-lysate and background runs; full Spectronaut report before any surface selection.	MassIVE / PRIDE	MSV000102332;PXD080445	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt	Cell surface capture (periodate/biocytin hydrazide) on intact K562 cells; streptavidin enrichment; DIA-PASEF (timsTOF), Spectronaut directDIA protein-group report (MSV000102332/PXD080445). One of eight methods compared side by side on the same cells with whole-cell-lysate and bead-background runs.	Method summarized from the paper (PMC13715755) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	timsTOF			K562 chronic myeloid leukemia cells	Spectronaut protein groups with >= 2 stripped peptides experiment-wide (the paper's rule); membership = quantified in >= 2 of 3 replicates of the csc arm; whole-cell lysate, bead and photocatalyst background runs kept as measurements only	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt: PG.ProteinGroups	PG.NrOfStrippedSequencesIdentified (Experiment-wide) ≥ 2	K562 / Cell surface capture (periodate/biocytin hydrazide): [28] 260204_WWH_csc_1_Slot2-19_1_9918.d.PG.Quantity, [29] 260204_WWH_csc_2_Slot2-20_1_9919.d.PG.Quantity, [30] 260204_WWH_csc_3_Slot2-21_1_9920.d.PG.Quantity (min_observed 2) | K562 / unenriched whole-cell lysate: [19] 260204_WWH_wcl_1_Slot2-1_1_9933.d.PG.Quantity, [20] 260204_WWH_wcl_2_Slot2-2_1_9934.d.PG.Quantity, [21] 260204_WWH_wcl_3_Slot2-3_1_9935.d.PG.Quantity (min_observed 2) | K562 / whole-cell lysate on beads (background): [16] 260204_WWH_wclbead_1_Slot2-25_1_9928.d.PG.Quantity, [17] 260204_WWH_wclbead_2_Slot2-26_1_9929.d.PG.Quantity, [18] 260204_WWH_wclbead_3_Slot2-27_1_9930.d.PG.Quantity (min_observed 2) | K562 / photocatalyst background control: [10] 260130_WWH_tfpa525_1_Slot1-34_1_9813.d.PG.Quantity, [11] 260130_WWH_tfpa525_2_Slot1-35_1_9814.d.PG.Quantity, [12] 260130_WWH_tfpa525_3_Slot1-36_1_9815.d.PG.Quantity (min_observed 2)	3526	414	0.11741349971639252	0.2	Homo sapiens		5	0	3526
ho-k562-conaey-2026	K562 Eosin Y on ConA lectin (Ho et al. 2026, Wells lab)	Ho et al. 2026	Ho WW	2026	42905542	10.1073/pnas.2623700123	below_screen	11.2% of its length-corrected amount in Canonical or Likely proteins, under 25%	One arm of a same-cell comparison of eight intact-cell surface chemistries with matched whole-cell-lysate and background runs; full Spectronaut report before any surface selection.	MassIVE / PRIDE	MSV000102332;PXD080445	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt	Eosin Y on ConA lectin on intact K562 cells; streptavidin enrichment; DIA-PASEF (timsTOF), Spectronaut directDIA protein-group report (MSV000102332/PXD080445). One of eight methods compared side by side on the same cells with whole-cell-lysate and bead-background runs.	Method summarized from the paper (PMC13715755) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	timsTOF			K562 chronic myeloid leukemia cells	Spectronaut protein groups with >= 2 stripped peptides experiment-wide (the paper's rule); membership = quantified in >= 2 of 3 replicates of the conaey arm; whole-cell lysate, bead and photocatalyst background runs kept as measurements only	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt: PG.ProteinGroups	PG.NrOfStrippedSequencesIdentified (Experiment-wide) ≥ 2	K562 / Eosin Y on ConA lectin: [25] 260204_WWH_conaey_1_Slot2-22_1_9923.d.PG.Quantity, [26] 260204_WWH_conaey_2_Slot2-23_1_9924.d.PG.Quantity, [27] 260204_WWH_conaey_3_Slot2-24_1_9925.d.PG.Quantity (min_observed 2) | K562 / unenriched whole-cell lysate: [19] 260204_WWH_wcl_1_Slot2-1_1_9933.d.PG.Quantity, [20] 260204_WWH_wcl_2_Slot2-2_1_9934.d.PG.Quantity, [21] 260204_WWH_wcl_3_Slot2-3_1_9935.d.PG.Quantity (min_observed 2) | K562 / whole-cell lysate on beads (background): [16] 260204_WWH_wclbead_1_Slot2-25_1_9928.d.PG.Quantity, [17] 260204_WWH_wclbead_2_Slot2-26_1_9929.d.PG.Quantity, [18] 260204_WWH_wclbead_3_Slot2-27_1_9930.d.PG.Quantity (min_observed 2) | K562 / photocatalyst background control: [10] 260130_WWH_tfpa525_1_Slot1-34_1_9813.d.PG.Quantity, [11] 260130_WWH_tfpa525_2_Slot1-35_1_9814.d.PG.Quantity, [12] 260130_WWH_tfpa525_3_Slot1-36_1_9815.d.PG.Quantity (min_observed 2)	4964	381	0.07675261885576148	0.2	Homo sapiens		5	0	4964
ho-k562-wgaey-2026	K562 Eosin Y on WGA lectin (Ho et al. 2026, Wells lab)	Ho et al. 2026	Ho WW	2026	42905542	10.1073/pnas.2623700123	below_screen	8.1% of its length-corrected amount in Canonical or Likely proteins, under 25%	One arm of a same-cell comparison of eight intact-cell surface chemistries with matched whole-cell-lysate and background runs; full Spectronaut report before any surface selection.	MassIVE / PRIDE	MSV000102332;PXD080445	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt	Eosin Y on WGA lectin on intact K562 cells; streptavidin enrichment; DIA-PASEF (timsTOF), Spectronaut directDIA protein-group report (MSV000102332/PXD080445). One of eight methods compared side by side on the same cells with whole-cell-lysate and bead-background runs.	Method summarized from the paper (PMC13715755) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	timsTOF			K562 chronic myeloid leukemia cells	Spectronaut protein groups with >= 2 stripped peptides experiment-wide (the paper's rule); membership = quantified in >= 2 of 3 replicates of the wgaey arm; whole-cell lysate, bead and photocatalyst background runs kept as measurements only	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt: PG.ProteinGroups	PG.NrOfStrippedSequencesIdentified (Experiment-wide) ≥ 2	K562 / Eosin Y on WGA lectin: [13] 260130_WWH_wgaey_1_Slot1-31_1_9809.d.PG.Quantity, [14] 260130_WWH_wgaey_2_Slot1-32_1_9810.d.PG.Quantity, [15] 260130_WWH_wgaey_3_Slot1-33_1_9811.d.PG.Quantity (min_observed 2) | K562 / unenriched whole-cell lysate: [19] 260204_WWH_wcl_1_Slot2-1_1_9933.d.PG.Quantity, [20] 260204_WWH_wcl_2_Slot2-2_1_9934.d.PG.Quantity, [21] 260204_WWH_wcl_3_Slot2-3_1_9935.d.PG.Quantity (min_observed 2) | K562 / whole-cell lysate on beads (background): [16] 260204_WWH_wclbead_1_Slot2-25_1_9928.d.PG.Quantity, [17] 260204_WWH_wclbead_2_Slot2-26_1_9929.d.PG.Quantity, [18] 260204_WWH_wclbead_3_Slot2-27_1_9930.d.PG.Quantity (min_observed 2) | K562 / photocatalyst background control: [10] 260130_WWH_tfpa525_1_Slot1-34_1_9813.d.PG.Quantity, [11] 260130_WWH_tfpa525_2_Slot1-35_1_9814.d.PG.Quantity, [12] 260130_WWH_tfpa525_3_Slot1-36_1_9815.d.PG.Quantity (min_observed 2)	4963	380	0.076566592786621	0.2	Homo sapiens		5	0	4963
ho-k562-choley-2026	K562 Eosin Y on a cholesterol membrane anchor (Ho et al. 2026, Wells lab)	Ho et al. 2026	Ho WW	2026	42905542	10.1073/pnas.2623700123	below_screen	10.5% of its length-corrected amount in Canonical or Likely proteins, under 25%	One arm of a same-cell comparison of eight intact-cell surface chemistries with matched whole-cell-lysate and background runs; full Spectronaut report before any surface selection.	MassIVE / PRIDE	MSV000102332;PXD080445	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt	Eosin Y on a cholesterol membrane anchor on intact K562 cells; streptavidin enrichment; DIA-PASEF (timsTOF), Spectronaut directDIA protein-group report (MSV000102332/PXD080445). One of eight methods compared side by side on the same cells with whole-cell-lysate and bead-background runs.	Method summarized from the paper (PMC13715755) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	timsTOF			K562 chronic myeloid leukemia cells	Spectronaut protein groups with >= 2 stripped peptides experiment-wide (the paper's rule); membership = quantified in >= 2 of 3 replicates of the choley arm; whole-cell lysate, bead and photocatalyst background runs kept as measurements only	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt: PG.ProteinGroups	PG.NrOfStrippedSequencesIdentified (Experiment-wide) ≥ 2	K562 / Eosin Y on a cholesterol membrane anchor: [1] 260130_WWH_choley_1_Slot1-25_1_9801.d.PG.Quantity, [2] 260130_WWH_choley_2_Slot1-26_1_9802.d.PG.Quantity, [3] 260130_WWH_choley_3_Slot1-27_1_9803.d.PG.Quantity (min_observed 2) | K562 / unenriched whole-cell lysate: [19] 260204_WWH_wcl_1_Slot2-1_1_9933.d.PG.Quantity, [20] 260204_WWH_wcl_2_Slot2-2_1_9934.d.PG.Quantity, [21] 260204_WWH_wcl_3_Slot2-3_1_9935.d.PG.Quantity (min_observed 2) | K562 / whole-cell lysate on beads (background): [16] 260204_WWH_wclbead_1_Slot2-25_1_9928.d.PG.Quantity, [17] 260204_WWH_wclbead_2_Slot2-26_1_9929.d.PG.Quantity, [18] 260204_WWH_wclbead_3_Slot2-27_1_9930.d.PG.Quantity (min_observed 2) | K562 / photocatalyst background control: [10] 260130_WWH_tfpa525_1_Slot1-34_1_9813.d.PG.Quantity, [11] 260130_WWH_tfpa525_2_Slot1-35_1_9814.d.PG.Quantity, [12] 260130_WWH_tfpa525_3_Slot1-36_1_9815.d.PG.Quantity (min_observed 2)	5398	397	0.0735457576880326	0.2	Homo sapiens		5	0	5398
ho-k562-nbaey-2026	K562 Eosin Y on an anti-ALFA nanobody (free in solution on untagged cells) (Ho et al. 2026, Wells lab)	Ho et al. 2026	Ho WW	2026	42905542	10.1073/pnas.2623700123	below_screen	9.7% of its length-corrected amount in Canonical or Likely proteins, under 25%	One arm of a same-cell comparison of eight intact-cell surface chemistries with matched whole-cell-lysate and background runs; full Spectronaut report before any surface selection.	MassIVE / PRIDE	MSV000102332;PXD080445	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt	Eosin Y on an anti-ALFA nanobody (free in solution on untagged cells) on intact K562 cells; streptavidin enrichment; DIA-PASEF (timsTOF), Spectronaut directDIA protein-group report (MSV000102332/PXD080445). One of eight methods compared side by side on the same cells with whole-cell-lysate and bead-background runs.	Method summarized from the paper (PMC13715755) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	timsTOF			K562 chronic myeloid leukemia cells	Spectronaut protein groups with >= 2 stripped peptides experiment-wide (the paper's rule); membership = quantified in >= 2 of 3 replicates of the nbaey arm; whole-cell lysate, bead and photocatalyst background runs kept as measurements only	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt: PG.ProteinGroups	PG.NrOfStrippedSequencesIdentified (Experiment-wide) ≥ 2	K562 / Eosin Y on an anti-ALFA nanobody (free in solution on untagged cells): [7] 260130_WWH_nbaey_1_Slot1-28_1_9805.d.PG.Quantity, [8] 260130_WWH_nbaey_2_Slot1-29_1_9806.d.PG.Quantity, [9] 260130_WWH_nbaey_3_Slot1-30_1_9807.d.PG.Quantity (min_observed 2) | K562 / unenriched whole-cell lysate: [19] 260204_WWH_wcl_1_Slot2-1_1_9933.d.PG.Quantity, [20] 260204_WWH_wcl_2_Slot2-2_1_9934.d.PG.Quantity, [21] 260204_WWH_wcl_3_Slot2-3_1_9935.d.PG.Quantity (min_observed 2) | K562 / whole-cell lysate on beads (background): [16] 260204_WWH_wclbead_1_Slot2-25_1_9928.d.PG.Quantity, [17] 260204_WWH_wclbead_2_Slot2-26_1_9929.d.PG.Quantity, [18] 260204_WWH_wclbead_3_Slot2-27_1_9930.d.PG.Quantity (min_observed 2) | K562 / photocatalyst background control: [10] 260130_WWH_tfpa525_1_Slot1-34_1_9813.d.PG.Quantity, [11] 260130_WWH_tfpa525_2_Slot1-35_1_9814.d.PG.Quantity, [12] 260130_WWH_tfpa525_3_Slot1-36_1_9815.d.PG.Quantity (min_observed 2)	5077	380	0.07484735079771519	0.2	Homo sapiens		5	0	5077
ho-k562-cscey-2026	K562 Eosin Y photocatalyst ligated to periodate-oxidized glycans (Ho et al. 2026, Wells lab)	Ho et al. 2026	Ho WW	2026	42905542	10.1073/pnas.2623700123	below_screen	9.6% of its length-corrected amount in Canonical or Likely proteins, under 25%	One arm of a same-cell comparison of eight intact-cell surface chemistries with matched whole-cell-lysate and background runs; full Spectronaut report before any surface selection.	MassIVE / PRIDE	MSV000102332;PXD080445	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt	Eosin Y photocatalyst ligated to periodate-oxidized glycans on intact K562 cells; streptavidin enrichment; DIA-PASEF (timsTOF), Spectronaut directDIA protein-group report (MSV000102332/PXD080445). One of eight methods compared side by side on the same cells with whole-cell-lysate and bead-background runs.	Method summarized from the paper (PMC13715755) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	timsTOF			K562 chronic myeloid leukemia cells	Spectronaut protein groups with >= 2 stripped peptides experiment-wide (the paper's rule); membership = quantified in >= 2 of 3 replicates of the cscey arm; whole-cell lysate, bead and photocatalyst background runs kept as measurements only	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt: PG.ProteinGroups	PG.NrOfStrippedSequencesIdentified (Experiment-wide) ≥ 2	K562 / Eosin Y photocatalyst ligated to periodate-oxidized glycans: [4] 260130_WWH_cscey50_1_rerun_Slot2-19_1_9837.d.PG.Quantity, [5] 260130_WWH_cscey50_2_rerun_Slot2-20_1_9838.d.PG.Quantity, [6] 260130_WWH_cscey50_3_rerun_Slot2-21_1_9839.d.PG.Quantity (min_observed 2) | K562 / unenriched whole-cell lysate: [19] 260204_WWH_wcl_1_Slot2-1_1_9933.d.PG.Quantity, [20] 260204_WWH_wcl_2_Slot2-2_1_9934.d.PG.Quantity, [21] 260204_WWH_wcl_3_Slot2-3_1_9935.d.PG.Quantity (min_observed 2) | K562 / whole-cell lysate on beads (background): [16] 260204_WWH_wclbead_1_Slot2-25_1_9928.d.PG.Quantity, [17] 260204_WWH_wclbead_2_Slot2-26_1_9929.d.PG.Quantity, [18] 260204_WWH_wclbead_3_Slot2-27_1_9930.d.PG.Quantity (min_observed 2) | K562 / photocatalyst background control: [10] 260130_WWH_tfpa525_1_Slot1-34_1_9813.d.PG.Quantity, [11] 260130_WWH_tfpa525_2_Slot1-35_1_9814.d.PG.Quantity, [12] 260130_WWH_tfpa525_3_Slot1-36_1_9815.d.PG.Quantity (min_observed 2)	5620	400	0.0711743772241993	0.2	Homo sapiens		6	0	5620
ho-k562-snhs-2026	K562 Sulfo-NHS biotin (Ho et al. 2026, Wells lab)	Ho et al. 2026	Ho WW	2026	42905542	10.1073/pnas.2623700123	below_screen	20.6% of its length-corrected amount in Canonical or Likely proteins, under 25%	One arm of a same-cell comparison of eight intact-cell surface chemistries with matched whole-cell-lysate and background runs; full Spectronaut report before any surface selection.	MassIVE / PRIDE	MSV000102332;PXD080445	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt	Sulfo-NHS biotin on intact K562 cells; streptavidin enrichment; DIA-PASEF (timsTOF), Spectronaut directDIA protein-group report (MSV000102332/PXD080445). One of eight methods compared side by side on the same cells with whole-cell-lysate and bead-background runs.	Method summarized from the paper (PMC13715755) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	timsTOF			K562 chronic myeloid leukemia cells	Spectronaut protein groups with >= 2 stripped peptides experiment-wide (the paper's rule); membership = quantified in >= 2 of 3 replicates of the snhs arm; whole-cell lysate, bead and photocatalyst background runs kept as measurements only	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt: PG.ProteinGroups	PG.NrOfStrippedSequencesIdentified (Experiment-wide) ≥ 2	K562 / Sulfo-NHS biotin: [31] 260204_WWH_nhs_1_reshoot_Slot2-31_1_9943.d.PG.Quantity, [32] 260204_WWH_nhs_2_reshoot_Slot2-32_1_9944.d.PG.Quantity, [33] 260204_WWH_nhs_3_reshoot_Slot2-33_1_9945.d.PG.Quantity (min_observed 2) | K562 / unenriched whole-cell lysate: [19] 260204_WWH_wcl_1_Slot2-1_1_9933.d.PG.Quantity, [20] 260204_WWH_wcl_2_Slot2-2_1_9934.d.PG.Quantity, [21] 260204_WWH_wcl_3_Slot2-3_1_9935.d.PG.Quantity (min_observed 2) | K562 / whole-cell lysate on beads (background): [16] 260204_WWH_wclbead_1_Slot2-25_1_9928.d.PG.Quantity, [17] 260204_WWH_wclbead_2_Slot2-26_1_9929.d.PG.Quantity, [18] 260204_WWH_wclbead_3_Slot2-27_1_9930.d.PG.Quantity (min_observed 2) | K562 / photocatalyst background control: [10] 260130_WWH_tfpa525_1_Slot1-34_1_9813.d.PG.Quantity, [11] 260130_WWH_tfpa525_2_Slot1-35_1_9814.d.PG.Quantity, [12] 260130_WWH_tfpa525_3_Slot1-36_1_9815.d.PG.Quantity (min_observed 2)	4393	375	0.08536307762349192	0.2	Homo sapiens		6	0	4393
ho-k562-wgahrp-2026	K562 WGA-HRP peroxidase proximity labeling (Ho et al. 2026, Wells lab)	Ho et al. 2026	Ho WW	2026	42905542	10.1073/pnas.2623700123	below_screen	19.3% of its length-corrected amount in Canonical or Likely proteins, under 25%	One arm of a same-cell comparison of eight intact-cell surface chemistries with matched whole-cell-lysate and background runs; full Spectronaut report before any surface selection.	MassIVE / PRIDE	MSV000102332;PXD080445	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt	WGA-HRP peroxidase proximity labeling on intact K562 cells; streptavidin enrichment; DIA-PASEF (timsTOF), Spectronaut directDIA protein-group report (MSV000102332/PXD080445). One of eight methods compared side by side on the same cells with whole-cell-lysate and bead-background runs.	Method summarized from the paper (PMC13715755) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	timsTOF			K562 chronic myeloid leukemia cells	Spectronaut protein groups with >= 2 stripped peptides experiment-wide (the paper's rule); membership = quantified in >= 2 of 3 replicates of the wgahrp arm; whole-cell lysate, bead and photocatalyst background runs kept as measurements only	20260227_092050_Slot1-25_k562_allnocrossrun_quant20_protein_Report.tsv.txt: PG.ProteinGroups	PG.NrOfStrippedSequencesIdentified (Experiment-wide) ≥ 2	K562 / WGA-HRP peroxidase proximity labeling: [22] 260204_WWH_wgahrp_1_reshoot_Slot2-28_1_9938.d.PG.Quantity, [23] 260204_WWH_wgahrp_2_reshoot_Slot2-29_1_9939.d.PG.Quantity, [24] 260204_WWH_wgahrp_3_reshoot_Slot2-30_1_9940.d.PG.Quantity (min_observed 2) | K562 / unenriched whole-cell lysate: [19] 260204_WWH_wcl_1_Slot2-1_1_9933.d.PG.Quantity, [20] 260204_WWH_wcl_2_Slot2-2_1_9934.d.PG.Quantity, [21] 260204_WWH_wcl_3_Slot2-3_1_9935.d.PG.Quantity (min_observed 2) | K562 / whole-cell lysate on beads (background): [16] 260204_WWH_wclbead_1_Slot2-25_1_9928.d.PG.Quantity, [17] 260204_WWH_wclbead_2_Slot2-26_1_9929.d.PG.Quantity, [18] 260204_WWH_wclbead_3_Slot2-27_1_9930.d.PG.Quantity (min_observed 2) | K562 / photocatalyst background control: [10] 260130_WWH_tfpa525_1_Slot1-34_1_9813.d.PG.Quantity, [11] 260130_WWH_tfpa525_2_Slot1-35_1_9814.d.PG.Quantity, [12] 260130_WWH_tfpa525_3_Slot1-36_1_9815.d.PG.Quantity (min_observed 2)	5498	420	0.07639141506002183	0.2	Homo sapiens		6	0	5498
bruno-mcf10a-yipf5-2026--yipf5-ko-re-expressing-yipf5-i98s	MCF10A sulfo-NHS-LC-biotin surfaceome, DIA · YIPF5 KO re-expressing YIPF5-I98S	Bruno et al. 2026	Bruno F	2026	41717013	10.1016/j.isci.2026.114791	perturbed	genetic perturbation: YIPF5 KO re-expressing YIPF5-I98S	genetic perturbation arm of bruno-mcf10a-yipf5-2026; shown, not counted. Membership follows the parent recipe's rule for this sample group.	MassIVE	PXD048266;MSV000093771	bruno_surface_identified_precursors.tsv	EZ-Link Sulfo-NHS-LC-biotin cell surface biotinylation, streptavidin pull-down, DIA	Method as described in the paper's Results ('cell surface biotinylation followed by streptavidin pull-down'), key resources table, and Methods (Spectronaut directDIA, global imputation); deposited methods docx not obtained (MassIVE HTTP 429) (full text PMC12915289).	streptavidin	not stated	Orbitrap Exploris 480		Instrument as listed in the ProteomeXchange records MSV000093771 and PXD048266.	MCF10A	MCF10A, YIPF5 KO re-expressing YIPF5-I98S: a non-baseline state of bruno-mcf10a-yipf5-2026, listed when observed in at least 2 of its 3 samples				3997	618	0.15461596197147862		Homo sapiens		0	0	3997
bruno-mcf10a-yipf5-2026--yipf5-ko-re-expressing-wild-type-yipf5	MCF10A sulfo-NHS-LC-biotin surfaceome, DIA · YIPF5 KO re-expressing wild-type YIPF5	Bruno et al. 2026	Bruno F	2026	41717013	10.1016/j.isci.2026.114791	perturbed	genetic perturbation: YIPF5 KO re-expressing wild-type YIPF5	genetic perturbation arm of bruno-mcf10a-yipf5-2026; shown, not counted. Membership follows the parent recipe's rule for this sample group.	MassIVE	PXD048266;MSV000093771	bruno_surface_identified_precursors.tsv	EZ-Link Sulfo-NHS-LC-biotin cell surface biotinylation, streptavidin pull-down, DIA	Method as described in the paper's Results ('cell surface biotinylation followed by streptavidin pull-down'), key resources table, and Methods (Spectronaut directDIA, global imputation); deposited methods docx not obtained (MassIVE HTTP 429) (full text PMC12915289).	streptavidin	not stated	Orbitrap Exploris 480		Instrument as listed in the ProteomeXchange records MSV000093771 and PXD048266.	MCF10A	MCF10A, YIPF5 KO re-expressing wild-type YIPF5: a non-baseline state of bruno-mcf10a-yipf5-2026, listed when observed in at least 2 of its 3 samples				4248	637	0.14995291902071564		Homo sapiens		0	0	4248
bruno-mcf10a-yipf5-2026--yipf5-knockout	MCF10A sulfo-NHS-LC-biotin surfaceome, DIA · YIPF5 knockout	Bruno et al. 2026	Bruno F	2026	41717013	10.1016/j.isci.2026.114791	perturbed	genetic perturbation: YIPF5 knockout	genetic perturbation arm of bruno-mcf10a-yipf5-2026; shown, not counted. Membership follows the parent recipe's rule for this sample group.	MassIVE	PXD048266;MSV000093771	bruno_surface_identified_precursors.tsv	EZ-Link Sulfo-NHS-LC-biotin cell surface biotinylation, streptavidin pull-down, DIA	Method as described in the paper's Results ('cell surface biotinylation followed by streptavidin pull-down'), key resources table, and Methods (Spectronaut directDIA, global imputation); deposited methods docx not obtained (MassIVE HTTP 429) (full text PMC12915289).	streptavidin	not stated	Orbitrap Exploris 480		Instrument as listed in the ProteomeXchange records MSV000093771 and PXD048266.	MCF10A	MCF10A, YIPF5 knockout: a non-baseline state of bruno-mcf10a-yipf5-2026, listed when observed in at least 2 of its 3 samples				4045	609	0.15055624227441286		Homo sapiens		0	0	4045
bruno-mcf10a-yipf5-2026	MCF10A sulfo-NHS-LC-biotin surfaceome, DIA · wild-type (baseline)	Bruno et al. 2026	Bruno F	2026	41717013	10.1016/j.isci.2026.114791	below_screen	15% Canonical or Likely proteins, under 20%	Intact-cell sulfo-NHS-LC-biotin capture of untreated wild-type MCF10A; membership uses per-run identified precursors, so the Spectronaut global imputation in the protein reports does not enter. The no-biotin control observes about half as many groups as each biotin run (2,493 vs 3,715-4,695), i.e. heavy nonspecific streptavidin background, which the specificity screen should weigh. KO, rescue and mutant arms are genetic perturbations.	MassIVE	PXD048266;MSV000093771	bruno_surface_identified_precursors.tsv	EZ-Link Sulfo-NHS-LC-biotin cell surface biotinylation, streptavidin pull-down, DIA	Method as described in the paper's Results ('cell surface biotinylation followed by streptavidin pull-down'), key resources table, and Methods (Spectronaut directDIA, global imputation); deposited methods docx not obtained (MassIVE HTTP 429) (full text PMC12915289).	streptavidin	not stated	Orbitrap Exploris 480		Instrument as listed in the ProteomeXchange records MSV000093771 and PXD048266.	MCF10A non-tumorigenic breast epithelial cell line (wild type; YIPF5 KO, KO + YIPF5-WT, KO + YIPF5-I98S)	MassIVE search/20231130_130343_210421_A60_surface_IPscheme_Report_peptides.tsv (Spectronaut 16 precursor report, MCF10A runs only, 772,902 precursor x run rows, 5,279 protein groups) rolled up to identified-precursor counts per protein group per run. The protein-level reports are globally imputed (every group valued in every run, no-biotin control included), so observation is taken from per-run precursor q-values: a group is observed in a run when >= 1 precursor has EG.Qvalue <= 0.01 and PG.Qvalue <= 0.01. Membership = observed in >= 2 of 3 MCF_WT_biot runs. No-biotin control (2,493 groups observed), YIPF5 KO, KO + YIPF5-WT and KO + YIPF5-I98S kept as measurements only. HeLa arms in the 120413 report are not described by the paper and not used; the paper's 2,902 surface proteins follow a nucleus/mitochondrion/ribosome annotation filter and are not used.	bruno_surface_identified_precursors.tsv: PG.ProteinAccessions		MCF10A / baseline wild-type sulfo-NHS-LC-biotin labeled: MCF_WT_biot|210413_TD_A60_Surface_07, MCF_WT_biot|210413_TD_A60_Surface_17, MCF_WT_biot|210413_TD_A60_Surface_37 (min_observed 2) | MCF10A / wild-type no-biotin control (not used for membership): MCF_WT_nobiot|210413_TD_A60_Surface_16 (min_observed 1) | MCF10A / YIPF5 knockout (not used for membership): MCF_KO|210413_TD_A60_Surface_08, MCF_KO|210413_TD_A60_Surface_18, MCF_KO|210413_TD_A60_Surface_38 (min_observed 2) | MCF10A / YIPF5 KO re-expressing wild-type YIPF5 (not used for membership): MCF_KO_WT|210413_TD_A60_Surface_09, MCF_KO_WT|210413_TD_A60_Surface_19, MCF_KO_WT|210413_TD_A60_Surface_39 (min_observed 2) | MCF10A / YIPF5 KO re-expressing YIPF5-I98S (not used for membership): MCF_KO_Mut|210413_TD_A60_Surface_10_20210415100405, MCF_KO_Mut|210413_TD_A60_Surface_20, MCF_KO_Mut|210413_TD_A60_Surface_40 (min_observed 2)	4152	629	0.15149325626204238	0.2	Homo sapiens		0	0	4152
zhou-molm13-2026	MOLM-13 HRP/biotin-XX-phenol cell-surface labeling	Zhou et al. 2026	Zhou Y	2026	41126722	10.1002/advs.202511573	below_screen	7.5% of its length-corrected amount in Canonical or Likely proteins, under 25%	Intact-cell HRP/biotin-XX-phenol labeling with matched untreated pulldown controls. Supplemental Dataset 1 is the full Perseus table (>= 2 unique peptides, reverse and contaminant hits removed) for every protein quantified in a labeled sample, with unimputed log2 LFQ values; the paper's imputed significance analysis is not used. No surface annotation selects rows.	iProX / ProteomeXchange (not yet released at ingestion)	PXD058892	ADVS-13-e11573-s005.xlsx sheet Molm-13 vs NC <https://pmc.ncbi.nlm.nih.gov/articles/PMC12849903/>	Intact MV4-11, MOLM-13, RS4;11 cells and healthy-donor PBMCs labeled with biotin-XX-phenol (BxxP) and H2O2 with horseradish peroxidase (HRP) catalysis; streptavidin capture; untreated pulldowns (no BxxP/H2O2) as background controls; MaxQuant 2.4.9 LFQ with match-between-runs, Perseus (reverse and contaminant hits removed, >= 2 unique peptides)	Method read from: PMC12849903 full text (Results 2.1, Methods 'LC-MS Analysis' and 'MS Data Processing'); Supplemental Dataset 1 (ADVS-13-e11573-s005.xlsx).	streptavidin beads (vendor not stated)	not stated	Orbitrap Exploris 480	DDA, 120-min gradient	Instrument as named in the paper's Methods, 'LC-MS Analysis' (full text PMC12849903).	MOLM-13 acute myeloid leukemia line (FLT3-ITD)	Supplemental Dataset 1 sheet 'Molm-13 vs NC': every protein quantified in a labeled sample. Membership = log2 LFQ quantified in >= 2 of 3 labeled replicates; the three untreated no-label pulldowns are measurements only.	ADVS-13-e11573-s005.xlsx: Unnamed: 8		MOLM-13 / BxxP/H2O2 HRP surface labeling: MOLM1, MOLM2, MOLM3 (min_observed 2) | MOLM-13 / untreated no-label pulldown control (not used for membership): MOLMNC1, MOLMNC2, MOLMNC3 (min_observed 1)	1676	133	0.07935560859188544	0.2	Homo sapiens		0	0	1676
stehn-mpnst-2026	MPNST sulfo-NHS surfaceome, cell lines	Stehn et al. 2026	Stehn CM	2026	42598732	10.1093/noajnl/vdag189	core		Live-cell sulfo-NHS-SS-biotin capture; Table S3 is the full non-normalised intensity table before any surface selection. Gene symbols only, joined through gene_resolver. No no-label control reported.	none (raw data on request)		Supplementary Table S3.xlsx sheet Cell Lines in supplementaryFiles › vdag189_supplementary_data.zip <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC13472686/supplementaryFiles> | Supplementary Table S3.uniprot_mapped.tsv	Pierce Cell Surface Biotinylation and Isolation Kit (sulfo-NHS-SS-biotin), Orbitrap Eclipse, Proteome Discoverer label-free quantification.	Method summarized from the paper (PMC13472686) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Eclipse			Malignant peripheral nerve sheath tumor lines (JH2-002, JH2-079, JH2-103, sNF96.2, ST88-14, STS26T, MPNST007)	Supplementary Table S3 'Cell Lines' sheet, non-normalised protein intensities; detected = intensity > 0 in a line. PDX sheet not used (mouse-host handling of the search not verified)	Supplementary Table S3.uniprot_mapped.tsv: uniprot_mapped		JH2-002 / baseline intact-cell surface biotinylation: JH2-002 (min_observed 1) | JH2-079 / baseline intact-cell surface biotinylation: JH2-079 (min_observed 1) | JH2-103 / baseline intact-cell surface biotinylation: JH2-103 (min_observed 1) | sNF96.2 / baseline intact-cell surface biotinylation: sNF96.2 (min_observed 1) | ST88-14 / baseline intact-cell surface biotinylation: ST88-14 (min_observed 1) | STS26T / baseline intact-cell surface biotinylation: STS26T (min_observed 1) | MPNST007 / baseline intact-cell surface biotinylation: MPNST007 (min_observed 1)	2674	744	0.2782348541510845	0.2	Homo sapiens		0	0	2674
cattaneo-crc-2026	MSI colorectal cancer organoid Mem-PER Plus membranes	Cattaneo et al. 2026	Cattaneo CM	2026	42126206	10.1158/2159-8290.CD-26-0542	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Mem-PER Plus detergent membrane extraction of patient-derived organoids; no surface label, and every run set carries a conditioned-medium treatment.	PRIDE (raw only)	PXD066343	cd-26-0542_supplementary_table_1_suppst1.xlsx sheet Foglio1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC13628094/supplementaryFiles>	Thermo Mem-PER Plus (89842) membrane fraction of patient-derived organoids, DIA, Spectronaut.	Method summarized from the paper (PMC13628094) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Exploris 480		Instrument as listed in the ProteomeXchange record PXD066343.	Patient-derived MSI colorectal cancer organoid MSI_03 cultured in conditioned media from other organoids	Supplementary Table 1 (complete Spectronaut protein-group list for MSI_03); membership = MS2 quantity in >= 2 of 3 runs of any run set named as a membrane fraction (VM_mem_*); the two non-membrane run sets are excluded. Tables 3 and 5 (MSI_06, MSI_05) do not label which runs are membrane fractions and are not used. Every run set is a conditioned-medium treatment.	cd-26-0542_supplementary_table_1_suppst1.xlsx: PG.ProteinGroups		MSI_03 organoid / membrane fraction, run set VM_mem_4: [7] VM_mem_4_1.raw.PG.MS2Quantity, [8] VM_mem_4_2.raw.PG.MS2Quantity, [9] VM_mem_4_3.raw.PG.MS2Quantity (min_observed 2) | MSI_03 organoid / membrane fraction, run set VM_mem_17: [10] VM_mem_17_1.raw.PG.MS2Quantity, [11] VM_mem_17_2.raw.PG.MS2Quantity, [12] VM_mem_17_3.raw.PG.MS2Quantity (min_observed 2) | MSI_03 organoid / membrane fraction, run set VM_mem_23: [13] VM_mem_23_1.raw.PG.MS2Quantity, [14] VM_mem_23_2.raw.PG.MS2Quantity, [15] VM_mem_23_3.raw.PG.MS2Quantity (min_observed 2) | MSI_03 organoid / membrane fraction, run set VM_mem_30: [16] VM_mem_30_1.raw.PG.MS2Quantity, [17] VM_mem_30_2.raw.PG.MS2Quantity, [18] VM_mem_30_3.raw.PG.MS2Quantity (min_observed 2)	8287	686	0.082780258235791	0.2	Homo sapiens		0	161	8287
zhou-mv411-2026	MV4-11 HRP/biotin-XX-phenol cell-surface labeling	Zhou et al. 2026	Zhou Y	2026	41126722	10.1002/advs.202511573	below_screen	7.4% of its length-corrected amount in Canonical or Likely proteins, under 25%	Intact-cell HRP/biotin-XX-phenol labeling with matched untreated pulldown controls. Supplemental Dataset 1 is the full Perseus table (>= 2 unique peptides, reverse and contaminant hits removed) for every protein quantified in a labeled sample, with unimputed log2 LFQ values; the paper's imputed significance analysis is not used. No surface annotation selects rows.	iProX / ProteomeXchange (not yet released at ingestion)	PXD058892	ADVS-13-e11573-s005.xlsx sheet MV4-11 vs NC <https://pmc.ncbi.nlm.nih.gov/articles/PMC12849903/>	Intact MV4-11, MOLM-13, RS4;11 cells and healthy-donor PBMCs labeled with biotin-XX-phenol (BxxP) and H2O2 with horseradish peroxidase (HRP) catalysis; streptavidin capture; untreated pulldowns (no BxxP/H2O2) as background controls; MaxQuant 2.4.9 LFQ with match-between-runs, Perseus (reverse and contaminant hits removed, >= 2 unique peptides)	Method read from: PMC12849903 full text (Results 2.1, Methods 'LC-MS Analysis' and 'MS Data Processing'); Supplemental Dataset 1 (ADVS-13-e11573-s005.xlsx).	streptavidin beads (vendor not stated)	not stated	Orbitrap Exploris 480	DDA, 120-min gradient	Instrument as named in the paper's Methods, 'LC-MS Analysis' (full text PMC12849903).	MV4-11 acute myeloid leukemia line (FLT3-ITD)	Supplemental Dataset 1 sheet 'MV4-11 vs NC': every protein quantified in a labeled sample. Membership = log2 LFQ quantified in >= 2 of 3 labeled replicates; the three untreated no-label pulldowns are measurements only.	ADVS-13-e11573-s005.xlsx: Unnamed: 8		MV4-11 / BxxP/H2O2 HRP surface labeling: MV1, MV2, MV3 (min_observed 2) | MV4-11 / untreated no-label pulldown control (not used for membership): MVNC1, MVNC2, MVNC3 (min_observed 1)	1746	136	0.07789232531500573	0.2	Homo sapiens		0	0	1746
buhl-mrt-organoid-2026	Malignant rhabdoid tumor and matched normal kidney organoid surface proteome, membrane-annotated list	Buhl et al. 2026	Buhl JL	2026		10.1038/s41467-026-79142-z	annotation_selected	author pre-filtered to annotated surface proteins	Intact-cell biotinylation, but the only public table is the authors' membrane-annotated selection (355 of 1,971) with imputed values, so it is shown and never counted. The full proteinGroups table has been requested from the authors (Claudia Janda, 2026-11-18).	PRIDE	PXD046834	41467_2026_79142_MOESM3_ESM.xlsx sheet Sheet1 <https://static-content.springer.com/esm/art%3A10.1038%2Fs41467-026-79142-z/MediaObjects/41467_2026_79142_MOESM3_ESM.xlsx> | 41467_2026_79142_MOESM3_ESM.uniprot_mapped.tsv	Biotinylation of intact organoid cells and streptavidin capture of biotinylated proteins; reagent not stated in any accessible text (Nature Communications 2026 methods not machine-readable here; raw files named SA_Biotin).	Method read from: Nat Commun 2026, doi:10.1038/s41467-026-79142-z (Supplementary Data 1); PRIDE PXD046834 file names; first-author correspondence 2026-11-18.	streptavidin (raw file names)	not stated	Orbitrap Exploris 480		Where we looked for the instrument: PRIDE PXD046834.	Patient-derived malignant rhabdoid tumor organoids (60T, 103T) and patient-matched normal kidney organoids (60H, 103H)	Supplementary Data 1 (41467_2026_79142_MOESM3_ESM.xlsx, Sheet1): 356 membrane-annotated protein groups (GO plasma membrane / cell surface and related annotation columns) of the 1,971 biotinylated, x 12 log2 LFQ columns (3 replicates each of 60H, 60T, 103H, 103T), every value filled (imputed). The PRIDE deposit's only processed table (101123_MRT_Project_PRIDE_Upload.xlsx) is the same 355-protein set. Presence counted for every row; per-organoid detection cannot be read. Rows are mapped by their first gene name (HGNC -> catalog canonical accession), because 86 of the authors' leading accessions are unreviewed TrEMBL entries.	41467_2026_79142_MOESM3_ESM.uniprot_mapped.tsv: uniprot_mapped		MRT organoid 60T / untreated tumor organoid: Log2 LFQ intensity 60T_1, Log2 LFQ intensity 60T_2, Log2 LFQ intensity 60T_3 (min_observed 1) | MRT organoid 103T / untreated tumor organoid: Log2 LFQ intensity 103T_1, Log2 LFQ intensity 103T_2, Log2 LFQ intensity 103T_3 (min_observed 1) | normal kidney organoid 60H / untreated normal kidney organoid: Log2 LFQ intensity 60H_1, Log2 LFQ intensity 60H_2, Log2 LFQ intensity 60H_3 (min_observed 1) | normal kidney organoid 103H / untreated normal kidney organoid: Log2 LFQ intensity 103H_1, Log2 LFQ intensity 103H_2, Log2 LFQ intensity 103H_3 (min_observed 1)	348	235	0.6752873563218391	0.2	Homo sapiens		0	0	348
mooney-os-2026	Osteosarcoma PDX surface-enriched proteome	Mooney et al. 2026	Mooney B	2026	42647168	10.1016/j.celrep.2026.117884	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Density-gradient plasma-membrane enrichment of whole PDX tumors; no reagent marks proteins on intact cells. Retained as osteosarcoma expression-in-membrane-fraction evidence.	PRIDE	PXD075484	mouse_human_Proteins.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/07/PXD075484/28122_U54_Sorensen_OsteoSurfaceEnriched_mouse_human_Proteins.txt> | tmt_layout_sample_id.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/07/PXD075484/tmt_layout_sample_id.txt>	Tumor homogenisation in sucrose, 60% sucrose cushion at 100,000 g, then density-gradient ultracentrifugation to enrich plasma membrane; TMT11, Orbitrap Eclipse; Proteome Discoverer 2.4 searched against human+mouse SwissProt (2021-07-16).	Method summarized from the paper (PMC13671662) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Eclipse			22 osteosarcoma patient-derived xenografts (human tumor in mouse hosts)	Surface-enriched (density-gradient) fraction of 22 OS PDXs, human+mouse search; reference SuperMix (12 non-OS lines) and pooled internal standard channels excluded from membership	mouse_human_Proteins.txt: Accession	Master = IsMasterProtein | Protein FDR Confidence Combined = High | Contaminant = false	OS17 / baseline PDX surface-enriched fraction: Abundance F1 126 Sample, Abundance F3 126 Sample (min_observed 1) | OS1 / baseline PDX surface-enriched fraction: Abundance F1 127N Sample, Abundance F3 127N Sample (min_observed 1) | OS36SJ / baseline PDX surface-enriched fraction: Abundance F1 127C Sample, Abundance F3 127C Sample (min_observed 1) | OS31 / baseline PDX surface-enriched fraction: Abundance F1 128N Sample, Abundance F5 127C Sample (min_observed 1) | OS43SJ / baseline PDX surface-enriched fraction: Abundance F1 128C Sample, Abundance F4 128C Sample (min_observed 1) | OS58SJ / baseline PDX surface-enriched fraction: Abundance F1 129N Sample, Abundance F5 128C Sample (min_observed 1) | OS2 / baseline PDX surface-enriched fraction: Abundance F1 129C Sample, Abundance F4 129C Sample (min_observed 1) | OS60 / baseline PDX surface-enriched fraction: Abundance F1 130N Sample, Abundance F4 128N Sample (min_observed 1) | OS526 / baseline PDX surface-enriched fraction: Abundance F1 130C Sample, Abundance F4 130N Sample (min_observed 1) | OS46SJ / baseline PDX surface-enriched fraction: Abundance F2 126 Sample, Abundance F4 126 Sample (min_observed 1) | OS39RSJ / baseline PDX surface-enriched fraction: Abundance F2 127N Sample, Abundance F4 127N Sample (min_observed 1) | OS33 / baseline PDX surface-enriched fraction: Abundance F2 127C Sample, Abundance F4 127C Sample (min_observed 1) | OS56SJ / baseline PDX surface-enriched fraction: Abundance F2 128N Sample, Abundance F5 128N Sample (min_observed 1) | OS9 / baseline PDX surface-enriched fraction: Abundance F2 128C Sample, Abundance F3 128C Sample (min_observed 1) | OS29 / baseline PDX surface-enriched fraction: Abundance F2 129N Sample, Abundance F3 129N Sample (min_observed 1) | OS34SJ / baseline PDX surface-enriched fraction: Abundance F2 129C Sample, Abundance F3 129C Sample (min_observed 1) | OS525 / baseline PDX surface-enriched fraction: Abundance F2 130N Sample, Abundance F3 130C Sample (min_observed 1) | OS774 / baseline PDX surface-enriched fraction: Abundance F2 130C Sample, Abundance F4 130C Sample (min_observed 1) | OS21 / baseline PDX surface-enriched fraction: Abundance F3 128N Sample, Abundance F5 126 Sample (min_observed 1) | OS42SJ / baseline PDX surface-enriched fraction: Abundance F3 130N Sample, Abundance F5 129C Sample (min_observed 1) | OS55SJ / baseline PDX surface-enriched fraction: Abundance F4 129N Sample, Abundance F5 129N Sample (min_observed 1) | OS51SJ / baseline PDX surface-enriched fraction: Abundance F5 127N Sample, Abundance F5 130N Sample (min_observed 1)	2159	459	0.2125984251968504	0.2	Homo sapiens	Human+mouse search: only human master proteins are retained; a human master protein can still carry shared human/mouse peptides, so a human accession is not proof of species-unique evidence.	611	0	2159
govindarajan-caf-csc-2026	Ovarian cancer-associated fibroblasts cell surface N-glycoproteomics	Govindarajan et al. 2026	Govindarajan M	2026		10.1186/s13059-026-04294-6	core		Intact-cell glycan labeling (CSC) on untreated cultured cells; every line is a baseline. Processed table of all CSC identifications, not annotation-selected. Published in Genome Biology after the 2025 preprint, whose table was not retrievable (sweep lead); Methods text not yet online, method taken from the abstract and Table S4.	MassIVE	MSV000099007	13059_2026_4294_MOESM2_ESM.xlsx sheet CSC_MEDIAN_NORM_LOG2_FOR_SUPP <https://static-content.springer.com/esm/art%3A10.1186%2Fs13059-026-04294-6/MediaObjects/13059_2026_4294_MOESM2_ESM.xlsx>	Cell-surface N-glycoproteomics (CSC) on intact untreated cells: surface glycans periodate-oxidized and labeled with biocytin hydrazide, streptavidin capture of glycopeptides, PNGase F release of formerly N-glycosylated peptides (Kislinger laboratory CSC). Full Methods not yet online for the accepted Genome Biology version; method from its abstract ('cell surface N-glycoproteomics') and Table S4A, and the lab's published CSC protocol (Govindarajan et al. 2026, Cell Rep Med).	Method read from: Genome Biol 2026, doi:10.1186/s13059-026-04294-6: abstract and Additional file 5 (Table S4A, LC-MS/MS parameters).	streptavidin (per the lab's CSC protocol; not restated in available text)	not stated	Orbitrap Q-Exactive	Easy-nLC 1000, 50 cm EasySpray column, DDA top-20, HCD 27%	Where we looked for the instrument: Additional file 5, Table S4A.	Primary cancer-associated fibroblasts CAF3028, CAF40879, CAF438	Table S1 (13059_2026_4294_MOESM2_ESM.xlsx, sheet 'CSC_MEDIAN_NORM_LOG2_FOR_SUPP'; 855 proteins x 9 cell types x 3 CSC replicates, median-normalized log2 intensities, blank = not detected). This arm: the cancer-associated fibroblasts (CAF3028, CAF40879, CAF438). Membership = a value in >= 2 of 3 replicates of a line, any line. The other cell groups of the paper are separate arms. No annotation filter: Table S2 (274 HGSC-enriched surface proteins) is the authors' selection and is not used.	13059_2026_4294_MOESM2_ESM.xlsx: protein		CAF3028 / untreated, cell surface capture: CSC_CAF3028_1, CSC_CAF3028_2, CSC_CAF3028_3 (min_observed 2) | CAF40879 / untreated, cell surface capture: CSC_CAF40879_1, CSC_CAF40879_2, CSC_CAF40879_3 (min_observed 2) | CAF438 / untreated, cell surface capture: CSC_CAF438_1, CSC_CAF438_2, CSC_CAF438_3 (min_observed 2)	606	427	0.7046204620462047	0.2	Homo sapiens		0	0	606
chen-pc3-2026	PC3 prostate cancer Mem-PER Plus membranes, TMT	Chen et al. 2026	Chen W	2026	42784206	10.3390/proteomes14030045	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Mem-PER Plus detergent membrane extraction; no surface label. One TMT plex pools control and treated cells.	PRIDE	PXD077611	20220713_Membrane_TMTALLProteins.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/09/PXD077611/20220713_Membrane_TMTALLProteins.xlsx>	Thermo Mem-PER Plus (89842) membrane fraction, TMT10, Proteome Discoverer.	Method summarized from the paper (PMC13611321) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Exploris 480		Instrument as listed in the ProteomeXchange record PXD077611.	PC3 prostate cancer cells (control and drug-treated channels in one TMT plex)	PRIDE PD export (6,039 master proteins); membership = High protein FDR confidence; TMT channels pool control and treated cells, so identification is not condition-specific	20220713_Membrane_TMTALLProteins.xlsx: Accession	Protein FDR Confidence: Combined = High		5712	493	0.08630952380952381	0.2	Homo sapiens		0	0	5712
laurent-gsc-2026	Patient-derived glioblastoma stem-like cultures, sulfo-NHS surfaceome	Laurent et al. 2026	Laurent A	2026	42695909	10.1021/acs.jproteome.6c00267	below_screen	22.8% of its length-corrected amount in Canonical or Likely proteins, under 25%	Intact-cell sulfo-NHS-SS-biotin capture on six untreated patient-derived GSC cultures; deposited summaries are full identification lists with no surface annotation filter. Protein-level FDR is not stated in the export, so a 2-unique-peptide rule is applied.	PRIDE	PXD075844	GSC-1_DDA_proteinSummaryExport.1.ssv in Protein_Peptide_result.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD075844/Protein_Peptide_result.zip> | GSC-1_DIA_proteinSummaryExport.1.ssv in Protein_Peptide_result.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD075844/Protein_Peptide_result.zip> | GSC-2_DDA_proteinSummaryExport.1.ssv in Protein_Peptide_result.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD075844/Protein_Peptide_result.zip> | GSC-2_DIA_proteinSummaryExport.1.ssv in Protein_Peptide_result.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD075844/Protein_Peptide_result.zip> | GSC-3_DDA_proteinSummaryExport.1.ssv in Protein_Peptide_result.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD075844/Protein_Peptide_result.zip> | GSC-3_DIA_proteinSummaryExport.1.ssv in Protein_Peptide_result.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD075844/Protein_Peptide_result.zip> | GSC-4_DDA_proteinSummaryExport.1.ssv in Protein_Peptide_result.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD075844/Protein_Peptide_result.zip> | GSC-4_DIA_proteinSummaryExport.1.ssv in Protein_Peptide_result.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD075844/Protein_Peptide_result.zip> | GSC-5_DDA_proteinSummaryExport.1.ssv in Protein_Peptide_result.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD075844/Protein_Peptide_result.zip> | GSC-5_DIA_proteinSummaryExport.1.ssv in Protein_Peptide_result.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD075844/Protein_Peptide_result.zip> | GSC-6_DDA_proteinSummaryExport.1.ssv in Protein_Peptide_result.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD075844/Protein_Peptide_result.zip> | GSC-6_DIA_proteinSummaryExport.1.ssv in Protein_Peptide_result.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD075844/Protein_Peptide_result.zip>	Pierce Cell Surface Protein Isolation Kit (sulfo-NHS-SS-biotin) on intact 3D GSC cultures, NeutrAvidin capture; chip-nanoLC on an Agilent 6560 IM-QTOF, three DDA and three DIA injections per culture; Spectrum Mill B06 against human SwissProt.	Method summarized from the paper (10.1021/acs.jproteome.6c00267) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q-TOF; Agilent Q-TOF			Six patient-derived glioblastoma stem-like cell cultures (GSC-1 to GSC-6)	Spectrum Mill protein summary exports, one per culture and acquisition mode (12 files in Protein_Peptide_result.zip). Membership = protein with >= 2 unique peptides in the DDA or DIA summary of a culture; single-peptide proteins (the majority of DIA rows, Spectrum Mill score >= 5) excluded. ProteinSummaryDetails files not used.	GSC-1_DDA_proteinSummaryExport.1.ssv: accession_number | GSC-1_DIA_proteinSummaryExport.1.ssv: accession_number | GSC-2_DDA_proteinSummaryExport.1.ssv: accession_number | GSC-2_DIA_proteinSummaryExport.1.ssv: accession_number | GSC-3_DDA_proteinSummaryExport.1.ssv: accession_number | GSC-3_DIA_proteinSummaryExport.1.ssv: accession_number | GSC-4_DDA_proteinSummaryExport.1.ssv: accession_number | GSC-4_DIA_proteinSummaryExport.1.ssv: accession_number | GSC-5_DDA_proteinSummaryExport.1.ssv: accession_number | GSC-5_DIA_proteinSummaryExport.1.ssv: accession_number | GSC-6_DDA_proteinSummaryExport.1.ssv: accession_number | GSC-6_DIA_proteinSummaryExport.1.ssv: accession_number	numPepsUnique ≥ 2 | numPepsUnique ≥ 2 | numPepsUnique ≥ 2 | numPepsUnique ≥ 2 | numPepsUnique ≥ 2 | numPepsUnique ≥ 2 | numPepsUnique ≥ 2 | numPepsUnique ≥ 2 | numPepsUnique ≥ 2 | numPepsUnique ≥ 2 | numPepsUnique ≥ 2 | numPepsUnique ≥ 2	GSC-1 / baseline sulfo-NHS-SS-biotin capture, DDA (3 injections merged by Spectrum Mill): numSpectra (min_observed 1) | GSC-1 / baseline sulfo-NHS-SS-biotin capture, DIA (3 injections merged by Spectrum Mill): numSpectra (min_observed 1) | GSC-2 / baseline sulfo-NHS-SS-biotin capture, DDA (3 injections merged by Spectrum Mill): numSpectra (min_observed 1) | GSC-2 / baseline sulfo-NHS-SS-biotin capture, DIA (3 injections merged by Spectrum Mill): numSpectra (min_observed 1) | GSC-3 / baseline sulfo-NHS-SS-biotin capture, DDA (3 injections merged by Spectrum Mill): numSpectra (min_observed 1) | GSC-3 / baseline sulfo-NHS-SS-biotin capture, DIA (3 injections merged by Spectrum Mill): numSpectra (min_observed 1) | GSC-4 / baseline sulfo-NHS-SS-biotin capture, DDA (3 injections merged by Spectrum Mill): numSpectra (min_observed 1) | GSC-4 / baseline sulfo-NHS-SS-biotin capture, DIA (3 injections merged by Spectrum Mill): numSpectra (min_observed 1) | GSC-5 / baseline sulfo-NHS-SS-biotin capture, DDA (3 injections merged by Spectrum Mill): numSpectra (min_observed 1) | GSC-5 / baseline sulfo-NHS-SS-biotin capture, DIA (3 injections merged by Spectrum Mill): numSpectra (min_observed 1) | GSC-6 / baseline sulfo-NHS-SS-biotin capture, DDA (3 injections merged by Spectrum Mill): numSpectra (min_observed 1) | GSC-6 / baseline sulfo-NHS-SS-biotin capture, DIA (3 injections merged by Spectrum Mill): numSpectra (min_observed 1)	4708	718	0.15250637213254037	0.2	Homo sapiens		0	1	4708
kuffa-crcpolar-2026	Polarised colon epithelial apical/basolateral sulfo-NHS surfaceome	Kuffa et al. 2026	Kuffa K	2026	42352331	10.3390/biom16060865	core		Untreated polarized monolayers labeled from one side at a time with membrane-impermeant sulfo-NHS-SS-biotin; full FragPipe table with per-run intensities. Peptide-level enrichment captures biotinylated peptides directly, protein-level captures whole proteins.	none found (supplementary tables only)		Supplementary_Table_S1.xlsx sheet Protein_data in supplementaryFiles › biomolecules-16-00865-s001.zip <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC13296770/supplementaryFiles>	Side-selective sulfo-NHS-SS-biotin labeling of apical or basolateral domains of 10-day transwell monolayers, peptide- and protein-level streptavidin enrichment; Orbitrap DDA, FragPipe 22 / IonQuant MBR against the human reference proteome (83,676 entries) plus a bovine medium-contaminant database.	Method summarized from the paper (PMC13296770) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Exploris 240	Waters ACQUITY UPLC M-Class LC coupled to Exploris 240	Instrument as named in the paper's Methods LC-MS (full text PMC13296770).	Colorectal carcinoma lines HCT116 and HT29, polarized on transwell inserts	Supplementary Table S1 sheet Protein_data (FragPipe protein table, 3,645 rows); drop rows flagged Contaminant '+' (bovine/porcine/chicken); membership = log2 intensity in >= 2 of 6 runs (3 biological x 2 technical) of any line x side x enrichment group. Apical and basolateral are both baseline labeling of untreated cells. HCT116 TKS4-KO cells are not in this sheet.	Supplementary_Table_S1.xlsx: Protein ID	drop rows flagged Contaminant	HCT116 / apical side-selective sulfo-NHS-SS-biotin, peptide-level streptavidin enrichment (polarized transwell monolayer): HCT-116_A1A_Peptide, HCT-116_A2A_Peptide, HCT-116_B1A_Peptide, HCT-116_B2A_Peptide, HCT-116_C1A_Peptide, HCT-116_C2A_Peptide (min_observed 2) | HCT116 / apical side-selective sulfo-NHS-SS-biotin, protein-level streptavidin enrichment (polarized transwell monolayer): HCT-116_A1A_Protein, HCT-116_A2A_Protein, HCT-116_B1A_Protein, HCT-116_B2A_Protein, HCT-116_C1A_Protein, HCT-116_C2A_Protein (min_observed 2) | HCT116 / basolateral side-selective sulfo-NHS-SS-biotin, peptide-level streptavidin enrichment (polarized transwell monolayer): HCT-116_A1B_Peptide, HCT-116_A2B_Peptide, HCT-116_B1B_Peptide, HCT-116_B2B_Peptide, HCT-116_C1B_Peptide, HCT-116_C2B_Peptide (min_observed 2) | HCT116 / basolateral side-selective sulfo-NHS-SS-biotin, protein-level streptavidin enrichment (polarized transwell monolayer): HCT-116_A1B_Protein, HCT-116_A2B_Protein, HCT-116_B1B_Protein, HCT-116_B2B_Protein, HCT-116_C1B_Protein, HCT-116_C2B_Protein (min_observed 2) | HT29 / apical side-selective sulfo-NHS-SS-biotin, peptide-level streptavidin enrichment (polarized transwell monolayer): HT-29_A1A_Peptide, HT-29_A2A_Peptide, HT-29_B1A_Peptide, HT-29_B2A_Peptide, HT-29_C1A_Peptide, HT-29_C2A_Peptide (min_observed 2) | HT29 / apical side-selective sulfo-NHS-SS-biotin, protein-level streptavidin enrichment (polarized transwell monolayer): HT-29_A1A_Protein, HT-29_A2A_Protein, HT-29_B1A_Protein, HT-29_B2A_Protein, HT-29_C1A_Protein, HT-29_C2A_Protein (min_observed 2) | HT29 / basolateral side-selective sulfo-NHS-SS-biotin, peptide-level streptavidin enrichment (polarized transwell monolayer): HT-29_A1B_Peptide, HT-29_A2B_Peptide, HT-29_B1B_Peptide, HT-29_B2B_Peptide, HT-29_C1B_Peptide, HT-29_C2B_Peptide (min_observed 2) | HT29 / basolateral side-selective sulfo-NHS-SS-biotin, protein-level streptavidin enrichment (polarized transwell monolayer): HT-29_A1B_Protein, HT-29_A2B_Protein, HT-29_B1B_Protein, HT-29_B2B_Protein, HT-29_C1B_Protein, HT-29_C2B_Protein (min_observed 2)	2974	520	0.17484868863483524	0.2	Homo sapiens		0	0	2974
zhou-rs411-2026	RS4;11 HRP/biotin-XX-phenol cell-surface labeling	Zhou et al. 2026	Zhou Y	2026	41126722	10.1002/advs.202511573	below_screen	11.8% of its length-corrected amount in Canonical or Likely proteins, under 25%	Intact-cell HRP/biotin-XX-phenol labeling with matched untreated pulldown controls. Supplemental Dataset 1 is the full Perseus table (>= 2 unique peptides, reverse and contaminant hits removed) for every protein quantified in a labeled sample, with unimputed log2 LFQ values; the paper's imputed significance analysis is not used. No surface annotation selects rows.	iProX / ProteomeXchange (not yet released at ingestion)	PXD058892	ADVS-13-e11573-s005.xlsx sheet RS4;11 vs NC <https://pmc.ncbi.nlm.nih.gov/articles/PMC12849903/>	Intact MV4-11, MOLM-13, RS4;11 cells and healthy-donor PBMCs labeled with biotin-XX-phenol (BxxP) and H2O2 with horseradish peroxidase (HRP) catalysis; streptavidin capture; untreated pulldowns (no BxxP/H2O2) as background controls; MaxQuant 2.4.9 LFQ with match-between-runs, Perseus (reverse and contaminant hits removed, >= 2 unique peptides)	Method read from: PMC12849903 full text (Results 2.1, Methods 'LC-MS Analysis' and 'MS Data Processing'); Supplemental Dataset 1 (ADVS-13-e11573-s005.xlsx).	streptavidin beads (vendor not stated)	not stated	Orbitrap Exploris 480	DDA, 120-min gradient	Instrument as named in the paper's Methods, 'LC-MS Analysis' (full text PMC12849903).	RS4;11 B-cell acute lymphoblastic leukemia line	Supplemental Dataset 1 sheet 'RS4;11 vs NC': every protein quantified in a labeled sample. Membership = log2 LFQ quantified in >= 2 of 3 labeled replicates; the three untreated no-label pulldowns are measurements only.	ADVS-13-e11573-s005.xlsx: Unnamed: 8		RS4;11 / BxxP/H2O2 HRP surface labeling: RS1, RS2, RS3 (min_observed 2) | RS4;11 / untreated no-label pulldown control (not used for membership): RSNC1, RSNC2, RSNC3 (min_observed 1)	1674	122	0.07287933094384708	0.2	Homo sapiens		0	0	1674
sucam-jhh4-carboxyl-2026	SUCAM JHH4 carboxyl partial export	Levi et al. 2026	Levi A	2026	42031070	10.1016/j.mcpro.2026.101572	below_screen	8% Canonical or Likely proteins, under 20%	Author S13C peptide export, exact reviewed-human entry-name mapping; unmatched IDs quarantined. At least two distinct peptides with min_expectancy <0.05 across available runs. Peptide rows may include aligned XICs; per-run identifications/unique-peptide assignments unresolved. Only available biological replicates retained, no mock rows recovered. No annotation whitelist; diagnostic presence, not enrichment or replicate-reproducibility evidence.	PRIDE	PXD068779	sucam-supp.zip <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC13202573/supplementaryFiles>	Surfaceome Capture by Multiplex (SUCAM) biotinylation on intact cells (1.2 million cells per reaction): amine labeling with 2 mM EZ-Link Sulfo-NHS-SS-biotin (Pierce 21331) + 2 mM EZ-Link NHS-PEG4-biotin (Pierce 21330), 30 min 4 C, then carboxyl activation (2 mM EDC + 5 mM sulfo-NHS, pH 5.7) and labeling with 2 mM EZ-Link Amine-PEG2-biotin (Thermo 21346), 40 min 4 C, glycine quench. Vehicle (PBS) mock-labeled cells processed in parallel as the bead-background control. Lysis in modified RIPA, nuclear pellet discarded, capture on Streptavidin Magnetic Beads (Pierce 88817) 3 h to overnight, RIPA/8 M urea/2 M NaCl/AMBIC washes, on-bead Trypsin/Lys-C digestion; LFQ with biotin-vs-vehicle comparison. A separate aminooxy-biotin (periodate/aniline, alkoxyamine-PEG4-biotin, streptavidin agarose) arm was used only for method comparison.	Method as described in the paper's Experimental Procedures (Mol Cell Proteomics 2026; full text PMC13202573).	Pierce Streptavidin Magnetic Beads (Thermo 88817; written '8817' in the text) for proteomics; Pierce Streptavidin Agarose Resin (20357) for western-blot pulldowns; high-capacity streptavidin agarose for the aminooxy arm	not reported	Q Exactive HF; LTQ Orbitrap Elite		Instrument as listed in the ProteomeXchange record PXD068779.	JHH4 hepatocellular carcinoma cells	JHH4 hepatocellular carcinoma cells				1256	95	0.07563694267515923	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			1256
sucam-jhh4-glyco-2026	SUCAM JHH4 glyco partial export	Levi et al. 2026	Levi A	2026	42031070	10.1016/j.mcpro.2026.101572	provisional	built from a partial author export (peptide-level table)	Author S13A peptide export, exact reviewed-human entry-name mapping; unmatched IDs quarantined. At least two distinct peptides with min_expectancy <0.05 across available runs. Peptide rows may include aligned XICs; per-run identifications/unique-peptide assignments unresolved. Only available biological replicates retained, no mock rows recovered. No annotation whitelist; diagnostic presence, not enrichment or replicate-reproducibility evidence.	PRIDE	PXD068779	sucam-supp.zip <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC13202573/supplementaryFiles>	Surfaceome Capture by Multiplex (SUCAM) biotinylation on intact cells (1.2 million cells per reaction): amine labeling with 2 mM EZ-Link Sulfo-NHS-SS-biotin (Pierce 21331) + 2 mM EZ-Link NHS-PEG4-biotin (Pierce 21330), 30 min 4 C, then carboxyl activation (2 mM EDC + 5 mM sulfo-NHS, pH 5.7) and labeling with 2 mM EZ-Link Amine-PEG2-biotin (Thermo 21346), 40 min 4 C, glycine quench. Vehicle (PBS) mock-labeled cells processed in parallel as the bead-background control. Lysis in modified RIPA, nuclear pellet discarded, capture on Streptavidin Magnetic Beads (Pierce 88817) 3 h to overnight, RIPA/8 M urea/2 M NaCl/AMBIC washes, on-bead Trypsin/Lys-C digestion; LFQ with biotin-vs-vehicle comparison. A separate aminooxy-biotin (periodate/aniline, alkoxyamine-PEG4-biotin, streptavidin agarose) arm was used only for method comparison.	Method as described in the paper's Experimental Procedures (Mol Cell Proteomics 2026; full text PMC13202573).	Pierce Streptavidin Magnetic Beads (Thermo 88817; written '8817' in the text) for proteomics; Pierce Streptavidin Agarose Resin (20357) for western-blot pulldowns; high-capacity streptavidin agarose for the aminooxy arm	not reported	Q Exactive HF; LTQ Orbitrap Elite		Instrument as listed in the ProteomeXchange record PXD068779.	JHH4 hepatocellular carcinoma cells	JHH4 hepatocellular carcinoma cells				1279	331	0.25879593432369036	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			1278
sucam-jhh4-multiplex-2026	SUCAM JHH4 multiplex partial export	Levi et al. 2026	Levi A	2026	42031070	10.1016/j.mcpro.2026.101572	below_screen	6% Canonical or Likely proteins, under 20%	Author S13B peptide export, exact reviewed-human entry-name mapping; unmatched IDs quarantined. At least two distinct peptides with min_expectancy <0.05 across available runs. Peptide rows may include aligned XICs; per-run identifications/unique-peptide assignments unresolved. Only available biological replicates retained, no mock rows recovered. No annotation whitelist; diagnostic presence, not enrichment or replicate-reproducibility evidence.	PRIDE	PXD068779	sucam-supp.zip <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC13202573/supplementaryFiles>	Surfaceome Capture by Multiplex (SUCAM) biotinylation on intact cells (1.2 million cells per reaction): amine labeling with 2 mM EZ-Link Sulfo-NHS-SS-biotin (Pierce 21331) + 2 mM EZ-Link NHS-PEG4-biotin (Pierce 21330), 30 min 4 C, then carboxyl activation (2 mM EDC + 5 mM sulfo-NHS, pH 5.7) and labeling with 2 mM EZ-Link Amine-PEG2-biotin (Thermo 21346), 40 min 4 C, glycine quench. Vehicle (PBS) mock-labeled cells processed in parallel as the bead-background control. Lysis in modified RIPA, nuclear pellet discarded, capture on Streptavidin Magnetic Beads (Pierce 88817) 3 h to overnight, RIPA/8 M urea/2 M NaCl/AMBIC washes, on-bead Trypsin/Lys-C digestion; LFQ with biotin-vs-vehicle comparison. A separate aminooxy-biotin (periodate/aniline, alkoxyamine-PEG4-biotin, streptavidin agarose) arm was used only for method comparison.	Method as described in the paper's Experimental Procedures (Mol Cell Proteomics 2026; full text PMC13202573).	Pierce Streptavidin Magnetic Beads (Thermo 88817; written '8817' in the text) for proteomics; Pierce Streptavidin Agarose Resin (20357) for western-blot pulldowns; high-capacity streptavidin agarose for the aminooxy arm	not reported	Q Exactive HF; LTQ Orbitrap Elite		Instrument as listed in the ProteomeXchange record PXD068779.	JHH4 hepatocellular carcinoma cells	JHH4 hepatocellular carcinoma cells				1713	96	0.05604203152364273	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			1713
sucam-2026	SUCAM leukemia	Levi et al. 2026	Levi A	2026	42031070	10.1016/j.mcpro.2026.101572	annotation_selected	author pre-filtered to annotated surface proteins	pre-filtered by surface annotation (annotation-selected); shown, not counted. Was provisional. provisional: threshold 43.2266%; borderline allowance 2.0%. Current broad GO plus Thorup SURFY proxy; source-specific historical ontology union remains unavailable.	PRIDE	PXD068779	control_surface_proteins.tsv	Surfaceome Capture by Multiplex (SUCAM) biotinylation on intact cells (1.2 million cells per reaction): amine labeling with 2 mM EZ-Link Sulfo-NHS-SS-biotin (Pierce 21331) + 2 mM EZ-Link NHS-PEG4-biotin (Pierce 21330), 30 min 4 C, then carboxyl activation (2 mM EDC + 5 mM sulfo-NHS, pH 5.7) and labeling with 2 mM EZ-Link Amine-PEG2-biotin (Thermo 21346), 40 min 4 C, glycine quench. Vehicle (PBS) mock-labeled cells processed in parallel as the bead-background control. Lysis in modified RIPA, nuclear pellet discarded, capture on Streptavidin Magnetic Beads (Pierce 88817) 3 h to overnight, RIPA/8 M urea/2 M NaCl/AMBIC washes, on-bead Trypsin/Lys-C digestion; LFQ with biotin-vs-vehicle comparison. A separate aminooxy-biotin (periodate/aniline, alkoxyamine-PEG4-biotin, streptavidin agarose) arm was used only for method comparison.	Method as described in the paper's Experimental Procedures (Mol Cell Proteomics 2026; full text PMC13202573).	Pierce Streptavidin Magnetic Beads (Thermo 88817; written '8817' in the text) for proteomics; Pierce Streptavidin Agarose Resin (20357) for western-blot pulldowns; high-capacity streptavidin agarose for the aminooxy arm	not reported	Q Exactive HF; LTQ Orbitrap Elite		Instrument as listed in the ProteomeXchange record PXD068779.	AML lines P31/Fuji, Kasumi-1, HL-60, NB4, MOLM13, NOMO1 and OCI-AML2	7 human acute myeloid leukemia (AML) cell lines: P31/Fuji, Kasumi-1, HL-60, NB4, MOLM13, NOMO1, OCI-AML2	control_surface_proteins.tsv: uniprot_accession			625	533	0.8528	0.43226605396661233	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			624
flores-um-2026	T128 uveal melanoma periodate/aminooxy-biotin surfaceome, RAB1A-manipulated and control lines pooled	Flores-González et al. 2026	Flores-González RE	2026	41708776	10.1038/s41418-026-01684-y	held	conditions are pooled in one list, with no separable baseline	Intact-cell periodate/aminooxy-biotin capture (sound chemistry), but the run-to-condition map (RAB1A OE / EV / shRAB1A / pLKO) is in neither the deposit nor the paper, so control-arm membership cannot be separated from the RAB1A knockdown and overexpression arms; the list pools perturbed and control lines. Admit as primary once the authors supply the sample map (control runs = EV + pLKO).	PRIDE	PXD069080	report.pg_matrix.samples.tsv	1 mM NaIO4 in Buffer A 30 min at 4 C in the dark, then 100 uM aminooxy-biotin (Biotium 90113) + 10 mM aniline 1 h at 4 C, all on ice; scraped into lysis buffer	Method as described in the paper's Methods 'Surface labeling', 'Sample preparation and mass spectrometry analysis', 'MS data analysis'; PRIDE PXD069080 protocol; DIA-NN report.log.txt in the 7z.	high-capacity streptavidin resin (Thermo 20357)	not reported	timsTOF Pro		Instrument as listed in the ProteomeXchange record PXD069080.	T128 uveal melanoma cells: RAB1A overexpression, empty vector, shRAB1A and pLKO control lines (run-to-condition assignment not public)	DIA-NN-Output.7z member report.pg_matrix.tsv (3,694 protein groups incl. Cont_ groups, 16 runs sample_01-16; PRIDE holds raw files for only 15). Membership = MaxLFQ quantity in >= 2 of the 16 runs, pooled over all four T128 lines because the deposit and paper do not say which run is which condition. Cont_ contaminant groups drop out on the accession pattern.	report.pg_matrix.samples.tsv: Protein.Group		T128 uveal melanoma / RAB1A OE, empty vector, shRAB1A and pLKO control pooled (run assignment unknown): sample_01, sample_02, sample_03, sample_04, sample_05, sample_06, sample_07, sample_08, sample_09, sample_10, sample_11, sample_12, sample_13, sample_14, sample_15, sample_16 (min_observed 2)	3526	572	0.16222348269994327	0.2	Homo sapiens		0	0	3526
xu-thp1-surface-2026	THP-1 macrophage intact-cell surface glycoproteome	Xu et al. 2026	Xu X	2026	42875461	10.1038/s41467-026-77775-8	core		Glycan oxidation on intact cells before lysis, with released N-glycosites; the paired lysate arm of the same paper isolates the effect of labeling intact cells.	PRIDE	PXD053647;PXD071681	41467_2026_77775_MOESM5_ESM.xlsx sheet Sheet1 <https://static-content.springer.com/esm/art%3A10.1038%2Fs41467-026-77775-8/MediaObjects/41467_2026_77775_MOESM5_ESM.xlsx>	Galactose oxidase/HRP oxidation of surface glycans on intact cells, hydrazide capture, PNGase F release, TMT. Surface arm of the same-cell comparison with lysate boronic-acid glycoproteomics (xu-thp1-lysate-2026).	Method summarized from the paper (PMC13669316) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Exploris 480		Instrument as listed in the ProteomeXchange records PXD053647 and PXD071681.	THP-1-derived macrophages (M0, with M1 and M2 polarization)	Supplementary Data 3 (548 surface glycoproteins); membership = log2 intensity in >= 2 of 3 M0 channels; M1/M2 kept as measurements	41467_2026_77775_MOESM5_ESM.xlsx: Uniprot ID		THP-1 M0 macrophages / baseline (M0): Log2 M0_1, Log2 M0_2, Log2 M0_3 (min_observed 2) | THP-1 macrophages / M1-polarized: Log2 M1_1, Log2 M1_2, Log2 M1_3 (min_observed 2) | THP-1 macrophages / M2-polarized: Log2 M2_1, Log2 M2_2, Log2 M2_3 (min_observed 2)	548	440	0.8029197080291971	0.2	Homo sapiens		0	0	548
srivastava-tnbc-cm-2026--cisplatin-resistant-crude-membrane	TNBC line crude membrane, DIA · cisplatin-resistant	Srivastava et al. 2026	Srivastava S	2026			perturbed	drug-resistant derivative: cisplatin-resistant	drug-resistant derivative arm of srivastava-tnbc-cm-2026; shown, not counted. Membership follows the parent recipe's rule for this sample group.	jPOST / ProteomeXchange	PXD064232;JPST003825	report.pg_matrix.tsv	differential ultracentrifugation crude membrane	Method read from: ProteomeXchange PXD064232 description; jPOST JPST003825 (page not accessible to us).	not stated	not stated	not stated in accessible text			TNBC line, cisplatin-resistant derivative	TNBC line, cisplatin-resistant derivative, cisplatin-resistant crude membrane (differential ultracentrifugation): a non-baseline state of srivastava-tnbc-cm-2026, listed when observed in at least 2 of its 3 samples				4397	400	0.09097111667045713		Homo sapiens		0	0	4397
srivastava-tnbc-cm-2026	TNBC line crude membrane, DIA · cisplatin-sensitive (baseline)	Srivastava et al. 2026	Srivastava S	2026			comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Crude-membrane fraction from lysed cells; complementary by family policy.	jPOST / ProteomeXchange	PXD064232;JPST003825	report.pg_matrix.tsv	differential ultracentrifugation crude membrane	Method read from: ProteomeXchange PXD064232 description; jPOST JPST003825 (page not accessible to us).	not stated	not stated	not stated in accessible text			Triple-negative breast cancer cell line, cisplatin-sensitive parent and cisplatin-resistant derivative (line not named in the deposit)	DIA-NN report.pg_matrix.tsv (4,558 protein groups, all 15 runs). Membership = non-missing intensity in >= 2 of 3 cisplatin-sensitive crude membrane (differential ultracentrifugation) runs; resistant-line runs kept as measurements only; Pool QC runs not used. No annotation filter in the matrix.	report.pg_matrix.tsv: Protein.Group		TNBC line, cisplatin-sensitive / baseline crude membrane (differential ultracentrifugation): G:\Shaswati_timsTOF\16042025_CSP_CM\CMS1_11042025_S1-C2_1_1205.d, G:\Shaswati_timsTOF\16042025_CSP_CM\CMS2_11042025_S1-C3_1_1206.d, G:\Shaswati_timsTOF\16042025_CSP_CM\CMS3_11042025_S1-C4_1_1207.d (min_observed 2) | TNBC line, cisplatin-resistant derivative / cisplatin-resistant crude membrane (differential ultracentrifugation) (not used for membership): G:\Shaswati_timsTOF\16042025_CSP_CM\CMR1_11042025_S1-C5_1_1208.d, G:\Shaswati_timsTOF\16042025_CSP_CM\CMR2_11042025_S1-C6_1_1209.d, G:\Shaswati_timsTOF\16042025_CSP_CM\CMR3_11042025_S1-C7_1_1210.d (min_observed 2)	4368	399	0.09134615384615384	0.2	Homo sapiens		0	0	4368
srivastava-tnbc-csp-2026--cisplatin-resistant-membrane-impermeable-biotin-surface	TNBC line surface biotinylation, DIA · cisplatin-resistant	Srivastava et al. 2026	Srivastava S	2026			perturbed	drug-resistant derivative: cisplatin-resistant	drug-resistant derivative arm of srivastava-tnbc-csp-2026; shown, not counted. Membership follows the parent recipe's rule for this sample group.	jPOST / ProteomeXchange	PXD064232;JPST003825	report.pg_matrix.tsv	membrane-impermeable biotinylation + affinity purification	Method read from: ProteomeXchange PXD064232 description; jPOST JPST003825 (page not accessible to us).	not stated	not stated	not stated in accessible text			TNBC line, cisplatin-resistant derivative	TNBC line, cisplatin-resistant derivative, cisplatin-resistant membrane-impermeable biotin surface capture: a non-baseline state of srivastava-tnbc-csp-2026, listed when observed in at least 2 of its 3 samples				4042	367	0.09079663532904503		Homo sapiens		0	0	4042
srivastava-tnbc-csp-2026	TNBC line surface biotinylation, DIA · cisplatin-sensitive (baseline)	Srivastava et al. 2026	Srivastava S	2026			held	the deposit doesn't name the cell line or reagent, and there is no paper	Intact-cell biotin capture with a clean per-run matrix, but the deposit does not name the cell line, the biotin reagent or any no-label control, and there is no paper; DIA-NN searched surface and crude-membrane runs together, so match-between-runs may carry crude-membrane identifications into surface runs. Hold until the line and method are confirmed.	jPOST / ProteomeXchange	PXD064232;JPST003825	report.pg_matrix.tsv	membrane-impermeable biotinylation + affinity purification	Method read from: ProteomeXchange PXD064232 description; jPOST JPST003825 (page not accessible to us).	not stated	not stated	not stated in accessible text			Triple-negative breast cancer cell line, cisplatin-sensitive parent and cisplatin-resistant derivative (line not named in the deposit)	DIA-NN report.pg_matrix.tsv (4,558 protein groups, all 15 runs). Membership = non-missing intensity in >= 2 of 3 cisplatin-sensitive membrane-impermeable biotin surface capture runs; resistant-line runs kept as measurements only; Pool QC runs not used. No annotation filter in the matrix.	report.pg_matrix.tsv: Protein.Group		TNBC line, cisplatin-sensitive / baseline membrane-impermeable biotin surface capture: G:\Shaswati_timsTOF\16042025_CSP_CM\CSPS1_11042025_S1-B2_1_1196.d, G:\Shaswati_timsTOF\16042025_CSP_CM\CSPS2_11042025_S1-B3_1_1197.d, G:\Shaswati_timsTOF\16042025_CSP_CM\CSPS3_11042025_S1-B4_1_1198.d (min_observed 2) | TNBC line, cisplatin-resistant derivative / cisplatin-resistant membrane-impermeable biotin surface capture (not used for membership): G:\Shaswati_timsTOF\16042025_CSP_CM\CSPR1_11042025_S1-B5_1_1199.d, G:\Shaswati_timsTOF\16042025_CSP_CM\CSPR2_11042025_S1-B6_1_1200.d, G:\Shaswati_timsTOF\16042025_CSP_CM\CSPR3_11042025_S1-B7_1_1201.d (min_observed 2)	3830	352	0.09190600522193211	0.2	Homo sapiens		0	0	3830
deoca-tnbc-membrane-2026	Triple-negative breast cancer lines and MCF-12F mixed membrane fractions, label-free HDMSE	de Oca et al. 2026	de Oca CSC	2026	42860891	10.1002/pmic.70189	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis-then-membrane-fraction preparation, so it carries no surface-accessibility evidence and enters as complementary membrane fractionation. Unperturbed cell lines; the deposited Progenesis table precedes any annotation.	PRIDE	PXD071351	Total_proteins.csv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD071351/Total_proteins.csv>	mixed membrane fraction from lysed cells, iST digestion, HDMSE label-free	Method read from: PRIDE PXD071351 sample processing protocol; paper not open access in Europe PMC.	none	not applicable	SYNAPT G2-Si		Instrument as listed in the ProteomeXchange record PXD071351.	MCF-12F breast epithelial and HCC1937, HCC1599, MDA-MB-231 TNBC cell lines	PRIDE Total_proteins.csv (Progenesis QI export, 11,864 protein rows, two banner lines above the header; columns named by column_overrides, raw-abundance block = columns 24-35; banner/header lines drop out on the accession check). Rows with Peptide count >= 2. Membership per line = raw abundance > 0 in >= 2 of 3 replicates; each line is its own group.	Total_proteins.csv: Accession	Peptide count ≥ 2	MCF-12F / baseline mixed membrane fraction: raw MCF_12F rep1, raw MCF_12F rep2, raw MCF_12F rep3 (min_observed 2) | HCC1937 / baseline mixed membrane fraction: raw HCC_1937 rep1, raw HCC_1937 rep2, raw HCC_1937 rep3 (min_observed 2) | HCC1599 / baseline mixed membrane fraction: raw HCC_1599 rep1, raw HCC_1599 rep2, raw HCC_1599 rep3 (min_observed 2) | MDA-MB-231 / baseline mixed membrane fraction: raw MDA_MB231 rep1, raw MDA_MB231 rep2, raw MDA_MB231 rep3 (min_observed 2)	4858	541	0.1113627006998765	0.2	Homo sapiens		1	14	4858
choi-u2os-memper-2026--lnpk-knockout-mem-per-plus-membrane-fraction	U-2 OS osteosarcoma Mem-PER Plus membrane fraction, DIA · LNPK knockout	Choi et al. 2026	Choi H	2026	41193816	10.1038/s41586-025-09718-0	perturbed	genetic perturbation: LNPK knockout	genetic perturbation arm of choi-u2os-memper-2026; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD068879	202410_hc_wtko_dia24spd_report.pg_matrix.xlsx sheet report.pg_matrix <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/12/PXD068879/202410_hc_wtko_dia24spd_report.pg_matrix.xlsx>	Mem-PER Plus membrane protein extraction kit (lysis then detergent phase)	Method read from: PRIDE PXD068879 sample processing protocol; paper Methods.	none	not stated	Orbitrap Ascend		Instrument as listed in the ProteomeXchange record PXD068879.	U-2 OS	U-2 OS, LNPK knockout Mem-PER Plus membrane fraction: a non-baseline state of choi-u2os-memper-2026, listed when observed in at least 3 of its 6 samples				5839	577	0.09881829080321973		Homo sapiens		0	0	5839
choi-u2os-memper-2026	U-2 OS osteosarcoma Mem-PER Plus membrane fraction, DIA · control (wild-type) (baseline)	Choi et al. 2026	Choi H	2026	41193816	10.1038/s41586-025-09718-0	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Kit-based (Mem-PER Plus) total membrane fraction after lysis; complementary evidence only. Adds a DIA membrane fraction for U-2 OS, which already has intact-cell data (tuomivaara-u2os-*), so it is useful as a same-line fractionation comparator.	PRIDE	PXD068879	202410_hc_wtko_dia24spd_report.pg_matrix.xlsx sheet report.pg_matrix <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/12/PXD068879/202410_hc_wtko_dia24spd_report.pg_matrix.xlsx>	Mem-PER Plus membrane protein extraction kit (lysis then detergent phase)	Method read from: PRIDE PXD068879 sample processing protocol; paper Methods.	none	not stated	Orbitrap Ascend		Instrument as listed in the ProteomeXchange record PXD068879.	U-2 OS osteosarcoma cell line	Deposited DIA-NN report.pg_matrix (9,901 protein groups; DIA-NN default 1% protein-group q-value). Membership = intensity present in >= 3 of 6 control (wild-type) runs (3 biological replicates x 2 injections). LNPK-knockout runs carried as measurements only. No annotation filter.	202410_hc_wtko_dia24spd_report.pg_matrix.xlsx: Protein.Group		U-2 OS / control (wild-type) Mem-PER Plus membrane fraction: wt1_r1, wt1_r2, wt2_r1, wt2_r2, wt3_r1, wt3_r2 (min_observed 3) | U-2 OS / LNPK knockout Mem-PER Plus membrane fraction (not used for membership): ko1_r1, ko1_r2, ko2_r1, ko2_r2, ko3_r1, ko3_r2 (min_observed 3)	6579	660	0.10031919744642043	0.2	Homo sapiens		0	0	6579
mazzone-rpe1-2026--heat-stress	hTERT-RPE-1 sulfo-NHS-SS-biotin surfaceome (Mazzone et al. 2026 preprint) · heat stress	Mazzone et al. 2026	Mazzone FR	2026		10.64898/2026.02.26.708128	perturbed	heat stress	stress arm of mazzone-rpe1-2026; shown, not counted. Membership follows the parent recipe's rule for this sample group.	none found (no ProteomeXchange identifier in the preprint)		media-3.xlsx sheet MS Data <https://www.biorxiv.org/content/biorxiv/early/2026/02/27/2026.02.26.708128/DC3/embed/media-3.xlsx>	Live-cell sulfo-NHS-SS-biotin labeling on ice (0.5 mg/ml, 30 min), RIPA lysis, streptavidin pull-down, label-free DDA; MaxQuant 2.6.4.0 LFQ, Perseus. Four replicates each of unstressed (CTR), no-biotin control (CTR_NB), osmotic stress (OS) and heat stress (HS).	Method summarized from the paper (10.64898/2026.02.26.708128) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive HF	LC-MS/MS of streptavidin pull-down and total proteome samples	Instrument as named in the paper's Methods (bioRxiv full text).	hTERT-RPE-1	hTERT-RPE-1, heat stress: a non-baseline state of mazzone-rpe1-2026, listed when observed in at least 3 of its 4 samples				2107	488	0.23160892263882296		Homo sapiens		0	2	2107
mazzone-rpe1-2026--osmotic-stress-750-mosm-kg	hTERT-RPE-1 sulfo-NHS-SS-biotin surfaceome (Mazzone et al. 2026 preprint) · osmotic stress 750 mOsm/kg	Mazzone et al. 2026	Mazzone FR	2026		10.64898/2026.02.26.708128	perturbed	osmotic stress 750 mOsm/kg	stress arm of mazzone-rpe1-2026; shown, not counted. Membership follows the parent recipe's rule for this sample group.	none found (no ProteomeXchange identifier in the preprint)		media-3.xlsx sheet MS Data <https://www.biorxiv.org/content/biorxiv/early/2026/02/27/2026.02.26.708128/DC3/embed/media-3.xlsx>	Live-cell sulfo-NHS-SS-biotin labeling on ice (0.5 mg/ml, 30 min), RIPA lysis, streptavidin pull-down, label-free DDA; MaxQuant 2.6.4.0 LFQ, Perseus. Four replicates each of unstressed (CTR), no-biotin control (CTR_NB), osmotic stress (OS) and heat stress (HS).	Method summarized from the paper (10.64898/2026.02.26.708128) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive HF	LC-MS/MS of streptavidin pull-down and total proteome samples	Instrument as named in the paper's Methods (bioRxiv full text).	hTERT-RPE-1	hTERT-RPE-1, osmotic stress 750 mOsm/kg: a non-baseline state of mazzone-rpe1-2026, listed when observed in at least 3 of its 4 samples				2035	493	0.24226044226044227		Homo sapiens		0	2	2035
mazzone-rpe1-2026	hTERT-RPE-1 sulfo-NHS-SS-biotin surfaceome (Mazzone et al. 2026 preprint) · unstressed (baseline)	Mazzone et al. 2026	Mazzone FR	2026		10.64898/2026.02.26.708128	held	the no-label control recovers the same signal	Unpublished preprint. The no-biotin control recovers nearly the same LFQ signal as the labeled arm for most groups (median CTR minus NB of about -0.1 log2), so labeled-arm detection alone is dominated by streptavidin background; promote only if an enrichment-over-NB rule is added.	none found (no ProteomeXchange identifier in the preprint)		media-3.xlsx sheet MS Data <https://www.biorxiv.org/content/biorxiv/early/2026/02/27/2026.02.26.708128/DC3/embed/media-3.xlsx>	Live-cell sulfo-NHS-SS-biotin labeling on ice (0.5 mg/ml, 30 min), RIPA lysis, streptavidin pull-down, label-free DDA; MaxQuant 2.6.4.0 LFQ, Perseus. Four replicates each of unstressed (CTR), no-biotin control (CTR_NB), osmotic stress (OS) and heat stress (HS).	Method summarized from the paper (10.64898/2026.02.26.708128) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive HF	LC-MS/MS of streptavidin pull-down and total proteome samples	Instrument as named in the paper's Methods (bioRxiv full text).	hTERT-RPE-1 telomerase-immortalized retinal pigment epithelium cells	Supplementary Table 1 (media-3.xlsx) 'MS Data' sheet, 2,469 protein groups already cleaned of reverse, contaminant and only-by-site groups by the authors. Membership = LFQ_CTR (non-imputed) observed in >= 3 of 4 unstressed labeled replicates. The Imp_ (imputed) columns are not used. No-biotin controls (LFQ_CTR_NB), osmotic stress and heat stress kept as non-membership measurements; enrichment over no-biotin is NOT required by this rule. Supplementary Table 2 (oxidative-stress run with its own CTR/NB) not ingested.	media-3.xlsx: Majority_protein_IDs		hTERT-RPE-1 / baseline unstressed, sulfo-NHS-SS-biotin labeled: LFQ_CTR_01, LFQ_CTR_02, LFQ_CTR_03, LFQ_CTR_04 (min_observed 3) | hTERT-RPE-1 / unstressed no-biotin control (background; not used for membership): LFQ_CTR_NB_01, LFQ_CTR_NB_02, LFQ_CTR_NB_03, LFQ_CTR_NB_04 (min_observed 3) | hTERT-RPE-1 / osmotic stress 750 mOsm/kg (not used for membership): LFQ_OS_01, LFQ_OS_02, LFQ_OS_03, LFQ_OS_04 (min_observed 3) | hTERT-RPE-1 / heat stress (not used for membership): LFQ_HS_01, LFQ_HS_02, LFQ_HS_03, LFQ_HS_04 (min_observed 3)	2005	464	0.2314214463840399	0.2	Homo sapiens		0	2	2005
nash-i3neuron-2026--hsv-1-dul56-infection-12-and-24-hpi	i3Neuron plasma-membrane profiling · HSV-1 dUL56 infection, 12 and 24 hpi	Nash et al. 2026	Nash DA	2026	42842648	10.1126/sciadv.aei1796	perturbed	HSV-1 dUL56 infection, 12 and 24 hpi	infection arm of nash-i3neuron-2026; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD076394	report.pg_matrix.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD076394/report.pg_matrix.tsv> | sdrf.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD076394/PXD076394_community_annotated.sdrf.tsv>	Plasma-membrane profiling: periodate oxidation and aniline-catalysed aminooxy-biotin labeling of intact cells, neutravidin capture; DIA on a Q Exactive Plus, DIA-NN 2.1 protein-group matrix.	Method summarized from the paper (10.1126/sciadv.aei1796) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive Plus			i3Neurons	i3Neurons, HSV-1 dUL56 infection, 12 and 24 hpi: a non-baseline state of nash-i3neuron-2026, listed when observed in at least 2 of its 5 samples				2124	660	0.3107344632768362		Homo sapiens		0	0	2124
nash-i3neuron-2026--hsv-1-wild-type-infection-12-and-24-hpi	i3Neuron plasma-membrane profiling · HSV-1 wild type infection, 12 and 24 hpi	Nash et al. 2026	Nash DA	2026	42842648	10.1126/sciadv.aei1796	perturbed	HSV-1 wild type infection, 12 and 24 hpi	infection arm of nash-i3neuron-2026; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD076394	report.pg_matrix.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD076394/report.pg_matrix.tsv> | sdrf.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD076394/PXD076394_community_annotated.sdrf.tsv>	Plasma-membrane profiling: periodate oxidation and aniline-catalysed aminooxy-biotin labeling of intact cells, neutravidin capture; DIA on a Q Exactive Plus, DIA-NN 2.1 protein-group matrix.	Method summarized from the paper (10.1126/sciadv.aei1796) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive Plus			i3Neurons	i3Neurons, HSV-1 wild type infection, 12 and 24 hpi: a non-baseline state of nash-i3neuron-2026, listed when observed in at least 2 of its 6 samples				2162	660	0.30527289546716		Homo sapiens		0	0	2162
nash-i3neuron-2026	i3Neuron plasma-membrane profiling · mock infection (baseline)	Nash et al. 2026	Nash DA	2026	42842648	10.1126/sciadv.aei1796	core		Intact-cell aminooxy-biotin PMP on human neurons; the DIA-NN matrix is the full identification list and the mock runs give an uninfected baseline. Only four mock runs (mixed 12/24 hpi), so membership pools time points.	PRIDE	PXD076394	report.pg_matrix.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD076394/report.pg_matrix.tsv> | sdrf.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2026/10/PXD076394/PXD076394_community_annotated.sdrf.tsv>	Plasma-membrane profiling: periodate oxidation and aniline-catalysed aminooxy-biotin labeling of intact cells, neutravidin capture; DIA on a Q Exactive Plus, DIA-NN 2.1 protein-group matrix.	Method summarized from the paper (10.1126/sciadv.aei1796) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive Plus			Human iPSC-derived cortical glutamatergic neurons (i3Neurons, NGN2 iPSC clone 1, CVCL_C7XJ)	DIA-NN report.pg_matrix.tsv (2,342 protein groups, includes HSV-1 proteins removed later by the human-only taxonomy step). Membership = quantified in >= 2 of the 4 mock-infected runs (3 at 24 hpi, 1 at 12 hpi; SDRF 'not infected'). HSV-1 WT and dUL56 runs at 12 and 24 hpi kept as measurements only.	report.pg_matrix.tsv: Protein.Group		i3Neurons / mock infection (baseline intact-cell aminooxy-biotin): 18_Mock_Rep1_24hpi, 23_Mock_Rep3_24hpi, 25_Mock_Rep4_24hpi, 30_Mock_Rep2_12hpi (min_observed 2) | i3Neurons / HSV-1 wild type infection, 12 and 24 hpi (not used for membership): 16_WT_Rep1_24hpi, 19_WT_Rep2_24hpi, 21_WT_Rep3_24hpi, 24_WT_Rep4_24hpi, 26_WT_Rep1_12hpi, 28_WT_Rep2_12hpi (min_observed 2) | i3Neurons / HSV-1 dUL56 infection, 12 and 24 hpi (not used for membership): 17_dUL56_Rep1_24hpi, 20_dUL56_Rep2_24hpi, 22_dUL56_Rep3_24hpi, 27_dUL56_Rep1_12hpi, 29_dUL56_Rep2_12hpi (min_observed 2)	2094	665	0.31757402101241644	0.2	Homo sapiens		0	0	2094
kasap-myeloma-csc-2025	AMO-1 and MM.1S myeloma periodate/biocytin-hydrazide surfaceome	Kasap et al. 2025	Kasap C	2025	40359480	10.1182/blood.2024025536	below_screen	19.2% of its length-corrected amount in Canonical or Likely proteins, under 25%	Intact-cell periodate/hydrazide capture of two untreated myeloma lines with per-replicate spectral counts; membership read from observed MS/MS evidence within each line. No no-label control; matched whole-cell proteomes are kept as measurements.	PRIDE	PXD048492	combined_protein.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/11/PXD048492/combined_protein.tsv>	sodium metaperiodate + biocytin hydrazide on intact cells, NeutrAvidin agarose, PreOmics on-bead digest	Method read from: PRIDE PXD048492 sample processing protocol; paper data-availability statement (surface proteomics of myeloma lines deposited as PXD048492).	NeutrAvidin agarose	not stated	timsTOF Pro; Q Exactive		Instrument as listed in the ProteomeXchange record PXD048492.	AMO-1 and MM.1S multiple myeloma cell lines	PRIDE combined_protein.tsv (FragPipe, 7,290 protein groups at the search's protein FDR). FragPipe 'contam_' groups dropped. Membership = spectral count > 0 in >= 2 of 3 surface-capture replicates (AMO1_R1-3; MM1S_R1-3), evaluated per line. Whole-cell proteome replicates (*_WCP_R1-3) kept as non-membership measurements. MaxLFQ/intensity columns not used (may include match-between-runs transfers).	combined_protein.tsv: Protein ID	drop rows where Protein matches ^contam_	AMO-1 / baseline periodate/biocytin-hydrazide surface capture: AMO1_R1 Spectral Count, AMO1_R2 Spectral Count, AMO1_R3 Spectral Count (min_observed 2) | MM.1S / baseline periodate/biocytin-hydrazide surface capture: MM1S_R1 Spectral Count, MM1S_R2 Spectral Count, MM1S_R3 Spectral Count (min_observed 2) | AMO-1 / whole-cell proteome (not used for membership): AMO1_WCP_R1 Spectral Count, AMO1_WCP_R2 Spectral Count, AMO1_WCP_R3 Spectral Count (min_observed 2) | MM.1S / whole-cell proteome (not used for membership): MM1S_WCP_R1 Spectral Count, MM1S_WCP_R2 Spectral Count, MM1S_WCP_R3 Spectral Count (min_observed 2)	4886	556	0.11379451494064674	0.2	Homo sapiens		0	0	4886
taggi-bbb-2025	Brain endothelial ProteoExtract native membranes · Ad-LacZ control (baseline)	Taggi et al. 2025	Taggi V	2025	40085356	10.1007/s12035-025-04807-7	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Kit-based native membrane extraction; no surface label. Control (Ad-LacZ) samples define membership.	MassIVE / PRIDE	MSV000096107;PXD056849	12035_2025_4807_MOESM1_ESM.xlsx sheet Supplementary_table_1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC12208971/supplementaryFiles>	Merck ProteoExtract Native Membrane Protein Extraction Kit, DIA, Spectronaut.	Method summarized from the paper (PMC12208971) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	timsTOF Ultra (Bruker); 7500 QTRAP (AB Sciex)	timsTOF Ultra: untargeted LC-MS/MS; 7500 QTRAP triple quadrupole: targeted peptide quantification	Instrument as named in the paper's Methods (full text PMC12208971).	Human brain endothelial cell lines hCMEC/D3 and hBMEC (control Ad-LacZ transduction)	Supplementary Table 1 (full list, 7,682 protein groups); membership = log2 intensity in >= 2 of 3 Ad-LacZ control samples of a line; Ad-OATP2B1 overexpression kept as measurements only	12035_2025_4807_MOESM1_ESM.xlsx: PG.ProteinGroups		hCMEC/D3 / Ad-LacZ control membrane fraction: sample 1, sample 2, sample 3 (min_observed 2) | hCMEC/D3 / Ad-OATP2B1 membrane fraction: sample 1.1, sample 2.1, sample 3.1 (min_observed 2) | hBMEC / Ad-LacZ control membrane fraction: sample 1.2, sample 2.2, sample 3.2 (min_observed 2) | hBMEC / Ad-OATP2B1 membrane fraction: sample 1.3, sample 2.3, sample 3.3 (min_observed 2)	7616	795	0.10438550420168068	0.2	Homo sapiens		0	0	7616
taggi-bbb-2025--hbmec-ad-oatp2b1-membrane-fraction	Brain endothelial ProteoExtract native membranes · hBMEC, Ad-OATP2B1	Taggi et al. 2025	Taggi V	2025	40085356	10.1007/s12035-025-04807-7	perturbed	genetic perturbation: Ad-OATP2B1	genetic perturbation arm of taggi-bbb-2025; shown, not counted. Membership follows the parent recipe's rule for this sample group.	MassIVE / PRIDE	MSV000096107;PXD056849	12035_2025_4807_MOESM1_ESM.xlsx sheet Supplementary_table_1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC12208971/supplementaryFiles>	Merck ProteoExtract Native Membrane Protein Extraction Kit, DIA, Spectronaut.	Method summarized from the paper (PMC12208971) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	timsTOF Ultra (Bruker); 7500 QTRAP (AB Sciex)	timsTOF Ultra: untargeted LC-MS/MS; 7500 QTRAP triple quadrupole: targeted peptide quantification	Instrument as named in the paper's Methods (full text PMC12208971).	hBMEC	hBMEC, Ad-OATP2B1 membrane fraction: a non-baseline state of taggi-bbb-2025, listed when observed in at least 2 of its 3 samples				7266	679	0.09344894026974952		Homo sapiens		0	0	7266
taggi-bbb-2025--hcmec-d3-ad-oatp2b1-membrane-fraction	Brain endothelial ProteoExtract native membranes · hCMEC/D3, Ad-OATP2B1	Taggi et al. 2025	Taggi V	2025	40085356	10.1007/s12035-025-04807-7	perturbed	genetic perturbation: Ad-OATP2B1	genetic perturbation arm of taggi-bbb-2025; shown, not counted. Membership follows the parent recipe's rule for this sample group.	MassIVE / PRIDE	MSV000096107;PXD056849	12035_2025_4807_MOESM1_ESM.xlsx sheet Supplementary_table_1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC12208971/supplementaryFiles>	Merck ProteoExtract Native Membrane Protein Extraction Kit, DIA, Spectronaut.	Method summarized from the paper (PMC12208971) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	timsTOF Ultra (Bruker); 7500 QTRAP (AB Sciex)	timsTOF Ultra: untargeted LC-MS/MS; 7500 QTRAP triple quadrupole: targeted peptide quantification	Instrument as named in the paper's Methods (full text PMC12208971).	hCMEC/D3	hCMEC/D3, Ad-OATP2B1 membrane fraction: a non-baseline state of taggi-bbb-2025, listed when observed in at least 2 of its 3 samples				7323	764	0.10432882698347672		Homo sapiens		0	0	7323
alvarez-bmec-2025	Brain endothelial and HUVEC sulfo-NHS surfaceomes with no-biotin controls	Alvarez et al. 2025	Alvarez PA	2025	40987287	10.1016/j.celrep.2025.116305	below_screen	10.9% of its length-corrected amount in Canonical or Likely proteins, under 25%	Intact-cell sulfo-NHS-SS-biotin capture of uninfected endothelial cells with matched no-biotin controls; the MSstats table is the full protein list before the authors' foreground and transmembrane selections. Match between runs was on, so the no-biotin runs recover many proteins at lower intensity; read the label-vs-control contrast from the measurements.	PRIDE	PXD059899	alvarez_protein_levels_wide.tsv | PA2_table_of_crossrun_normalized_protein_levels.csv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/11/PXD059899/PA2_table_of_crossrun_normalized_protein_levels.csv>	Pierce Cell Surface Biotinylation and Isolation Kit (Thermo A44390), sulfo-NHS-SS-biotin on cells lifted and washed 5x in DPBS, then lysis and neutravidin enrichment; minus-biotin controls processed in parallel	Method as described in the paper's STAR Methods 'Proteomics sample processing' and PRIDE PXD059899 sample protocol; QC exclusions in 'Proteomics data analysis'.	neutravidin (kit)	not reported	timsTOF HT		Instrument as listed in the ProteomeXchange record PXD059899.	hPSC-derived brain microvascular endothelial-like cells (H9 / IMR90-4 differentiations), HCMEC/D3 brain endothelial line, HUVEC (uninfected)	PRIDE PA2_table_of_crossrun_normalized_protein_levels.csv (MSstats ProteinLevelData, 4,442 protein groups keyed by UniProt entry name; every row has >= 1 measured and 0 imputed features), pivoted to one column per run and mapped entry name -> accession. Membership = protein summarised in >= 2 plus-biotin runs of that cell type (iB+ 1,3; C+ 1,3; U+ 1,2,3 after the authors excluded C+.2 and iB+.2). No-biotin runs (iB- 1-3, C- 2,3, U- 1,3) kept as measurements only. The authors' biotin-vs-control foreground list and transmembrane filter are not used.	alvarez_protein_levels_wide.tsv: uniprot_accession		hPSC-derived brain microvascular endothelial-like cells (hPSC-BMELCs) / baseline sulfo-NHS-SS-biotin labeled: iB_plus_ve_1, iB_plus_ve_3 (min_observed 2) | hPSC-derived brain microvascular endothelial-like cells (hPSC-BMELCs) / no-biotin control (not used for membership): iB_minus_ve_1, iB_minus_ve_2, iB_minus_ve_3 (min_observed 2) | HCMEC/D3 / baseline sulfo-NHS-SS-biotin labeled: C_plus_ve_1, C_plus_ve_3 (min_observed 2) | HCMEC/D3 / no-biotin control (not used for membership): C_minus_ve_2, C_minus_ve_3 (min_observed 2) | HUVEC / baseline sulfo-NHS-SS-biotin labeled: U_plus_ve_1, U_plus_ve_2, U_plus_ve_3 (min_observed 2) | HUVEC / no-biotin control (not used for membership): U_minus_ve_1, U_minus_ve_3 (min_observed 2)	4250	437	0.1028235294117647	0.2	Homo sapiens		0	0	4250
friedlova-cervix-2025--ifn-alpha	Cervical carcinoma sulfo-NHS surfaceome, PRIDE static table · IFN-alpha	Friedlová et al. 2025	Friedlová N	2025	40314078	10.3892/or.2025.8904	perturbed	drug, ligand or treatment: IFN-alpha	drug, ligand or treatment arm of friedlova-cervix-2025; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD053951	220223_22SP003_static_all.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/05/PXD053951/220223_22SP003_static_all.xlsx>	EZ-Link sulfo-NHS-SS-biotin (0.8 mM) on Accutase-detached intact cells, streptavidin capture; Orbitrap Fusion DDA, Proteome Discoverer 2.2 Sequest HT against SwissProt human (2017-10-25) plus PD contaminants.	Method summarized from the paper (PMC12059461) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion			cervical carcinoma (line/genotype unresolved)	cervical carcinoma (line/genotype unresolved), IFN-alpha: a non-baseline state of friedlova-cervix-2025, listed when observed in at least 2 of its 3 samples				1386	418	0.30158730158730157		Homo sapiens		0	0	1386
friedlova-cervix-2025--ifn-gamma	Cervical carcinoma sulfo-NHS surfaceome, PRIDE static table · IFN-gamma	Friedlová et al. 2025	Friedlová N	2025	40314078	10.3892/or.2025.8904	perturbed	drug, ligand or treatment: IFN-gamma	drug, ligand or treatment arm of friedlova-cervix-2025; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD053951	220223_22SP003_static_all.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/05/PXD053951/220223_22SP003_static_all.xlsx>	EZ-Link sulfo-NHS-SS-biotin (0.8 mM) on Accutase-detached intact cells, streptavidin capture; Orbitrap Fusion DDA, Proteome Discoverer 2.2 Sequest HT against SwissProt human (2017-10-25) plus PD contaminants.	Method summarized from the paper (PMC12059461) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion			cervical carcinoma (line/genotype unresolved)	cervical carcinoma (line/genotype unresolved), IFN-gamma: a non-baseline state of friedlova-cervix-2025, listed when observed in at least 2 of its 3 samples				1374	416	0.3027656477438137		Homo sapiens		0	0	1374
friedlova-cervix-2025	Cervical carcinoma sulfo-NHS surfaceome, PRIDE static table · untreated (baseline)	Friedlová et al. 2025	Friedlová N	2025	40314078	10.3892/or.2025.8904	held	the deposited table doesn't match the paper's design	The deposited protein table's Ctrl / IFN-alpha / IFN-gamma design does not match the paper's experiment (SiHa wt vs IFITM1 KO, pulse SILAC +/- IFN-gamma), so the cell line and genotype behind the Ctrl channels are unresolved. Hold until the authors confirm what 22SP003 'static' measured.	PRIDE	PXD053951	220223_22SP003_static_all.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/05/PXD053951/220223_22SP003_static_all.xlsx>	EZ-Link sulfo-NHS-SS-biotin (0.8 mM) on Accutase-detached intact cells, streptavidin capture; Orbitrap Fusion DDA, Proteome Discoverer 2.2 Sequest HT against SwissProt human (2017-10-25) plus PD contaminants.	Method summarized from the paper (PMC12059461) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion			Cervical carcinoma cells (paper: SiHa wt and IFITM1 KO; the deposited table's line and genotype are not stated)	PRIDE 220223_22SP003_static_all.xlsx 'Proteins' sheet (PD hierarchical export; protein rows only); High protein FDR confidence; drop non-human contaminants; membership = abundance in >= 2 of 3 Ctrl channels (F2/F5/F8). IFN-alpha and IFN-gamma channels kept as measurements only.	220223_22SP003_static_all.xlsx: Accession	Protein FDR Confidence: Combined = High | drop rows where Description matches ^(?!.*OS=Homo sapiens)	cervical carcinoma (line/genotype unresolved) / Ctrl (untreated) channel: Abundance: F2: Control, Ctrl, 1, Abundance: F5: Control, Ctrl, 2, Abundance: F8: Control, Ctrl, 3 (min_observed 2) | cervical carcinoma (line/genotype unresolved) / IFN-alpha (not used for membership): Abundance: F4: Sample, INFa, 1, Abundance: F7: Sample, INFa, 2, Abundance: F10: Sample, INFa, 3 (min_observed 2) | cervical carcinoma (line/genotype unresolved) / IFN-gamma (not used for membership): Abundance: F3: Sample, INFg, 1, Abundance: F6: Sample, INFg, 2, Abundance: F9: Sample, INFg, 3 (min_observed 2)	1374	413	0.3005822416302766	0.2	Homo sapiens		0	0	1374
martins-crc3d-2025	Colorectal cancer spheroid Mem-PER Plus membrane fraction · 3D spheroid, non-targeting siRNA (baseline)	Martins et al. 2025	Martins F	2025	40274922	10.1038/s41598-025-94549-2	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Kit-based total membrane fraction (Mem-PER Plus); no surface label. Common CRC lines, but the only 3D spheroid membrane data in the family.	PRIDE	PXD059013	martins_mztab_psms_by_sample.tsv | Pheno.csv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/05/PXD059013/Pheno.csv>	Thermo Mem-PER Plus membrane protein extraction from 3D spheroids; label-free LC-MS/MS, MaxQuant (mzTab reports 2.1.0.0; paper states 1.5.3.30).	Method summarized from the paper (PMC12022182) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive HF		Instrument as listed in the ProteomeXchange record PXD059013.	Colorectal cancer lines HCT116, SW480, LS174T, SW837 grown as 3D spheroids	mzTab PRT protein groups (3,279; 51 CON__/REV__ removed) with non-decoy PSM counts per biological sample from the PSM section (two injections summed); membership = PSMs > 0 in >= 2 of 3 non-targeting (NT) samples of a line; siKRAS samples kept as measurements only.	martins_mztab_psms_by_sample.tsv: protein_ids		HCT116 / 3D spheroid, non-targeting siRNA, Mem-PER Plus membrane fraction: HCT_116_3D_NT_rep1, HCT_116_3D_NT_rep2, HCT_116_3D_NT_rep3 (min_observed 2) | SW480 / 3D spheroid, non-targeting siRNA, Mem-PER Plus membrane fraction: SW480_3D_NT_rep1, SW480_3D_NT_rep2, SW480_3D_NT_rep3 (min_observed 2) | LS174T / 3D spheroid, non-targeting siRNA, Mem-PER Plus membrane fraction: LS174T_3D_NT_rep1, LS174T_3D_NT_rep2, LS174T_3D_NT_rep3 (min_observed 2) | SW837 / 3D spheroid, non-targeting siRNA, Mem-PER Plus membrane fraction: SW837_3D_NT_rep1, SW837_3D_NT_rep2, SW837_3D_NT_rep3 (min_observed 2) | HCT116 / 3D spheroid, KRAS siRNA, Mem-PER Plus membrane fraction: HCT_116_3D_SiKRAS_rep1, HCT_116_3D_SiKRAS_rep2, HCT_116_3D_SiKRAS_rep3 (min_observed 2) | SW480 / 3D spheroid, KRAS siRNA, Mem-PER Plus membrane fraction: SW480_3D_SiKRAS_rep1, SW480_3D_SiKRAS_rep2, SW480_3D_SiKRAS_rep3 (min_observed 2) | LS174T / 3D spheroid, KRAS siRNA, Mem-PER Plus membrane fraction: LS174T_3D_SiKRAS_rep1, LS174T_3D_SiKRAS_rep2, LS174T_3D_SiKRAS_rep3 (min_observed 2) | SW837 / 3D spheroid, KRAS siRNA, Mem-PER Plus membrane fraction: SW837_3D_SiKRAS_rep1, SW837_3D_SiKRAS_rep2, SW837_3D_SiKRAS_rep3 (min_observed 2)	2810	269	0.09572953736654805	0.2	Homo sapiens		0	45	2810
martins-crc3d-2025--hct116-3d-spheroid-kras-sirna-mem-per-plus-membrane-fraction	Colorectal cancer spheroid Mem-PER Plus membrane fraction · HCT116, 3D spheroid, KRAS siRNA	Martins et al. 2025	Martins F	2025	40274922	10.1038/s41598-025-94549-2	perturbed	genetic perturbation: 3D spheroid, KRAS siRNA	genetic perturbation arm of martins-crc3d-2025; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD059013	martins_mztab_psms_by_sample.tsv | Pheno.csv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/05/PXD059013/Pheno.csv>	Thermo Mem-PER Plus membrane protein extraction from 3D spheroids; label-free LC-MS/MS, MaxQuant (mzTab reports 2.1.0.0; paper states 1.5.3.30).	Method summarized from the paper (PMC12022182) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive HF		Instrument as listed in the ProteomeXchange record PXD059013.	HCT116	HCT116, 3D spheroid, KRAS siRNA, Mem-PER Plus membrane fraction: a non-baseline state of martins-crc3d-2025, listed when observed in at least 2 of its 3 samples				2100	166	0.07904761904761905		Homo sapiens		0	25	2100
martins-crc3d-2025--ls174t-3d-spheroid-kras-sirna-mem-per-plus-membrane-fraction	Colorectal cancer spheroid Mem-PER Plus membrane fraction · LS174T, 3D spheroid, KRAS siRNA	Martins et al. 2025	Martins F	2025	40274922	10.1038/s41598-025-94549-2	perturbed	genetic perturbation: 3D spheroid, KRAS siRNA	genetic perturbation arm of martins-crc3d-2025; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD059013	martins_mztab_psms_by_sample.tsv | Pheno.csv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/05/PXD059013/Pheno.csv>	Thermo Mem-PER Plus membrane protein extraction from 3D spheroids; label-free LC-MS/MS, MaxQuant (mzTab reports 2.1.0.0; paper states 1.5.3.30).	Method summarized from the paper (PMC12022182) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive HF		Instrument as listed in the ProteomeXchange record PXD059013.	LS174T	LS174T, 3D spheroid, KRAS siRNA, Mem-PER Plus membrane fraction: a non-baseline state of martins-crc3d-2025, listed when observed in at least 2 of its 3 samples				1958	168	0.08580183861082738		Homo sapiens		0	26	1958
martins-crc3d-2025--sw480-3d-spheroid-kras-sirna-mem-per-plus-membrane-fraction	Colorectal cancer spheroid Mem-PER Plus membrane fraction · SW480, 3D spheroid, KRAS siRNA	Martins et al. 2025	Martins F	2025	40274922	10.1038/s41598-025-94549-2	perturbed	genetic perturbation: 3D spheroid, KRAS siRNA	genetic perturbation arm of martins-crc3d-2025; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD059013	martins_mztab_psms_by_sample.tsv | Pheno.csv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/05/PXD059013/Pheno.csv>	Thermo Mem-PER Plus membrane protein extraction from 3D spheroids; label-free LC-MS/MS, MaxQuant (mzTab reports 2.1.0.0; paper states 1.5.3.30).	Method summarized from the paper (PMC12022182) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive HF		Instrument as listed in the ProteomeXchange record PXD059013.	SW480	SW480, 3D spheroid, KRAS siRNA, Mem-PER Plus membrane fraction: a non-baseline state of martins-crc3d-2025, listed when observed in at least 2 of its 3 samples				2227	175	0.07858105074090704		Homo sapiens		0	31	2227
martins-crc3d-2025--sw837-3d-spheroid-kras-sirna-mem-per-plus-membrane-fraction	Colorectal cancer spheroid Mem-PER Plus membrane fraction · SW837, 3D spheroid, KRAS siRNA	Martins et al. 2025	Martins F	2025	40274922	10.1038/s41598-025-94549-2	perturbed	genetic perturbation: 3D spheroid, KRAS siRNA	genetic perturbation arm of martins-crc3d-2025; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD059013	martins_mztab_psms_by_sample.tsv | Pheno.csv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/05/PXD059013/Pheno.csv>	Thermo Mem-PER Plus membrane protein extraction from 3D spheroids; label-free LC-MS/MS, MaxQuant (mzTab reports 2.1.0.0; paper states 1.5.3.30).	Method summarized from the paper (PMC12022182) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive HF		Instrument as listed in the ProteomeXchange record PXD059013.	SW837	SW837, 3D spheroid, KRAS siRNA, Mem-PER Plus membrane fraction: a non-baseline state of martins-crc3d-2025, listed when observed in at least 2 of its 3 samples				2032	208	0.10236220472440945		Homo sapiens		0	29	2032
furan-biotin	Furan-biotin (MCF7)	Fernández et al. 2025	Fernández E	2025	41102986	10.1021/acs.jproteome.5c00597	core		Original identification and specimen caveats retained in previous_reason.	PRIDE	PXD059552	proteinGroups_CMB736.txt <https://www.ebi.ac.uk/pride/archive/projects/PXD059552> | intermediate_SDRF.sdrf	Intact subconfluent MCF-7 cells (100 mm plates) washed with ice-cold PBS and labeled on ice for 15 min with 500 uM furan-biotin probe FB1 (lysine/cysteine-reactive after oxidative furan activation with N-bromosuccinimide) or, for comparison, 500 uM EZ-Link Sulfo-NHS-biotin (Thermo); DMSO-vehicle cells as negative control; >=3 replicates. Lysis in HEPES/DOC/SDS/NP-40 buffer, 2 mg protein captured on 50 uL NeutrAvidin agarose resin (Thermo Fisher) 2.5 h at 4 C (800 ug on 30 uL for the DIA runs), washes incl. 2 M urea, on-bead reduction/alkylation and trypsin digestion; Orbitrap Fusion Lumos DDA (MaxQuant LFQ, missing values imputed for statistics) and DIA (DIA-NN MaxLFQ). Surface annotation by CIRFESS.	Method as described in the paper's Methods 2.3 (J Proteome Res 2025; full text PMC12604038).	NeutrAvidin agarose resin (Thermo Fisher Scientific; catalog number not stated)	not reported	Orbitrap Fusion Lumos			MCF7 breast adenocarcinoma cells	MCF7 (human breast adenocarcinoma) cells	proteinGroups_CMB736.txt: Majority protein IDs	Q-value ≤ 0.01 | drop rows flagged Reverse, Potential contaminant, Only identified by site	MCF-7 / BF_NBS: LFQ intensity BF_NBS_1, LFQ intensity BF_NBS_2, LFQ intensity BF_NBS_3 (min_observed 2) | MCF-7 / BF: LFQ intensity BF_1, LFQ intensity BF_2, LFQ intensity BF_3 (min_observed 2) | MCF-7 / DMSO: LFQ intensity DMSO_1, LFQ intensity DMSO_2, LFQ intensity DMSO_3 (min_observed 2) | MCF-7 / BF6_NBS: LFQ intensity BF6_NBS_1, LFQ intensity BF6_NBS_2, LFQ intensity BF6_NBS_3 (min_observed 2)	264	144	0.5454545454545454	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			264
ito-huvec-hdlec-2025	HUVEC and dermal lymphatic endothelial sulfo-NHS-SS surfaceome with internalization	Ito et al. 2025	Ito S	2025	40835443	10.1248/bpb.b25-00128	core		Intact-cell sulfo-NHS-SS-biotin labeling at 4 C of unperturbed primary endothelial cells with a no-biotin control; the cell-surface lists are the complete label-vs-control calls per cell type (they retain cytoskeletal and other non-surface hits such as ACTB, MYH9, KMT2C). Only means and SDs of n = 3 are published, so per-replicate detection cannot be checked.	none (J-STAGE supplementary PDF only)		48_b25-00128_1.pdf <https://www.jstage.jst.go.jp/article/bpb/48/8/48_b25-00128/_supplement/_download/48_b25-00128_1.pdf> | ito_table_s1.tsv	EZ-Link Sulfo-NHS-SS-Biotin 0.4 mM in ice-cold HBSS, 30 min 4 C, glycine quench; no-biotin control	Method read from: J-STAGE open-access article PDF, Materials and Methods (Internalization Assay; Identification of Cell-Surface Proteins) and Results.	streptavidin magnetic beads (Thermo Fisher)	not reported	TripleTOF 5600 (SCIEX)	SWATH-MS, Dionex Ultimate 3000 RSLCnano	Instrument as named in the paper's Methods (J-STAGE full text).	HUVEC (umbilical vein endothelial cells) and HDLEC (human dermal lymphatic endothelial cells), PromoCell primary cells	Supplementary Table 1 (supplement PDF pages 3-30): HUVEC 862 cell-surface and 254 internalized proteins; HDLEC 821 cell-surface and 290 internalized proteins (all four equal to the Results text). Cell-surface calls are label-vs-no-biotin-control peptide criteria (exclusive quantification, or mean > 10 SD of control), not annotation. Membership = listed in the cell-surface fraction of that cell type (mean intensity > 0). Internalized-fraction lists (a subset after a 37 C chase and MESNA stripping) kept as measurements only. Supplementary Table 2 (cell-type-enriched selection) not used.	ito_table_s1.tsv: uniprot_accession		HUVEC / baseline sulfo-NHS-SS-biotin cell-surface fraction: HUVEC_surface_mean (min_observed 1) | HUVEC / internalized fraction after 37 C chase and MESNA stripping (not used for membership): HUVEC_internalized_mean (min_observed 1) | HDLEC / baseline sulfo-NHS-SS-biotin cell-surface fraction: HDLEC_surface_mean (min_observed 1) | HDLEC / internalized fraction after 37 C chase and MESNA stripping (not used for membership): HDLEC_internalized_mean (min_observed 1)	948	417	0.439873417721519	0.2	Homo sapiens		0	0	948
werner-jmml-cd34-2025	JMML and healthy-donor CD34+ cells, WGA-HRP surface biotinylation	Werner et al. 2025	Werner J	2025	40268927	10.1038/s41467-025-59040-6	below_screen	11.8% of its length-corrected amount in Canonical or Likely proteins, under 25%	Intact-cell WGA-HRP labeling of unperturbed primary CD34+ cells; the deposited table is the full FragPipe identification list before any surface annotation. Healthy and JMML groups are separate cell populations, not perturbations. No no-label control was run, and donors are pooled within each group by FragPipe, so a single detection in any donor admits a protein.	PRIDE	PXD052910	combined_protein.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/02/PXD052910/combined_protein.tsv>	WGA-HRP + biotin-tyramide + H2O2 on intact CD34+ cells in PBS, NeutrAvidin agarose capture	Method as described in the paper's Methods, 'Cell surface protein labeling' and mass spectrometry sections; PRIDE sample protocol says periodate/glycan but the paper text is WGA-HRP (full text PMC12019388).	NeutrAvidin agarose (Thermo 29204)	not stated	timsTOF Pro		Instrument as listed in the ProteomeXchange record PXD052910.	Primary CD34+ cells from JMML patient blood/marrow (n = 9) and healthy-donor G-CSF-mobilised leukapheresis CD34+ cells (n = 3)	Deposited FragPipe combined_protein.tsv (4,171 protein rows, all identifications before the paper's UniProt-membrane and surface-database filters). contam_ rows dropped. FragPipe pools the replicates of each experiment group into one column, so membership = Spectral Count > 0 within the group (Control = healthy CD34+, JMML = JMML CD34+); per-donor columns are not in the deposit.	combined_protein.tsv: Protein ID	drop rows where Protein matches contam_	healthy-donor CD34+ (G-CSF mobilised) / baseline WGA-HRP surface labeled: Control Spectral Count (min_observed 1) | JMML CD34+ / baseline WGA-HRP surface labeled: JMML Spectral Count (min_observed 1)	4163	337	0.080951237088638	0.2	Homo sapiens		0	0	4163
marhelava-ball-pdx-2025	KMT2A-rearranged B-ALL PDX cells, sulfo-NHS-LC-biotin surfaceome with no-biotin controls	Marhelava et al. 2025	Marhelava K	2025	40186066	10.1038/s41375-025-02580-z	below_screen	15.2% of its length-corrected amount in Canonical or Likely proteins, under 25%	Intact-cell sulfo-NHS capture of unperturbed PDX leukemia cells, four labeling replicates per PDX with matched no-biotin controls; the deposited proteinGroups precedes the paper's GO membrane flag and per-PDX enrichment test.	PRIDE	PXD058992	proteinGroups.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/06/PXD058992/proteinGroups.txt>	EZ-Link Sulfo-NHS-LC-Biotin (Thermo 21335) on intact cells, PBS-only no-biotin control	Method read from: PRIDE PXD058992 sample processing protocol; PMC12133591 Results/Fig. 1.	NeutrAvidin agarose (Thermo 29201)	not stated	Orbitrap Exploris 480		Instrument as listed in the ProteomeXchange record PXD058992.	Six KMT2A-rearranged B-cell precursor ALL patient-derived xenografts expanded in NSG mice (spleen)	Deposited MaxQuant proteinGroups.txt (5,095 groups) before the Perseus GO membrane-term flag. Reverse, potential contaminant and only-identified-by-site rows dropped. Per PDX, membership = raw Intensity > 0 in >= 2 of 4 biotin replicates; the two non-biotinylated controls per PDX are measurements only.	proteinGroups.txt: Protein IDs	drop rows flagged Reverse, Potential contaminant, Only identified by site	KMT2A-r B-ALL PDX OBL9 / baseline sulfo-NHS-LC-biotin labeled: Intensity 08fir_OBL9biot1_b, Intensity 09fir_OBL9biot2_b, Intensity 10fir_OBL9biot3_b, Intensity 11fir_OBL9biot4_b (min_observed 2) | KMT2A-r B-ALL PDX OBL9 / non-biotinylated control (not used for membership): Intensity 06fir_OBL9NB1_b, Intensity 07fir_OBL9NB2_b (min_observed 1) | KMT2A-r B-ALL PDX OBL30 / baseline sulfo-NHS-LC-biotin labeled: Intensity 14fir_OBL30biot1, Intensity 15fir_OBL30biot2, Intensity 16fir_OBL30biot3, Intensity 17fir_OBL30biot4 (min_observed 2) | KMT2A-r B-ALL PDX OBL30 / non-biotinylated control (not used for membership): Intensity 12fir_OBL30NB1, Intensity 13fir_OBL30NB2 (min_observed 1) | KMT2A-r B-ALL PDX ALL5 / baseline sulfo-NHS-LC-biotin labeled: Intensity 20fir_ALL5biot1, Intensity 21fir_ALL5biot2, Intensity 22fir_ALL5biot3, Intensity 23fir_ALL5biot4 (min_observed 2) | KMT2A-r B-ALL PDX ALL5 / non-biotinylated control (not used for membership): Intensity 18fir_ALL5NB1, Intensity 19fir_ALL5NB2 (min_observed 1) | KMT2A-r B-ALL PDX ALL6 / baseline sulfo-NHS-LC-biotin labeled: Intensity 26fir_ALL6biot1, Intensity 27fir_ALL6biot2, Intensity 28fir_ALL6biot3, Intensity 29fir_ALL6biot4 (min_observed 2) | KMT2A-r B-ALL PDX ALL6 / non-biotinylated control (not used for membership): Intensity 24fir_ALL6NB1, Intensity 25fir_ALL6NB2 (min_observed 1) | KMT2A-r B-ALL PDX ALL7 / baseline sulfo-NHS-LC-biotin labeled: Intensity 32fir_ALL7biot1, Intensity 33fir_ALL7biot2, Intensity 34fir_ALL7biot3, Intensity 35fir_ALL7biot4 (min_observed 2) | KMT2A-r B-ALL PDX ALL7 / non-biotinylated control (not used for membership): Intensity 30fir_ALL7NB1, Intensity 31fir_ALL7NB2 (min_observed 1) | KMT2A-r B-ALL PDX ALL11 / baseline sulfo-NHS-LC-biotin labeled: Intensity 38fir_ALL11biot1, Intensity 39fir_ALL11biot2, Intensity 40fir_ALL11biot3, Intensity 41fir_ALL11biot4 (min_observed 2) | KMT2A-r B-ALL PDX ALL11 / non-biotinylated control (not used for membership): Intensity 36fir_ALL11NB1, Intensity 37fir_ALL11NB2 (min_observed 1)	4653	466	0.10015044057597249	0.2	Homo sapiens	Xenograft cells (>= 90% human); search used a human-only database, so residual mouse cells can only contribute peptides shared with or mis-assigned to human proteins.	0	0	4653
laccid-2025	LaccID CD8 T	Lee et al. 2025	Lee SY	2025	40751001	10.1038/s41589-025-01973-6	core		Intact-cell LaccID proximity labeling with a matched no-LaccID control in the same TMT plex. The deposited Spectrum Mill export precedes the authors' coverage, p-value and calibrated false-positive cutoffs.	PRIDE	PXD062870;MSV000095684	proteinProteinCentricColumnsExport.SGT.2.ssv	Genetically encoded cell-surface proximity labeling: primary human CD8+ T cells lentivirally expressing surface-displayed LaccID (an O2-dependent laccase evolved from an ancestral fungal laccase; active selectively at the plasma membrane) were labeled live with 250 uM biotin-methoxyphenol (BMP) for 2 h at 37 C, quenched with 10 mM sodium ascorbate / 5 mM Trolox; 40 million cells per sample (LaccID-only T cells for the monoculture arm used here; TCR- or CAR-expressing T cells cocultured 24 h with A375 tumor cells at 3:1 for the other arms). RIPA lysis with quenchers, azide and benzonase; capture on streptavidin magnetic beads 1 h RT; washes with RIPA, 1 M KCl, 0.1 M Na2CO3, 2 M urea; on-bead trypsin digestion, TMTpro labeling (18 samples), basic reverse-phase fractionation, Orbitrap LC-MS/MS, Spectrum Mill search. Labeling is radical-mediated (phenoxyl radical on Tyr), so proteins near the surface enzyme are tagged whether or not they are glycosylated.	Method as described in the paper's Methods 'Sample preparation for T cell proteomics' and 'On-bead trypsin digestion' (Nat Chem Biol 2025; full text PMC12643941).	streptavidin magnetic beads (vendor/catalog not stated in this paper; protocol follows their ref. 7, the Ting-lab TurboID/APEX enrichment protocol)	not reported	Orbitrap Exploris 480		Instrument as listed in the ProteomeXchange records MSV000095684 and PXD062870.	Human T-cell LaccID-only monoculture (CAR/TCR and tumor cocultures excluded)	Spectrum Mill export before the authors' coverage, p-value and calibrated cutoffs; membership = positive in both LaccID-only monoculture channels (133C, 134C) and at least 2-fold over the matched no-LaccID monoculture channels (130C, 131N), by the mean of Spectrum Mill log2 median ratios to the common reference. Human rows only (species = HUMAN; 21 bovine serum rows and 5 others dropped). The TrEMBL row A0A1W2PP10 is dropped as a duplicate of VPS35, which the table also reports under its canonical accession Q96QK1.	proteinProteinCentricColumnsExport.SGT.2.ssv: accession_number	species = HUMAN | drop rows where accession_number matches A0A1W2PP10 | keep proteins at least 2-fold above the no-LaccID control (mean of the 2 labeled versus 2 control channels); a protein the control did not detect stays	Human T cells / LaccID monoculture: TMT_133C_total, TMT_134C_total (min_observed 2) | Human T cells / no-LaccID control (not used for membership): TMT_130C_total, TMT_131N_total (min_observed 2)	1605	418	0.2604361370716511	0.2	Homo sapiens		0	1	1605
holmes-2025	Microglia WGA-HRP	Holmes et al. 2025	Holmes BB	2025	40883746	10.1186/s13024-025-00883-4	below_screen	pre-filtered list below its raised bar (35% vs 57%)	Current GO PM/cell-surface proxy is not the historical GOCC-restricted search FASTA.	PRIDE	PXD060977	control_surface_proteins.tsv	Intact iPSC-derived iTF Microglia (WTC11 background) lifted with Versene, resuspended in DPBS pH 6.5 and surface-labeled with cell-tethered WGA-HRP (0.5 uM, 5 min on ice) followed by 500 uM biotin tyramide and 1 mM H2O2 for 2 min at 37 C (Kirkemo 2022 protocol); quenched with 10 mM sodium ascorbate / 1 mM sodium pyruvate; pellets flash frozen. Lysis in 2x RIPA with protease inhibitors and sonication; biotinylated proteins captured on NeutrAvidin agarose (Thermo Scientific 29204) 1 h at 4 C, washed in RIPA, 2 M NaCl PBS and 2 M urea; on-bead digestion with the PreOmics iST kit (Trypsin + LysC); LC-MS/MS and MaxQuant LFQ. The inventory row uses the vehicle-treated arm; Abeta40/Abeta42 fibril and LPS arms are the comparisons.	Method as described in the paper's Methods 'iTF Microglia cell surface labeling' and 'Proteomic preparation' (Mol Neurodegener 2025; full text PMC12398132).	NeutrAvidin agarose beads (Thermo Scientific, Cat. 29204); WGA-HRP conjugate (preparation per Kirkemo 2022); biotin tyramide	not reported	timsTOF Pro 2		Instrument as listed in the ProteomeXchange record PXD060977.	iPSC-derived induced-transcription-factor microglia (WTC11 background)	iPSC-derived human induced-transcription-factor microglia (iTF Microglia; APOE3-homozygous WTC11 background, Coriell GM25256, with doxycycline-inducible CEBPA/CEBPB/IRF5/IRF8/MAFB/PU1)	control_surface_proteins.tsv: uniprot_accession			1096	388	0.354014598540146	0.5715530545080736	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			1096
liu-ovcar8-hydrazide-2025--atg9a-knockout-periodate-biocytin-hydrazide-labelled	OVCAR-8 ovarian carcinoma periodate/biocytin-hydrazide surface glycoproteome · ATG9A knockout	Liu et al. 2025	Liu T	2025	40595560	10.1038/s41467-025-60745-x	perturbed	genetic perturbation: ATG9A knockout, periodate/biocytin-hydrazide intact cells	genetic perturbation arm of liu-ovcar8-hydrazide-2025; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD053872	combined_protein.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/04/PXD053872/combined_protein.tsv>	1.6 mM NaIO4 20 min 4 C on intact cells, 1 mM biocytin hydrazide + 1 mM aniline, then RIPA lysis	Method as described in the paper's Methods (surface proteomics); PRIDE PXD053872 protocol; experiment_annotation.tsv maps runs to sgGAL4/sgATG9A (full text PMC12216399).	Pierce high-capacity streptavidin	not stated	timsTOF Pro 2		Instrument as listed in the ProteomeXchange record PXD053872.	OVCAR-8	OVCAR-8, ATG9A knockout, periodate/biocytin-hydrazide labeled intact cells: a non-baseline state of liu-ovcar8-hydrazide-2025, listed when observed in at least 2 of its 3 samples				1546	541	0.3499353169469599		Homo sapiens		0	0	1546
liu-ovcar8-hydrazide-2025	OVCAR-8 ovarian carcinoma periodate/biocytin-hydrazide surface glycoproteome · sgGAL4 control (baseline)	Liu et al. 2025	Liu T	2025	40595560	10.1038/s41467-025-60745-x	core		Intact-cell periodate/hydrazide glycan labeling; the sgGAL4 (non-human-target guide) control arm is an unperturbed baseline. Deposited table is the full FragPipe protein report, not annotation-selected.	PRIDE	PXD053872	combined_protein.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/04/PXD053872/combined_protein.tsv>	1.6 mM NaIO4 20 min 4 C on intact cells, 1 mM biocytin hydrazide + 1 mM aniline, then RIPA lysis	Method as described in the paper's Methods (surface proteomics); PRIDE PXD053872 protocol; experiment_annotation.tsv maps runs to sgGAL4/sgATG9A (full text PMC12216399).	Pierce high-capacity streptavidin	not stated	timsTOF Pro 2		Instrument as listed in the ProteomeXchange record PXD053872.	OVCAR-8 high-grade serous ovarian carcinoma cell line	Deposited FragPipe combined_protein.tsv for the surface experiment (1,675 protein groups; FragPipe default 1% protein FDR). Human (Organism = Homo sapiens) rows only. Membership = spectral count > 0 in >= 2 of 3 sgGAL4 control replicates. sgATG9A knockout replicates carried as measurements only. Whole_cell_combined_protein.tsv (whole-cell proteome) not used. No annotation filter.	combined_protein.tsv: Protein ID	Organism = Homo sapiens	OVCAR-8 / sgGAL4 control, periodate/biocytin-hydrazide labeled intact cells: OVCAR_8_sgGAL4_1 Spectral Count, OVCAR_8_sgGAL4_2 Spectral Count, OVCAR_8_sgGAL4_3 Spectral Count (min_observed 2) | OVCAR-8 / ATG9A knockout, periodate/biocytin-hydrazide labeled intact cells (not used for membership): OVCAR_8_sgATG9A_1 Spectral Count, OVCAR_8_sgATG9A_2 Spectral Count, OVCAR_8_sgATG9A_3 Spectral Count (min_observed 2)	1526	553	0.3623853211009174	0.2	Homo sapiens		0	0	1526
p4936-membrane-nmti-2025--100-nm-imp1088-nmt-inhibitor-18-h	P493-6 B-cell Triton X-114 membrane fraction (PXD054019) · 100 nM IMP1088 NMT inhibitor 18 h			2025			perturbed	drug, ligand or treatment: 100 nM IMP1088 NMT inhibitor 18 h	drug, ligand or treatment arm of p4936-membrane-nmti-2025; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD054019	report.pg_matrix.tsv	Triton X-114 phase partitioning (per PMID 29170741)	Method read from: PRIDE PXD054019 sample and data processing protocols; P4936_Experimental_samples.csv.	none	not applicable	timsTOF HT		Instrument as listed in the ProteomeXchange record PXD054019.	P493-6	P493-6, 100 nM IMP1088 NMT inhibitor 18 h: a non-baseline state of p4936-membrane-nmti-2025, listed when observed in at least 2 of its 4 samples				3459	422	0.12200057820179243		Homo sapiens		0	0	3459
p4936-membrane-nmti-2025	P493-6 B-cell Triton X-114 membrane fraction (PXD054019) · DMSO vehicle (baseline)			2025			comparator	cells broken open and membranes purified, so it can't show a protein faces outward	TX-114 detergent-phase partitioning enriches integral and lipid-anchored membrane proteins of all compartments after lysis, so it is complementary fractionation evidence and never votes. Same lab and protocol as shep21n-membrane-nmti-2025.	PRIDE	PXD054019	report.pg_matrix.tsv	Triton X-114 phase partitioning (per PMID 29170741)	Method read from: PRIDE PXD054019 sample and data processing protocols; P4936_Experimental_samples.csv.	none	not applicable	timsTOF HT		Instrument as listed in the ProteomeXchange record PXD054019.	P493-6 EBV-immortalized B-lymphoblastoid line with tetracycline-repressible MYC (MYC-high state)	DIA-NN results/report.pg_matrix.tsv from the deposited results.zip (3,773 protein groups; CON_ contaminant groups fail the accession check). Columns renamed by position from Windows .d paths; P4936_Experimental_samples.csv maps R1-R4 = DMSO, IMP100 R1-R4 = 100 nM IMP1088. Membership = quantity > 0 in >= 2 of 4 DMSO replicates. NMTi replicates kept as non-membership measurements. No annotation filter.	report.pg_matrix.tsv: Protein.Group		P493-6 / baseline DMSO vehicle, TX-114 detergent phase: DMSO_R1, DMSO_R2, DMSO_R3, DMSO_R4 (min_observed 2) | P493-6 / 100 nM IMP1088 NMT inhibitor 18 h (not used for membership): IMP1088_R1, IMP1088_R2, IMP1088_R3, IMP1088_R4 (min_observed 2)	3485	419	0.12022955523672883	0.2	Homo sapiens		0	0	3485
zimmerman-pdac-xenograft-2025	Pancreatic cancer xenograft plasma-membrane fraction, AP2S1 knockout series	Zimmerman et al. 2025	Zimmerman SP	2025	40050266	10.1038/s41467-025-57521-2	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Plasma-membrane protein isolation kit on xenograft tumor lysate: membrane fractionation, so a non-voting comparator. Values are imputed, which no longer holds an arm on its own (presence counted). Mouse stroma is present in the tumors but the search was human-only, so a human accession cannot be shown to be tumor-derived.	PRIDE / ProteomeXchange	PXD042404	41467_2025_57521_MOESM6_ESM.xlsx sheet Table 4 Normalized Data <https://static-content.springer.com/esm/art%3A10.1038%2Fs41467-025-57521-2/MediaObjects/41467_2025_57521_MOESM6_ESM.xlsx>	Minute Plasma Membrane Protein Isolation kit (Invent Biotechnologies) on xenograft tumor pieces; S-Trap digestion; Orbitrap Fusion Lumos + FAIMSPro DDA; Proteome Discoverer 2.5, SwissProt human; peptide-level imputation before protein summing	Method read from: PMC11885535 full text (Methods 'Mass spectrometry' and 'Proteomics data analysis'; Fig. 4a legend, n = 3 technical replicates per condition).	none	not stated	Orbitrap Fusion Lumos	FAIMSPro, DDA	Instrument as named in the paper's Methods (full text PMC11885535).	Subcutaneous pancreatic cancer xenografts in mice (CFPAC-1, PANC-1, BxPC-3); mouse stroma present but searched against human proteins only	Supplementary Data 4 (41467_2025_57521_MOESM6_ESM.xlsx, sheet 'Table 4 Normalized Data'; 6,559 protein groups x 18 columns = 3 lines x -/+ doxycycline x 3 technical replicates per condition, per the Fig. 4a legend; 30 tumors were grown). Values are imputed, so membership = presence in the table (every row passed the authors' identification filters), read from the no-doxycycline columns; doxycycline-induced knockout columns kept as measurements only. The nine spiked non-human standards in the search database (yeast ADH, rabbit phosphorylase, bovine casein and similar) are dropped by their OS= species field.	41467_2025_57521_MOESM6_ESM.xlsx: Accession	drop rows where Description matches OS=(?!Homo sapiens)	BxPC-3 xenograft / no doxycycline (sgAP2S1 not induced), membrane fraction: BXPC3_minDox Normalized, BXPC3_minDox Normalized.1, BXPC3_minDox Normalized.2 (min_observed 1; floor 0) | BxPC-3 xenograft / doxycycline-induced sgAP2S1 knockout, membrane fraction (not used for membership): BXPC3_plusDox Normalized, BXPC3_plusDox Normalized.1, BXPC3_plusDox Normalized.2 (min_observed 1; floor 0) | PANC-1 xenograft / no doxycycline (sgAP2S1 not induced), membrane fraction: PANC1_minDox Normalized, PANC1_minDox Normalized.1, PANC1_minDox Normalized.2 (min_observed 1; floor 0) | PANC-1 xenograft / doxycycline-induced sgAP2S1 knockout, membrane fraction (not used for membership): PANC1_plusDox Normalized, PANC1_plusDox Normalized.1, PANC1_plusDox Normalized.2 (min_observed 1; floor 0) | CFPAC-1 xenograft / no doxycycline (sgAP2S1 not induced), membrane fraction: CFPAC1_minDox Normalized, CFPAC1_minDox Normalized.1, CFPAC1_minDox Normalized.2 (min_observed 1; floor 0) | CFPAC-1 xenograft / doxycycline-induced sgAP2S1 knockout, membrane fraction (not used for membership): CFPAC1_plusDox Normalized, CFPAC1_plusDox Normalized.1, CFPAC1_plusDox Normalized.2 (min_observed 1; floor 0)	6540	894	0.13669724770642203	0.2	Homo sapiens		0	1	6540
shep21n-membrane-nmti-2025--50-nm-imp1088-nmt-inhibitor-18-h	SHEP21N neuroblastoma Triton X-114 membrane fraction (PXD054008) · 50 nM IMP1088 NMT inhibitor 18 h			2025			perturbed	drug, ligand or treatment: 50 nM IMP1088 NMT inhibitor 18 h	drug, ligand or treatment arm of shep21n-membrane-nmti-2025; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD054008	proteinGroups.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/07/PXD054008/proteinGroups.txt>	Triton X-114 phase partitioning (per PMID 29170741)	Method read from: PRIDE PXD054008 sample and data processing protocols; S21N_Experimental_samples.csv.	none	not applicable	Orbitrap Eclipse		Instrument as listed in the ProteomeXchange record PXD054008.	SHEP21N neuroblastoma	SHEP21N neuroblastoma, 50 nM IMP1088 NMT inhibitor 18 h: a non-baseline state of shep21n-membrane-nmti-2025, listed when observed in at least 2 of its 3 samples				3726	387	0.10386473429951691		Homo sapiens		0	39	3726
shep21n-membrane-nmti-2025	SHEP21N neuroblastoma Triton X-114 membrane fraction (PXD054008) · DMSO vehicle (baseline)			2025			comparator	cells broken open and membranes purified, so it can't show a protein faces outward	TX-114 detergent-phase partitioning enriches integral/lipid-anchored membrane proteins from all compartments after lysis, so it is complementary fractionation evidence and never votes. Adds a second neuroblastoma background (SHEP, mesenchymal/S-type) beside SH-SY5Y.	PRIDE	PXD054008	proteinGroups.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/07/PXD054008/proteinGroups.txt>	Triton X-114 phase partitioning (per PMID 29170741)	Method read from: PRIDE PXD054008 sample and data processing protocols; S21N_Experimental_samples.csv.	none	not applicable	Orbitrap Eclipse		Instrument as listed in the ProteomeXchange record PXD054008.	SHEP21N neuroblastoma cell line (SHEP subclone with tetracycline-repressible MYCN)	Deposited MaxQuant proteinGroups.txt (raw files 13-18; S21N_Experimental_samples.csv maps 13-15 = DMSO, 16-18 = 50 nM IMP1088). Rows with Reverse, Potential contaminant or Only identified by site = '+' dropped. Membership = raw 'Intensity 13/14/15' > 0 in >= 2 of 3 DMSO replicates. NMTi replicates kept as non-membership measurements. No annotation filter.	proteinGroups.txt: Protein IDs	drop rows flagged Reverse, Potential contaminant, Only identified by site	SHEP21N neuroblastoma / baseline DMSO vehicle, TX-114 detergent phase: Intensity 13, Intensity 14, Intensity 15 (min_observed 2) | SHEP21N neuroblastoma / 50 nM IMP1088 NMT inhibitor 18 h (not used for membership): Intensity 16, Intensity 17, Intensity 18 (min_observed 2)	3730	389	0.10428954423592493	0.2	Homo sapiens		0	39	3730
breyer-2025	Sensory-neuron surfaceome	Breyer et al. 2025	Breyer M	2025	40173182	10.1371/journal.pone.0320056	held	conditions are pooled in one list, with no separable baseline	pools Fabry and control donors; control-only membership can't be recovered.	supplement		control_surface_proteins.tsv	Intact iPSC-derived sensory-like neurons (six weeks matured; two 6-well plates pooled per differentiation, three differentiations per genotype) labeled in situ with sulfo-NHS-SS-biotin for 10 min at room temperature using the Pierce Cell Surface Protein Biotinylation and Isolation Kit (Thermo Fisher); washed with ice-cold TBS, scraped, lysed 30 min on ice in kit lysis buffer with protease inhibitors; biotinylated proteins bound 30 min to a NeutrAvidin-agarose spin column and eluted with 10 mM DTT; acetone precipitation, in-gel digestion, LC-MS/MS with MaxQuant LFQ. Controls: Matrigel-only wells run through the whole protocol, and (first experiment) non-biotinylated neurons pulled down on NeutrAvidin, which gave no visible protein.	Method as described in the paper's Methods 'Surface protein extraction' (PLoS One 2025; full text PMC11964241).	NeutrAvidin agarose spin columns supplied in the Pierce Cell Surface Protein Biotinylation and Isolation Kit (Thermo Fisher; kit catalog number not stated in the paper, the current kit is A44390)	not reported	Orbitrap Fusion	NanoLC-MS/MS of surfaceome samples	Instrument as named in the paper's Methods, NanoLC-MS/MS analysis (full text PMC11964241).	iPSC-derived sensory-like neurons; Fabry and control donors	iPSC-derived sensory-like neurons (Fabry + control donors)	control_surface_proteins.tsv: uniprot_accession			1371	454	0.3311451495258935	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			1371
thorup-nge	Thorup NGE arm	Thorup et al. 2025	Thorup JR	2025	41175941	10.1016/j.mcpro.2025.101437	annotation_selected	author pre-filtered to SURFY-predicted surface proteins	pre-filtered by surface annotation (annotation-selected); shown, not counted. Was provisional. provisional: threshold 81.4891%; borderline allowance 2.0%. Exact complete author-supplied SURFY universe, Table S1A; annotation selection still limits possible discoveries.	MassIVE	MSV000098694	control_surface_proteins.tsv	N-glycopeptide enrichment (NGE) on intact HEK293T cells (1e5 to 5e6 cells per sample; fresh and cryopreserved compared): cells oxidized with 1.6 mM sodium metaperiodate in PBS pH 6.5 for 15 min at 4 C, then surface aldehydes labeled with 500 uM alkoxyamine-PEG4-biotin + 5 mM 5-methoxyanthranilic acid catalyst in 1% FBS/PBS pH 6.5 for 30 min at 4 C. Pellets lysed in 8 M urea/2% SDS with Benzonase, TCEP/IAA, S-Trap trypsin + Lys-C digestion; biotinylated PEPTIDES captured on streptavidin magnetic beads (GenScript; 10 uL per 100 ug peptide) 3 h RT, washed (5 M NaCl, StimLys buffer, 50% ACN, Na2CO3 pH 11, ABC), formerly N-glycosylated peptides released with Rapid PNGase F (NEB) overnight; SDB-RPS desalting; Orbitrap Exploris 480 DIA, Spectronaut 19. Controls: labeling without NaIO4. The table used is the SURFY-filtered CSP list (Table S1B).	Method as described in the paper's Experimental Procedures 'N-glycoprotein Labeling' and 'Lysis, Digestion, and Enrichment' (Mol Cell Proteomics 2025; full text PMC12702325).	streptavidin magnetic beads (GenScript; catalog number not stated); Rapid PNGase F (New England Biolabs); alkoxyamine-PEG4-biotin and 5-methoxyanthranilic acid (Thermo Fisher)	not reported	Orbitrap Exploris 480			HEK293T embryonic-kidney-derived benchmark cells	HEK293T (human embryonic kidney) benchmark cells	control_surface_proteins.tsv: uniprot_accession			580	505	0.8706896551724138	0.8148909392479169	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			580
thorup-wgahrp	Thorup WGA-HRP arm	Thorup et al. 2025	Thorup JR	2025	41175941	10.1016/j.mcpro.2025.101437	annotation_selected	author pre-filtered to SURFY-predicted surface proteins	pre-filtered by surface annotation (annotation-selected); shown, not counted. Was provisional. provisional: threshold 81.4891%; borderline allowance 2.0%. Exact complete author-supplied SURFY universe, Table S1A; annotation selection still limits possible discoveries.	MassIVE	MSV000098694	control_surface_proteins.tsv	WGA-HRP proximity biotinylation on intact HEK293T cells (same input series and fresh/cryopreserved design as the NGE arm): cells washed in PBS pH 6.5, incubated with 0.5 uM WGA-HRP (Vector Laboratories) + 1 mM CaCl2 for 5 min on ice, then 0.5 mM biotinyl tyramide (Sigma-Aldrich) and 0.003% H2O2 for 2 min at 37 C; quenched with sodium pyruvate / sodium ascorbate / Trolox. Lysis in 1x RIPA + 1% Triton X-100 with Halt inhibitors; biotinylated PROTEINS captured on 100 uL High Capacity NeutrAvidin agarose resin (Thermo Fisher) 1 h at 4 C, washed in Bio-Spin columns (RIPA, 1 M NaCl, 50% ACN, 3 M and 6 M urea, TEAB), on-resin TCEP/IAA and overnight trypsin + Lys-C digestion; Exploris 480 DIA, Spectronaut 19. Control: labeling without WGA-HRP. Table used is the SURFY-filtered CSP list (Table S1C).	Method as described in the paper's Experimental Procedures 'Wheat Germ Agglutinin-HRP Labeling' and 'WGA-HRP Lysis, Enrichment, and Digestion' (Mol Cell Proteomics 2025; full text PMC12702325).	High Capacity NeutrAvidin agarose resin (Thermo Fisher Scientific; catalog number not stated); WGA-HRP (Vector Laboratories); biotinyl tyramide (Sigma-Aldrich)	not reported	Orbitrap Exploris 480			HEK293T embryonic-kidney-derived benchmark cells	HEK293T (human embryonic kidney) benchmark cells	control_surface_proteins.tsv: uniprot_accession			511	431	0.8434442270058709	0.8148909392479169	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			511
nicholson-gm2-2025	i3Neuron GM2 gangliosidosis models, plasma-membrane profiling	Nicholson et al. 2025	Nicholson AS	2025	40608809	10.1371/journal.pbio.3003265	held	the sample-to-condition map is unpublished	Intact-cell aminooxy-biotin PMP on human neurons, full PD protein lists, but the TMT channel-to-condition map is unpublished, so SCRM controls cannot be separated from knockdown channels; held as a pooled identification catalogue.	PRIDE	PXD064632	JD_AN_PMPtmt_0222.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/06/PXD064632/JD_AN_PMPtmt_0222.xlsx> | JD_AN_PMPtmt_0624.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2025/06/PXD064632/JD_AN_PMPtmt_0624.xlsx>	Plasma-membrane profiling: periodate/aniline-catalysed aminooxy-biotin labeling of intact neurons, streptavidin capture, TMTpro 15-plex, MultiNotch MS3 on an Orbitrap Lumos; Proteome Discoverer 2.2 (Mascot for the 14 dpi plex, Sequest HT for the 28 dpi plex).	Method summarized from the paper (PMC12251256) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion Lumos			Human iPSC-derived glutamatergic neurons (i3N dCas9 CRISPRi lines: SCRM control, HEXA, HEXB and GLB1 knockdowns)	PD protein exports JD_AN_PMPtmt_0222 (14 dpi: SCRM, dHEXA-1/2, dHEXB-1/2 x 3 replicates) and JD_AN_PMPtmt_0624 (28 dpi: SCRM, dHEXA, dGLB1). Master proteins at High protein FDR confidence; membership = grouped abundance in >= 2 of 15 channels of a plex, pooling SCRM and knockdown channels because no channel map is published (no SDRF, not in the paper or its Cambridge data deposit). WCP plexes not used.	JD_AN_PMPtmt_0222.xlsx: Accession | JD_AN_PMPtmt_0624.xlsx: Accession	Master = Master Protein | Protein FDR Confidence: Combined = High | Master = Master Protein | Protein FDR Confidence: Combined = High	i3Neurons (14 dpi) / pooled TMTpro channels: SCRM control plus CRISPRi knockdowns (channel map not published): Abundances (Grouped): 126, Abundances (Grouped): 127N, Abundances (Grouped): 127C, Abundances (Grouped): 128N, Abundances (Grouped): 128C, Abundances (Grouped): 129N, Abundances (Grouped): 129C, Abundances (Grouped): 130N, Abundances (Grouped): 130C, Abundances (Grouped): 131N, Abundances (Grouped): 131C, Abundances (Grouped): 132N, Abundances (Grouped): 132C, Abundances (Grouped): 133N, Abundances (Grouped): 133C (min_observed 2) | i3Neurons (28 dpi) / pooled TMTpro channels: SCRM control plus CRISPRi knockdowns (channel map not published): Abundances (Grouped): F1, 126, Abundances (Grouped): F1, 127N, Abundances (Grouped): F1, 127C, Abundances (Grouped): F1, 128N, Abundances (Grouped): F1, 128C, Abundances (Grouped): F1, 129N, Abundances (Grouped): F1, 129C, Abundances (Grouped): F1, 130N, Abundances (Grouped): F1, 130C, Abundances (Grouped): F1, 131N, Abundances (Grouped): F1, 131C, Abundances (Grouped): F1, 132N, Abundances (Grouped): F1, 132C, Abundances (Grouped): F1, 133N, Abundances (Grouped): F1, 133C (min_observed 2)	2716	723	0.26620029455081	0.2	Homo sapiens		3	0	2716
cd38-myeloma-2024	CD38 myeloma adapted CSC	Choudhry et al. 2024	Choudhry P	2024	40453054	10.1016/j.bneo.2024.100025	core		Original identification and specimen caveats retained in previous_reason.	PRIDE	PXD027594	proteinGroups.txt in CD38i_vs_scri_txt.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2021/07/PXD027594/CD38i_vs_scri_txt.zip> | summary.txt	Adapted N-glycoprotein cell surface capture (Wiita-lab 'antigen escape profiling' protocol, as in Ferguson et al. 2022): intact myeloma cells (AMO1, RPMI-8226, KMS-12 family; CD38-knockdown vs control) oxidized with sodium periodate and labeled with biocytin hydrazide on live cells, RIPA lysis, biotinylated glycoproteins captured on NeutrAvidin agarose, on-bead trypsin digestion of the whole captured glycoprotein (protein-level, no PNGase F step); Q Exactive Plus, MaxQuant LFQ. The main text gives only this summary and refers to the supplemental Methods and to Ferguson 2022 for details.	Method as described in the paper's Methods (one-paragraph summary) + PRIDE protocol text (Blood Neoplasia 2024; full text PMC12093323).	NeutrAvidin agarose (per PRIDE PXD sampleProcessingProtocol and Ferguson 2022; catalog number not stated)	not reported	Q Exactive Plus			Multiple-myeloma lines AMO1, RPMI-8226 and K12/KMS-12 family	Human multiple myeloma cell lines: AMO1, RPMI-8226, and K12 (referred to as K12/KMS-12 in study materials; KMS-12-family myeloma line). All samples human-derived cell lines; no mouse/primary tissue in this file pair.	proteinGroups.txt: Majority protein IDs	Q-value ≤ 0.01 | drop rows flagged Reverse, Potential contaminant, Only identified by site	AMO1 / scrambled control: LFQ intensity AMO1_Scri_1, LFQ intensity AMO1_Scri_2, LFQ intensity AMO1_Scri_3 (min_observed 2) | JTC / scrambled control: LFQ intensity JTC_Scri_1, LFQ intensity JTC_Scri_2, LFQ intensity JTC_Scri_3 (min_observed 2) | K12 / scrambled control: LFQ intensity K12_Scri_1, LFQ intensity K12_Scri_2, LFQ intensity K12_Scri_3 (min_observed 2) | RPMI / scrambled control: LFQ intensity RPMI_Scri_1, LFQ intensity RPMI_Scri_2, LFQ intensity RPMI_Scri_3 (min_observed 2)	3122	457	0.14638052530429213	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			3098
khan-chordoma-2024	Chordoma organelle fractionation, plasma-membrane fraction	Khan et al. 2024	Khan S	2024	38454495	10.1186/s40478-024-01751-w	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Organelle-resolved fractionation; the PM fraction is a density fraction, not a surface label, so it is complementary evidence. Only chordoma (notochordal bone tumor of the axial skeleton) membrane data in the compendium.	MassIVE	MSV000089171	khan_tableS1_plasma_membrane_log2.tsv	Differential ultracentrifugation of four chordoma lines into six subcellular fractions (cytosol, microsome, mitochondria, nuclear pellet, nuclear soluble, plasma membrane), three replicates each; label-free LC-MS/MS (MaxQuant). Only the plasma-membrane fraction is used.	Method summarized from the paper (PMC10921702) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion		Instrument as listed in the ProteomeXchange record MSV000089171.	Chordoma cell lines U-CH17P, U-CH17M, U-CH17S and U-CH11R	Supplementary Table S1 'Total proteins' (7,688 protein groups), plasma-membrane fraction log2 intensities only; membership = observed (non-placeholder) in >= 2 of 3 PM replicates of a line. The other five fractions and the authors' PM-vs-nonPM statistics are not used. Annotation columns (CD, SPC, SURFY, etc.) are carried but never filter rows.	khan_tableS1_plasma_membrane_log2.tsv: Peptide.IDs		chordoma line U-CH17P / baseline plasma-membrane fraction (ultracentrifugation): U-CH17P_Plasma_Membrane_1, U-CH17P_Plasma_Membrane_2, U-CH17P_Plasma_Membrane_3 (min_observed 2) | chordoma line U-CH17M / baseline plasma-membrane fraction (ultracentrifugation): U-CH17M_Plasma_Membrane_1, U-CH17M_Plasma_Membrane_2, U-CH17M_Plasma_Membrane_3 (min_observed 2) | chordoma line U-CH17S / baseline plasma-membrane fraction (ultracentrifugation): U-CH17S_Plasma_Membrane_1, U-CH17S_Plasma_Membrane_2, U-CH17S_Plasma_Membrane_3 (min_observed 2) | chordoma line U-CH11R / baseline plasma-membrane fraction (ultracentrifugation): U-CH11R_Plasma_Membrane_1, U-CH11R_Plasma_Membrane_2, U-CH11R_Plasma_Membrane_3 (min_observed 2)	4109	681	0.1657337551715746	0.2	Homo sapiens		0	0	4109
mooney-ewing-2024	Ewing sarcoma PDX/CDX surface-enriched proteome	Mooney et al. 2024	Mooney B	2024	37812652	10.1158/1078-0432.CCR-23-2187	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Density-gradient plasma-membrane enrichment of whole PDX tumors; no reagent marks proteins on intact cells. Retained as osteosarcoma expression-in-membrane-fraction evidence.	PRIDE	PXD043375	mouse_human_Proteins.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD043375/28122_U54_Sorensen_EwingSurfaceEnriched_mouse_human_Proteins.txt> | tmt_layout_surface.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD043375/tmt_layout_surface.txt>	Tumor homogenisation in sucrose, 60% sucrose cushion at 100,000 g, then density-gradient ultracentrifugation to enrich plasma membrane; TMT11, Orbitrap Eclipse; Proteome Discoverer 2.4 searched against human+mouse SwissProt (2021-07-16).	Method summarized from the paper (PMC10905525) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Eclipse			19 Ewing sarcoma patient- and cell-line-derived xenografts (human tumor in mouse hosts)	Surface-enriched (density-gradient) fraction of 19 EwS PDX/CDX, human+mouse search; SuperMix and pooled internal standard channels excluded from membership	mouse_human_Proteins.txt: Accession	Master = IsMasterProtein | Protein FDR Confidence Combined = High | Contaminant = false	CT1 / baseline PDX surface-enriched fraction: Abundance F21 126 Sample, Abundance F23 129C Sample (min_observed 1) | ES1 / baseline PDX surface-enriched fraction: Abundance F21 127N Sample, Abundance F22 127N Sample (min_observed 1) | CHLA10 / baseline PDX surface-enriched fraction: Abundance F21 127C Sample, Abundance F24 129N Sample (min_observed 1) | ES6 / baseline PDX surface-enriched fraction: Abundance F21 128N Sample, Abundance F21 129N Sample (min_observed 1) | EW9 / baseline PDX surface-enriched fraction: Abundance F21 128C Sample, Abundance F24 128C Sample (min_observed 1) | EW8 / baseline PDX surface-enriched fraction: Abundance F21 129C Sample, Abundance F23 128C Sample (min_observed 1) | ES8 / baseline PDX surface-enriched fraction: Abundance F21 130N Sample, Abundance F25 129C Sample (min_observed 1) | CHLA258 / baseline PDX surface-enriched fraction: Abundance F22 126 Sample, Abundance F24 129C Sample (min_observed 1) | EW5 / baseline PDX surface-enriched fraction: Abundance F22 127C Sample, Abundance F24 126 Sample (min_observed 1) | ES4 / baseline PDX surface-enriched fraction: Abundance F22 128N Sample, Abundance F23 127C Sample (min_observed 1) | TC7 / baseline PDX surface-enriched fraction: Abundance F22 128C Sample, Abundance F25 127N Sample (min_observed 1) | NCHEWS1 / baseline PDX surface-enriched fraction: Abundance F22 129N Sample, Abundance F24 127C Sample (min_observed 1) | SKNEP / baseline PDX surface-enriched fraction: Abundance F22 129C Sample, Abundance F25 126 Sample (min_observed 1) | TC32 / baseline PDX surface-enriched fraction: Abundance F23 126 Sample, Abundance F25 128C Sample (min_observed 1) | EW12 / baseline PDX surface-enriched fraction: Abundance F23 127N Sample, Abundance F25 128N Sample (min_observed 1) | EW13 / baseline PDX surface-enriched fraction: Abundance F23 128N Sample, Abundance F25 130N Sample (min_observed 1) | ES3 / baseline PDX surface-enriched fraction: Abundance F23 129N Sample, Abundance F24 128N Sample (min_observed 1) | ES7 / baseline PDX surface-enriched fraction: Abundance F23 130N Sample, Abundance F25 129N Sample (min_observed 1) | ES2 / baseline PDX surface-enriched fraction: Abundance F24 127N Sample, Abundance F25 127C Sample (min_observed 1)	2504	493	0.1968849840255591	0.2	Homo sapiens	Human+mouse search: only human master proteins are retained; a human master protein can still carry shared human/mouse peptides, so a human accession is not proof of species-unique evidence.	601	0	2504
gasf-wang-2024	GASF recovered probe-bearing human peptides	Wang et al. 2024	Wang T	2024	38589397	10.1038/s41467-024-47033-w	provisional	built from a partial author export (peptide-level table)	Earlier-stage iProX export: used unique K(*) peptides, peptide quality >=20, exact peptide/accession match to at least one non-transferred feature with probe-adduct mass within 15 ppm. No GO filter. SILAC dose/label-swap union; not a no-probe contrast. Site localization and extracellular orientation are not revalidated; author search FDR inherited.	supplement	PXD042888	gasf-search.zip <https://download.iprox.cn/IPX0006545000/IPX0006545001/search_.A-Za-z0-9.zip>	Global Analysis of Surface Functionality (GASF): living HeLa cells labeled with 100 uM OPA-S-S-alkyne (ortho-phthalaldehyde lysine-reactive warhead, disulfide linker, terminal alkyne) in PBS for minutes at room temperature (1 to 10 min titrated; viability checked by WST-1); the disulfide is cleaved in the reducing cytosol so any probe that enters cells is not captured. Cells lysed, lysates clicked (CuAAC with BTTP ligand) to azide-PEG4-biotin (Click Chemistry Tools), labeled proteins enriched on NeutrAvidin beads (Thermo Fisher), on-bead trypsin digestion and reductive release of probe-modified peptides; LC-MS/MS with isotopic ratio (R value) quantification of lysine reactivity, 2,639 surface lysines quantified. HEK293T profiled qualitatively only.	Method as described in the paper's Methods 'Materials', labeling and click sections (Nat Commun 2024; full text PMC11001985).	NeutrAvidin agarose beads (Thermo Fisher Scientific; catalog number not stated); azide-PEG4-biotin (Click Chemistry Tools)	not reported	timsTOF Pro		Instrument as listed in the ProteomeXchange record PXD042888.	HeLa cervical adenocarcinoma cells	HeLa cervical adenocarcinoma cells				1354	303	0.22378138847858198	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			1354
vaish-hek293tshaving-2024--1-h-alpha-synuclein-amyloid-challenge	HEK293T intact-cell trypsin shaving · 1 h alpha-synuclein amyloid challenge	Vaish et al. 2024	Vaish H	2024	38973669	10.1007/s12038-024-00457-4	perturbed	drug, ligand or treatment: 1 h alpha-synuclein amyloid challenge	drug, ligand or treatment arm of vaish-hek293tshaving-2024; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD046280	proteinGroups.txt	membrane shaving of intact cells (protease release of surface-exposed domains), from the PRIDE PXD046280 sample processing protocol and the abstract	Method read from: PRIDE PXD046280 protocols; MaxQuant summary.txt experiment names (BR1-3 ctrl / 5 min / 30 min / 1 hr); Europe PMC abstract. Paper full text (Springer J Biosci) not opened.	none	not stated	Q Exactive HF; Q Exactive		Instrument as listed in the ProteomeXchange record PXD046280.	HEK293T	HEK293T, 1 h alpha-synuclein amyloid challenge: a non-baseline state of vaish-hek293tshaving-2024, listed when observed in at least 2 of its 3 samples				1375	76	0.05527272727272727		Homo sapiens		0	19	1374
vaish-hek293tshaving-2024--30-min-alpha-synuclein-amyloid-challenge	HEK293T intact-cell trypsin shaving · 30 min alpha-synuclein amyloid challenge	Vaish et al. 2024	Vaish H	2024	38973669	10.1007/s12038-024-00457-4	perturbed	drug, ligand or treatment: 30 min alpha-synuclein amyloid challenge	drug, ligand or treatment arm of vaish-hek293tshaving-2024; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD046280	proteinGroups.txt	membrane shaving of intact cells (protease release of surface-exposed domains), from the PRIDE PXD046280 sample processing protocol and the abstract	Method read from: PRIDE PXD046280 protocols; MaxQuant summary.txt experiment names (BR1-3 ctrl / 5 min / 30 min / 1 hr); Europe PMC abstract. Paper full text (Springer J Biosci) not opened.	none	not stated	Q Exactive HF; Q Exactive		Instrument as listed in the ProteomeXchange record PXD046280.	HEK293T	HEK293T, 30 min alpha-synuclein amyloid challenge: a non-baseline state of vaish-hek293tshaving-2024, listed when observed in at least 2 of its 3 samples				1384	81	0.05852601156069364		Homo sapiens		0	22	1383
vaish-hek293tshaving-2024--5-min-alpha-synuclein-amyloid-challenge	HEK293T intact-cell trypsin shaving · 5 min alpha-synuclein amyloid challenge	Vaish et al. 2024	Vaish H	2024	38973669	10.1007/s12038-024-00457-4	perturbed	drug, ligand or treatment: 5 min alpha-synuclein amyloid challenge	drug, ligand or treatment arm of vaish-hek293tshaving-2024; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD046280	proteinGroups.txt	membrane shaving of intact cells (protease release of surface-exposed domains), from the PRIDE PXD046280 sample processing protocol and the abstract	Method read from: PRIDE PXD046280 protocols; MaxQuant summary.txt experiment names (BR1-3 ctrl / 5 min / 30 min / 1 hr); Europe PMC abstract. Paper full text (Springer J Biosci) not opened.	none	not stated	Q Exactive HF; Q Exactive		Instrument as listed in the ProteomeXchange record PXD046280.	HEK293T	HEK293T, 5 min alpha-synuclein amyloid challenge: a non-baseline state of vaish-hek293tshaving-2024, listed when observed in at least 2 of its 3 samples				1342	79	0.05886736214605067		Homo sapiens		0	21	1342
vaish-hek293tshaving-2024	HEK293T intact-cell trypsin shaving · untreated (baseline)	Vaish et al. 2024	Vaish H	2024	38973669	10.1007/s12038-024-00457-4	held	the shaved fraction is mostly intracellular proteins	Protease shaving of intact cells would carry surface-accessibility evidence (as lazar-skbr3shaving-2022), and the untreated control replicates give a per-replicate baseline, but the shaved fraction is dominated by intracellular proteins: only 53 of 1,326 accessions (4.0%) fall in the canonical+likely surfaceome, far below other intact-cell inputs, which points to release from damaged or lysed cells. There is no no-protease control to separate shaved from leaked protein, and the paper's shaving conditions (protease, duration, viability check) could not be read because the Springer full text is not open. Hold until those are confirmed.	PRIDE	PXD046280	proteinGroups.txt	membrane shaving of intact cells (protease release of surface-exposed domains), from the PRIDE PXD046280 sample processing protocol and the abstract	Method read from: PRIDE PXD046280 protocols; MaxQuant summary.txt experiment names (BR1-3 ctrl / 5 min / 30 min / 1 hr); Europe PMC abstract. Paper full text (Springer J Biosci) not opened.	none	not stated	Q Exactive HF; Q Exactive		Instrument as listed in the ProteomeXchange record PXD046280.	HEK293T human embryonic kidney cell line	PRIDE PXD046280 shaving.search.zip member proteinGroups.txt (MaxQuant 2.0.3.0; 12 runs = BR1-3 x ctrl / 5 min / 30 min / 1 hr). Rows flagged Only identified by site, Reverse or Potential contaminant removed. Membership = razor+unique peptides > 0 in >= 2 of the 3 untreated control ('ctrl') replicates. Amyloid-challenged time points kept as measurements only. The separate '6days' membrane-fraction experiment (6days.search.zip, PFF vs ctrl membrane fractions) is not used.	proteinGroups.txt: Majority protein IDs	drop rows flagged Only identified by site, Reverse, Potential contaminant	HEK293T / untreated control (no alpha-synuclein amyloid), intact-cell trypsin shaving: Razor + unique peptides BR1 ctrl, Razor + unique peptides BR2 ctrl, Razor + unique peptides BR3 ctrl (min_observed 2) | HEK293T / 5 min alpha-synuclein amyloid challenge (not used for membership): Razor + unique peptides BR1 5 min, Razor + unique peptides BR2 5 min, Razor + unique peptides BR3 5 min (min_observed 2) | HEK293T / 30 min alpha-synuclein amyloid challenge (not used for membership): Razor + unique peptides BR1 30 min, Razor + unique peptides BR2 30 min, Razor + unique peptides BR3 30 min (min_observed 2) | HEK293T / 1 h alpha-synuclein amyloid challenge (not used for membership): Razor + unique peptides BR1 1 hr, Razor + unique peptides BR2 1 hr, Razor + unique peptides BR3 1 hr (min_observed 2)	1292	80	0.06191950464396285	0.2	Homo sapiens		0	19	1292
hunter-hfff-pmp-2024	HFFF-TERT fibroblast plasma membrane profiling, control vs LMAN2L knockdown/knockout	Hunter et al. 2024	Hunter LM	2024	38687323	10.1099/jgv.0.001980	core		Weekes-lab PMP (same lab and method as Soh, Depierreux and Fielding) on uninfected fibroblasts; membership uses only non-targeting siRNA and CRISPR-control channels. Overlaps the Depierreux fibroblast entry in cell type, so the two are not independent cell types.	PRIDE	PXD050878	jgv-105-01980-s001.xlsx sheet Table S2_Data in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11083459/supplementaryFiles>	Plasma membrane profiling (Weekes lab): live-cell sodium periodate/aniline oxidation of sialic-acid glycans and aminooxy-biotin labeling, streptavidin enrichment, on-bead trypsin digestion, TMT multiplexing, LC-MS3. One TMTpro plex (Table S1): control siRNA x3, LMAN2L siRNA x3, CRISPR control x2, LMAN2L bulk CRISPR KO; uninfected cells.	Method summarized from the paper (PMC11083459) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion Lumos		Instrument as listed in the ProteomeXchange record PXD050878.	HFFF-TERT telomerase-immortalized human foetal foreskin fibroblasts (uninfected)	Supplementary Table S2 'Table S2_Data' sheet (1,555 proteins, contaminants and reverse hits already removed by the authors; header on row 5). The 'PM filter' column is an annotation and is not applied. Membership = control siRNA channel > 0 (any of 3) or CRISPR control channel > 0 (any of 2). LMAN2L siRNA and LMAN2L CRISPR-KO channels kept as non-membership measurements.	jgv-105-01980-s001.xlsx: Protein Id		HFFF-TERT fibroblasts / baseline non-targeting siRNA control, PMP: Control siRNA #1, Control siRNA #2, Control siRNA #3 (min_observed 1) | HFFF-TERT fibroblasts / baseline CRISPR control, PMP: CRISPR control #1, CRISPR control #2 (min_observed 1) | HFFF-TERT fibroblasts / LMAN2L siRNA knockdown (not used for membership): LMAN2L siRNA #1, LMAN2L siRNA #2, LMAN2L siRNA #3 (min_observed 1) | HFFF-TERT fibroblasts / LMAN2L CRISPR knockout (not used for membership): LMAN2L bulk CRISPR KO (min_observed 1)	1535	566	0.36872964169381106	0.2	Homo sapiens		0	0	1535
udeshi-2024	Human primary dendritic cells	Udeshi et al. 2024	Udeshi ND	2024	39132986	10.4049/jimmunol.2400089	below_screen	12% Canonical or Likely proteins, under 20%	Original identification and specimen caveats retained in previous_reason.			NIHMS2013126-supplement-2.xlsx sheet Tab 1 <https://pubmed.ncbi.nlm.nih.gov/39132986/>	Primary human BDCA-1/3+ conventional dendritic cells (magnetic negative selection from fresh buffy coats; ~7.4e6 cells per group; unstimulated vs 18 h Pam3CSK4) labeled intact with 250 ug/mL Sulfo-NHS-SS-biotin (Thermo Fisher A39258) in PBS for 10 min at room temperature, quenched with ice-cold Tris-buffered saline; snap frozen. Lysis in high-SDS RIPA diluted to 0.2% SDS; biotinylated proteins captured on 300 uL Streptavidin magnetic beads (Thermo Fisher 88817) overnight at 4 C; washes with 0.2% SDS RIPA, 1 M KCl, 0.1 M Na2CO3, 2 M urea; on-bead trypsin digestion (2 M urea/Tris, 0.4 ug trypsin); TMT-multiplexed LC-MS/MS of pooled donors. Non-biotinylated cells carried through the pulldown as the specificity control (silver stain / streptavidin blot).	Method as described in the paper's Materials and Methods 'Cell-surface biotinylation', 'Cell lysis', 'Streptavidin bead enrichment' (J Immunol 2024; full text PMC11408084).	Pierce Streptavidin Magnetic Beads (Thermo Fisher 88817); Sulfo-NHS-SS-biotin (Thermo Fisher A39258). The only lot number in the paper is for human AB serum (Sigma H3667, Lot SLCF0444), not for beads	beads: not reported	Exploris (model not specified, ThermoFisher)	DDA, HCD MS/MS r=15,000; 154-min gradient	Instrument as named in the paper's Methods LC-MS/MS (full text PMC11408084).	Primary unstimulated dendritic cells; pooled-donor TMT experiments	Unstimulated dendritic cells: both labeled/control log2 TMT ratios >0, >=2 unique peptides; no annotation exclusion list	NIHMS2013126-supplement-2.xlsx: UniProtID	Species = HUMAN | NumPepsUnique ≥ 2	dendritic cells / unstimulated versus unlabeled unstimulated: TMT_130:127, nostim1:nostimctrl, TMT_129:127, nostim2:nostimctrl (min_observed 2)	2623	311	0.11856652687762105	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			2583
hypoxic-gbm-2024	Hypoxic GBM TS-MAP	de Oliveira et al. 2024	de Oliveira KG	2024	38414005	10.1186/s40478-024-01740-z	below_screen	15% Canonical or Likely proteins, under 20%	Original identification and specimen caveats retained in previous_reason.	PRIDE	PXD048880	control_surface_proteins.tsv	Tumor surfaceome mapping (TS-MAP): subconfluent primary GBM cultures (U3034, U3017, U3047, AB1) and U87MG, 24 h normoxia or 1% O2 hypoxia, chilled on ice to block internalization, washed in Mg/Ca-PBS pH 8 and labeled with 1 mg/mL membrane-impermeable EZ-Link Sulfo-NHS-SS-biotin (Thermo Scientific 21331) for 30 min on ice, quenched with 0.1 M glycine. (Endocytome arm: biotinylated cells returned to 37 C for 2 h, residual surface biotin stripped with 200 mM MesNa, free biotin blocked with streptavidin.) RIPA lysis, lysate diluted and filtered, biotinylated proteins bound to a 1 mL HiTrap Streptavidin HP column (GE Healthcare 17-5112-01) on a peristaltic pump, washed on an HPLC system with Triton/RIPA/1 M NaCl buffers and eluted with 150 mM MesNa; LC-MS/MS (Proteome Discoverer export). The inventory uses the normoxic surfaceome arm.	Method as described in the paper's Methods 'Biotinylation of surface and endocytosed proteins (TS-MAP)' and 'High-affinity chromatography enrichment' (Acta Neuropathol Commun 2024; full text PMC10898066).	HiTrap Streptavidin HP 1 mL column (GE Healthcare / Cytiva 17-5112-01); EZ-Link Sulfo-NHS-SS-biotin (Thermo 21331)	not reported	Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD048880.	Glioblastoma cultures U3034, U3017, U3047 and AB1; exact AB1 line identity unresolved	Patient-derived (primary) human GBM cultures with HGCC-style names U3034, U3017, U3047 (Lund/Uppsala Human Glioblastoma Cell Culture resource nomenclature), plus a fourth culture labeled 'AB1' in the source files. AB1's precise identity (a fourth patient-derived line vs. the established line U87MG mentioned elsewhere in the paper's abstract/validation work) could not be confirmed from the retrieved PRIDE project metadata or the Search-export filenames -- flagged for the user rather than guessed.	control_surface_proteins.tsv: uniprot_accession			4430	677	0.1528216704288939	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			4424
lasa-2024	LASA AML atlas	Bordeleau et al. 2024	Bordeleau ME	2024	38838225	10.1016/j.celrep.2024.114260	held	the input sample and baseline can't be identified in the published table	Primary AML cohort and subgroup/normal-cell comparisons are biological contrasts. Publisher methods describe cell-surface biotinylation; current table has imputed abundance and unresolved input/sample selection relative to SPAT. No verified matched omission-control protein filter rescues this <20% input.	PRIDE	PXD043772	mmc3.xlsx sheet Mass spect data per specimen <https://pubmed.ncbi.nlm.nih.gov/38838225/> | lasa-proteinGroups.txt <https://www.ebi.ac.uk/pride/archive/projects/PXD043772>	Cell Surface Biotinylation (CSB; adapted from published methods) on intact primary human AML cells: 100 Leucegene specimens selected for >=60 million available cells and high blast proportion; cells chilled on ice, rinsed in PBS pH 7.4 with 1 mM CaCl2 / 0.5 mM MgCl2, incubated with 1 mg/mL Sulfo-NHS-LC-biotin (membrane-impermeant, NON-cleavable) for 1 h at 4 C, quenched with 100 mM glycine 10 min at 4 C; lysed 30 min in Surfaceome Lysis Buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris pH 7.6, 5 mM iodoacetamide, cOmplete inhibitors, Na3VO4, PMSF), debris and nuclei removed at 2,800 g and 16,000 g; biotinylated proteins captured on high-capacity streptavidin agarose resin (Thermo Fisher Scientific) 2 h at 4 C, washed with SLB, PBS/0.5% SDS, PBS/0.5% SDS/100 mM DTT, 6 M urea/Tris with 50 mM iodoacetamide, urea, PBS and water; on-bead trypsin digestion (Sigma proteomics grade, 4 ug overnight + 4 ug 4 h, 37 C); biotinylation efficiency checked by streptavidin-HRP blot. Easy-nLC 1200 + Q Exactive HF DDA (56 min gradient); MaxQuant 1.6.2.10 against UniProt human (March 2022); proteins with <2 unique peptides and CRAPome contaminants (>=5% of control runs) removed; DEP with vsn normalization and knn imputation (imputed values are not counted as detections in our table). Surface annotation by SPAT v3.3.	Method read from: Cell Reports 2024 (PMID 38838225) STAR Methods 'Analysis of primary human AML cells by cell surface proteomics', read from the author's PDF (2026-10-29); PRIDE PXD043772 for the MS/data-processing text.	high-capacity streptavidin agarose resin (Thermo Fisher Scientific; catalog number not stated); Sulfo-NHS-LC-biotin (vendor not stated)	not reported	Q Exactive HF			Primary AML specimens, Leucegene cohort (100 specimens); baseline mapping unresolved	All per-specimen rows after peptide/missingness filtering, VSN and KNN imputation; upstream raw-run sample mapping unresolved	mmc3.xlsx: uniprot ID			3064	484	0.15796344647519583	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			3053
hamilton-nb-2024	Neuroblastoma cell-line plasma-membrane proteome	Hamilton et al. 2024	Hamilton AK	2024	39454577	10.1016/j.ccell.2024.10.003	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Ultracentrifugation plasma-membrane enrichment of cultured cells; no surface label. The 12 CDX/PDX xenografts were searched against human only, so host proteins cannot be excluded and that table is not used.	PRIDE	PXD047474	proteinGroups_CellLine.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2024/10/PXD047474/proteinGroups_CellLine.txt>	Sucrose cushion plus 37-42.8% step gradient (100,000 g, 18 h) plasma-membrane enrichment; label-free MaxQuant iBAQ against human UniProt.	Method summarized from the paper (PMC11560519) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD047474.	9 neuroblastoma cell lines (SK-N-BE(2)C, NB-EBc1, IMR-5, Kelly, NB-LS, NGP, NLF, SK-N-AS, SH-SY5Y)	Cell-line plasma-membrane fractions; xenograft table excluded because its human-only search cannot separate mouse host proteins	proteinGroups_CellLine.txt: Majority.protein.IDs	Q.value ≤ 0.01 | drop rows flagged Reverse, Potential.contaminant, Only.identified.by.site	SK-N-Be2c / baseline plasma-membrane fraction: iBAQ.SK-N-Be2c_1-1, iBAQ.SK-N-Be2c_1-2, iBAQ.SK-N-Be2c_1-3, iBAQ.SK-N-Be2c_2-1, iBAQ.SK-N-Be2c_2-2, iBAQ.SK-N-Be2c_2-3 (min_observed 2) | NB-EBC1 / baseline plasma-membrane fraction: iBAQ.NB-EBC1_1-1, iBAQ.NB-EBC1_1-2, iBAQ.NB-EBC1_1-3, iBAQ.NB-EBC1_2-1, iBAQ.NB-EBC1_2-2, iBAQ.NB-EBC1_2-3 (min_observed 2) | IMR5 / baseline plasma-membrane fraction: iBAQ.IMR5_1_1, iBAQ.IMR5_1-1, iBAQ.IMR5_1-2, iBAQ.IMR5_2-1, iBAQ.IMR5_2-2 (min_observed 2) | Kelly / baseline plasma-membrane fraction: iBAQ.Kelly_1-1, iBAQ.Kelly_1-2, iBAQ.Kelly_1-3, iBAQ.Kelly_2-1, iBAQ.Kelly_2-2, iBAQ.Kelly_2-3 (min_observed 2) | NBLS / baseline plasma-membrane fraction: iBAQ.NBLS_1-1, iBAQ.NBLS_1-2, iBAQ.NBLS_1-3, iBAQ.NBLS_2-1, iBAQ.NBLS_2-2, iBAQ.NBLS_2-3 (min_observed 2) | NGP / baseline plasma-membrane fraction: iBAQ.NGP_1-1, iBAQ.NGP_1-2, iBAQ.NGP_1-3, iBAQ.NGP_2-1, iBAQ.NGP_2-2, iBAQ.NGP_2-3 (min_observed 2) | NLF / baseline plasma-membrane fraction: iBAQ.NLF_1-1, iBAQ.NLF_1-2, iBAQ.NLF_1-3, iBAQ.NLF_2-1, iBAQ.NLF_2-2, iBAQ.NLF_2-3, iBAQ.NLF_3-1, iBAQ.NLF_3-2, iBAQ.NLF_3-3 (min_observed 2) | SKNAS / baseline plasma-membrane fraction: iBAQ.SKNAS_1-1, iBAQ.SKNAS_1-2, iBAQ.SKNAS_1-3, iBAQ.SKNAS_2-1, iBAQ.SKNAS_2-2, iBAQ.SKNAS_2-3 (min_observed 2) | SH-SY5Y / baseline plasma-membrane fraction: iBAQ.SH-SY5Y_1-1, iBAQ.SH-SY5Y_1-2, iBAQ.SH-SY5Y_2-1, iBAQ.SH-SY5Y_2-2, iBAQ.SH-SY5Y_3-1, iBAQ.SH-SY5Y_3-2 (min_observed 2)	6904	942	0.13644264194669756	0.2	Homo sapiens		0	0	6904
herhaus-8988t-2024--irgq-knockout-biotin-labelled	PaTu 8988T pancreatic cancer sulfo-NHS-LC surfaceome with no-biotin control · IRGQ knockout	Herhaus et al. 2024	Herhaus L	2024	39481378	10.1016/j.cell.2024.09.048	perturbed	genetic perturbation: IRGQ knockout	genetic perturbation arm of herhaus-8988t-2024; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD045259	proteinGroups_8988t_membraneOME.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2024/11/PXD045259/proteinGroups_8988t_membraneOME.txt>	Sulfo-NHS-LC-Biotin 1 mM on intact cells, 30 min at 4 C, Tris quench (PRIDE sample processing protocol)	Method read from: PRIDE PXD045259 sample processing protocol; paper full text not open access in Europe PMC.	streptavidin (per PRIDE protocol)	not stated	Q Exactive HF		Instrument as listed in the ProteomeXchange record PXD045259.	PaTu 8988T	PaTu 8988T, IRGQ knockout biotin labeled: a non-baseline state of herhaus-8988t-2024, listed when observed in at least 2 of its 3 samples				1164	251	0.21563573883161513		Homo sapiens		0	0	1164
herhaus-8988t-2024	PaTu 8988T pancreatic cancer sulfo-NHS-LC surfaceome with no-biotin control · IRGQ wild-type (baseline)	Herhaus et al. 2024	Herhaus L	2024	39481378	10.1016/j.cell.2024.09.048	core		Intact-cell sulfo-NHS capture with matched no-biotin controls; the deposited proteinGroups is the full MaxQuant output before any annotation. WT is the unperturbed baseline; IRGQ KO is a genetic perturbation.	PRIDE	PXD045259	proteinGroups_8988t_membraneOME.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2024/11/PXD045259/proteinGroups_8988t_membraneOME.txt>	Sulfo-NHS-LC-Biotin 1 mM on intact cells, 30 min at 4 C, Tris quench (PRIDE sample processing protocol)	Method read from: PRIDE PXD045259 sample processing protocol; paper full text not open access in Europe PMC.	streptavidin (per PRIDE protocol)	not stated	Q Exactive HF		Instrument as listed in the ProteomeXchange record PXD045259.	PaTu 8988T pancreatic ductal adenocarcinoma cell line	PRIDE proteinGroups_8988t_membraneOME.txt (MaxQuant). Reverse, Potential contaminant and Only identified by site rows removed. Membership = raw Intensity > 0 in >= 2 of 3 WT_Biotin replicates. WT no-biotin, IRGQ KO biotin and KO no-biotin samples kept as measurements only.	proteinGroups_8988t_membraneOME.txt: Majority protein IDs	drop rows flagged Reverse, Potential contaminant, Only identified by site	PaTu 8988T / IRGQ wild-type sulfo-NHS-LC-biotin labeled: Intensity WT_Biotin_01, Intensity WT_Biotin_02, Intensity WT_Biotin_03 (min_observed 2) | PaTu 8988T / IRGQ wild-type no-biotin control (not used for membership): Intensity WT__01, Intensity WT__02, Intensity WT__03 (min_observed 2) | PaTu 8988T / IRGQ knockout biotin labeled (not used for membership): Intensity KO_Biotin_01, Intensity KO_Biotin_02, Intensity KO_Biotin_03 (min_observed 2) | PaTu 8988T / IRGQ knockout no-biotin control (not used for membership): Intensity KO__01, Intensity KO__02, Intensity KO__03 (min_observed 2)	1178	254	0.21561969439728354	0.2	Homo sapiens		0	0	1178
deng-2024	Senescence surfaceome	Deng et al. 2024	Deng Y	2024	39228130	10.1111/acel.14312	annotation_selected	author pre-filtered to membrane- or surface-annotated proteins	pre-filtered by surface annotation (annotation-selected-and-imputed); shown, not counted. Was below_adjusted_screen. below_adjusted_screen: threshold 43.7072%; borderline allowance 2.0%. Current GO surface/extracellular proxy; historical annotation version and imputation are not reconstructed.	ProteomeXchange/jPOST	PXD048921;JPST002467	control_surface_proteins.tsv	Intact cells (~2e7 per sample; NHLF and HUVEC primary human cells, plus mouse MEF/astrocytes excluded here) washed in ice-cold DPBS with Ca/Mg (pH 8) and labeled with 0.5 mg/mL Sulfo-NHS-SS-Biotin (Thermo Fisher #21331) for 30 min at 4 C; quenched with 0.1 M glycine 30 min at 4 C; lysed in 50 mM HEPES / 150 mM NaCl / 1 mM EDTA / 1.5% SDS; biotinylated proteins captured on streptavidin magnetic beads (Thermo Fisher #65601, Dynabeads MyOne Streptavidin C1) overnight at 4 C, washed four times, eluted by boiling in 2% SDS / 0.1 M DTT; FASP trypsin digestion, label-free quantitative LC-MS/MS. Proliferating vs senescent/quiescent conditions compared; no no-biotin control described in the main text.	Method as described in the paper's Methods 2.8 'Cell surface protein extraction' (Aging Cell 2024; full text PMC11634743).	Dynabeads MyOne Streptavidin C1 (Thermo Fisher #65601); EZ-Link Sulfo-NHS-SS-Biotin (#21331)	not reported	Orbitrap Exploris 480		Instrument as listed in the ProteomeXchange record PXD048921.	Normal human lung fibroblasts (NHLF) and umbilical-vein endothelial cells (HUVEC)	Two human primary cell types: normal human lung fibroblasts (NHLF, Lonza #CC-2512) and human umbilical vein endothelial cells (HUVEC, Lonza #C2517A). (The study additionally profiles mouse MEF and astrocytes (AST) - those mouse conditions are EXCLUDED from this extraction.)	control_surface_proteins.tsv: uniprot_accession			966	224	0.2318840579710145	0.43707207734365944	Homo sapiens	Paper includes mouse data; only the documented human cell/column subset is retained.			966
xu-thp1-trafficking-2024	THP-1 metabolic azido-sugar surface N-glycoproteome · DMSO control, experiment 1 (baseline)	Xu et al. 2024	Xu X	2024	38593903	10.1016/j.mcpro.2024.100761	core		Surface glycans are tagged on intact cells (membrane-impermeable DBCO-sulfo-biotin after metabolic GalNAz incorporation) and N-glycopeptides are released by PNGase F, so membership rests on surface-tagged glycosites. TMT: control-channel intensities are quantification within a plex identified from all channels, so membership is the quantified list rather than a per-channel identification; same Wu-lab cell type as xu-thp1-surface-2026 (different chemistry, monocytes rather than macrophages).	PRIDE	PXD048888	mmc2.xlsx sheet Sheet1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11087972/supplementaryFiles> | mmc2.xlsx sheet Sheet2 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11087972/supplementaryFiles>	Ac4GalNAz 100 uM for 48 h during inhibitor treatment, then DBCO-sulfo-biotin (membrane impermeable) click on washed live cells; glycopeptides enriched after digestion; PNGase F/18O site tagging	Method as described in the paper's Experimental Procedures 'Cell Culture, Metabolic Labeling, and Surface Glycoprotein Tagging Using Click Chemistry', 'Enrichment of Glycopeptides', 'TMT Labeling'.	high-capacity NeutrAvidin agarose (Thermo)	not reported	LTQ Orbitrap Elite	DDA Top15 after high-pH fractionation	Instrument as named in the paper's Methods LC-MS/MS (full text PMC11087972).	THP-1 monocytic leukemia cells (undifferentiated)	mmc2 Supplemental Table S1A and S1B (TMT reporter intensities of 396 surface N-glycoproteins quantified in both biological-duplicate experiments, one plex each). Membership = reporter intensity > 0 in both DMSO-control channels (129C, 130C) of an experiment. Thapsigargin, tunicamycin and castanospermine+kifunensine channels kept as measurements only. Table S2 (pooled-channel identification lists, 492/485 proteins, 580 union) not used because identification pools treated and control cells.	mmc2.xlsx: UniProt_ID | mmc2.xlsx: UniProt_ID		THP-1 monocytes / DMSO control, experiment 1: Control 1 (129C), Control 2 (130C) (min_observed 2) | THP-1 monocytes / thapsigargin 100 nM, experiment 1 (not used for membership): Tg 1 (126), Tg 2 (127N) (min_observed 2) | THP-1 monocytes / tunicamycin 1 ug/ml, experiment 1 (not used for membership): TM 1 (127C), TM 2 (128N) (min_observed 2) | THP-1 monocytes / castanospermine + kifunensine, experiment 1 (not used for membership): Cas_Kif 1(128C), Cas_Kif 2 (129N) (min_observed 2) | THP-1 monocytes / DMSO control, experiment 2: Control 1 (129C), Control 2 (130C) (min_observed 2) | THP-1 monocytes / thapsigargin 100 nM, experiment 2 (not used for membership): Tg 1 (126), Tg 2 (127N) (min_observed 2) | THP-1 monocytes / tunicamycin 1 ug/ml, experiment 2 (not used for membership): TM 1 (127C), TM 2 (128N) (min_observed 2) | THP-1 monocytes / castanospermine + kifunensine, experiment 2 (not used for membership): Cas_Kif 1(128C), Cas_Kif 2 (129N) (min_observed 2)	397	283	0.7128463476070529	0.2	Homo sapiens		0	0	397
xu-thp1-trafficking-2024--castanospermine-kifunensine-experiment-1	THP-1 metabolic azido-sugar surface N-glycoproteome · castanospermine + kifunensine, experiment 1	Xu et al. 2024	Xu X	2024	38593903	10.1016/j.mcpro.2024.100761	perturbed	drug, ligand or treatment: castanospermine + kifunensine, experiment 1	drug, ligand or treatment arm of xu-thp1-trafficking-2024; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD048888	mmc2.xlsx sheet Sheet1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11087972/supplementaryFiles> | mmc2.xlsx sheet Sheet2 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11087972/supplementaryFiles>	Ac4GalNAz 100 uM for 48 h during inhibitor treatment, then DBCO-sulfo-biotin (membrane impermeable) click on washed live cells; glycopeptides enriched after digestion; PNGase F/18O site tagging	Method as described in the paper's Experimental Procedures 'Cell Culture, Metabolic Labeling, and Surface Glycoprotein Tagging Using Click Chemistry', 'Enrichment of Glycopeptides', 'TMT Labeling'.	high-capacity NeutrAvidin agarose (Thermo)	not reported	LTQ Orbitrap Elite	DDA Top15 after high-pH fractionation	Instrument as named in the paper's Methods LC-MS/MS (full text PMC11087972).	THP-1 monocytes	THP-1 monocytes, castanospermine + kifunensine, experiment 1: a non-baseline state of xu-thp1-trafficking-2024, listed when observed in at least 2 of its 2 samples				396	282	0.7121212121212122		Homo sapiens		0	0	396
xu-thp1-trafficking-2024--castanospermine-kifunensine-experiment-2	THP-1 metabolic azido-sugar surface N-glycoproteome · castanospermine + kifunensine, experiment 2	Xu et al. 2024	Xu X	2024	38593903	10.1016/j.mcpro.2024.100761	perturbed	drug, ligand or treatment: castanospermine + kifunensine, experiment 2	drug, ligand or treatment arm of xu-thp1-trafficking-2024; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD048888	mmc2.xlsx sheet Sheet1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11087972/supplementaryFiles> | mmc2.xlsx sheet Sheet2 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11087972/supplementaryFiles>	Ac4GalNAz 100 uM for 48 h during inhibitor treatment, then DBCO-sulfo-biotin (membrane impermeable) click on washed live cells; glycopeptides enriched after digestion; PNGase F/18O site tagging	Method as described in the paper's Experimental Procedures 'Cell Culture, Metabolic Labeling, and Surface Glycoprotein Tagging Using Click Chemistry', 'Enrichment of Glycopeptides', 'TMT Labeling'.	high-capacity NeutrAvidin agarose (Thermo)	not reported	LTQ Orbitrap Elite	DDA Top15 after high-pH fractionation	Instrument as named in the paper's Methods LC-MS/MS (full text PMC11087972).	THP-1 monocytes	THP-1 monocytes, castanospermine + kifunensine, experiment 2: a non-baseline state of xu-thp1-trafficking-2024, listed when observed in at least 2 of its 2 samples				396	283	0.7146464646464646		Homo sapiens		0	0	396
xu-thp1-trafficking-2024--thapsigargin-100-nm-experiment-1	THP-1 metabolic azido-sugar surface N-glycoproteome · thapsigargin 100 nM, experiment 1	Xu et al. 2024	Xu X	2024	38593903	10.1016/j.mcpro.2024.100761	perturbed	drug, ligand or treatment: thapsigargin 100 nM, experiment 1	drug, ligand or treatment arm of xu-thp1-trafficking-2024; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD048888	mmc2.xlsx sheet Sheet1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11087972/supplementaryFiles> | mmc2.xlsx sheet Sheet2 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11087972/supplementaryFiles>	Ac4GalNAz 100 uM for 48 h during inhibitor treatment, then DBCO-sulfo-biotin (membrane impermeable) click on washed live cells; glycopeptides enriched after digestion; PNGase F/18O site tagging	Method as described in the paper's Experimental Procedures 'Cell Culture, Metabolic Labeling, and Surface Glycoprotein Tagging Using Click Chemistry', 'Enrichment of Glycopeptides', 'TMT Labeling'.	high-capacity NeutrAvidin agarose (Thermo)	not reported	LTQ Orbitrap Elite	DDA Top15 after high-pH fractionation	Instrument as named in the paper's Methods LC-MS/MS (full text PMC11087972).	THP-1 monocytes	THP-1 monocytes, thapsigargin 100 nM, experiment 1: a non-baseline state of xu-thp1-trafficking-2024, listed when observed in at least 2 of its 2 samples				396	282	0.7121212121212122		Homo sapiens		0	0	396
xu-thp1-trafficking-2024--thapsigargin-100-nm-experiment-2	THP-1 metabolic azido-sugar surface N-glycoproteome · thapsigargin 100 nM, experiment 2	Xu et al. 2024	Xu X	2024	38593903	10.1016/j.mcpro.2024.100761	perturbed	drug, ligand or treatment: thapsigargin 100 nM, experiment 2	drug, ligand or treatment arm of xu-thp1-trafficking-2024; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD048888	mmc2.xlsx sheet Sheet1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11087972/supplementaryFiles> | mmc2.xlsx sheet Sheet2 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11087972/supplementaryFiles>	Ac4GalNAz 100 uM for 48 h during inhibitor treatment, then DBCO-sulfo-biotin (membrane impermeable) click on washed live cells; glycopeptides enriched after digestion; PNGase F/18O site tagging	Method as described in the paper's Experimental Procedures 'Cell Culture, Metabolic Labeling, and Surface Glycoprotein Tagging Using Click Chemistry', 'Enrichment of Glycopeptides', 'TMT Labeling'.	high-capacity NeutrAvidin agarose (Thermo)	not reported	LTQ Orbitrap Elite	DDA Top15 after high-pH fractionation	Instrument as named in the paper's Methods LC-MS/MS (full text PMC11087972).	THP-1 monocytes	THP-1 monocytes, thapsigargin 100 nM, experiment 2: a non-baseline state of xu-thp1-trafficking-2024, listed when observed in at least 2 of its 2 samples				394	281	0.7131979695431472		Homo sapiens		0	0	394
xu-thp1-trafficking-2024--tunicamycin-1-ug-ml-experiment-1	THP-1 metabolic azido-sugar surface N-glycoproteome · tunicamycin 1 ug/ml, experiment 1	Xu et al. 2024	Xu X	2024	38593903	10.1016/j.mcpro.2024.100761	perturbed	drug, ligand or treatment: tunicamycin 1 ug/ml, experiment 1	drug, ligand or treatment arm of xu-thp1-trafficking-2024; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD048888	mmc2.xlsx sheet Sheet1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11087972/supplementaryFiles> | mmc2.xlsx sheet Sheet2 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11087972/supplementaryFiles>	Ac4GalNAz 100 uM for 48 h during inhibitor treatment, then DBCO-sulfo-biotin (membrane impermeable) click on washed live cells; glycopeptides enriched after digestion; PNGase F/18O site tagging	Method as described in the paper's Experimental Procedures 'Cell Culture, Metabolic Labeling, and Surface Glycoprotein Tagging Using Click Chemistry', 'Enrichment of Glycopeptides', 'TMT Labeling'.	high-capacity NeutrAvidin agarose (Thermo)	not reported	LTQ Orbitrap Elite	DDA Top15 after high-pH fractionation	Instrument as named in the paper's Methods LC-MS/MS (full text PMC11087972).	THP-1 monocytes	THP-1 monocytes, tunicamycin 1 ug/ml, experiment 1: a non-baseline state of xu-thp1-trafficking-2024, listed when observed in at least 2 of its 2 samples				384	274	0.7135416666666666		Homo sapiens		0	0	384
xu-thp1-trafficking-2024--tunicamycin-1-ug-ml-experiment-2	THP-1 metabolic azido-sugar surface N-glycoproteome · tunicamycin 1 ug/ml, experiment 2	Xu et al. 2024	Xu X	2024	38593903	10.1016/j.mcpro.2024.100761	perturbed	drug, ligand or treatment: tunicamycin 1 ug/ml, experiment 2	drug, ligand or treatment arm of xu-thp1-trafficking-2024; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD048888	mmc2.xlsx sheet Sheet1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11087972/supplementaryFiles> | mmc2.xlsx sheet Sheet2 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11087972/supplementaryFiles>	Ac4GalNAz 100 uM for 48 h during inhibitor treatment, then DBCO-sulfo-biotin (membrane impermeable) click on washed live cells; glycopeptides enriched after digestion; PNGase F/18O site tagging	Method as described in the paper's Experimental Procedures 'Cell Culture, Metabolic Labeling, and Surface Glycoprotein Tagging Using Click Chemistry', 'Enrichment of Glycopeptides', 'TMT Labeling'.	high-capacity NeutrAvidin agarose (Thermo)	not reported	LTQ Orbitrap Elite	DDA Top15 after high-pH fractionation	Instrument as named in the paper's Methods LC-MS/MS (full text PMC11087972).	THP-1 monocytes	THP-1 monocytes, tunicamycin 1 ug/ml, experiment 2: a non-baseline state of xu-thp1-trafficking-2024, listed when observed in at least 2 of its 2 samples				386	277	0.7176165803108808		Homo sapiens		0	0	386
reeves-2024	Trophoblast APEX	Reeves et al. 2024	Reeves AE	2024	39289808	10.1021/acschembio.4c00443	comparator	labeling reaches the inner side of the membrane	No-APEX2 controls and >=10-fold enrichment precede biological CTB/STB comparisons alongside GO/SCL membrane selection. Full text explicitly reports inner-leaflet labeling (about 25% of membrane-filtered proteins). Exclude from extracellular discovery; retain as membrane-proximity diagnostic.	PRIDE	PXD055086	control_surface_proteins.tsv	Cell-surface engineering / APEX2 proximity labeling on live BeWo cells (cytotrophoblast state, and forskolin-induced syncytiotrophoblast state): GGGYC-tagged cholesterol inserted into the plasma membrane, then APEX2-LPETG conjugated to it by engineered sortase A (eSrtA); cells incubated with biotin phenol (5 min, optimized to favor membrane over soluble proteins) and H2O2 to generate biotin-phenoxyl radicals that tag proximal surface proteins (labeling radius ~20 nm, so some inner-leaflet proteins are also tagged). Negative control: identical treatment without APEX2-LPETG. Lysis, streptavidin-bead enrichment, on-bead trypsin digestion, TMT multiplexing, LC-MS/MS; three experimental replicates; proteins called at >10-fold enrichment over the no-APEX2 control, then filtered by UniProt GO/subcellular-location plasma-membrane terms. Reagent-level details (bead product, cell numbers, H2O2 time) are in the Supplemental Information (Document S1), not the main text.	Method as described in the paper's Results 'Mass spectrometry-based proteomics of the dynamic BeWo plasma membrane proteome' and Figure 1D/2A legends (ACS Chem Biol 2024; full text PMC11863573).	streptavidin beads (product in Supplemental Information; not stated in main text)	not reported	Orbitrap Fusion Lumos		Instrument as listed in the ProteomeXchange records PXD052032 and PXD055086.	BeWo placental choriocarcinoma/trophoblast model; cytotrophoblast versus syncytiotrophoblast differentiation	BeWo (ATCC) human choriocarcinoma trophoblast cell line, forskolin-induced differentiation model: cytotrophoblast (CTB)-like state (vehicle/DMSO) vs syncytiotrophoblast (STB)-like state (100 uM forskolin, for MS proteomics; daily dosing for 48 or 72 h per the general protocol -- SI methods do not pin down which duration was used for the specific 30-sample MS proteomics batch)	control_surface_proteins.tsv: uniprot_accession			287	109	0.3797909407665505	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			287
tuomivaara-u2os-slapshot-2024	U2OS SLAPSHOT soluble-APEX2 surface labeling	Tuomivaara et al. 2024	Tuomivaara ST	2024	39210032	10.1038/s42003-024-06729-x	below_screen	10.2% of its length-corrected amount in Canonical or Likely proteins, under 25%	Intact-cell peroxidase labeling with an exogenous enzyme, five replicates, each control-subtracted against a matched non-labeled sample. Expect lower surface overlap than CSC: the authors report many intracellular/EV-associated proteins (Supplementary Data 2) and SLAPSHOT tags Tyr/Trp rather than glycans.	PRIDE	PXD041387	42003_2024_6729_MOESM4_ESM.xlsx sheet Suppl. Data 1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11362511/supplementaryFiles>	soluble His-APEX2 + biotin-XX-tyramide + H2O2 on intact cells	Method as described in the paper's Methods 'SLAPSHOT and CSC labeling of U2OS cells for proteomics', 'Proteomics data analysis'; Results Fig. 2a; Supplementary Data 1 caption.	streptavidin (type not restated in the U2OS proteomics section)	not stated	Q Exactive		Instrument as listed in the ProteomeXchange record PXD041387.	U2OS osteosarcoma cell line	Supplementary Data 1 (3,731 protein groups; MaxQuant reverse, contaminant, only-by-site and all-zero rows removed by the authors). iBAQ values per replicate after the authors subtracted the paired non-labeled control (zero = not detected; no imputation). Membership = SLAPSHOT iBAQ > 0 in >= 2 of 5 replicates. The other method's columns are kept as measurements only. Localization annotation columns carried, never used to select rows. Supplementary Data 3 (Jurkat TMT time course, imputed) not used.	42003_2024_6729_MOESM4_ESM.xlsx: ID		U2OS / baseline intact-cell SLAPSHOT labeling, iBAQ after subtracting the paired non-labeled control: iBAQ SLAPSHOT 1, iBAQ SLAPSHOT 2, iBAQ SLAPSHOT 3, iBAQ SLAPSHOT 4, iBAQ SLAPSHOT 5 (min_observed 2) | U2OS / CSC labeling of the same replicate sets (not used for membership): iBAQ CSC 1, iBAQ CSC 2, iBAQ CSC 3, iBAQ CSC 4, iBAQ CSC 5 (min_observed 2)	2902	245	0.08442453480358374	0.2	Homo sapiens		0	2	2902
tuomivaara-u2os-csc-2024	U2OS periodate/biocytin-hydrazide surface glycoprotein capture	Tuomivaara et al. 2024	Tuomivaara ST	2024	39210032	10.1038/s42003-024-06729-x	core		Intact-cell periodate/hydrazide glycoprotein capture (protein-level, no PNGase F glycopeptide release, hence glycoprotein-capture), five replicates, each control-subtracted against a matched non-labeled sample. Run side by side with the SLAPSHOT arm on the same cells.	PRIDE	PXD041387	42003_2024_6729_MOESM4_ESM.xlsx sheet Suppl. Data 1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11362511/supplementaryFiles>	NaIO4 1.6 mM then biocytin hydrazide 10 uM + aniline on intact cells, protein-level capture	Method as described in the paper's Methods 'SLAPSHOT and CSC labeling of U2OS cells for proteomics', 'Proteomics data analysis'; Results Fig. 2a; Supplementary Data 1 caption.	streptavidin (type not restated in the U2OS proteomics section)	not stated	Q Exactive		Instrument as listed in the ProteomeXchange record PXD041387.	U2OS osteosarcoma cell line	Supplementary Data 1 (3,731 protein groups; MaxQuant reverse, contaminant, only-by-site and all-zero rows removed by the authors). iBAQ values per replicate after the authors subtracted the paired non-labeled control (zero = not detected; no imputation). Membership = CSC iBAQ > 0 in >= 2 of 5 replicates. The other method's columns are kept as measurements only. Localization annotation columns carried, never used to select rows. Supplementary Data 3 (Jurkat TMT time course, imputed) not used.	42003_2024_6729_MOESM4_ESM.xlsx: ID		U2OS / baseline intact-cell CSC labeling, iBAQ after subtracting the paired non-labeled control: iBAQ CSC 1, iBAQ CSC 2, iBAQ CSC 3, iBAQ CSC 4, iBAQ CSC 5 (min_observed 2) | U2OS / SLAPSHOT labeling of the same replicate sets (not used for membership): iBAQ SLAPSHOT 1, iBAQ SLAPSHOT 2, iBAQ SLAPSHOT 3, iBAQ SLAPSHOT 4, iBAQ SLAPSHOT 5 (min_observed 2)	1161	330	0.2842377260981912	0.2	Homo sapiens		0	1	1161
yin-u937-pm-itraq-2024	U937 and HIV-1-latent U1 monocytic plasma-membrane fraction, iTRAQ 8-plex	Yin et al. 2024	Yin L	2024	38750478	10.1186/s12953-024-00230-3	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis-then-fractionation plasma-membrane kit, so complementary by family policy. U937 is the uninfected parental baseline; U1 carries integrated HIV-1 and is a perturbed arm.	iProX	PXD037308;IPX0005164000	yin_pm_itraq_proteins.tsv	Abcam Plasma Membrane Protein Extraction Kit ab65400, iTRAQ 8-plex	Method as described in the paper's Methods ('PM enrichment', 'iTRAQ label', 'Protein identification and quantification') (full text PMC11095035).	none	not stated	TripleTOF 5600		Instrument as listed in the ProteomeXchange record PXD037308.	U937 histiocytic lymphoma / monocytic cell line (and its HIV-1-latent subclone U1)	iProX ProteinPilot ProteinSummary.txt for injections 2-1-01 and 2-1-02 (3,612 and 3,716 rows). Reversed decoys dropped; ProteinPilot Unused >= 1.3 (95% protein confidence) per injection: 2,804 and 2,796 targets (paper's 1% global FDR: 2,767 and 2,748); union across injections 3,020 accessions. Membership = U937 channel ratios (117-119:121) present in >= 2 of 3. U1 (HIV-1-latent) channels kept as measurements only. iTRAQ identification is pooled across all channels, so per-line membership rests on reporter-ratio presence.	yin_pm_itraq_proteins.tsv: Accession		U937 / baseline uninfected U937 plasma-membrane fraction: 117:121, 118:121, 119:121 (min_observed 2) | U1 (HIV-1-latent U937 subclone) / HIV-1 latently infected (not used for membership): 114:121, 115:121, 116:121 (min_observed 2)	2975	444	0.1492436974789916	0.2	Homo sapiens		0	0	2975
veneer-2024	Veneer microscale CSC	Berg Luecke et al. 2024	Berg Luecke L	2024	38412263	10.1021/acs.jproteome.3c00800	core		Original identification and specimen caveats retained in previous_reason.	MassIVE	MSV000093424;MSV000093894	pr3c00800_si_002.xlsx sheet Table S7 <https://pubmed.ncbi.nlm.nih.gov/38412263/>	Microscale cell surface capture (uCSC; Gundry-lab glycan-directed CSC) on intact human RPMI 1788 B cells, ~15 million cells per sample: periodate oxidation of surface glycans on live cells, biocytin hydrazide labeling, lysis, streptavidin capture and PNGase F (New England Biolabs) release of formerly N-glycosylated peptides, as in their uCSC protocol (Berg Luecke et al.); four replicates with PNGase F release and two biotinylated-but-no-PNGase F replicates as a specificity comparison. Dionex UltiMate 3000 RSLC + Orbitrap Exploris 480; searched with Proteome Discoverer 2.4 and tiered by the Veneer tool (high/medium/low/zero evidence tiers). The inventory table is the untreated all-tier Veneer export. Labeling, bead and wash details are in the paper's Supplemental Methods, not the main text.	Method as described in the paper's Methods 'Microscale Cell Surface Capture Analysis of B Cells' (J Proteome Res 2024; full text PMC11301670).	per the uCSC protocol the paper cites (CellSurfer, Berg Luecke 2023): Streptavidin MagBeads (GenScript L00424), peptide-level capture, PNGase F (NEB) release; exact product for this experiment is stated only in the Supplemental Methods	not reported	Orbitrap Exploris 480			B-cell glycocapture control experiment; untreated all-tier export	Untreated control, all four assignment tiers; noPNG-only identifications excluded	pr3c00800_si_002.xlsx: Protein accessions	keep rows where any of Control: High surface protein assignment tier, Control: Medium surface protein assignment tier, Control: Low surface protein assignment tier, Control: Zero surface protein assignment tier = 1		889	399	0.44881889763779526	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			889
tremblay-dcsc-2023	A549, OVCAR3 and U87MG direct cell surface capture	Tremblay et al. 2023	Tremblay TL	2023	37680365	10.1016/j.mex.2023.102349	core		Intact-cell periodate oxidation with direct hydrazide capture and PNGase F release: a CSC-style N-glycopeptide readout of unperturbed cultures. One sample per line, no no-oxidation control in the table, so specificity rests on the glycopeptide (deamidated sequon) requirement.	none found (supplementary table only)		mmc1.xlsx sheet A549 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC10480300/supplementaryFiles> | mmc1.xlsx sheet OVCAR3 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC10480300/supplementaryFiles> | mmc1.xlsx sheet U87MG in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC10480300/supplementaryFiles>	periodate oxidation of intact cells, direct hydrazide-bead capture, PNGase F glycopeptide release (D-CSC)	Method read from: PMC10480300 main text 'Oxidation of cell surface proteins' and 'Method validation'.	hydrazide gel beads	not stated	Thermo Scientific QE-HX	Written as QE-HX in the method validation (A549, OVCAR3, U87MG), nanoLC-MS; likely Q Exactive HF-X but only the abbreviation is stated	Instrument as named in the paper's Method validation (full text PMC10480300).	A549 lung adenocarcinoma, OVCAR3 ovarian adenocarcinoma and U87MG glioblastoma cell lines	Supplementary Table 1 (mmc1.xlsx), one sheet per line (A549 2,193; OVCAR3 2,310; U87MG 2,331 FragPipe glycopeptide rows, each with a single 'Protein ID'). Every listed glycopeptide (FragPipe-filtered, spectral count >= 1) counts; membership = protein has >= 1 glycopeptide row in that line. No annotation filter was applied to the table (the paper's CSPA/SURFY comparison is separate).	mmc1.xlsx: Protein ID | mmc1.xlsx: Protein ID | mmc1.xlsx: Protein ID		A549 / baseline D-CSC (periodate on intact cells, hydrazide bead capture): Spectral Count (min_observed 1) | OVCAR3 / baseline D-CSC (periodate on intact cells, hydrazide bead capture): Spectral Count (min_observed 1) | U87MG / baseline D-CSC (periodate on intact cells, hydrazide bead capture): Spectral Count (min_observed 1)	730	584	0.8	0.2	Homo sapiens		0	0	730
cellsurfer-2023	CellSurfer cardiac	Luecke et al. 2023	Luecke LB	2023	36950336	10.1038/s44161-022-00200-y	annotation_selected	author pre-filtered to transmembrane or signal-peptide proteins	pre-filtered by surface annotation (prediction-selected); shown, not counted. Was provisional. provisional: threshold 47.0851%; borderline allowance 2.0%. TM/signal/lipid proxy does not reproduce CIRFESS/SPC and all SCM gates.	MassIVE	MSV000088624	control_surface_proteins.tsv	Microscale Cell Surface Capture (uCSC, CellSurfer 'Prepare' module) on intact primary adult human cardiac cells (cardiomyocytes, cardiac fibroblasts, microvascular endothelial and coronary artery smooth-muscle cells isolated from donor hearts; 250,000 to 10 million cells): all steps on ice; cells oxidized with 1 mM sodium metaperiodate in PBS/0.1% FBS pH 6.0 for 15 min, quenched with 2 mM sodium sulfite, labeled with 10 mM biocytin hydrazide + 50 mM 2-(aminomethyl)imidazole catalyst for 60 min at 4 C. Total lysis by VialTweeter sonication in ammonium bicarbonate/Invitrosol/ACN, TCEP/IAA, trypsin digestion; 135 to 1,289 ug peptide boiled in SDS/Tween binding buffer and captured 1 h on 100 uL Streptavidin MagBeads (GenScript L00424) on an automated liquid handler; washes with 2% SDS, high-salt Tween, Na2CO3 and ABC; formerly N-glycosylated peptides released with PNGase F overnight; SP2 cleanup; LC-MS/MS with Veneer tiering by deamidated-sequon evidence. Bead binding capacity checked by the AVIDITY assay.	Method as described in the paper's Methods 'uCSC workflow' (Nat Cardiovasc Res 2023; full text PMC10030153).	Streptavidin MagBeads (GenScript L00424); biocytin hydrazide	not reported (bead capacity is QC'd per batch by the AVIDITY assay instead)	Q Exactive; Orbitrap Fusion Lumos; Orbitrap Exploris 480		Instrument as listed in the ProteomeXchange record MSV000088624.	Adult donor-heart cardiomyocytes, fibroblasts, microvascular endothelial and coronary smooth-muscle cells	Primary adult human heart cells isolated from donor hearts: four cardiac cell populations — cardiomyocytes, cardiac fibroblasts, cardiac microvascular endothelial cells, and coronary artery smooth muscle cells (reference/baseline surfaceome). Separate arms profiled failing vs non-failing cardiomyocytes, hPSC-derived cardiac derivatives, and a human B-cell line (method validation).	control_surface_proteins.tsv: uniprot_accession			1144	685	0.5987762237762237	0.47085130205355774	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			1140
calligaris-chs-2023	Chondrosarcoma SUSPECS surfaceome	Calligaris et al. 2023	Calligaris M	2023	37388246	10.3389/fmolb.2023.1162504	held	conditions are pooled in one list, with no separable baseline	Live-cell metabolic glycan labeling with a membrane-impermeable click reagent. The published list pools control and ADAM15-knockdown cells, so a baseline list is not separable (same rule as leung-2019 and kalxdorf-2017). Localisation columns in the sheet are descriptive, not a filter.	PRIDE	PXD042402	Table1.XLSX sheet SUSPECS in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC10304831/supplementaryFiles>	SUSPECS: ManNAz metabolic labeling of sialoglycans, live-cell sulfo-DBCO-biotin click at 4 C, streptavidin pulldown, MaxQuant LFQ.	Method summarized from the paper (PMC10304831) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive		Instrument as listed in the ProteomeXchange record PXD042402.	SW1353 (HTB-94) chondrosarcoma cells	Table 1 SUSPECS sheet, all proteins identified by SUSPECS; pooled across control and ADAM15-knockdown siRNA conditions	Table1.XLSX: Majority Protein Ids			814	418	0.5135135135135135	0.2	Homo sapiens		0	0	814
cyssurf-yan	Cys-Surf (Yan)	Yan et al. 2023	Yan T	2023	38155636	10.1021/jacsau.3c00707	core		Original identification and specimen caveats retained in previous_reason.	PRIDE	PXD042403	control_surface_proteins.tsv	Cys-Surf two-stage enrichment on live Jurkat cells (plus primary CD4+/CD8+ T cells and HEK293T for other experiments): cysteines first capped in situ with iodoacetamide-alkyne, then glycan-directed cell surface capture (CSC) on intact cells (sodium periodate oxidation, 1 mM aminooxy-biotin saturating label), lysis, SP3 protein cleanup (Sera-Mag beads, EtOH washes, 0.2% SDS elution), capture of biotinylated glycoproteins on 50 uL Pierce streptavidin agarose 2 h RT, washes, on-bead reduction/alkylation and trypsin digestion; released peptides clicked (CuAAC) to biotin-azide and the IAA-labeled cysteine peptides enriched a second time on NeutrAvidin resin; LC-MS/MS with isotopic (light/heavy) ratios for oxidation state and ligandability. PNGase F check: ~53% of CSC peptides carried deamidated sequons, ~93% of those on annotated surface proteins. The inventory uses the baseline Jurkat identification list.	Method as described in the paper's Methods 'Proteomic Sample Preparation for Cys-Surf' (protein- and peptide-level enrichment) (JACS Au 2023; full text PMC10751780).	Pierce Streptavidin Agarose (Thermo; catalog number not stated in main text, reagents in Table S6); NeutrAvidin agarose for the second (peptide) enrichment; Sera-Mag SpeedBeads for SP3	not reported (FBS lot 214B17 is the only lot given)	Orbitrap Eclipse		Instrument as listed in the ProteomeXchange record PXD042403.	Jurkat T-cell leukemia cells; baseline cysteine-labeling list	Human cell line Jurkat (T-cell leukemia) for baseline identification, oxidation-state quantification, and exogenous reductant/oxidant experiments; primary human CD4+/CD8+ T cells for the activation experiment.	control_surface_proteins.tsv: uniprot_accession			1231	295	0.239642567018684	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			1230
pandey-dipg-2023	DIPG periodate/aminooxy-biotin surfaceome	Pandey et al. 2023	Pandey K	2023	37637064	10.3389/fonc.2023.1192448	provisional	values are imputed: presence counted, per-sample detection not available	Live-cell periodate/aminooxy-biotin glycoprotein capture; Table 7a precedes the CSPA and TMHMM selections. Held (2026-11-02, same rule as breyer-2025): intensities are fully imputed in the published matrix, so per-line detection cannot be recovered and no observed-membership list is available. Needs the upstream MaxQuant proteinGroups before imputation.	none (surface data not deposited)		Table_7.xlsx sheet 7a-Total surface proteins in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC10455951/supplementaryFiles>	Sodium periodate oxidation and aminooxy-biotin with aniline on live cells, streptavidin capture, MaxQuant LFQ; Perseus processing with imputation.	Method summarized from the paper (PMC10455951) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Bruker Impact II	Cell surfaceome (amino-oxy-biotin) peptides on Impact II; same paper also used Q Exactive Plus (whole proteome, immunopeptidomics) and Orbitrap Fusion Tribrid (HLA peptides), not the surface capture	Instrument as named in the paper's Methods 2.8 Cell surfaceome sample preparation (full text PMC10455951).	7 patient-derived diffuse intrinsic pontine glioma lines (SU-DIPG-4, -13, -17, -19, -21, -25, -33)	Supplementary Table 7a, total surface proteins (all identifications, before CSPA/TMHMM selection in 7c/7d); intensities are imputed, so per-line detection cannot be recovered and the list is used whole	Table_7.xlsx: majority protein ids	q-value ≤ 0.01 | drop rows flagged only identified by site, potential contaminant		2956	1008	0.34100135317997293	0.2	Homo sapiens		0	6	2956
oates-macrophage-2023	Ex vivo monocyte-derived macrophage sulfo-NHS surfaceome · M0 unpolarized (baseline)	Oates et al. 2023	Oates TC	2023	37694300	10.1111/imcb.12687	below_screen	15.8% of its length-corrected amount in Canonical or Likely proteins, under 25%	Intact-cell sulfo-NHS capture on primary macrophages; the deposited PD table precedes the paper's CSPA surface filter, and channel labels in the column headers map each TMT channel to its subtype. M0 is the unperturbed baseline; polarized subtypes are cytokine-treated arms. No no-biotin control.	PRIDE	PXD032823;PXD032905;PXD032966	250520_Charlie_Severn_Beads_11Plex_TMT.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD032823/250520_Charlie_Severn_Beads_11Plex_TMT.xlsx> | Charlie_Severn_11Plex_Surfaceome_TMT.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD032905/Charlie_Severn_11Plex_Surfaceome_TMT.xlsx>	EZ-Link Sulfo-NHS-SS-Biotin on intact cells on ice, streptavidin pull-down, TMT 11-plex	Method read from: PMC10953363 methods (surface biotinylation and streptavidin immunoprecipitation).	streptavidin	not stated	Orbitrap Fusion		Instrument as listed in the ProteomeXchange records PXD032823, PXD032905 and PXD032966.	Primary human monocyte-derived macrophages (M0, M1, M2a, M2c)	PRIDE PD export 250520_Charlie_Severn_Beads_11Plex_TMT.xlsx sheet Proteins (3,228 protein rows, before the paper's CSPA filter). Contaminant == False; nonhuman rows dropped by the pipeline. Membership = PD reporter abundance present in both M0 (Con) channels 126 and 127N. M1, M2a and M2c cytokine-polarized channels kept as measurements only. Second TMT11 plex (PXD032905; PXD032966 is a byte-identical duplicate deposit) Charlie_Severn_11Plex_Surfaceome_TMT.xlsx sheet Proteins (1,652 rows, before CSPA filtering; Contaminant == False): M0, M1, M2c and dexamethasone-treated M1 channels, all kept as measurements only, so membership still comes from the first plex alone.	250520_Charlie_Severn_Beads_11Plex_TMT.xlsx: Accession | Charlie_Severn_11Plex_Surfaceome_TMT.xlsx: Accession	Contaminant = false | Contaminant = false	monocyte-derived macrophage / M0 unpolarized baseline sulfo-NHS-SS-biotin labeled: Abundance: F2: 126, Sample, Con, Abundance: F2: 127N, Sample, Con (min_observed 2) | monocyte-derived macrophage / M1 polarized (not used for membership): Abundance: F2: 127C, Sample, M1, Abundance: F2: 128N, Sample, M1, Abundance: F2: 128C, Sample, M1 (min_observed 2) | monocyte-derived macrophage / M2a polarized (not used for membership): Abundance: F2: 129N, Sample, M2a, Abundance: F2: 129C, Sample, M2a, Abundance: F2: 130N, Sample, M2a (min_observed 2) | monocyte-derived macrophage / M2c polarized (not used for membership): Abundance: F2: 130C, Sample, M2c, Abundance: F2: 131N, Sample, M2c, Abundance: F2: 131C, Sample, M2c (min_observed 2) | monocyte-derived macrophage / M0 unpolarized, dexamethasone-experiment plex (not used for membership): Abundance: F1: 126, Sample, Donor M0 Con, Abundance: F1: 127N, Sample, Donor M0 Con (min_observed 2) | monocyte-derived macrophage / M1 polarized, dexamethasone-experiment plex (not used for membership): Abundance: F1: 127C, Sample, Donor1 M1, Abundance: F1: 128N, Sample, Donor2 M1, Abundance: F1: 128C, Sample, Donor3 M1 (min_observed 2) | monocyte-derived macrophage / M2c polarized, dexamethasone-experiment plex (not used for membership): Abundance: F1: 129N, Sample, Donor1 M2c, Abundance: F1: 129C, Sample, Donor2 M2c, Abundance: F1: 130N, Sample, Donor3 M2c (min_observed 2) | monocyte-derived macrophage / M1 treated with dexamethasone 48 h (not used for membership): Abundance: F1: 130C, Sample, Donor1 Dex Treat, Abundance: F1: 131N, Sample, Donor2 Dex Treat, Abundance: F1: 131C, Sample, Donor3 Dex Treat (min_observed 2)	1384	166	0.1199421965317919	0.2	Homo sapiens		0	191	1384
oates-macrophage-2023--m1-polarised	Ex vivo monocyte-derived macrophage sulfo-NHS surfaceome · M1 polarized	Oates et al. 2023	Oates TC	2023	37694300	10.1111/imcb.12687	perturbed	differentiation or activation: M1 polarised	differentiation or activation arm of oates-macrophage-2023; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD032823;PXD032905;PXD032966	250520_Charlie_Severn_Beads_11Plex_TMT.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD032823/250520_Charlie_Severn_Beads_11Plex_TMT.xlsx> | Charlie_Severn_11Plex_Surfaceome_TMT.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD032905/Charlie_Severn_11Plex_Surfaceome_TMT.xlsx>	EZ-Link Sulfo-NHS-SS-Biotin on intact cells on ice, streptavidin pull-down, TMT 11-plex	Method read from: PMC10953363 methods (surface biotinylation and streptavidin immunoprecipitation).	streptavidin	not stated	Orbitrap Fusion		Instrument as listed in the ProteomeXchange records PXD032823, PXD032905 and PXD032966.	monocyte-derived macrophage	monocyte-derived macrophage, M1 polarized: a non-baseline state of oates-macrophage-2023, listed when observed in at least 2 of its 3 samples				1389	166	0.11951043916486681		Homo sapiens		0	196	1389
oates-macrophage-2023--m1-polarised-dexamethasone-experiment-plex	Ex vivo monocyte-derived macrophage sulfo-NHS surfaceome · M1 polarized, dexamethasone-experiment plex	Oates et al. 2023	Oates TC	2023	37694300	10.1111/imcb.12687	perturbed	differentiation or activation: M1 polarised, dexamethasone-experiment plex	differentiation or activation arm of oates-macrophage-2023; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD032823;PXD032905;PXD032966	250520_Charlie_Severn_Beads_11Plex_TMT.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD032823/250520_Charlie_Severn_Beads_11Plex_TMT.xlsx> | Charlie_Severn_11Plex_Surfaceome_TMT.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD032905/Charlie_Severn_11Plex_Surfaceome_TMT.xlsx>	EZ-Link Sulfo-NHS-SS-Biotin on intact cells on ice, streptavidin pull-down, TMT 11-plex	Method read from: PMC10953363 methods (surface biotinylation and streptavidin immunoprecipitation).	streptavidin	not stated	Orbitrap Fusion		Instrument as listed in the ProteomeXchange records PXD032823, PXD032905 and PXD032966.	monocyte-derived macrophage	monocyte-derived macrophage, M1 polarized, dexamethasone-experiment plex: a non-baseline state of oates-macrophage-2023, listed when observed in at least 2 of its 3 samples				1129	156	0.13817537643932684		Homo sapiens		0	175	1128
oates-macrophage-2023--m1-treated-with-dexamethasone-48-h	Ex vivo monocyte-derived macrophage sulfo-NHS surfaceome · M1 treated with dexamethasone 48 h	Oates et al. 2023	Oates TC	2023	37694300	10.1111/imcb.12687	perturbed	differentiation or activation: M1 treated with dexamethasone 48 h	differentiation or activation arm of oates-macrophage-2023; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD032823;PXD032905;PXD032966	250520_Charlie_Severn_Beads_11Plex_TMT.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD032823/250520_Charlie_Severn_Beads_11Plex_TMT.xlsx> | Charlie_Severn_11Plex_Surfaceome_TMT.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD032905/Charlie_Severn_11Plex_Surfaceome_TMT.xlsx>	EZ-Link Sulfo-NHS-SS-Biotin on intact cells on ice, streptavidin pull-down, TMT 11-plex	Method read from: PMC10953363 methods (surface biotinylation and streptavidin immunoprecipitation).	streptavidin	not stated	Orbitrap Fusion		Instrument as listed in the ProteomeXchange records PXD032823, PXD032905 and PXD032966.	monocyte-derived macrophage	monocyte-derived macrophage, M1 treated with dexamethasone 48 h: a non-baseline state of oates-macrophage-2023, listed when observed in at least 2 of its 3 samples				1129	156	0.13817537643932684		Homo sapiens		0	175	1128
oates-macrophage-2023--m2a-polarised	Ex vivo monocyte-derived macrophage sulfo-NHS surfaceome · M2a polarized	Oates et al. 2023	Oates TC	2023	37694300	10.1111/imcb.12687	perturbed	differentiation or activation: M2a polarised	differentiation or activation arm of oates-macrophage-2023; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD032823;PXD032905;PXD032966	250520_Charlie_Severn_Beads_11Plex_TMT.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD032823/250520_Charlie_Severn_Beads_11Plex_TMT.xlsx> | Charlie_Severn_11Plex_Surfaceome_TMT.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD032905/Charlie_Severn_11Plex_Surfaceome_TMT.xlsx>	EZ-Link Sulfo-NHS-SS-Biotin on intact cells on ice, streptavidin pull-down, TMT 11-plex	Method read from: PMC10953363 methods (surface biotinylation and streptavidin immunoprecipitation).	streptavidin	not stated	Orbitrap Fusion		Instrument as listed in the ProteomeXchange records PXD032823, PXD032905 and PXD032966.	monocyte-derived macrophage	monocyte-derived macrophage, M2a polarized: a non-baseline state of oates-macrophage-2023, listed when observed in at least 2 of its 3 samples				1381	164	0.11875452570601014		Homo sapiens		0	195	1381
oates-macrophage-2023--m2c-polarised	Ex vivo monocyte-derived macrophage sulfo-NHS surfaceome · M2c polarized	Oates et al. 2023	Oates TC	2023	37694300	10.1111/imcb.12687	perturbed	differentiation or activation: M2c polarised	differentiation or activation arm of oates-macrophage-2023; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD032823;PXD032905;PXD032966	250520_Charlie_Severn_Beads_11Plex_TMT.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD032823/250520_Charlie_Severn_Beads_11Plex_TMT.xlsx> | Charlie_Severn_11Plex_Surfaceome_TMT.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD032905/Charlie_Severn_11Plex_Surfaceome_TMT.xlsx>	EZ-Link Sulfo-NHS-SS-Biotin on intact cells on ice, streptavidin pull-down, TMT 11-plex	Method read from: PMC10953363 methods (surface biotinylation and streptavidin immunoprecipitation).	streptavidin	not stated	Orbitrap Fusion		Instrument as listed in the ProteomeXchange records PXD032823, PXD032905 and PXD032966.	monocyte-derived macrophage	monocyte-derived macrophage, M2c polarized: a non-baseline state of oates-macrophage-2023, listed when observed in at least 2 of its 3 samples				1361	163	0.11976487876561352		Homo sapiens		0	185	1361
oates-macrophage-2023--m2c-polarised-dexamethasone-experiment-plex	Ex vivo monocyte-derived macrophage sulfo-NHS surfaceome · M2c polarized, dexamethasone-experiment plex	Oates et al. 2023	Oates TC	2023	37694300	10.1111/imcb.12687	perturbed	differentiation or activation: M2c polarised, dexamethasone-experiment plex	differentiation or activation arm of oates-macrophage-2023; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD032823;PXD032905;PXD032966	250520_Charlie_Severn_Beads_11Plex_TMT.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD032823/250520_Charlie_Severn_Beads_11Plex_TMT.xlsx> | Charlie_Severn_11Plex_Surfaceome_TMT.xlsx sheet Proteins <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD032905/Charlie_Severn_11Plex_Surfaceome_TMT.xlsx>	EZ-Link Sulfo-NHS-SS-Biotin on intact cells on ice, streptavidin pull-down, TMT 11-plex	Method read from: PMC10953363 methods (surface biotinylation and streptavidin immunoprecipitation).	streptavidin	not stated	Orbitrap Fusion		Instrument as listed in the ProteomeXchange records PXD032823, PXD032905 and PXD032966.	monocyte-derived macrophage	monocyte-derived macrophage, M2c polarized, dexamethasone-experiment plex: a non-baseline state of oates-macrophage-2023, listed when observed in at least 2 of its 3 samples				1129	156	0.13817537643932684		Homo sapiens		0	175	1128
jiang-hela-mol-fusion-2023	HeLa whole-membrane proteome by metal-organic-layer adsorption and membrane fusion	Jiang et al. 2023	Jiang Q	2023	37920345	10.1039/d3sc03725h	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Material is adsorbed to living cells but membranes are collected after lysis and the method deliberately captures organelle membranes by fusion (77% membrane-protein specificity, PM plus mitochondria, ER, Golgi, nucleus), so it cannot show extracellular exposure; complementary by the membrane-fractionation family policy.	PRIDE	PXD044945	SC-014-D3SC03725H-s002.xlsx sheet Identified proteins using 480 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC10619618/supplementaryFiles>	MOL-DpaZn cell-surface adsorption, mild lysis, membrane fusion capture of total membranes	Method as described in the paper's Results ('Reproducibility and universality', Fig. 5) and Discussion (full text PMC10619618).	none (MOL nanosheets)	not stated	Orbitrap Fusion Lumos; LTQ Orbitrap Velos; Orbitrap Exploris 480; Q Exactive		Instrument as listed in the ProteomeXchange record PXD044945.	HeLa cervical adenocarcinoma cell line	ESI Data 2 (s002.xlsx) sheet 'Identified proteins using 480': every protein identified from the 10-fraction Exploris 480 analysis, with the authors' membrane/extracellular/other annotation columns not used as filters. Membership = listed (authors' identification FDR); no per-sample values. Data 1 (single-shot, 2,001 proteins), the SY5Y apoptosis ratios (Data 4) and the GPCR/CD/transporter sub-sheet not used.	SC-014-D3SC03725H-s002.xlsx: Uniprot Accession			9701	919	0.09473250180393773	0.2	Homo sapiens		0	1	9701
zhao-peptidisc-2023	HeLa, Panc-1 and pancreatic stellate cell peptidisc membrane libraries	Zhao et al. 2023	Zhao Z	2023	37295717	10.1016/j.mcpro.2023.100588	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Peptidisc capture of a 110,000 g crude membrane DDM extract: lysis precedes any enrichment and the paper states the pellet contains PM, ER, Golgi and vesicle membranes, so this is membrane fractionation (complementary, no surface vote). Adds a non-malignant pancreatic stellate line.	PRIDE	PXD039990	proteinGroups.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/10/PXD039990/proteinGroups.txt> | PancproteinGroups.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/10/PXD039990/PancproteinGroups.txt>	Crude membrane ultracentrifugation, DDM solubilisation, His-peptidisc reconstitution, Ni-NTA purification	Method as described in the paper's Experimental Procedures 'Preparation of the Peptidisc Libraries'; Fig. 3C/4 legends; PRIDE summary.txt raw-file-to-experiment map.	Ni-NTA resin (Qiagen)	not stated	LTQ Orbitrap Elite		Instrument as listed in the ProteomeXchange record PXD039990.	HeLa cervical carcinoma line; Panc-1 pancreatic ductal adenocarcinoma line; hPSC non-malignant human pancreatic stellate cell line	PRIDE MaxQuant outputs: proteinGroups.txt (HeLa, 12 experiments) and PancproteinGroups.txt (Panc-1, hPSC, KCC4 pulldown). Rows with Reverse, Potential contaminant or Only identified by site '+' dropped; protein Q-value <= 0.01. Membership = raw Intensity > 0 in >= 2 of 3 Purified Library (Ni-NTA) replicates within a line: HeLa 'Purified Library_1-3', Panc-1_1-3, hPSC_1-3. HeLa DDM extracts and Starting Library kept as non-membership measurements; SILAC centrifugation, carbonate-wash, Bio Lib and KCC4 antibody pulldown experiments not read.	proteinGroups.txt: Protein IDs | PancproteinGroups.txt: Protein IDs	Q-value ≤ 0.01 | drop rows flagged Reverse, Potential contaminant, Only identified by site | Q-value ≤ 0.01 | drop rows flagged Reverse, Potential contaminant, Only identified by site	HeLa / baseline, Ni-NTA purified peptidisc membrane library: Intensity Purified Library_1, Intensity Purified Library_2, Intensity Purified Library_3 (min_observed 2) | HeLa / crude membrane DDM extract and unpurified peptidisc library (not used for membership): Intensity DDM_1, Intensity DDM_2, Intensity DDM_2 repeat, Intensity Starting Library (min_observed 1) | Panc-1 / baseline, Ni-NTA purified peptidisc membrane library: Intensity Panc-1_1, Intensity Panc-1_2, Intensity Panc-1_3 (min_observed 2) | Human pancreatic stellate cells (hPSC) / baseline, Ni-NTA purified peptidisc membrane library: Intensity hPSC_1, Intensity hPSC_2, Intensity hPSC_3 (min_observed 2)	2133	367	0.17205813408345053	0.2	Homo sapiens		0	28	2133
li-hepg2-pecsl-insulin-2023--insulin-10s-then-pecsl-labelled	HepG2 10-s peroxidase-mediated (PECSL) surface biotinylation · insulin 10s	Li et al. 2023	Li Y	2023	37272674	10.1021/acs.analchem.3c01354	perturbed	drug, ligand or treatment: insulin 10s	drug, ligand or treatment arm of li-hepg2-pecsl-insulin-2023; shown, not counted. Membership follows the parent recipe's rule for this sample group.	jPOST / ProteomeXchange	PXD036376;JPST001827	Figure 2_proteinGroups.txt	PubMed abstract 37272674 ('in situ perturbation-free and rapid surface proteomic profiling at a temporal resolution of ten seconds'); PROXI/jPOST description PXD036376 (rapid enzymatic surface labeling, PECSL, label-free quantification); deposited file names Figure2_PECSL_Insulin<time>_HepG2_Bio1-3 and Figure2_PECSL_InsulinControl_HepG2_Bio1-3.	Method read from: PubMed abstract; ProteomeCentral PROXI record PXD036376; jPOST JPST001827 FTP file list. ACS full text not accessible to us, so the HepG2 protocol was not read.	streptavidin (per the PECSL method of li-hela-pecsl-2021; not re-read for this paper)	not reported	Q Exactive		Instrument as listed in the ProteomeXchange record PXD036376.	HepG2	HepG2, insulin 10s then PECSL labeled: a non-baseline state of li-hepg2-pecsl-insulin-2023, listed when observed in at least 2 of its 3 samples				2790	324	0.11612903225806452		Homo sapiens		0	0	2790
li-hepg2-pecsl-insulin-2023--insulin-12h-then-pecsl-labelled	HepG2 10-s peroxidase-mediated (PECSL) surface biotinylation · insulin 12h	Li et al. 2023	Li Y	2023	37272674	10.1021/acs.analchem.3c01354	perturbed	drug, ligand or treatment: insulin 12h	drug, ligand or treatment arm of li-hepg2-pecsl-insulin-2023; shown, not counted. Membership follows the parent recipe's rule for this sample group.	jPOST / ProteomeXchange	PXD036376;JPST001827	Figure 2_proteinGroups.txt	PubMed abstract 37272674 ('in situ perturbation-free and rapid surface proteomic profiling at a temporal resolution of ten seconds'); PROXI/jPOST description PXD036376 (rapid enzymatic surface labeling, PECSL, label-free quantification); deposited file names Figure2_PECSL_Insulin<time>_HepG2_Bio1-3 and Figure2_PECSL_InsulinControl_HepG2_Bio1-3.	Method read from: PubMed abstract; ProteomeCentral PROXI record PXD036376; jPOST JPST001827 FTP file list. ACS full text not accessible to us, so the HepG2 protocol was not read.	streptavidin (per the PECSL method of li-hela-pecsl-2021; not re-read for this paper)	not reported	Q Exactive		Instrument as listed in the ProteomeXchange record PXD036376.	HepG2	HepG2, insulin 12h then PECSL labeled: a non-baseline state of li-hepg2-pecsl-insulin-2023, listed when observed in at least 2 of its 3 samples				2738	320	0.1168736303871439		Homo sapiens		0	0	2738
li-hepg2-pecsl-insulin-2023--insulin-24h-then-pecsl-labelled	HepG2 10-s peroxidase-mediated (PECSL) surface biotinylation · insulin 24h	Li et al. 2023	Li Y	2023	37272674	10.1021/acs.analchem.3c01354	perturbed	drug, ligand or treatment: insulin 24h	drug, ligand or treatment arm of li-hepg2-pecsl-insulin-2023; shown, not counted. Membership follows the parent recipe's rule for this sample group.	jPOST / ProteomeXchange	PXD036376;JPST001827	Figure 2_proteinGroups.txt	PubMed abstract 37272674 ('in situ perturbation-free and rapid surface proteomic profiling at a temporal resolution of ten seconds'); PROXI/jPOST description PXD036376 (rapid enzymatic surface labeling, PECSL, label-free quantification); deposited file names Figure2_PECSL_Insulin<time>_HepG2_Bio1-3 and Figure2_PECSL_InsulinControl_HepG2_Bio1-3.	Method read from: PubMed abstract; ProteomeCentral PROXI record PXD036376; jPOST JPST001827 FTP file list. ACS full text not accessible to us, so the HepG2 protocol was not read.	streptavidin (per the PECSL method of li-hela-pecsl-2021; not re-read for this paper)	not reported	Q Exactive		Instrument as listed in the ProteomeXchange record PXD036376.	HepG2	HepG2, insulin 24h then PECSL labeled: a non-baseline state of li-hepg2-pecsl-insulin-2023, listed when observed in at least 2 of its 3 samples				2731	317	0.11607469791285244		Homo sapiens		0	0	2731
li-hepg2-pecsl-insulin-2023--insulin-2h-then-pecsl-labelled	HepG2 10-s peroxidase-mediated (PECSL) surface biotinylation · insulin 2h	Li et al. 2023	Li Y	2023	37272674	10.1021/acs.analchem.3c01354	perturbed	drug, ligand or treatment: insulin 2h	drug, ligand or treatment arm of li-hepg2-pecsl-insulin-2023; shown, not counted. Membership follows the parent recipe's rule for this sample group.	jPOST / ProteomeXchange	PXD036376;JPST001827	Figure 2_proteinGroups.txt	PubMed abstract 37272674 ('in situ perturbation-free and rapid surface proteomic profiling at a temporal resolution of ten seconds'); PROXI/jPOST description PXD036376 (rapid enzymatic surface labeling, PECSL, label-free quantification); deposited file names Figure2_PECSL_Insulin<time>_HepG2_Bio1-3 and Figure2_PECSL_InsulinControl_HepG2_Bio1-3.	Method read from: PubMed abstract; ProteomeCentral PROXI record PXD036376; jPOST JPST001827 FTP file list. ACS full text not accessible to us, so the HepG2 protocol was not read.	streptavidin (per the PECSL method of li-hela-pecsl-2021; not re-read for this paper)	not reported	Q Exactive		Instrument as listed in the ProteomeXchange record PXD036376.	HepG2	HepG2, insulin 2h then PECSL labeled: a non-baseline state of li-hepg2-pecsl-insulin-2023, listed when observed in at least 2 of its 3 samples				2784	325	0.11673850574712644		Homo sapiens		0	0	2784
li-hepg2-pecsl-insulin-2023--insulin-2min-then-pecsl-labelled	HepG2 10-s peroxidase-mediated (PECSL) surface biotinylation · insulin 2min	Li et al. 2023	Li Y	2023	37272674	10.1021/acs.analchem.3c01354	perturbed	drug, ligand or treatment: insulin 2min	drug, ligand or treatment arm of li-hepg2-pecsl-insulin-2023; shown, not counted. Membership follows the parent recipe's rule for this sample group.	jPOST / ProteomeXchange	PXD036376;JPST001827	Figure 2_proteinGroups.txt	PubMed abstract 37272674 ('in situ perturbation-free and rapid surface proteomic profiling at a temporal resolution of ten seconds'); PROXI/jPOST description PXD036376 (rapid enzymatic surface labeling, PECSL, label-free quantification); deposited file names Figure2_PECSL_Insulin<time>_HepG2_Bio1-3 and Figure2_PECSL_InsulinControl_HepG2_Bio1-3.	Method read from: PubMed abstract; ProteomeCentral PROXI record PXD036376; jPOST JPST001827 FTP file list. ACS full text not accessible to us, so the HepG2 protocol was not read.	streptavidin (per the PECSL method of li-hela-pecsl-2021; not re-read for this paper)	not reported	Q Exactive		Instrument as listed in the ProteomeXchange record PXD036376.	HepG2	HepG2, insulin 2min then PECSL labeled: a non-baseline state of li-hepg2-pecsl-insulin-2023, listed when observed in at least 2 of its 3 samples				2785	322	0.11561938958707361		Homo sapiens		0	0	2785
li-hepg2-pecsl-insulin-2023--insulin-30min-then-pecsl-labelled	HepG2 10-s peroxidase-mediated (PECSL) surface biotinylation · insulin 30min	Li et al. 2023	Li Y	2023	37272674	10.1021/acs.analchem.3c01354	perturbed	drug, ligand or treatment: insulin 30min	drug, ligand or treatment arm of li-hepg2-pecsl-insulin-2023; shown, not counted. Membership follows the parent recipe's rule for this sample group.	jPOST / ProteomeXchange	PXD036376;JPST001827	Figure 2_proteinGroups.txt	PubMed abstract 37272674 ('in situ perturbation-free and rapid surface proteomic profiling at a temporal resolution of ten seconds'); PROXI/jPOST description PXD036376 (rapid enzymatic surface labeling, PECSL, label-free quantification); deposited file names Figure2_PECSL_Insulin<time>_HepG2_Bio1-3 and Figure2_PECSL_InsulinControl_HepG2_Bio1-3.	Method read from: PubMed abstract; ProteomeCentral PROXI record PXD036376; jPOST JPST001827 FTP file list. ACS full text not accessible to us, so the HepG2 protocol was not read.	streptavidin (per the PECSL method of li-hela-pecsl-2021; not re-read for this paper)	not reported	Q Exactive		Instrument as listed in the ProteomeXchange record PXD036376.	HepG2	HepG2, insulin 30min then PECSL labeled: a non-baseline state of li-hepg2-pecsl-insulin-2023, listed when observed in at least 2 of its 3 samples				2772	324	0.11688311688311688		Homo sapiens		0	0	2772
li-hepg2-pecsl-insulin-2023--insulin-30s-then-pecsl-labelled	HepG2 10-s peroxidase-mediated (PECSL) surface biotinylation · insulin 30s	Li et al. 2023	Li Y	2023	37272674	10.1021/acs.analchem.3c01354	perturbed	drug, ligand or treatment: insulin 30s	drug, ligand or treatment arm of li-hepg2-pecsl-insulin-2023; shown, not counted. Membership follows the parent recipe's rule for this sample group.	jPOST / ProteomeXchange	PXD036376;JPST001827	Figure 2_proteinGroups.txt	PubMed abstract 37272674 ('in situ perturbation-free and rapid surface proteomic profiling at a temporal resolution of ten seconds'); PROXI/jPOST description PXD036376 (rapid enzymatic surface labeling, PECSL, label-free quantification); deposited file names Figure2_PECSL_Insulin<time>_HepG2_Bio1-3 and Figure2_PECSL_InsulinControl_HepG2_Bio1-3.	Method read from: PubMed abstract; ProteomeCentral PROXI record PXD036376; jPOST JPST001827 FTP file list. ACS full text not accessible to us, so the HepG2 protocol was not read.	streptavidin (per the PECSL method of li-hela-pecsl-2021; not re-read for this paper)	not reported	Q Exactive		Instrument as listed in the ProteomeXchange record PXD036376.	HepG2	HepG2, insulin 30s then PECSL labeled: a non-baseline state of li-hepg2-pecsl-insulin-2023, listed when observed in at least 2 of its 3 samples				2759	325	0.11779630300833635		Homo sapiens		0	0	2759
li-hepg2-pecsl-insulin-2023--insulin-5min-then-pecsl-labelled	HepG2 10-s peroxidase-mediated (PECSL) surface biotinylation · insulin 5min	Li et al. 2023	Li Y	2023	37272674	10.1021/acs.analchem.3c01354	perturbed	drug, ligand or treatment: insulin 5min	drug, ligand or treatment arm of li-hepg2-pecsl-insulin-2023; shown, not counted. Membership follows the parent recipe's rule for this sample group.	jPOST / ProteomeXchange	PXD036376;JPST001827	Figure 2_proteinGroups.txt	PubMed abstract 37272674 ('in situ perturbation-free and rapid surface proteomic profiling at a temporal resolution of ten seconds'); PROXI/jPOST description PXD036376 (rapid enzymatic surface labeling, PECSL, label-free quantification); deposited file names Figure2_PECSL_Insulin<time>_HepG2_Bio1-3 and Figure2_PECSL_InsulinControl_HepG2_Bio1-3.	Method read from: PubMed abstract; ProteomeCentral PROXI record PXD036376; jPOST JPST001827 FTP file list. ACS full text not accessible to us, so the HepG2 protocol was not read.	streptavidin (per the PECSL method of li-hela-pecsl-2021; not re-read for this paper)	not reported	Q Exactive		Instrument as listed in the ProteomeXchange record PXD036376.	HepG2	HepG2, insulin 5min then PECSL labeled: a non-baseline state of li-hepg2-pecsl-insulin-2023, listed when observed in at least 2 of its 3 samples				2779	322	0.11586901763224182		Homo sapiens		0	0	2779
li-hepg2-pecsl-insulin-2023	HepG2 10-s peroxidase-mediated (PECSL) surface biotinylation · no insulin (baseline)	Li et al. 2023	Li Y	2023	37272674	10.1021/acs.analchem.3c01354	below_screen	18.5% of its length-corrected amount in Canonical or Likely proteins, under 25%	Intact-cell 10-s peroxidase-mediated labeling of unstimulated HepG2 (control arm of the insulin time course); membership from observed raw intensities of the control replicates. This deposit has no processed no-probe negative-control table (H2O2_0min_Ctrl exists as raw files only), unlike li-hela-pecsl-2021.	jPOST / ProteomeXchange	PXD036376;JPST001827	Figure 2_proteinGroups.txt	PubMed abstract 37272674 ('in situ perturbation-free and rapid surface proteomic profiling at a temporal resolution of ten seconds'); PROXI/jPOST description PXD036376 (rapid enzymatic surface labeling, PECSL, label-free quantification); deposited file names Figure2_PECSL_Insulin<time>_HepG2_Bio1-3 and Figure2_PECSL_InsulinControl_HepG2_Bio1-3.	Method read from: PubMed abstract; ProteomeCentral PROXI record PXD036376; jPOST JPST001827 FTP file list. ACS full text not accessible to us, so the HepG2 protocol was not read.	streptavidin (per the PECSL method of li-hela-pecsl-2021; not re-read for this paper)	not reported	Q Exactive		Instrument as listed in the ProteomeXchange record PXD036376.	HepG2 hepatocellular carcinoma cell line	Deposited 'Figure 2_proteinGroups.txt' (HepG2 insulin time course, 2,973 protein groups). Reverse, potential contaminant and only-identified-by-site rows dropped (2,877 left). Membership = raw Intensity > 0 in >= 2 of 3 unstimulated Control replicates (2,790). The eight insulin time points are measurements only. HeLa files of the same deposit (Figure 1B/1C, S1 method comparisons) not used; the HeLa PECSL baseline is already li-hela-pecsl-2021.	Figure 2_proteinGroups.txt: Protein IDs	drop rows flagged Reverse, Potential contaminant, Only identified by site	HepG2 / baseline PECSL labeled, no insulin: Intensity Control_HepG2_Bio1, Intensity Control_HepG2_Bio2, Intensity Control_HepG2_Bio3 (min_observed 2) | HepG2 / insulin 10s then PECSL labeled (not used for membership): Intensity 10s_HepG2_Bio1, Intensity 10s_HepG2_Bio2, Intensity 10s_HepG2_Bio3 (min_observed 2) | HepG2 / insulin 30s then PECSL labeled (not used for membership): Intensity 30s_HepG2_Bio1, Intensity 30s_HepG2_Bio2, Intensity 30s_HepG2_Bio3 (min_observed 2) | HepG2 / insulin 2min then PECSL labeled (not used for membership): Intensity 2min_HepG2_Bio1, Intensity 2min_HepG2_Bio2, Intensity 2min_HepG2_Bio3 (min_observed 2) | HepG2 / insulin 5min then PECSL labeled (not used for membership): Intensity 5min_HepG2_Bio1, Intensity 5min_HepG2_Bio2, Intensity 5min_HepG2_Bio3 (min_observed 2) | HepG2 / insulin 30min then PECSL labeled (not used for membership): Intensity 30min_HepG2_Bio1, Intensity 30min_HepG2_Bio2, Intensity 30min_HepG2_Bio3 (min_observed 2) | HepG2 / insulin 2h then PECSL labeled (not used for membership): Intensity 2h_HepG2_Bio1, Intensity 2h_HepG2_Bio2, Intensity 2h_HepG2_Bio3 (min_observed 2) | HepG2 / insulin 12h then PECSL labeled (not used for membership): Intensity 12h_HepG2_Bio1, Intensity 12h_HepG2_Bio2, Intensity 12h_HepG2_Bio3 (min_observed 2) | HepG2 / insulin 24h then PECSL labeled (not used for membership): Intensity 24h_HepG2_Bio1, Intensity 24h_HepG2_Bio2, Intensity 24h_HepG2_Bio3 (min_observed 2)	2787	324	0.116254036598493	0.2	Homo sapiens		0	0	2787
mandal-nomo1-csc-2023	Nomo-1 AML periodate/biocytin-hydrazide surfaceome	Mandal et al. 2023	Mandal K	2023	37904046	10.1038/s43018-023-00652-6	below_screen	13% Canonical or Likely proteins, under 20%	Intact-cell periodate/biocytin-hydrazide labeling of an unperturbed AML line; observed ProteinProphet identifications. No no-label control is deposited, and whole captured proteins (not glycopeptides) are read out, so intracellular carry-over is expected.	PRIDE	PXD035404;PXD035589;PXD035591	mandal_nomo1_protxml_proteins.tsv	periodate + biocytin hydrazide on intact cells, streptavidin capture, on-bead digestion	Method read from: PXD035404 sample/data processing protocols; paper Methods 'Structural surfaceomics'.	streptavidin	not stated	Q Exactive Plus; Orbitrap Fusion Lumos; timsTOF Pro		Instrument as listed in the ProteomeXchange records PXD035404, PXD035589 and PXD035591.	Nomo-1 acute myeloid leukemia cell line	PXD035404 combined.prot.xml (the Nomo-1 surfaceome database run; one labeled sample, SEC fractions 9-18), parsed to one row per ProteinProphet protein entry (8,619 rows). Kept: protein probability >= 0.7127, the probability at which the file's own error table reaches 1% false-positive error; rev_ decoys and contam_ entries removed. Every protein entry of a group is a row (the engine uses each entry's own accession). The cross-linked arms (PXD035589, PXD035591) are XL-MS peptide-pair tables and are not used.	mandal_nomo1_protxml_proteins.tsv: protein_name	protein_probability ≥ 0.7127 | drop rows where protein_name matches rev_|contam_		5413	710	0.131165712174395	0.2	Homo sapiens		0	0	5413
yumoto-pc3-2023	PC3 G0 and G1 sorted cells, Mem-PER Plus membranes	Yumoto et al. 2023	Yumoto K	2023	36805918	10.1016/j.tranon.2023.101642	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Mem-PER Plus detergent membrane extraction of sorted, untreated cells; no surface label. Independent of chen-pc3-2026 (different lab, design and deposit).	PRIDE	PXD037378	mmc2.xlsx sheet RAW DATA in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9971552/supplementaryFiles> | mmc2.uniprot_mapped.tsv	MEM-PER Plus Membrane Protein Extraction kit (Thermo 89842) on FACS-sorted G0 and G1 PC3-VC cells	Method as described in the paper's Methods 'Extraction of membrane proteins' and 'Proteomic mass spectrometry analysis'; PRIDE PXD037378 protocol.	none	not reported	Q Exactive		Instrument as listed in the ProteomeXchange record PXD037378.	PC3 prostate cancer cells with p27/CDT1 cell-cycle reporters, sorted into G0 and G1 populations (unperturbed culture)	mmc2 'RAW DATA' (3,791 identified proteins, spectrum counts for G1 and G0, one sample each). Membership = spectrum count > 0 in that population. Gene symbol taken from 'GN=' in the description; the 34 contaminant-database rows (trypsin, keratins, immunoglobulin, without GN=) carry no symbol and drop out. 'Sheet2' (manually selected surface candidates) not used.	mmc2.uniprot_mapped.tsv: uniprot_mapped		PC3 / G1-sorted cells, membrane fraction: G1 (min_observed 1) | PC3 / G0-sorted (quiescent) cells, membrane fraction: G0 (min_observed 1)	3721	296	0.07954850846546627	0.2	Homo sapiens		0	0	3721
wang-prostate-primary-2023	Patient-derived prostate cancer and BPH primary cells, sulfo-NHS-SS-biotin surfaceome	Wang et al. 2023	Wang Z	2023	37121942	10.1038/s41392-023-01393-9	core		Intact-cell sulfo-NHS-SS-biotin capture on untreated patient-derived primary cultures (prostate cancer and BPH); the deposited proteinGroups is the full identification table before the authors' GO/TMHMM surface selection. Technical duplicates only (one culture per patient), so membership requires detection in both runs. First primary prostate epithelial surfaceome in the compendium.	jPOST	PXD031476;JPST001448	Surfaceome quantification data_20 PCa vs 8 BPH_proteinGroups.txt	sulfo-NHS-SS-biotin, 0.25 mg/ml, 30 min 4 C on washed intact primary cells, glycine quench, then RIPA lysis	Method as described in the paper's Methods 'Cell-surface proteome profiling by amine-reactive cell-surface biotinylation method'; Results para on Fig 1f (full text PMC10149505).	streptavidin agarose	not stated	Q Exactive HF		Instrument as listed in the ProteomeXchange record PXD031476.	Patient-derived primary cell cultures from 20 prostate cancer (Gleason 6-10) and 8 benign prostatic hyperplasia (BPH) specimens	Deposited MaxQuant proteinGroups 'Surfaceome quantification data_20 PCa vs 8 BPH' (4,950 protein groups, 56 LFQ columns = 28 cultures x 2 technical runs). Reverse, potential contaminant and only-by-site groups removed; protein Q-value <= 0.01. Membership per culture = LFQ intensity > 0 in both technical runs. No GO/TMHMM filter applied (the paper's 2,644 'cell-surface proteins' are a GO/TMHMM-selected subset and are not used).	Surfaceome quantification data_20 PCa vs 8 BPH_proteinGroups.txt: Protein IDs	Q-value ≤ 0.01 | drop rows flagged Reverse, Potential contaminant, Only identified by site	Benign prostatic hyperplasia primary cells, patient BPH-1 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity BPH1_1, LFQ intensity BPH1_2 (min_observed 2) | Benign prostatic hyperplasia primary cells, patient BPH-2 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity BPH2_1, LFQ intensity BPH2_2 (min_observed 2) | Benign prostatic hyperplasia primary cells, patient BPH-3 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity BPH3_1, LFQ intensity BPH3_2 (min_observed 2) | Benign prostatic hyperplasia primary cells, patient BPH-5 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity BPH5_1, LFQ intensity BPH5_2 (min_observed 2) | Benign prostatic hyperplasia primary cells, patient BPH-6 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity BPH6_1, LFQ intensity BPH6_2 (min_observed 2) | Benign prostatic hyperplasia primary cells, patient BPH-7 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity BPH7_1, LFQ intensity BPH7_2 (min_observed 2) | Benign prostatic hyperplasia primary cells, patient BPH-8 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity BPH8_1, LFQ intensity BPH8_2 (min_observed 2) | Benign prostatic hyperplasia primary cells, patient BPH-9 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity BPH9_1, LFQ intensity BPH9_2 (min_observed 2) | Prostate cancer primary cells, patient GS 6-2 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS6-2_1, LFQ intensity GS6-2_2 (min_observed 2) | Prostate cancer primary cells, patient GS 6-5 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS6-5_1, LFQ intensity GS6-5_2 (min_observed 2) | Prostate cancer primary cells, patient GS 6-6 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS6-6_1, LFQ intensity GS6-6_2 (min_observed 2) | Prostate cancer primary cells, patient GS 6-7 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS6-7_1, LFQ intensity GS6-7_2 (min_observed 2) | Prostate cancer primary cells, patient GS 7-3 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS7-3_1, LFQ intensity GS7-3_2 (min_observed 2) | Prostate cancer primary cells, patient GS 7-5 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS7-5_1, LFQ intensity GS7-5_2 (min_observed 2) | Prostate cancer primary cells, patient GS 7-6 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS7-6_1, LFQ intensity GS7-6_2 (min_observed 2) | Prostate cancer primary cells, patient GS 7-7 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS7-7_1, LFQ intensity GS7-7_2 (min_observed 2) | Prostate cancer primary cells, patient GS 7-8 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS7-8_1, LFQ intensity GS7-8_2 (min_observed 2) | Prostate cancer primary cells, patient GS 8-1 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS8-1_1, LFQ intensity GS8-1_2 (min_observed 2) | Prostate cancer primary cells, patient GS 8-2 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS8-2_1, LFQ intensity GS8-2_2 (min_observed 2) | Prostate cancer primary cells, patient GS 8-4 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS8-4_1, LFQ intensity GS8-4_2 (min_observed 2) | Prostate cancer primary cells, patient GS 8-5 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS8-5_1, LFQ intensity GS8-5_2 (min_observed 2) | Prostate cancer primary cells, patient GS 9-1 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS9-1_1, LFQ intensity GS9-1_2 (min_observed 2) | Prostate cancer primary cells, patient GS 9-3 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS9-3_1, LFQ intensity GS9-3_2 (min_observed 2) | Prostate cancer primary cells, patient GS 9-4 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS9-4_1, LFQ intensity GS9-4_2 (min_observed 2) | Prostate cancer primary cells, patient GS 9-5 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS9-5_1, LFQ intensity GS9-5_2 (min_observed 2) | Prostate cancer primary cells, patient GS 9-6 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS9-6_1, LFQ intensity GS9-6_2 (min_observed 2) | Prostate cancer primary cells, patient GS 10-1 / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity GS10-1_1, LFQ intensity GS10-1_2 (min_observed 2) | Prostate cancer primary cells, Gleason 8 culture run in the 0504 batch (column 0504GS8; most likely GS 8-2, not stated) / baseline sulfo-NHS-SS-biotin labeled primary culture: LFQ intensity 0504GS8_1, LFQ intensity 0504GS8_2 (min_observed 2)	3989	509	0.127600902481825	0.2	Homo sapiens		0	0	3989
potts-pbmc-pmp-2023	Peripheral blood mononuclear cell plasma membrane profiling, healthy vs COVID-19	Potts et al. 2023	Potts M	2023	37302069	10.1016/j.celrep.2023.112613	core		Weekes-lab PMP on primary PBMCs; healthy-control channels in each of two independent multiplexes define membership, so it rests on unperturbed donor cells. PBMC is a mixed population (T, B, NK cells, monocytes); proteins come from whichever subset expresses them.	PRIDE	PXD040703	mmc5.xlsx sheet F - PMP All Data in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC10243220/supplementaryFiles>	periodate/aminooxy-biotin PMP on live thawed PBMCs	Method as described in the paper's STAR Methods 'Plasma membrane profiling' (full text PMC10243220).	high-affinity streptavidin agarose (Pierce)	not stated	Orbitrap Fusion Lumos		Instrument as listed in the ProteomeXchange record PXD040703.	Primary human peripheral blood mononuclear cells (PBMC)	Table S3 (mmc5.xlsx) 'F - PMP All Data' (597 proteins; Species all HUMAN). Membership = reporter > 0 in a healthy-control channel within PMP1 (CV0902, CV0904, CV0902 repeat) or within PMP2 (CV0915, CV0917, CV0939). COVID-19 donor channels kept as non-membership measurements; ratio columns, the 'PM?' and 'RBC?' annotation columns and the WCL sheets are not used to select rows. Healthy-control identity: CV09xx donors are controls in Table S1 ('S2' sheet) and are the channels without a '_Ratio' column (ratios are to healthy controls).	mmc5.xlsx: Protein Id	Species = HUMAN	PBMC / healthy-control donors, PMP (multiplex PMP1): CV0902_PMP1, CV0904_PMP1, CV0902_2_PMP1 (min_observed 1) | PBMC / healthy-control donors, PMP (multiplex PMP2): CV0915_PMP2, CV0917_PMP2, CV0939_PMP2 (min_observed 1) | PBMC / COVID-19 donors, severity classes A-E (not used for membership): CV0025_PMP1, CV0144_PMP1, CV0052_PMP1, CV0059_PMP1, CV0068_PMP1, CV0074_PMP1, CV0084_PMP1, CV0176_PMP1, CV0200_PMP1, CV0050_PMP2, CV0058_PMP2, CV0062_PMP2, CV0073_PMP2, CV0155_PMP2, CV0160_PMP2, CV0171_PMP2, CV0180_PMP2, CV0198_PMP2, CV0201_PMP2, CV0231_PMP2, CV0257_PMP2, CV0279_PMP2 (min_observed 1)	555	266	0.47927927927927927	0.2	Homo sapiens		0	5	555
vit-ppgl-hptc-2023	Pheochromocytoma/paraganglioma and adrenal medulla hpTC membrane transmembrane peptides	Vit et al. 2023	Vit O	2023	37749499	10.1186/s12014-023-09428-7	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Carbonate-washed tissue membranes with transmembrane-segment enrichment: a membrane-fractionation input (complementary, no surface vote). Only PPGL and adrenal medulla membrane data in the compendium.	PRIDE	PXD039788	hptc_all_groups_lfq_proteinGroups.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/09/PXD039788/hptc_all_groups_lfq_proteinGroups.txt>	Hypotonic homogenization of pulverized tissue, 500 g clearing, DNase, 20,000 g membrane pellet washed twice in 100 mM Na2CO3; on-membrane trypsin at high pH, then CNBr in 70% TFA to release membrane-embedded transmembrane segments (hpTC); Orbitrap Fusion DDA; MaxQuant 1.6.0.7 LFQ, Swiss-Prot human 2021_05, 1% protein/PSM FDR.	Method as described in the paper's Methods 'Proteomic analyses' (hpTC, SPEG, N-glyco-FASP, SDC-trypsin) and 'Data processing'; PRIDE file list.	none (CNBr/trypsin on carbonate-washed membranes)	not stated	Orbitrap Fusion			Resected pheochromocytoma/paraganglioma tumors (22 patients: 15 cluster 1, 4 cluster 2, 3 unassigned) and pooled normal adrenal medulla (5 pools)	PRIDE PXD039788 hptc_all_groups_lfq_proteinGroups.txt: MaxQuant protein groups for all 22 tumors and 5 control pools searched together; reverse, contaminant and only-by-site groups removed. Membership = Intensity > 0 in >= 1 tumor of a molecular cluster (each tumor is a different patient) or in >= 2 of 5 adrenal-medulla pools. The paper's '>= 2 unique peptides in >= 80% of a group' filter (used for its statistics), its deepTMHMM/GO plasma-membrane selections and the per-cluster re-searches are not used. The SDC-trypsin arm is a total tissue lysate and is not ingested.	hptc_all_groups_lfq_proteinGroups.txt: Protein IDs	drop rows flagged Reverse, Potential contaminant, Only identified by site	Cluster 1 (pseudohypoxia) PPGL tumor tissue, 15 patients / surgical tissue, carbonate-washed crude membranes, hpTC transmembrane-peptide enrichment: Intensity CL1_1, Intensity CL1_2, Intensity CL1_3, Intensity CL1_4, Intensity CL1_5, Intensity CL1_6, Intensity CL1_7, Intensity CL1_8, Intensity CL1_9, Intensity CL1_10, Intensity CL1_11, Intensity CL1_12, Intensity CL1_13, Intensity CL1_14, Intensity CL1_15 (min_observed 1) | Cluster 2 (kinase-signalling, RET) PPGL tumor tissue, 4 patients / surgical tissue, carbonate-washed crude membranes, hpTC transmembrane-peptide enrichment: Intensity CL2_16, Intensity CL2_17, Intensity CL2_18, Intensity CL2_19 (min_observed 1) | Unassigned (no known driver variant) PPGL tumor tissue, 3 patients / surgical tissue, carbonate-washed crude membranes, hpTC transmembrane-peptide enrichment: Intensity SPOR_20, Intensity SPOR_21, Intensity SPOR_22 (min_observed 1) | Normal adrenal medulla, 5 pools of 10 donors / surgical tissue, carbonate-washed crude membranes, hpTC transmembrane-peptide enrichment: Intensity CTRL1, Intensity CTRL2, Intensity CTRL3, Intensity CTRL4, Intensity CTRL5 (min_observed 2)	2158	412	0.19091751621872105	0.2	Homo sapiens		0	0	2158
shi-rd-ev71-2023	RD rhabdomyosarcoma enriched-membrane iTRAQ, mock reference channel	Shi et al. 2023	Shi H	2023	36254857	10.1002/pmic.202200362	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis-then-membrane-enrichment of a rhabdomyosarcoma line; complementary by family policy. baseline_verified is false because the 114 = mock channel assignment is inferred, not read from the (closed-access) paper.	iProX	PXD036208;IPX0004890000	ProteinPilot_ZLJ-W-first_ProteinSummary114-zlj-20190113.xls <http://download.iprox.org/IPX0004890000/IPX0004890001/ProteinPilot_ZLJ-W-first_ProteinSummary114-zlj-20190113.xls> | ProteinPilot_ZLJ-W-second_ProteinSummary114-zlj-20190114.xls <http://download.iprox.org/IPX0004890000/IPX0004890001/ProteinPilot_ZLJ-W-second_ProteinSummary114-zlj-20190114.xls>	membrane enrichment after lysis, iTRAQ 4-plex (PX/iProX description and Proteomics 2023 abstract)	Method read from: ProteomeXchange PXD036208 description; Europe PMC abstract of PMID 36254857 (full text closed).	none	not stated	Q Exactive		Instrument as listed in the ProteomeXchange record PXD036208.	RD embryonal rhabdomyosarcoma cell line	Both iProX ProteinPilot ProteinSummary files (run 'first' 2,542 rows, run 'second' 2,156 rows; already cut at Unused >= 1.3, i.e. 95% protein confidence). Reversed decoys dropped. Membership = protein with a quantified 114 (mock reference) reporter, read as any non-empty 115:114, 116:114 or 117:114 ratio, in either run; ratio values are infected:mock and are kept as measurements only. The 114 = mock assignment is inferred from the ProteinPilot file names ('ProteinSummary114') and the time-course design in the abstract, not read from the paper.	ProteinPilot_ZLJ-W-first_ProteinSummary114-zlj-20190113.xls: Accession | ProteinPilot_ZLJ-W-second_ProteinSummary114-zlj-20190114.xls: Accession	Unused ≥ 1.3 | drop rows where Name matches REVERSED | Unused ≥ 1.3 | drop rows where Name matches REVERSED	RD / mock reference channel 114 quantified, iTRAQ run 1: 115:114, 116:114, 117:114 (min_observed 1) | RD / mock reference channel 114 quantified, iTRAQ run 2: 115:114, 116:114, 117:114 (min_observed 1)	2892	490	0.169432918395574	0.2	Homo sapiens		0	0	2892
jayabal-retinoblastoma-2023	Retinoblastoma Y79 and RB383 sulfo-NHS-SS-biotin surfaceomes	Jayabal et al. 2023	Jayabal P	2023	36773293	10.1016/j.celrep.2023.112103	below_screen	8% Canonical or Likely proteins, under 20%	Intact-cell sulfo-NHS-SS-biotin capture on untreated retinoblastoma cells; the deposited ProteinProphet results are the full identification sets. Single labeling per line and no no-label control, so membership is identification-level only. First retinoblastoma (retinal tumor) surfaceome in the compendium.	PRIDE	PXD039517;PXD039518	jayabal_y79_proteinprophet_p0.9.tsv | jayabal_rb383_proteinprophet_p0.9.tsv	EZ-Link sulfo-NHS-SS-biotin on intact cells (protocol cited as ref 45), streptavidin agarose	Method as described in the paper's STAR Methods 'Mass spectrometry'; PRIDE PXD039517/PXD039518 protocols (full text PMC10412738).	streptavidin agarose	not stated	LTQ Orbitrap Velos		Instrument as listed in the ProteomeXchange records PXD039517 and PXD039518.	Retinoblastoma cell lines Y79 and patient-derived RB383	ProteinProphet protXML per line (PXD039517 Y79, PXD039518 RB383). Proteins with ProteinProphet probability >= 0.9 (protein FDR 0.9% Y79, 0.8% RB383 per the protXML error table, as stated in the paper); CONTAM_ entries removed. Every passing protein is a member (single labeling run per line). No annotation filter; the paper's Tables S4/S5 (high-confidence lists) are not in the Europe PMC supplement.	jayabal_y79_proteinprophet_p0.9.tsv: uniprot_accession | jayabal_rb383_proteinprophet_p0.9.tsv: uniprot_accession	protein_probability ≥ 0.9 | protein_probability ≥ 0.9	Y79 / baseline sulfo-NHS-SS-biotin labeled intact cells: total_number_peptides (min_observed 1) | RB383 / baseline sulfo-NHS-SS-biotin labeled intact cells: total_number_peptides (min_observed 1)	2894	224	0.07740152038700761	0.2	Homo sapiens		0	0	2894
rms-2023	Rhabdomyosarcoma proteomics 2023	Timpanaro et al. 2023	Timpanaro A	2023	36768928	10.3390/ijms24032601	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Current reconstructed proteinGroups come from membrane fractionation, not the separate biotinylation pilot. MRC5/myoblast ratios are biological comparisons. Retain as complementary evidence only; membrane fractionation cannot establish extracellular access.			proteinGroups.txt in 20210720_MQout_AT.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/03/PXD039480/20210720_MQout_AT.zip> | mqpar.xml in 20210720_MQout_AT.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/03/PXD039480/20210720_MQout_AT.zip> | summary.txt in 20210720_MQout_AT.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/03/PXD039480/20210720_MQout_AT.zip>	NOT a cell-surface labeling method. Membrane/surface proteins were enriched by differential (ultra)centrifugation: 1e7 cells scraped, hypotonic buffer (50 mM mannitol / 5 mM HEPES), 1 min sonication, 600 g clearing, then 15,000 g, CaCl2 wash, 3,000 g, 48,000 g pelleting with high-pH / high-salt washes to strip peripheral proteins; the membrane pellet was digested and analysed by LC-MS/MS (MaxQuant). The authors compared this with Sulfo-NHS-SS-biotin surface biotinylation (Thermo kit A44390, NeutrAvidin agarose, DTT elution) only in a pilot on Rh4 cells, found ~49% intracellular proteins with biotinylation vs ~35% with centrifugation, and used centrifugation for all 11 RMS lines, 3 PDXs, MRC-5 and myoblast controls. No surface-labeling evidence exists for the inventory table; surface membership is annotation-based (Bausch-Fluck list).	Method as described in the paper's Results 2.1 and Methods 4.2 'Cell Surface Proteins Isolation' (Int J Mol Sci 2023; full text PMC9917031).	none (membrane fractionation); NeutrAvidin agarose from Thermo kit A44390 used only in the discarded pilot	not applicable	Orbitrap Fusion Lumos		Instrument as listed in the ProteomeXchange record PXD039480.	Rhabdomyosarcoma cell lines and patient-derived xenografts; myoblast and MRC-5 controls; membrane fractions	Differential centrifugation membrane fraction, Table S1 RMS/PDX iTop3 means after peptide-level imputation; not the separate biotinylation pilot	proteinGroups.txt: Majority protein IDs	Q-value ≤ 0.01 | drop rows flagged Reverse, Potential contaminant, Only identified by site	JR / baseline membrane fraction: LFQ intensity JR_1, LFQ intensity JR_2, LFQ intensity JR_3 (min_observed 2) | MRC5 / baseline membrane fraction: LFQ intensity MRC5_1, LFQ intensity MRC5_2, LFQ intensity MRC5_3 (min_observed 2) | Myo / baseline membrane fraction: LFQ intensity Myo_1, LFQ intensity Myo_2, LFQ intensity Myo_3 (min_observed 2) | PDXs16 / baseline membrane fraction: LFQ intensity PDXs16_1, LFQ intensity PDXs16_2, LFQ intensity PDXs16_3 (min_observed 2) | PDXs29 / baseline membrane fraction: LFQ intensity PDXs29_1, LFQ intensity PDXs29_2, LFQ intensity PDXs29_3 (min_observed 2) | PDXs35 / baseline membrane fraction: LFQ intensity PDXs35_1, LFQ intensity PDXs35_2, LFQ intensity PDXs35_3 (min_observed 2) | RD / baseline membrane fraction: LFQ intensity RD_1, LFQ intensity RD_2, LFQ intensity RD_3 (min_observed 2) | RH4 / baseline membrane fraction: LFQ intensity RH4_1, LFQ intensity RH4_2, LFQ intensity RH4_3 (min_observed 2) | RMS / baseline membrane fraction: LFQ intensity RMS_1, LFQ intensity RMS_2, LFQ intensity RMS_3 (min_observed 2) | Rh18 / baseline membrane fraction: LFQ intensity Rh18_1, LFQ intensity Rh18_2, LFQ intensity Rh18_3 (min_observed 2) | Rh28 / baseline membrane fraction: LFQ intensity Rh28_1, LFQ intensity Rh28_2, LFQ intensity Rh28_3 (min_observed 2) | Rh30 / baseline membrane fraction: LFQ intensity Rh30_1, LFQ intensity Rh30_2, LFQ intensity Rh30_3 (min_observed 2) | Rh36 / baseline membrane fraction: LFQ intensity Rh36_1, LFQ intensity Rh36_2, LFQ intensity Rh36_3 (min_observed 2) | Rh5 / baseline membrane fraction: LFQ intensity Rh5_1, LFQ intensity Rh5_2, LFQ intensity Rh5_3 (min_observed 2) | Ruch3 / baseline membrane fraction: LFQ intensity Ruch3_1, LFQ intensity Ruch3_2, LFQ intensity Ruch3_3 (min_observed 2) | TTC442 / baseline membrane fraction: LFQ intensity TTC442_1, LFQ intensity TTC442_2, LFQ intensity TTC442_3 (min_observed 2)	6616	768	0.11608222490931076	0.2	Homo sapiens	Human cancer in mouse hosts; sample origin does not establish species specificity of every peptide. Host/species-ambiguous evidence must be excluded.			6610
harant-sma-srm-2023--sma-resistant-membrane-fragments-of-jurkat-mutant-lines	SMA-resistant raft-like membrane fragments of nine human cell types · Jurkat mutant lines	Harant et al. 2023	Harant K	2023	36898346	10.1016/j.bpc.2023.106989	perturbed	genetic perturbation: SMA-resistant membrane fragments of Jurkat mutant lines	genetic perturbation arm of harant-sma-srm-2023; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD031828	proteinGroups.reviewed_lead.tsv	SMA copolymer solubilisation, sucrose-gradient separation of SMA-resistant membrane fragments (PRIDE protocol; paper not open access)	Method read from: PXD031828 project description, sample/data processing protocols and mqpar.xml (raw-file-to-experiment map).	none	not stated	Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD031828.	Jurkat mutants (GPI-anchor-deficient; J.CaM1 Lck-deficient)	Jurkat mutants (GPI-anchor-deficient; J.CaM1 Lck-deficient), SMA-resistant membrane fragments of Jurkat mutant lines: a non-baseline state of harant-sma-srm-2023, listed when observed in at least 1 of its 2 samples				1522	154	0.1011826544021025		Homo sapiens		0	11	1522
harant-sma-srm-2023	SMA-resistant raft-like membrane fragments of nine human cell types · nine cell types (baseline)	Harant et al. 2023	Harant K	2023	36898346	10.1016/j.bpc.2023.106989	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Raft-like membrane fraction after SMA solubilisation of lysed membranes: membrane fractionation, complementary by family policy. Single SRM sample per line, no replicates; the paper's Table S1 is a selected list (SRM/lysate ratio > 5 in >= 3 lines) and is not used.	PRIDE	PXD031828	proteinGroups.reviewed_lead.tsv	SMA copolymer solubilisation, sucrose-gradient separation of SMA-resistant membrane fragments (PRIDE protocol; paper not open access)	Method read from: PXD031828 project description, sample/data processing protocols and mqpar.xml (raw-file-to-experiment map).	none	not stated	Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD031828.	Jurkat, KG1a, HL-60, K562, Nalm6, Ramos, HEK 293 and HeLa lines; human erythrocytes	PXD031828 proteinGroups.txt (MaxQuant, 1% protein FDR): reverse, potential-contaminant and only-by-site groups removed; lead accession = first Swiss-Prot member of the group (5,921 of 6,579 groups; the search database listed TrEMBL entries first). Membership = Intensity > 0 in the SRM experiment of a line (each a single SRM sample from two fraction runs; experiment-to-raw-file map read from the deposited mqpar.xml: two-run experiments named by line are SRMs, single-run '<line> all' are total lysates). Total lysates, Jurkat GPI-anchor-deficient and J.CaM1 mutant SRMs, negative control, medium and a 'Jurkat new' test run kept as non-membership measurements. The 'KG1' experiment is a single 859-series run like the other total lysates and is treated as a lysate.	proteinGroups.reviewed_lead.tsv: lead_reviewed_accession	drop rows flagged Reverse, Potential contaminant, Only identified by site	Jurkat T-ALL / SMA-resistant membrane fragments (raft-like), gradient fractions 1-5: Intensity Jurkat (min_observed 1) | KG1a AML / SMA-resistant membrane fragments (raft-like), gradient fractions 1-5: Intensity KG1a (min_observed 1) | erythrocytes / SMA-resistant membrane fragments (raft-like), gradient fractions 1-5: Intensity Ery (min_observed 1) | HEK 293 / SMA-resistant membrane fragments (raft-like), gradient fractions 1-5: Intensity HEK 293 (min_observed 1) | HeLa / SMA-resistant membrane fragments (raft-like), gradient fractions 1-5: Intensity HeLa (min_observed 1) | Nalm6 B-ALL / SMA-resistant membrane fragments (raft-like), gradient fractions 1-5: Intensity Nalm6 (min_observed 1) | Ramos Burkitt lymphoma / SMA-resistant membrane fragments (raft-like), gradient fractions 1-5: Intensity Ramos (min_observed 1) | HL-60 AML / SMA-resistant membrane fragments (raft-like), gradient fractions 1-5: Intensity HL-60 (min_observed 1) | K562 CML / SMA-resistant membrane fragments (raft-like), gradient fractions 1-5: Intensity K562 (min_observed 1) | Jurkat mutants (GPI-anchor-deficient; J.CaM1 Lck-deficient) / SMA-resistant membrane fragments of Jurkat mutant lines (not used for membership): Intensity J-GPI-, Intensity J.Cam.1 (min_observed 1) | same lines, total lysates / total cell lysate comparators (not used for membership): Intensity Jurkat all, Intensity ramos all, Intensity HL 60 all, Intensity gpi all, Intensity lck all, Intensity rbc all, Intensity hek all, Intensity hela all, Intensity k652 all, Intensity nalm all, Intensity KG1 (min_observed 1) | controls / negative control, culture medium and an unlabeled Jurkat test run (not used for membership): Intensity neg ctrl, Intensity medium, Intensity Jurkat new (min_observed 1)	3727	397	0.10651998926750737	0.2	Homo sapiens		0	52	3727
vilen-apex-2022	Vilen APEX human author calls	Vilen et al. 2023	Vilen Z	2023	35443134	10.1021/acschembio.1c00865	annotation_selected	author pre-filtered to transmembrane or signal-peptide proteins	pre-filtered by surface annotation (annotation-selected); shown, not counted. Was provisional. provisional: Method-specific author selected calls from human Tables S1/S3/S4; one publication across both arms. Missing earlier-stage export and inconsistent printed p thresholds prevent reconstruction of author statistics. Topology proxy penalizes unknown selection; context union is detection only. No numerical negative-control values recovered.	PRIDE	PXD031845	cb1c00865_si_001.pdf <https://ndownloader.figshare.com/files/34856429>	Cell-surface engineering + APEX2 radical biotinylation on live HPAF-II pancreatic adenocarcinoma cells (2D adherent culture; 3D spheroids and two other lines in other arms): GGGYC-PEG2000-cholesterol inserted into membranes (1 h, 37 C), APEX2-LPETG conjugated to it by engineered sortase A (1 h, 37 C), then 500 uM biotin phenol in serum-free medium + 1.3 mM CaCl2 (30 min) and 1 mM H2O2 for 1 to 2 min; quenched with azide/Trolox/ascorbate. Compared head-to-head with the sialic-acid (periodate/aminooxy-biotin) method. Cells lysed by sonication, methanol precipitation, 6 M urea/SDS, TCEP/IAA, capture on streptavidin agarose beads (1.5 h RT), on-bead trypsin digestion, TMT labeling (Thermo A34808), Orbitrap Fusion Tribrid LC-MS/MS. Labeling was dependent on APEX2, lipid and sortase (microscopy controls).	Method as described in the paper's Methods 'Cell surface labeling' and 'Proteomics preparation' (ACS Chem Biol 2022; full text PMC9901301).	streptavidin agarose beads (vendor/catalog not stated)	not reported	Orbitrap Fusion			HPAF-II pancreatic adenocarcinoma (2D and 3D); JEG-3 choriocarcinoma (2D)	HPAF-II pancreatic adenocarcinoma (2D and 3D); JEG-3 choriocarcinoma (2D)				379	243	0.6411609498680739	0.47085130205355774	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			379
vilen-sia-2022	Vilen SIA human author calls	Vilen et al. 2023	Vilen Z	2023	35443134	10.1021/acschembio.1c00865	annotation_selected	author pre-filtered to transmembrane or signal-peptide proteins	pre-filtered by surface annotation (annotation-selected); shown, not counted. Was provisional. provisional: Method-specific author selected calls from human Tables S1/S3/S4; one publication across both arms. Missing earlier-stage export and inconsistent printed p thresholds prevent reconstruction of author statistics. Topology proxy penalizes unknown selection; context union is detection only. No numerical negative-control values recovered.	PRIDE	PXD031845	cb1c00865_si_001.pdf <https://ndownloader.figshare.com/files/34856429>	Cell-surface engineering + APEX2 radical biotinylation on live HPAF-II pancreatic adenocarcinoma cells (2D adherent culture; 3D spheroids and two other lines in other arms): GGGYC-PEG2000-cholesterol inserted into membranes (1 h, 37 C), APEX2-LPETG conjugated to it by engineered sortase A (1 h, 37 C), then 500 uM biotin phenol in serum-free medium + 1.3 mM CaCl2 (30 min) and 1 mM H2O2 for 1 to 2 min; quenched with azide/Trolox/ascorbate. Compared head-to-head with the sialic-acid (periodate/aminooxy-biotin) method. Cells lysed by sonication, methanol precipitation, 6 M urea/SDS, TCEP/IAA, capture on streptavidin agarose beads (1.5 h RT), on-bead trypsin digestion, TMT labeling (Thermo A34808), Orbitrap Fusion Tribrid LC-MS/MS. Labeling was dependent on APEX2, lipid and sortase (microscopy controls).	Method as described in the paper's Methods 'Cell surface labeling' and 'Proteomics preparation' (ACS Chem Biol 2022; full text PMC9901301).	streptavidin agarose beads (vendor/catalog not stated)	not reported	Orbitrap Fusion			HPAF-II pancreatic adenocarcinoma (2D and 3D); JEG-3 choriocarcinoma (2D)	HPAF-II pancreatic adenocarcinoma (2D and 3D); JEG-3 choriocarcinoma (2D)				360	240	0.6666666666666666	0.47085130205355774	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			360
sbiosite-2023	sBioSITe PC-3	Garapati et al. 2023	Garapati K	2023	38053024	10.1186/s12014-023-09445-6	core		Original identification and specimen caveats retained in previous_reason.	PRIDE	PXD044519	control_surface_proteins.tsv	surface Biotinylation Site Identification Technology (sBioSITe): live PC-3 cells (~80% confluent, four 15 cm dishes per replicate, 3 replicates) washed and incubated with 0.4 mM membrane-impermeant NON-cleavable sulfo-NHS-LC-biotin (APExBIO) in ice-cold PBS for 30 min at 4 C, quenched twice with 50 mM glycine, scraped and pelleted. Modified-RIPA lysis with sonication, 6 mg protein reduced/alkylated and trypsin digested, C18 desalted; biotinylated PEPTIDES enriched 2 h at 4 C on agarose-immobilized rabbit anti-biotin antibody (Bethyl A150-109A), washed, eluted with 80% ACN / 0.2% TFA; Orbitrap Exploris 480, Sequest HT + Percolator 1% FDR. Surface call = biotinylated peptide detected in all three replicates (Table S2); peptide-level site evidence (biotinylated lysine) proves extracellular exposure at labeling time.	Method as described in the paper's Methods 'Cell culture and labeling of surface proteins', 'Enrichment of biotinylated peptides' (Clin Proteomics 2023; full text PMC10696767).	agarose-immobilized rabbit anti-biotin antibody (Bethyl Laboratories A150-109A); sulfo-NHS-LC-biotin from APExBIO (not Thermo)	not reported	Orbitrap Exploris 480			PC-3 prostate cancer cells	Human cell line: PC-3 prostate cancer (adherent, cultured in 15 cm dishes).	control_surface_proteins.tsv: uniprot_accession			1409	424	0.30092264017033354	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			1408
fielding-a549-pmp-2022	A549-ACE2-TMPRSS2 plasma membrane profiling, mock vs SARS-CoV-2	Fielding et al. 2022	Fielding CA	2022	35587364	10.7554/elife.74489	core		Weekes/Stanton-lab PMP (same aminooxy-biotin method as the other Weekes entries) with triplicate mock channels. The cell line is an engineered cancer line, and the paper's 'Membrane' GO flag is not applied.	PRIDE	PXD025000	elife-74489-supp1.xlsx sheet Master in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9239683/supplementaryFiles>	Plasma membrane profiling (Weekes lab): live-cell sodium periodate/aniline oxidation of sialic-acid glycans and aminooxy-biotin labeling, streptavidin enrichment, on-bead trypsin digestion, TMT multiplexing, LC-MS3. One TMT plex: mock and 12/24/48 h SARS-CoV-2 (MOI 5), biological triplicates; PEAKS search, SwissProt then TrEMBL.	Method summarized from the paper (PMC9239683) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD025000.	A549 lung adenocarcinoma line engineered to express ACE2 and TMPRSS2 (AAT)	Supplementary file 1 'Master' sheet (6,421 protein rows; the 'Membrane' GO column is an annotation, not a filter, and is not used). Rows restricted to #Unique >= 2, the authors' quantification filter (4,953 proteins, matching the paper), and Taxonomy = Homo sapiens. Membership = >= 2 of 3 Mock TMT channels > 0. 12 h, 24 h and 48 h infected channels kept as non-membership measurements.	elife-74489-supp1.xlsx: Accession	Taxonomy = Homo sapiens | #Unique ≥ 2	A549-ACE2-TMPRSS2 (AAT) / baseline mock-infected, PMP: Mock_1, Mock_2, Mock_3 (min_observed 2) | A549-ACE2-TMPRSS2 (AAT) / SARS-CoV-2 12 h (not used for membership): 12h_1, 12h_2, 12h_3 (min_observed 2) | A549-ACE2-TMPRSS2 (AAT) / SARS-CoV-2 24 h (not used for membership): 24h_1, 24h_2, 24h_3 (min_observed 2) | A549-ACE2-TMPRSS2 (AAT) / SARS-CoV-2 48 h (not used for membership): 48h_1, 48h_2, 48h_3 (min_observed 2)	4930	728	0.14766734279918864	0.2	Homo sapiens		0	0	4930
capdeville-daoy-2022--daoy-sgcontrol-hgf-20-ng-ml-30-min	DAOY medulloblastoma sulfo-NHS surfaceome · HGF 20 ng/mL 30 min	Capdeville et al. 2022	Capdeville C	2022	35296518	10.26508/lsa.202201380	perturbed	drug, ligand or treatment: HGF 20 ng/mL 30 min	drug, ligand or treatment arm of capdeville-daoy-2022; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD030597	MQ-report-Proteomics-p3067_AllKO_vs_AllContrl.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2022/03/PXD030597/MQ-report-Proteomics-p3067_AllKO_vs_AllContrl.txt> | sdrf.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2022/03/PXD030597/PXD030597_community_annotated.sdrf.tsv>	EZ-Link sulfo-NHS-SS-biotin labeling of intact cells at 4 C, NeutrAvidin capture, DTT elution, iST digestion; DDA on a Q Exactive HF-X; MaxQuant 1.6.2.3 (peptide FDR 1%, protein FDR 5%), SRMService report filtered to >= 2 peptides.	Method summarized from the paper (PMC8926928) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive HF-X; Q Exactive HF			DAOY sgControl	DAOY sgControl, HGF 20 ng/mL 30 min: a non-baseline state of capdeville-daoy-2022, listed when observed in at least 2 of its 4 samples				4319	409	0.09469784672377865		Homo sapiens		0	0	4319
capdeville-daoy-2022--daoy-sgmap4k4-map4k4-knockout-hgf	DAOY medulloblastoma sulfo-NHS surfaceome · MAP4K4 knockout + HGF	Capdeville et al. 2022	Capdeville C	2022	35296518	10.26508/lsa.202201380	perturbed	genetic perturbation: MAP4K4 knockout + HGF	genetic perturbation arm of capdeville-daoy-2022; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD030597	MQ-report-Proteomics-p3067_AllKO_vs_AllContrl.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2022/03/PXD030597/MQ-report-Proteomics-p3067_AllKO_vs_AllContrl.txt> | sdrf.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2022/03/PXD030597/PXD030597_community_annotated.sdrf.tsv>	EZ-Link sulfo-NHS-SS-biotin labeling of intact cells at 4 C, NeutrAvidin capture, DTT elution, iST digestion; DDA on a Q Exactive HF-X; MaxQuant 1.6.2.3 (peptide FDR 1%, protein FDR 5%), SRMService report filtered to >= 2 peptides.	Method summarized from the paper (PMC8926928) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive HF-X; Q Exactive HF			DAOY sgMAP4K4	DAOY sgMAP4K4, MAP4K4 knockout + HGF: a non-baseline state of capdeville-daoy-2022, listed when observed in at least 2 of its 4 samples				4323	419	0.0969234328012954		Homo sapiens		0	0	4323
capdeville-daoy-2022--daoy-sgmap4k4-map4k4-knockout-serum-starved	DAOY medulloblastoma sulfo-NHS surfaceome · MAP4K4 knockout, serum-starved	Capdeville et al. 2022	Capdeville C	2022	35296518	10.26508/lsa.202201380	perturbed	genetic perturbation: MAP4K4 knockout, serum-starved	genetic perturbation arm of capdeville-daoy-2022; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD030597	MQ-report-Proteomics-p3067_AllKO_vs_AllContrl.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2022/03/PXD030597/MQ-report-Proteomics-p3067_AllKO_vs_AllContrl.txt> | sdrf.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2022/03/PXD030597/PXD030597_community_annotated.sdrf.tsv>	EZ-Link sulfo-NHS-SS-biotin labeling of intact cells at 4 C, NeutrAvidin capture, DTT elution, iST digestion; DDA on a Q Exactive HF-X; MaxQuant 1.6.2.3 (peptide FDR 1%, protein FDR 5%), SRMService report filtered to >= 2 peptides.	Method summarized from the paper (PMC8926928) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive HF-X; Q Exactive HF			DAOY sgMAP4K4	DAOY sgMAP4K4, MAP4K4 knockout, serum-starved: a non-baseline state of capdeville-daoy-2022, listed when observed in at least 2 of its 4 samples				4292	418	0.09739049394221808		Homo sapiens		0	0	4292
capdeville-daoy-2022	DAOY medulloblastoma sulfo-NHS surfaceome · serum-starved, no HGF (baseline)	Capdeville et al. 2022	Capdeville C	2022	35296518	10.26508/lsa.202201380	core		Intact-cell sulfo-NHS-SS-biotin capture; the PRIDE MaxQuant report is the full >= 2-peptide list before the paper's TMHMM/PM-annotation filtering, and the starved sgControl runs give a baseline. Protein FDR was 5%, looser than usual.	PRIDE	PXD030597	MQ-report-Proteomics-p3067_AllKO_vs_AllContrl.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2022/03/PXD030597/MQ-report-Proteomics-p3067_AllKO_vs_AllContrl.txt> | sdrf.tsv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2022/03/PXD030597/PXD030597_community_annotated.sdrf.tsv>	EZ-Link sulfo-NHS-SS-biotin labeling of intact cells at 4 C, NeutrAvidin capture, DTT elution, iST digestion; DDA on a Q Exactive HF-X; MaxQuant 1.6.2.3 (peptide FDR 1%, protein FDR 5%), SRMService report filtered to >= 2 peptides.	Method summarized from the paper (PMC8926928) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive HF-X; Q Exactive HF			DAOY medulloblastoma cell line (sgControl CRISPR line)	MQ-report-Proteomics-p3067_AllKO_vs_AllContrl.txt (4,563 protein groups, >= 2 peptides). Leading REV__/CON__ groups excluded. Membership = raw intensity > 0 in >= 2 of 4 sgControl serum-starved runs (gC_0); sgControl + HGF (gC_1) and sgMAP4K4 runs (gM4_0, gM4_1) kept as measurements only. Paper Tables S1-S2 (TMHMM / PM-annotation filtered) not used.	MQ-report-Proteomics-p3067_AllKO_vs_AllContrl.txt: TopProteinName	drop rows where ProteinName matches ^(?:REV__|CON__)	DAOY sgControl / serum-starved, no HGF (baseline intact-cell sulfo-NHS-SS-biotin): 003_S197173_gC_0_2_Control.raw, 008_S197172_gC_0_1_Control.raw, 009_S197175_gC_0_4_Control.raw, 010_S197174_gC_0_3_Control.raw (min_observed 2) | DAOY sgControl / HGF 20 ng/mL 30 min (not used for membership): 002_S197176_gC_1_1_Control_nodil.raw, 004_S197178_gC_1_3_Control.raw, 018_S197177_gC_1_2_Control.raw, 020_S197179_gC_1_4_Control.raw (min_observed 2) | DAOY sgMAP4K4 / MAP4K4 knockout, serum-starved (not used for membership): 013_S197183_gM4_0_4_KO.raw, 016_S197182_gM4_0_3_KO.raw, 019_S197180_gM4_0_1_KO.raw, 021_S197181_gM4_0_2_KO.raw (min_observed 2) | DAOY sgMAP4K4 / MAP4K4 knockout + HGF (not used for membership): 005_S197185_gM4_1_2_KO.raw, 007_S197187_gM4_1_4_KO.raw, 014_S197184_gM4_1_1_KO.raw, 015_S197186_gM4_1_3_KO.raw (min_observed 2)	4310	418	0.09698375870069606	0.2	Homo sapiens		0	0	4310
sheikh-hap1-seel-2022	HAP1 (DAG1-null) ST6GAL1 exo-enzymatic biotin-sialic acid labeling	Sheikh et al. 2022	Sheikh MO	2022	35750689	10.1038/s41467-022-31205-7	core		Enzymatic biotinylation of glycans on intact cells (an extracellular sialyltransferase cannot reach intracellular glycans), anti-biotin capture. The PRIDE summary is the complete 1% FDR list before the paper's figure filters. Single runs; the unlabeled control detects 202 of 264 rows at lower counts, so label-vs-control contrast should be read from the measurements. The line carries a DAG1 knockout (the model background, not a perturbation arm).	PRIDE	PXD024251	1-ProteomicsResultsSummary.xlsx sheet 18mer-SEEL.1PerPro <https://ftp.pride.ebi.ac.uk/pride/data/archive/2022/06/PXD024251/1-ProteomicsResultsSummary.xlsx>	ST6GAL1-mediated transfer of biotinylated CMP-Neu5Ac (+/- matriglycan) to intact HAP1-DAG1- cells, anti-biotin IP	Method read from: Results 'matriglycan modified cells' paragraph and Fig. 4e legend; Methods 'Cell-surface glyco-engineering'; PRIDE xlsx header rows.	anti-biotin antibody immunoprecipitation	not stated	Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD024251.	HAP1 near-haploid CML-derived line, DAG1 knockout	PRIDE 1-ProteomicsResultsSummary.xlsx sheet '18mer-SEEL.1PerPro' (264 protein rows, one per protein, contaminants removed, 1% FDR; columns per arm: Score, Peptides, % coverage, Normalized SC). Membership = Normalized SC > 0 in the Biotin-only arm or in the Biotin-18-mer arm (one run each; 225 and 178 rows, 239 together; columns checked against the Chart Summary sheet, e.g. PTK7 68 vs 22). Unlabeled-cell control (202 rows > 0) kept as a non-membership measurement. The sheet's 'Localization' column and the paper's figure filters (>= 10 SC, control-free, UniProt localisation, sequon) are not used.	1-ProteomicsResultsSummary.xlsx: UNIPROT ID		HAP1 DAG1- / baseline, ST6GAL1 SEEL with CMP-Neu5Ac-biotin: NSC_biotin_only (min_observed 1) | HAP1 DAG1- / baseline, ST6GAL1 SEEL with CMP-Neu5Ac-biotin-matriglycan (8 repeats): NSC_biotin_18mer (min_observed 1) | HAP1 DAG1- / unlabeled-cell negative control (not used for membership): NSC_unlabelled (min_observed 1)	227	86	0.3788546255506608	0.2	Homo sapiens		0	10	227
depierreux-hfff-pmp-2022--mg132-treated-mock-or-infected	HFFF-TERT fibroblast plasma membrane profiling · MG132-treated mock or infected	Depierreux et al. 2022	Depierreux DM	2022	35727847	10.1371/journal.ppat.1010612	perturbed	infection: MG132-treated mock or infected	infection arm of depierreux-hfff-pmp-2022; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD033407	ppat.1010612.s004.xlsx sheet Data original in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9307158/supplementaryFiles> | ppat.1010612.s004.xlsx sheet repeat3 18h in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9307158/supplementaryFiles>	Plasma membrane profiling (Weekes lab): live-cell sodium periodate/aniline oxidation of sialic-acid glycans and aminooxy-biotin labeling, streptavidin enrichment, on-bead trypsin digestion, TMT multiplexing, LC-MS3. Two TMT biological repeats (PMP4, PMP5; 'PMP1/PMP2' in the paper) with mock at 90 min and 18 h, VACV time points and MG132 arms; a third 18 h repeat (PM1, mock vs VACV 18 h).	Method summarized from the paper (PMC9307158) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion Lumos		Instrument as listed in the ProteomeXchange record PXD033407.	HFFF-TERT fibroblasts	HFFF-TERT fibroblasts, MG132-treated mock or infected: a non-baseline state of depierreux-hfff-pmp-2022, listed when observed in at least 1 of its 4 samples				2560	701	0.273828125		Homo sapiens		0	0	2560
depierreux-hfff-pmp-2022	HFFF-TERT fibroblast plasma membrane profiling · mock-infected (repeat PM4) (baseline)	Depierreux et al. 2022	Depierreux DM	2022	35727847	10.1371/journal.ppat.1010612	core		Weekes-lab PMP (same lab and method as Soh, Fielding and Hunter) on fibroblasts; three independent TMT repeats each carry mock channels, so membership rests on uninfected, untreated cells. The source sheet also holds whole-cell-lysate rows, which the non-zero PM-mock rule excludes.	PRIDE	PXD033407	ppat.1010612.s004.xlsx sheet Data original in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9307158/supplementaryFiles> | ppat.1010612.s004.xlsx sheet repeat3 18h in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9307158/supplementaryFiles>	Plasma membrane profiling (Weekes lab): live-cell sodium periodate/aniline oxidation of sialic-acid glycans and aminooxy-biotin labeling, streptavidin enrichment, on-bead trypsin digestion, TMT multiplexing, LC-MS3. Two TMT biological repeats (PMP4, PMP5; 'PMP1/PMP2' in the paper) with mock at 90 min and 18 h, VACV time points and MG132 arms; a third 18 h repeat (PM1, mock vs VACV 18 h).	Method summarized from the paper (PMC9307158) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion Lumos		Instrument as listed in the ProteomeXchange record PXD033407.	HFFF-TERT telomerase-immortalized human foetal foreskin fibroblasts	S1 Table (ppat.1010612.s004.xlsx) 'Data original' sheet, which merges PMP and whole-cell-lysate rows; PMP rows are those with a non-zero PM reporter. Membership = mock channel (Mock 90 min or Mock 18 h) > 0 within repeat PM4 or PM5, or Mock > 0 in the third repeat ('repeat3 18h' sheet). VACV-infected, Mock+MG132 and VACV+MG132 channels kept as non-membership measurements; MGC6 and WCL channels (whole-cell experiments) not read. Species = HUMAN only (173 VACV rows dropped).	ppat.1010612.s004.xlsx: Protein Id | ppat.1010612.s004.xlsx: Protein Id	Species = HUMAN | Species = HUMAN	HFFF-TERT fibroblasts / baseline mock-infected, PMP (repeat PM4): VACV_PM4_Mock_90min, VACV_PM4_Mock_18h (min_observed 1) | HFFF-TERT fibroblasts / baseline mock-infected, PMP (repeat PM5): VACV_PM5_Mock_90min, VACV_PM5_Mock_18h (min_observed 1) | HFFF-TERT fibroblasts / vaccinia-infected (not used for membership): VACV_PM4_VACV_90m, VACV_PM4_VACV_6h, VACV_PM4_VACV_12h, VACV_PM4_VACV_18h, VACV_PM5_VACV_90m, VACV_PM5_VACV_6h, VACV_PM5_VACV_12h, VACV_PM5_VACV_18h (min_observed 1) | HFFF-TERT fibroblasts / MG132-treated mock or infected (not used for membership): VACV_PM4_Mock+MG, VACV_PM5_Mock+MG, VACV_PM4_VACV+MG, VACV_PM5_VACV+MG (min_observed 1) | HFFF-TERT fibroblasts / baseline mock-infected, PMP (repeat PM1, 18 h): VACV_PM1_Mock (min_observed 1) | HFFF-TERT fibroblasts / vaccinia-infected 18 h (not used for membership): VACV_PM1_VACV_18h (min_observed 1)	2615	709	0.2711281070745698	0.2	Homo sapiens		0	0	2615
depierreux-hfff-pmp-2022--vaccinia-infected	HFFF-TERT fibroblast plasma membrane profiling · vaccinia-infected	Depierreux et al. 2022	Depierreux DM	2022	35727847	10.1371/journal.ppat.1010612	perturbed	infection: vaccinia-infected	infection arm of depierreux-hfff-pmp-2022; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD033407	ppat.1010612.s004.xlsx sheet Data original in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9307158/supplementaryFiles> | ppat.1010612.s004.xlsx sheet repeat3 18h in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9307158/supplementaryFiles>	Plasma membrane profiling (Weekes lab): live-cell sodium periodate/aniline oxidation of sialic-acid glycans and aminooxy-biotin labeling, streptavidin enrichment, on-bead trypsin digestion, TMT multiplexing, LC-MS3. Two TMT biological repeats (PMP4, PMP5; 'PMP1/PMP2' in the paper) with mock at 90 min and 18 h, VACV time points and MG132 arms; a third 18 h repeat (PM1, mock vs VACV 18 h).	Method summarized from the paper (PMC9307158) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion Lumos		Instrument as listed in the ProteomeXchange record PXD033407.	HFFF-TERT fibroblasts	HFFF-TERT fibroblasts, vaccinia-infected: a non-baseline state of depierreux-hfff-pmp-2022, listed when observed in at least 1 of its 8 samples				2560	701	0.273828125		Homo sapiens		0	0	2560
depierreux-hfff-pmp-2022--vaccinia-infected-18-h	HFFF-TERT fibroblast plasma membrane profiling · vaccinia-infected 18 h	Depierreux et al. 2022	Depierreux DM	2022	35727847	10.1371/journal.ppat.1010612	perturbed	infection: vaccinia-infected 18 h	infection arm of depierreux-hfff-pmp-2022; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD033407	ppat.1010612.s004.xlsx sheet Data original in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9307158/supplementaryFiles> | ppat.1010612.s004.xlsx sheet repeat3 18h in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9307158/supplementaryFiles>	Plasma membrane profiling (Weekes lab): live-cell sodium periodate/aniline oxidation of sialic-acid glycans and aminooxy-biotin labeling, streptavidin enrichment, on-bead trypsin digestion, TMT multiplexing, LC-MS3. Two TMT biological repeats (PMP4, PMP5; 'PMP1/PMP2' in the paper) with mock at 90 min and 18 h, VACV time points and MG132 arms; a third 18 h repeat (PM1, mock vs VACV 18 h).	Method summarized from the paper (PMC9307158) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion Lumos		Instrument as listed in the ProteomeXchange record PXD033407.	HFFF-TERT fibroblasts	HFFF-TERT fibroblasts, vaccinia-infected 18 h: a non-baseline state of depierreux-hfff-pmp-2022, listed when observed in at least 1 of its 1 samples				1121	496	0.4424620874219447		Homo sapiens		0	0	1121
lango-hl60-2022	HL60 sulfo-NHS-SS-biotin labeled-peptide surfaceome	Langó et al. 2022	Langó T	2022	36613715	10.3390/ijms24010273	core		Intact-cell sulfo-NHS-SS-biotin with peptide-level capture, so every listed peptide carries the label remnant; all 47 runs are untreated HL60 under method variants. No no-biotin control; membership is the authors' observation-count filter (labeled position seen >= 3 times), which uses no annotation.	MassIVE	MSV000090149	Table S6.xlsx sheet Labelled_peptides in supplementaryFiles › ijms-24-00273-s001.zip <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9820203/supplementaryFiles>	Sulfo-NHS-SS-biotin on intact HL60; labeled peptides identified by the +87.998 (non-alkylated) or +145.020 Da (alkylated) remnant	Method read from: Results 2.1-2.6, Methods 4.10 'Assessment of Identified Proteins and Peptides'; Table S6 header.	NeutrAvidin agarose column	not stated	maXis II		Instrument as listed in the ProteomeXchange record MSV000090149.	HL60 acute promyelocytic leukemia cell line	Supplementary Table S6 'Labelled_peptides' (191,334 labeled-peptide PSM rows from 47 MS/MS runs of untreated HL60 under method variants: SPE A-D, second elution, LC gradients, precursor charge settings). Only peptides carrying the labeling remnant are listed. Membership = Protein_ID of rows whose labeled position was identified >= 3 times across the 47 runs (authors' count column; 415 proteins, 1,596 positions). TM/non-TM, UniProt-subcellular and GO-surface columns carried, never used to select rows. Tables S4/S5 (all peptides) not used.	Table S6.xlsx: Protein_ID	At least three times labelled position in the 47 MS/MS runs (yes/no) = yes		414	162	0.391304347826087	0.2	Homo sapiens		0	1	414
nishino-hela-egf-2022	HeLa sulfo-NHS-biotin labeled-peptide surfaceome, Tamavidin 2-REV, TMT11 EGF time course	Nishino et al. 2022	Nishino K	2022	35979633	10.1021/acs.jproteome.2c00130	core		Every retained row is a biotinylated (labeled) peptide from intact-cell sulfo-NHS labeling, so it is direct site-level evidence; TMT channel identities are in the PD column headers. The 0-min channels are the unstimulated baseline; EGF arms are perturbations.	jPOST	JPST001515;PXD032062	nishino_biotin_peptide_protein_abundance.tsv	Sulfo-NHS-biotin surface biotinylation of HeLa, Tamavidin 2-REV biotinylated-peptide enrichment, TMT11	Method read from: ProteomeCentral PXD032062 description and PMID 35979633 abstract (full text not open access; not read).	Tamavidin 2-REV	not stated	not stated in accessible text			HeLa cervical adenocarcinoma cell line	jPOST JPST001515 PD PeptideGroups.txt (8,984 peptide groups). Kept peptide groups with a Biotin modification, Qvality q-value <= 0.01 and a single master protein (8,378 groups, 1,914 proteins); summed raw TMT abundance per channel per master protein. Membership = biotinylated-peptide reporter abundance in >= 2 of the 3 unstimulated (0 min) channels 126, 127C, 128C. EGF 5, 10 and 30 min channels kept as measurements only.	nishino_biotin_peptide_protein_abundance.tsv: Master Protein Accessions		HeLa / baseline unstimulated (0 min) sulfo-NHS-biotin labeled peptides: 126 Sample 0 min, 127C Sample 0 min, 128C Sample 0 min (min_observed 2) | HeLa / EGF 5 min (not used for membership): 127N Sample 5 min, 128N Sample 5 min, 129N Sample 5 min (min_observed 2) | HeLa / EGF 10 min (not used for membership): 129C Sample 10 min, 130C Sample 10 min, 131C Sample 10 min (min_observed 2) | HeLa / EGF 30 min (not used for membership): 130N Sample 30 min, 131N Sample 30 min (min_observed 2)	1792	351	0.19587053571428573	0.2	Homo sapiens		0	0	1792
mori-liver-pm-2022	Human liver plasma-membrane fraction, ProteinPilot identification list	Mori et al. 2022	Mori A	2022	36131112	10.1007/s11095-022-03387-8	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Tissue plasma-membrane fraction prepared after homogenisation; complementary by family policy. A single pooled identification list from a peptide-selection (methods) study.	jPOST / ProteomeXchange	PXD034402;JPST001658	220408_IDA_1+2+3_ProteinSummary.txt	plasma-membrane fraction of human liver (fractionation details not in the abstract; paper not open access)	Method read from: PubMed abstract 36131112; jPOST JPST001658 file list.	none	not stated	TripleTOF 5600		Instrument as listed in the ProteomeXchange record PXD034402.	Human liver tissue, plasma-membrane fraction	ProteinPilot ProteinSummary for IDA runs 1+2+3 combined (2,146 rows). Membership = ProteinPilot Unused score >= 1.3 (95% confidence), 1,231 proteins. One pooled list; no per-sample columns; SWATH runs not used.	220408_IDA_1+2+3_ProteinSummary.txt: Accession	Unused ≥ 1.3		1228	183	0.1490228013029316	0.2	Homo sapiens		0	1	1228
ferguson-2022	Myeloma adapted CSC	Ferguson et al. 2022	Ferguson ID	2022	35840578	10.1038/s41467-022-31810-6	core		Original identification and specimen caveats retained in previous_reason.	PRIDE	PXD022482;PXD022553;PXD032031	proteinGroups_MM_Leukemia.txt <https://pubmed.ncbi.nlm.nih.gov/35840578/>	Wiita-lab N-glycoprotein cell surface capture on intact cells: harvested myeloma cells (25e6 to 30e6 for the macro protocol; <1e6 to 5e6 for the micro protocol) washed in cold D-PBS, oxidized with 1.6 mM NaIO4 (Thermo 1379822) 20 min at 4 C, washed, labeled with biocytin hydrazide (Biotium 90060, 10 uL per mL) + aniline (1 uL per mL) for 90 min (macro) or 60 min (micro) at 4 C, snap frozen. Lysis in 2x RIPA + HALT inhibitors + EDTA with probe sonication; biotinylated glycoproteins captured 2 h at 4 C on 500 uL High Capacity NeutrAvidin agarose (Thermo PI29204; macro) or 100 uL NeutrAvidin agarose (Thermo 29200; micro) in Bio-Rad chromatography columns, washed with RIPA/EDTA, PBS/1 M NaCl and 2 M urea/ABC; on-bead trypsin digestion (protein-level, no PNGase F), C18 cleanup; LC-MS/MS with MaxQuant LFQ (and TMT for primary B cells). The inventory uses the four baseline cell lines with >=2 nonzero LFQ observations per line.	Method as described in the paper's Methods 'Cell surface protein labeling', 'Macro-cell-surface-capture', 'Micro-cell-surface-capture' (Nat Commun 2022; full text PMC9287322).	High Capacity NeutrAvidin Agarose (Thermo PI29204) for macro-CSC; NeutrAvidin Agarose (Thermo 29200) for micro-CSC; biocytin hydrazide (Biotium 90060)	not reported	Q Exactive; Orbitrap Fusion Lumos; Q Exactive Plus		Instrument as listed in the ProteomeXchange records PXD022482, PXD022553 and PXD032031.	Four baseline multiple-myeloma cell lines; patient extensions not yet integrated	Four myeloma baseline lines, >=2 nonzero LFQ observations within a line; resistant/drug arms excluded	proteinGroups_MM_Leukemia.txt: Protein IDs	Unique peptides ≥ 1 | drop rows flagged Reverse, Potential contaminant, Only identified by site	AMO1 / baseline: LFQ intensity AMO1 324-07, LFQ intensity AMO1 420-03, LFQ intensity AMO1 801-03 (min_observed 2) | KMS12 / baseline: LFQ intensity KMS12 scr-1, LFQ intensity KMS12 scr-2, LFQ intensity KMS12 scr-3 (min_observed 2) | L363 / baseline: LFQ intensity L363 WT-1, LFQ intensity L363 WT-2 (min_observed 2) | RPMI / baseline: LFQ intensity RPMI 430-01, LFQ intensity RPMI 811-01, LFQ intensity RPMI 811-03 (min_observed 2)	1154	510	0.44194107452339687	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			1136
optimized-csc-aml-2022	Optimized CSC AML	Köhnke et al. 2022	Köhnke T	2022	35681175	10.1186/s40364-022-00390-4	annotation_selected	author pre-filtered to transmembrane or signal-peptide proteins	pre-filtered by surface annotation (annotation-and-topology-selected); shown, not counted. Was provisional. provisional: threshold 47.0851%; borderline allowance 2.0%. Topology proxy does not reproduce downstream normal-tissue/target-prioritization selection.	supplement		control_surface_proteins.tsv	Wollscheid-style Cell Surface Capture on intact AML cells (1e8 cells per sample: primary AML specimens, AML PDX cells recovered from NSG mice, and AML cell lines): live cells oxidized with sodium metaperiodate and labeled with biocytin hydrazide (Biomol; reduced to 5.4 mM from the original 6.5 mM) for Glyco-CSC / Cys-Glyco-CSC, or with NHS-SS-biotin (Thermo) without oxidation for Lys-CSC; hypotonic lysis (Bioruptor instead of Dounce), ultracentrifugation to collect membranes, TCEP/IAA, double trypsin digestion in an iodoacetamide/BHES digestion buffer; biotinylated glycopeptides bound to Streptavidin Plus UltraLink Resin, washed, released with PNGase F (Glyco-CSC) or reducing agents (Cys/Lys-CSC); Orbitrap Elite DDA, MaxQuant (UniProt Aug 2015), deamidation accepted as N-glycosite only if localization >0.75 in an N-X-S/T motif outside a TM domain on a protein with TM/signal peptide; annotated against the Cell Surface Protein Atlas.	Method as described in the paper's Methods 'Cell Surface Capture (CSC)' and 'Modifications to the CSC protocol' (Biomark Res 2022; full text PMC9185890).	Streptavidin Plus UltraLink Resin (Thermo/Pierce; catalog number not stated); biocytin hydrazide (Biomol)	not reported	Orbitrap Elite			Primary AML specimens, patient-derived xenografts and AML cell lines	primary AML (PDX + patient) + HL-60/OCI-AML3	control_surface_proteins.tsv: uniprot_accession			569	366	0.6432337434094904	0.47085130205355774	Homo sapiens	Human cancer in mouse hosts; sample origin does not establish species specificity of every peptide. Host/species-ambiguous evidence must be excluded.			568
hammoud-mdm-raft-2022--etya-50-um-1-h	Primary human monocyte-derived macrophage detergent-resistant raft fraction · ETYA 50 uM 1 h	Hammoud et al. 2022	Hammoud MK	2022	35451191	10.1002/1878-0261.13221	perturbed	drug, ligand or treatment: ETYA 50 uM 1 h	drug, ligand or treatment arm of hammoud-mdm-raft-2022; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD028434	MOL2-16-3146-s002.xlsx sheet S6 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9441005/supplementaryFiles>	1% Triton X-100 lysis, sucrose step-gradient flotation, raft fraction 4 (flotillin/CD71/GAPDH immunoblot-verified)	Method as described in the paper's Methods 2.9 'Isolation of lipid rafts', 2.10 'Proteomic analysis of lipid rafts'; Table S6 legend sheet.	none	not stated	Q Exactive HF		Instrument as listed in the ProteomeXchange record PXD028434.	Monocyte-derived macrophages	Monocyte-derived macrophages, ETYA 50 uM 1 h: a non-baseline state of hammoud-mdm-raft-2022, listed when observed in at least 2 of its 5 samples				1711	327	0.19111630625365283		Homo sapiens		0	20	1711
hammoud-mdm-raft-2022--arachidonic-acid-50-um-1-h	Primary human monocyte-derived macrophage detergent-resistant raft fraction · arachidonic acid 50 uM 1 h	Hammoud et al. 2022	Hammoud MK	2022	35451191	10.1002/1878-0261.13221	perturbed	drug, ligand or treatment: arachidonic acid 50 uM 1 h	drug, ligand or treatment arm of hammoud-mdm-raft-2022; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD028434	MOL2-16-3146-s002.xlsx sheet S6 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9441005/supplementaryFiles>	1% Triton X-100 lysis, sucrose step-gradient flotation, raft fraction 4 (flotillin/CD71/GAPDH immunoblot-verified)	Method as described in the paper's Methods 2.9 'Isolation of lipid rafts', 2.10 'Proteomic analysis of lipid rafts'; Table S6 legend sheet.	none	not stated	Q Exactive HF		Instrument as listed in the ProteomeXchange record PXD028434.	Monocyte-derived macrophages	Monocyte-derived macrophages, arachidonic acid 50 uM 1 h: a non-baseline state of hammoud-mdm-raft-2022, listed when observed in at least 2 of its 5 samples				1581	320	0.20240354206198607		Homo sapiens		0	19	1581
hammoud-mdm-raft-2022	Primary human monocyte-derived macrophage detergent-resistant raft fraction · ethanol vehicle 1 h (baseline)	Hammoud et al. 2022	Hammoud MK	2022	35451191	10.1002/1878-0261.13221	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Detergent-resistant membrane (lipid raft) flotation after Triton X-100 lysis: membrane fractionation, complementary, no surface vote. Primary macrophages from five donors with vehicle controls; perturbation arms are measurements only.	PRIDE	PXD028434	MOL2-16-3146-s002.xlsx sheet S6 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9441005/supplementaryFiles>	1% Triton X-100 lysis, sucrose step-gradient flotation, raft fraction 4 (flotillin/CD71/GAPDH immunoblot-verified)	Method as described in the paper's Methods 2.9 'Isolation of lipid rafts', 2.10 'Proteomic analysis of lipid rafts'; Table S6 legend sheet.	none	not stated	Q Exactive HF		Instrument as listed in the ProteomeXchange record PXD028434.	Primary human blood monocyte-derived macrophages (MDM)	Supplementary Table S6 (MOL2-16-3146-s002.xlsx sheet 'S6'): 1,837 MaxQuant protein groups with preprocessed log2 LFQ per donor (R1-R5) for EtOH, DMSO, AA and ETYA arms; missing values are left blank (not imputed in the table). Membership = observed log2 LFQ in >= 2 of 5 donors in the EtOH vehicle arm or in the DMSO vehicle arm (each evaluated separately). AA and ETYA arms kept as non-membership measurements. Accession = first UniProt id of the 'uniprot' column.	MOL2-16-3146-s002.xlsx: uniprot		Monocyte-derived macrophages / baseline, ethanol vehicle 1 h, sucrose-gradient raft fraction: EtOH.R1, EtOH.R2, EtOH.R3, EtOH.R4, EtOH.R5 (min_observed 2) | Monocyte-derived macrophages / baseline, DMSO vehicle 1 h, sucrose-gradient raft fraction: DMSO.R1, DMSO.R2, DMSO.R3, DMSO.R4, DMSO.R5 (min_observed 2) | Monocyte-derived macrophages / arachidonic acid 50 uM 1 h (not used for membership): AA.R1, AA.R2, AA.R3, AA.R4, AA.R5 (min_observed 2) | Monocyte-derived macrophages / ETYA 50 uM 1 h (not used for membership): ETYA.R1, ETYA.R2, ETYA.R3, ETYA.R4, ETYA.R5 (min_observed 2)	1765	341	0.19320113314447593	0.2	Homo sapiens		0	25	1765
kirkemo-2022	RWPE-1 WGA-HRP/APEX	Kirkemo et al. 2022	Kirkemo LL	2022	35257663	10.7554/elife.73982	core		Original identification and specimen caveats retained in previous_reason.	PRIDE	PXD028523	control_surface_proteins.tsv	Cell-tethered WGA-HRP proximity biotinylation on intact cells (RWPE-1 prostate epithelial cells, empty-vector arm used here; also MYC arm and small EVs): cells grown 3 days, lifted with Versene, washed in PBS pH 6.5, 500,000 cells per sample resuspended in 0.5 uM WGA-HRP for 5 min on ice, then 500 uM biotin tyramide and 1 mM H2O2 for 2 min at 37 C, quenched with 5 mM Trolox / 10 mM sodium ascorbate / 1 mM sodium pyruvate; flash frozen. Lysis in 2x RIPA with protease inhibitors, sonication; capture on 100 uL NeutrAvidin agarose (Thermo Fisher 29204) 1 h at 4 C in Bio-Spin columns, washed with RIPA, 1 M NaCl PBS and 2 M urea; on-bead TCEP/IAA and Trypsin/LysC digestion, C18 cleanup; LC-MS/MS (MaxQuant). Benchmarked against biocytin-hydrazide CSC (1.5e6 cells, 1.6 mM periodate) and soluble (non-tethered) HRP/APEX2 controls.	Method read from: eLife 2022, PMC8983049, Methods 'Cell-tethered APEX2 ... WGA-HRP ... cell surface labeling' and 'Proteomic preparation for surface enriched samples'.	High Capacity NeutrAvidin agarose (Thermo Fisher Scientific 29204); WGA-HRP (commercial lectin-HRP conjugate); biotin tyramide	not reported	timsTOF Pro		Instrument as listed in the ProteomeXchange record PXD028523.	RWPE-1 prostate epithelial empty-vector intact cells; excludes exosome and MYC arms	Human cell lines: RWPE-1 prostate epithelial (control/empty-vector and MYC-transformed) intact cells and their small extracellular vesicles (exosomes); plus human pancreatic cancer benchmark cell lines KP-4 and PaTu-8902 (chemistry-comparison experiments). All Homo sapiens (NEWT 9606); no non-human samples in this deposition.	control_surface_proteins.tsv: uniprot_accession			1321	454	0.34367903103709313	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			1320
anderson-2022	SEMA4A myeloma PMP	Anderson et al. 2022	Anderson GSF	2022	35134130	10.1182/blood.2021015161	core		Original identification and specimen caveats retained in previous_reason.	PRIDE	PXD014165	bloodBLD2021015161-suppl1.xlsx sheet Data S1 <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11022854/supplementaryFiles> | bloodBLD2021015161-suppl2.xlsx sheet Data S2 <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11022854/supplementaryFiles>	Plasma membrane profiling (PMP; Weekes/Lehner protocol): intact myeloma cell lines (1e8 cells per line, 10 lines in one TMT-10plex) and CD138+ primary myeloma plasma cells (1e7 cells per patient, 8 patients + 2 repeat lines in a second 10plex) subjected to a 'one-pot' periodate oxidation of surface sialoglycans and aminooxy-biotin oxime ligation on live cells; lysis, streptavidin pulldown of biotinylated glycoproteins, on-bead trypsin digestion, TMT labeling, offline high-pH fractionation (UltiMate 3000) and Orbitrap Fusion MS3 quantification. Proteins annotated as plasma membrane, endogenously biotinylated contaminants, or unrecognized; endogenously biotinylated carboxylases are the known background. Reagent-level details are in the Blood supplemental Methods.	Method as described in the paper's Methods 'Plasma membrane profiling' and Figure 1A legend (Blood 2022; full text PMC11022854).	streptavidin agarose (per the PMP protocol; product stated only in supplemental Methods); aminooxy-biotin (Biotium)	not reported	Orbitrap Fusion			Multiple-myeloma cell lines and primary CD138+ patient plasma cells	Human multiple-myeloma cell lines and primary patient myeloma cells. Data S1 = 10 MM cell lines (OCIMY7, INA6, KMS12BM, MM1.S, SKMM1, OCIMY5, NCIH929, JIM3, OPM2, LP1). Data S2 = 8 primary patient CD138+ myeloma plasma-cell samples (PM004, PM014, PM035, PM040, PM044, PM049, PM066, PM068) plus 2 MM cell lines (KMS12, JIM3).	bloodBLD2021015161-suppl1.xlsx: Accession | bloodBLD2021015161-suppl2.xlsx: Accession	Protein FDR Confidence = High | # Unique Peptides ≥ 1 | Protein FDR Confidence = High | # Unique Peptides ≥ 1	OCIMY7 / baseline: OCIMY7 (min_observed 1) | INA6 / baseline: INA6 (min_observed 1) | KMS12BM / baseline: KMS12BM (min_observed 1) | MM1.S / baseline: MM1.S (min_observed 1) | SKMM1 / baseline: SKMM1 (min_observed 1) | OCIMY5 / baseline: OCIMY5 (min_observed 1) | NCIH929 / baseline: NCIH929 (min_observed 1) | JIM3 / baseline: JIM3 (min_observed 1) | OPM2 / baseline: OPM2 (min_observed 1) | LP1 / baseline: LP1 (min_observed 1) | KMS12 / baseline: KMS12 (min_observed 1) | JIM3 / baseline: JIM3 (min_observed 1) | PM004 / baseline: PM004 (min_observed 1) | PM014 / baseline: PM014 (min_observed 1) | PM035 / baseline: PM035 (min_observed 1) | PM040 / baseline: PM040 (min_observed 1) | PM044 / baseline: PM044 (min_observed 1) | PM049 / baseline: PM049 (min_observed 1) | PM066 / baseline: PM066 (min_observed 1) | PM068 / baseline: PM068 (min_observed 1)	5096	1035	0.20310047095761383	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			5027
gangras-shsy5y-2022	SH-SY5Y neuroblastoma sulfo-NHS surfaceome with no-biotin control	Gangras et al. 2022	Gangras P	2022	36499391	10.3390/ijms232315062	core		Intact-cell sulfo-NHS capture with a matched no-biotin control; Table S2 is the full peptide table before any surface annotation. The control detects most accessions at lower signal, so the label-vs-control contrast should be read from the measurements.	none (supplementary tables only)		Table S2.xlsx sheet MappedToIsoformUnawareDb in supplementaryFiles › ijms-23-15062-s001.zip <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC9739866/supplementaryFiles>	Sulfo-NHS-SS-biotin labeling of intact undifferentiated SH-SY5Y cells with a no-biotin control processed in parallel, streptavidin capture, label-free LC-MS/MS; peptide-level log2 AUC with limma biotin-vs-control statistics.	Method summarized from the paper (PMC9739866) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion Lumos	peptide analysis with Thermo Easy-nLC	Instrument as named in the paper's Methods 4.4 (full text PMC9739866).	SH-SY5Y neuroblastoma cell line	Table S2 'MappedToIsoformUnawareDb' (10,309 peptides, 889 accessions). Peptides with id q-value <= 0.01; membership = peptide log2 AUC above the -3.32 missing-value placeholder in >= 2 of 3 biotin replicates. No-biotin control replicates kept as measurements only. Table S1 (SPC/SURFY-selected) not used.	Table S2.xlsx: Uniprot accession	Peptide id_qval ≤ 0.01	SH-SY5Y / baseline sulfo-NHS-SS-biotin labeled: Biotin_rep1_log2auc, Biotin_rep2_log2auc, Biotin_rep3_log2auc (min_observed 2; floor -3.32) | SH-SY5Y / no-biotin control (not used for membership): Cntrl_rep1_log2auc, Cntrl_rep2_log2auc, Cntrl_rep3_log2auc (min_observed 2; floor -3.32)	885	309	0.34915254237288135	0.2	Homo sapiens		0	0	885
lazar-skbr3shaving-2022	SKBR3 TrypLE surface shaving	Lazar et al. 2022	Lazar IM	2022	35913978	10.1371/journal.pone.0272384	held	conditions are pooled in one list, with no separable baseline	Intact-cell labeling with a full >= 2-unique-peptide list, but serum-starved and serum-restimulated cells are pooled in one consensus search, so no untreated baseline can be isolated from this table. Per-replicate blocks in Karcini 2022 MOESM2 are unaligned independent lists and do not fit the extractor.	PRIDE	PXD028978	pone.0272384.s001.xlsx sheet TrypLE enrichment <https://journals.plos.org/plosone/article/file?type=supplementary&id=10.1371/journal.pone.0272384.s001>	Short (2-4 min) TrypLE Select (recombinant trypsin-like protease) shaving of intact cells, released peptides re-digested with trypsin; Q Exactive DDA, Proteome Discoverer 2.5 Sequest HT against reviewed human UniProt (20,433 entries, 2019).	Method summarized from the paper (PMC9342750) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive			SKBR3 HER2+ breast cancer cell line (serum-starved and serum-restimulated states pooled)	PLoS One S1 File sheet 'TrypLE enrichment': Proteome Discoverer multiconsensus of all runs for this chemistry (3 serum-free + 3 serum-treated biological replicates x 3 technical runs), already restricted by the authors to proteins with >= 2 unique peptides; keep Master Protein rows with High protein FDR confidence; drop non-human (bovine serum, porcine trypsin) entries. The two culture states cannot be separated in this table. Companion paper Karcini 2022 Sci Rep (PMID 35760832) holds per-replicate blocks.	pone.0272384.s001.xlsx: Accession	Master = Master Protein | Protein FDR Confidence: A Sequest HT = High | drop rows where Description matches ^(?!.*OS=Homo sapiens)	SKBR3 / serum-free (48 h) and serum-restimulated (24 h) states pooled: # PSMs (min_observed 1)	1962	133	0.06778797145769623	0.2	Homo sapiens		0	0	1962
lazar-skbr3amine-2022	SKBR3 amine biotinylation	Lazar et al. 2022	Lazar IM	2022	35913978	10.1371/journal.pone.0272384	held	conditions are pooled in one list, with no separable baseline	Intact-cell labeling with a full >= 2-unique-peptide list, but serum-starved and serum-restimulated cells are pooled in one consensus search, so no untreated baseline can be isolated from this table. Per-replicate blocks in Karcini 2022 MOESM2 are unaligned independent lists and do not fit the extractor.	PRIDE	PXD028977	pone.0272384.s001.xlsx sheet Amine group enrichment method <https://journals.plos.org/plosone/article/file?type=supplementary&id=10.1371/journal.pone.0272384.s001>	EZ-Link sulfo-NHS-SS-biotin labeling of intact cells (Pierce kit), NeutrAvidin pulldown with on-bead digestion and DTT elution arms combined; Q Exactive DDA, Proteome Discoverer 2.5 Sequest HT against reviewed human UniProt (20,433 entries, 2019).	Method summarized from the paper (PMC9342750) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive			SKBR3 HER2+ breast cancer cell line (serum-starved and serum-restimulated states pooled)	PLoS One S1 File sheet 'Amine group enrichment method': Proteome Discoverer multiconsensus of all runs for this chemistry (3 serum-free + 3 serum-treated biological replicates x 3 technical runs), already restricted by the authors to proteins with >= 2 unique peptides; keep Master Protein rows with High protein FDR confidence; drop non-human (bovine serum, porcine trypsin) entries. The two culture states cannot be separated in this table. Companion paper Karcini 2022 Sci Rep (PMID 35760832) holds per-replicate blocks.	pone.0272384.s001.xlsx: Accession	Master = Master Protein | Protein FDR Confidence: A Sequest HT = High | drop rows where Description matches ^(?!.*OS=Homo sapiens)	SKBR3 / serum-free (48 h) and serum-restimulated (24 h) states pooled: # PSMs (min_observed 1)	2301	350	0.1521077792264233	0.2	Homo sapiens		0	0	2301
lazar-skbr3glyco-2022	SKBR3 glycoprotein capture	Lazar et al. 2022	Lazar IM	2022	35913978	10.1371/journal.pone.0272384	held	conditions are pooled in one list, with no separable baseline	Intact-cell labeling with a full >= 2-unique-peptide list, but serum-starved and serum-restimulated cells are pooled in one consensus search, so no untreated baseline can be isolated from this table. Per-replicate blocks in Karcini 2022 MOESM2 are unaligned independent lists and do not fit the extractor.	PRIDE	PXD028976	pone.0272384.s001.xlsx sheet Glycoprotein enrichment method <https://journals.plos.org/plosone/article/file?type=supplementary&id=10.1371/journal.pone.0272384.s001>	Sodium meta-periodate oxidation of intact-cell glycans, EZ-Link alkoxyamine-PEG4-biotin (aniline-catalysed) labeling, NeutrAvidin pulldown; Q Exactive DDA, Proteome Discoverer 2.5 Sequest HT against reviewed human UniProt (20,433 entries, 2019).	Method summarized from the paper (PMC9342750) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive			SKBR3 HER2+ breast cancer cell line (serum-starved and serum-restimulated states pooled)	PLoS One S1 File sheet 'Glycoprotein enrichment method': Proteome Discoverer multiconsensus of all runs for this chemistry (3 serum-free + 3 serum-treated biological replicates x 3 technical runs), already restricted by the authors to proteins with >= 2 unique peptides; keep Master Protein rows with High protein FDR confidence; drop non-human (bovine serum, porcine trypsin) entries. The two culture states cannot be separated in this table. Companion paper Karcini 2022 Sci Rep (PMID 35760832) holds per-replicate blocks.	pone.0272384.s001.xlsx: Accession	Master = Master Protein | Protein FDR Confidence: A Sequest HT = High | drop rows where Description matches ^(?!.*OS=Homo sapiens)	SKBR3 / serum-free (48 h) and serum-restimulated (24 h) states pooled: # PSMs (min_observed 1)	1912	492	0.25732217573221755	0.2	Homo sapiens		0	0	1912
byrnes-2022	T-cell surface proteome	Byrnes et al. 2022	Byrnes JR	2022	35217172	10.1016/j.mcpro.2022.100217	held	conditions are pooled in one list, with no separable baseline	SILAC contrasts represent T-cell activation/hypoxia and cell populations. Skyline quantification uses a curated extracellular/membrane universe excluding nuclear/mitochondrial annotations; missing MS2 can be quantified by aligned MS1. Current pooled baseline is unresolved.			mmc1.xlsx sheet Combined_Output <https://pubmed.ncbi.nlm.nih.gov/35217172/> | mmc2.xlsx sheet Combined_Output <https://pubmed.ncbi.nlm.nih.gov/35217172/> | mmc3.xlsx sheet Combined_Output <https://pubmed.ncbi.nlm.nih.gov/35217172/> | mmc4.xlsx sheet Combined_Output <https://pubmed.ncbi.nlm.nih.gov/35217172/> | mmc5.xlsx sheet Combined_Output <https://pubmed.ncbi.nlm.nih.gov/35217172/>	Glycan-directed cell surface capture on intact primary human T cells (CD8+ effector and CD4+CD25- / regulatory populations; SILAC heavy/light cells mixed 1:1 in forward and reverse mode after activation, hypoxia or coculture): cells washed in PBS pH 6.5, oxidized with 1.6 mM NaIO4 for 20 min at 4 C, biotinylated with 1 mM biocytin hydrazide (Biotium) + 10 mM aniline for 90 min at 4 C, flash frozen. RIPA lysis with probe sonication; biotinylated glycoproteins captured on NeutrAvidin agarose (Thermo) 1 h at 4 C in Poly-Prep columns, washed with RIPA, 2 M NaCl PBS and 2 M urea; on-bead TCEP/IAA and trypsin digestion; LC-MS/MS with SILAC ratios (Wells lab).	Method as described in the paper's Methods 'Cell Surface Capture' (Mol Cell Proteomics 2022; full text PMC9006863).	NeutrAvidin-coated agarose beads (Thermo; catalog number not stated)	not reported	Q Exactive Plus	LC-MS/MS of tryptic fractions	Instrument as named in the paper's Methods (full text PMC9006863).	Primary T-cell populations including CD8+ effectors and regulatory T cells; activation/hypoxia/coculture comparisons	Full outputs across five T-cell populations; SILAC mixed control/activation ratios need baseline assignment	mmc1.xlsx: Protein.Accession | mmc2.xlsx: Protein.Accession | mmc3.xlsx: Protein.Accession | mmc4.xlsx: Protein.Accession | mmc5.xlsx: Protein.Accession			1264	621	0.4912974683544304	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			1230
nix-ball-2021	B-ALL CD72 CSC	Nix et al. 2021	Nix MA	2021	33727310	10.1158/2159-8290.cd-20-0242	provisional	within 2 points of the 20% screen (19.7%)	Original identification and specimen caveats retained in previous_reason.			control_surface_proteins.tsv	N-linked glycosylation-site biotin labeling (Wells/Wiita CSC) on live cells: 3e7 live B-ALL cells (cell-line panel; also MLLr PDX and primary samples) washed in ice-cold PBS, oxidized with 1.6 mM sodium metaperiodate (VWR 13798-22) 20 min at 4 C, washed, labeled with 1 mM biocytin hydrazide (Biotium 90060) + 10 mM aniline (Sigma 242284) for 90 min at 4 C, washed and frozen; biological triplicates from consecutive passages. RIPA (Millipore 20-188) + HALT lysis with sonication; clarified lysate bound to 500 uL NeutrAvidin agarose (Thermo 29200) 2 h at 4 C, gravity washes with 50 mL each of RIPA/EDTA, PBS/1 M NaCl and 2 M urea/ABC; on-bead simultaneous TCEP/IAA and trypsin (Pierce 90057) digestion overnight; LC-MS/MS with MaxQuant LFQ (protein-level capture, no PNGase F).	Method as described in the paper's Methods 'Cell Surface Protein Labeling' and 'Cell lysis, cell surface protein enrichment, and peptide digestion' (Cancer Discov 2021; full text PMC8338785).	NeutrAvidin Agarose Resin (Thermo 29200); biocytin hydrazide (Biotium 90060)	not reported (CD72 IHC antibody lot R40911 is the only lot number given)	Q Exactive Plus	surface proteomics LC-MS/MS of B-ALL cell lines	Where we looked for the instrument: PMC8338785 Methods; PRIDE PXD016800 lists Q Exactive.	B-cell acute lymphoblastic leukemia cell-line panel	See original source metadata	control_surface_proteins.tsv: uniprot_accession			3825	755	0.19738562091503267	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			3783
orfanou-breast-2021	Breast cancer and MCF10A Mem-PER Plus membranes	Orfanou et al. 2021	Orfanou IM	2021	33842315	10.3389/fonc.2021.608201	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Mem-PER Plus detergent membrane extraction; no surface label.	PRIDE (msf only)	PXD021819	Table_1.xlsx in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC8034292/supplementaryFiles> | Table_2.xlsx in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC8034292/supplementaryFiles>	Thermo Mem-PER Plus membrane fraction, label-free LC-MS/MS, Proteome Discoverer.	Method summarized from the paper (PMC8034292) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	LTQ Orbitrap Elite		Instrument as listed in the ProteomeXchange record PXD021819.	HCC1954 (HER2+) and MDA-MB-231 breast cancer lines, MCF10A breast epithelial line	Supplementary Tables 1 and 2 (complete lists); membership = normalized area in >= 2 of 4 replicates of a line	Table_1.xlsx: Uniprot ID | Table_2.xlsx: Uniprot ID		HCC1954 / membrane fraction: Normalized_Area 1, Normalized_Area 2, Normalized_Area 3, Normalized_Area 4 (min_observed 2) | MCF10A / membrane fraction: Normalized_Area 1.1, Normalized_Area 2.1, Normalized_Area 3.1, Normalized_Area 4.1 (min_observed 2) | MDA-MB-231 / membrane fraction: Normalized_Area 1, Normalized_Area 2, Normalized_Area 3, Normalized_Area 4 (min_observed 2) | MCF10A / membrane fraction: Normalized_Area 1.1, Normalized_Area 2.1, Normalized_Area 3.1, Normalized_Area 4.1 (min_observed 2)	1400	288	0.2057142857142857	0.2	Homo sapiens		0	0	1400
olivieri-rbc-drm-2021	Erythrocyte membrane microdomain (detergent-resistant membrane) proteome	Olivieri et al. 2021	Olivieri A	2021	34880413	10.1038/s42003-021-02900-w	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Detergent-resistant membrane (raft) fraction of lysed erythrocyte ghosts: membrane fractionation, so complementary evidence that never votes. Adds a primary erythrocyte raft proteome.	PRIDE / MassIVE	PXD022385;MSV000086413	42003_2021_2900_MOESM3_ESM.xlsx sheet RBC proteomes <https://static-content.springer.com/esm/art%3A10.1038%2Fs42003-021-02900-w/MediaObjects/42003_2021_2900_MOESM3_ESM.xlsx>	Detergent-resistant, cholesterol-rich membrane microdomains floated on sucrose gradients from primary human erythrocyte ghosts; floating fractions analysed by LC-MS/MS (Proteome Discoverer, SwissProt human).	Method read from: Commun Biol 2021 abstract and Supplementary Data 2 headers; PMC8655059 supplementary listing.	not applicable	not reported	Agilent Q-TOF			Primary human erythrocytes (membrane microdomains)	Supplementary Data 2 'RBC proteomes' (200 proteins with peptide counts in six replicate microdomain preparations R1-R6); membership = peptides > 0 in >= 2 of 6 replicates. The comparison columns to other erythrocyte studies (whole cells, ghosts, surface) are not used.	42003_2021_2900_MOESM3_ESM.xlsx: ID		erythrocyte / baseline detergent-resistant membrane microdomains: R1, R2, R3, R4, R5, R6 (min_observed 2)	173	38	0.21965317919075145	0.2	Homo sapiens		0	0	173
rose-gbm-2021	Glioblastoma lines and astrocyte sulfo-NHS-SS-biotin surfaceome with no-biotin controls	Rose et al. 2021	Rose M	2021	34646273	10.3389/fimmu.2021.746168	core		Intact-cell sulfo-NHS-SS-biotin capture of three unperturbed lines; proteinGroups is the full MaxQuant output before any surface annotation. The deposit's no-biotin controls are kept as measurements so the label-vs-control contrast can be read; the paper itself never uses them.	PRIDE	PXD027110	proteinGroups.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2021/11/PXD027110/proteinGroups.txt>	EZ-Link Sulfo-NHS-SS-Biotin on intact washed adherent cells, Tris quench, Triton X-114 phase partition, streptavidin UltraLink resin, DTT elution	Method as described in the paper's Methods 'Cell Surface Protein Biotinylation and Triton X-114 Phase Partitioning' and 'Purification of Biotinylated Proteins'; PRIDE reading-samples.docx defines WOBiotin = no-biotin control.	Streptavidin UltraLink Resin (Pierce)	not stated	Q Exactive		Instrument as listed in the ProteomeXchange record PXD027110.	Glioblastoma lines NCH82 and U-87 MG; immortalized human astrocytes	PRIDE PXD027110 MaxQuant proteinGroups.txt (3,029 groups; 30 reverse, 73 contaminant, 8 only-by-site removed = 2,920, the paper's stated total and the row set of its Data Sheet 1). Membership = LFQ intensity > 0 in >= 2 of 3 biotin replicates of a line. No-biotin (WOBiotin) triplicates per line kept as measurements only. Table 1 / Supplementary Tables 2-3 (HPA/CSPA-selected) not used.	proteinGroups.txt: Protein IDs	drop rows flagged Reverse, Potential contaminant, Only identified by site	Immortalized human astrocytes (Innoprot P10251-IM) / baseline sulfo-NHS-SS-biotin labeled, Triton X-114 detergent phase, streptavidin: LFQ intensity Ast-Biotin1, LFQ intensity Ast-Biotin2, LFQ intensity Ast-Biotin3 (min_observed 2) | NCH82 glioma line / baseline sulfo-NHS-SS-biotin labeled, Triton X-114 detergent phase, streptavidin: LFQ intensity NCH82-Biotin1, LFQ intensity NCH82-Biotin2, LFQ intensity NCH82-Biotin3 (min_observed 2) | U-87 MG glioblastoma line / baseline sulfo-NHS-SS-biotin labeled, Triton X-114 detergent phase, streptavidin: LFQ intensity U87-Biotin1, LFQ intensity U87-Biotin2, LFQ intensity U87-Biotin3 (min_observed 2) | Immortalized human astrocytes (Innoprot P10251-IM) / no-biotin control processed in parallel (not used for membership): LFQ intensity Ast-WOBiotin1, LFQ intensity Ast-WOBiotin2, LFQ intensity Ast-WOBiotin3 (min_observed 2) | NCH82 glioma line / no-biotin control processed in parallel (not used for membership): LFQ intensity NCH82-WOBiotin1, LFQ intensity NCH82-WOBiotin2, LFQ intensity NCH82-WOBiotin3 (min_observed 2) | U-87 MG glioblastoma line / no-biotin control processed in parallel (not used for membership): LFQ intensity U87-WOBiotin1, LFQ intensity U87-WOBiotin2, LFQ intensity U87-WOBiotin3 (min_observed 2)	1631	285	0.1747394236664623	0.2	Homo sapiens		0	0	1631
li-hela-pecsl-2021	HeLa 1-min peroxidase-mediated (PECSL) surface biotinylation with negative control	Li et al. 2021	Li Y	2021	33660993	10.1021/acs.analchem.0c04970	core		Intact-cell peroxidase-mediated labeling of unperturbed HeLa with a matched negative control; the deposited proteinGroups precedes the paper's annotation counts.	jPOST / ProteomeXchange	PXD022744;JPST001019	Figure 3_proteinGroups_MaxQuant.txt	peroxidase-mediated oxidative tyrosine coupling, 1 min, intact cells	Method read from: PubMed abstract 33660993; jPOST JPST001019 file names (paper not in PMC).	streptavidin (type not verified)	not stated	Q Exactive		Instrument as listed in the ProteomeXchange record PXD022744.	HeLa cervical carcinoma cell line	Deposited 'Figure 3_proteinGroups_MaxQuant.txt' (quantitative positive-vs-negative-control experiment). Reverse, potential contaminant and only-identified-by-site rows dropped. Membership = raw Intensity > 0 in >= 2 of 4 one-minute labeling replicates; the four negative-control replicates are measurements only. Time-course and insulin files not used.	Figure 3_proteinGroups_MaxQuant.txt: Protein IDs	drop rows flagged Reverse, Potential contaminant, Only identified by site	HeLa / baseline 1-min PECSL labeled: Intensity 1min_bio1, Intensity 1min_bio2, Intensity 1min_bio3, Intensity 1min_bio4 (min_observed 2) | HeLa / negative control (not used for membership): Intensity Ctrl_bio1, Intensity Ctrl_bio2, Intensity Ctrl_bio3, Intensity Ctrl_bio4 (min_observed 2)	2314	409	0.17675021607605879	0.2	Homo sapiens		0	0	2314
tobys-hela-ap2-2021	HeLa periodate/aminooxy-biotin SILAC surfaceome, mock vs AP-2 mu2 knockdown	Tobys et al. 2021	Tobys D	2021	33225555	10.1111/tra.12770	core		Intact-cell periodate/aminooxy-biotin labeling (PMP); the light SILAC channel is the mock-treated control in every replicate, so membership rests on observed baseline iBAQ. The knockdown channel is kept as measurements only. The table was not filtered by annotation.	PRIDE (cited by the paper; not public as of 2026-11-06)	PXD014925	tra12770-sup-0002-tables1.xlsx <https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1111%2Ftra.12770&file=tra12770-sup-0002-TableS1.xlsx>	1 mM NaIO4 at 4 C, 200 uM aminooxy-biotin + 10 mM aniline pH 6.7 90 min 4 C on intact mixed SILAC cells (Weekes et al. protocol)	Method read from: Open-access author PDF (d-nb.info/1226665241/34), Results 2.1 and Methods 4.5.	Pierce high-capacity streptavidin agarose (20359)	not stated	not stated in accessible text		Where we looked for the instrument: Europe PMC abstract only; PXD014925 not found in PRIDE or ProteomeXchange API.	HeLa cervical adenocarcinoma cell line	Table S1 sheet A 'HeLa mu2 KD total surfaceome' (2,412 proteins, the authors' list of proteins present in >= 3 of 6 replicates, not filtered by GO). Membership = light (mock-treated) iBAQ reported in >= 3 of the 6 replicates (all 2,412 rows pass). Heavy (mu2-knockdown) iBAQ kept as measurements only. H/L ratios, the q-value hit flag and sheets B-D (top-upregulated, iBAQ ranking with topology annotation, GPI list) not used. First UniProt ID per row; many are TrEMBL entries as reported.	tra12770-sup-0002-tables1.xlsx: UniProt ID		HeLa / baseline mock-treated (light SILAC) periodate/aminooxy-biotin surface capture: replicate_1_iBAQ_light_mock, replicate_2_iBAQ_light_mock, replicate_3_iBAQ_light_mock, replicate_4_iBAQ_light_mock, replicate_5_iBAQ_light_mock, replicate_6_iBAQ_light_mock (min_observed 3) | HeLa / AP-2 mu2 siRNA knockdown (heavy SILAC) (not used for membership): replicate_1_iBAQ_heavy_mu2KD, replicate_2_iBAQ_heavy_mu2KD, replicate_3_iBAQ_heavy_mu2KD, replicate_4_iBAQ_heavy_mu2KD, replicate_5_iBAQ_heavy_mu2KD, replicate_6_iBAQ_heavy_mu2KD (min_observed 3)	2310	531	0.22987012987012986	0.2	Homo sapiens		0	50	2310
soday-2021	Immune IFN PMP	Soday et al. 2021	Soday L	2021	33628210	10.3389/fimmu.2021.600056	core		Original identification and specimen caveats retained in previous_reason.	PRIDE	PXD022834	PRIDEunmodifiedproteins_sodayetal.xlsx sheet CD4_10plex_fractions_SN250 | TableS5_labellingandMSfiledetails.xlsx | PRIDEunmodifiedproteins_sodayetal.xlsx sheet Monocytes_fractions_SN250	Plasma membrane profiling on intact primary CD14+ monocytes and CD4+ T cells (five donors each, with and without overnight IFN-alpha2a): cells washed in ice-cold PBS with Mg/Ca and treated with a one-pot oxidation/biotinylation mix of 1 mM sodium metaperiodate (Thermo), 100 mM aminooxy-biotin (Biotium) and 10 mM aniline (Acros) in PBS pH 6.7 for 30 min at 4 C in the dark, quenched with 1 mM glycerol; lysed in 1% Triton X-100 with iodoacetamide, nuclei removed; biotinylated glycoproteins enriched on high-affinity streptavidin agarose beads (Thermo), washed with lysis buffer, 0.5% SDS and urea on Poly-Prep columns, on-bead DTT/IAA and trypsin digestion (3 h); TMT 10-plex, MS3 quantification. The authors cite prior work showing this labeling is confined to the cell surface with no endosomal/lysosomal labeling.	Method as described in the paper's Methods 'Plasma Membrane Enrichment' (Front Immunol 2021; full text PMC7897682).	high-affinity streptavidin agarose beads (Thermo; catalog number not stated)	not reported	Orbitrap Fusion Lumos; Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD022834.	Primary CD14+ monocytes and CD4+ T cells from leukapheresis/PBMC donors	Primary human immune cells: CD14+ monocytes (donors 1-5) and CD4+ T cells (donors 6-10), negatively selected from leukapheresis/PBMCs (NHSBT). Monocytes cultured in X-Vivo 15 serum-free medium; CD4+ T cells in RPMI-1640 + 10% human AB serum. (The PRIDE deposit additionally contains human THP-1 monocytic cell line and pan-monocyte single-shot runs, and monocyte single-shot 1h/2h/3h time-courses; these supporting runs are NOT included in the primary-cell control surface list.)	PRIDEunmodifiedproteins_sodayetal.xlsx: Protein Id | PRIDEunmodifiedproteins_sodayetal.xlsx: Protein Id	drop rows where Protein Id matches (?i)contaminant|reverse|decoy | drop rows where Protein Id matches (?i)contaminant|reverse|decoy	Primary CD4+ T cells / unstimulated: CD4_F~rq_127a_sn_sum, CD4_F~rq_128a_sn_sum, CD4_F~rq_129a_sn_sum, CD4_F~rq_130a_sn_sum, CD4_F~rq_131a_sn_sum (min_observed 2) | Primary CD14+ monocytes / unstimulated: mono_F~rq_127a_sn_sum, mono_F~rq_128a_sn_sum, mono_F~rq_129a_sn_sum, mono_F~rq_130a_sn_sum, mono_F~rq_131a_sn_sum (min_observed 2)	1250	438	0.3504	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			1229
nayak-k562-memper-glyco-2021	K562 MEM-PER membrane-fraction N-glycoproteome, TMT	Nayak et al. 2021	Nayak S	2021	34596409	10.1021/acs.jproteome.1c00451	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis-then-fractionate (Mem-PER detergent extraction) followed by glycopeptide enrichment: complementary by family policy. Reports glycoproteins of every membrane compartment (LAMPs, ER chaperones lead the list), so it cannot show surface exposure.	none (supporting information only)		pr1c00451_si_002.xlsx sheet S2b-Membrane_Glycoproteins <https://pubs.acs.org/jprobs/article-supplement/460228/xlsx/pr1c00451_si_002/>	Mem-PER membrane/cytosol extraction then N-glycopeptide enrichment, TMT (abstract; workbook sheet titles)	Method read from: Europe PMC abstract; Supplemental Data S2 index sheet.	none (glycopeptide enrichment, chemistry not read)	not stated	not stated in accessible text		Where we looked for the instrument: ACS refused automated access; Europe PMC abstract only; no free full text in PubMed Central.	K562 chronic myeloid leukemia cell line	Supplemental Data S2, sheet S2b-Membrane_Glycoproteins: 487 master proteins (glycoproteins) from the K562 membrane preparation, abundances in two membrane channels M1 and M2. Membership = abundance > 0 in >= 1 of 2 channels (all 487 are quantified in both). Cytosolic preparation (S2e) and the mouse liver workbook (S3) not used. No other filter.	pr1c00451_si_002.xlsx: Master Protein Accessions		K562 / baseline Mem-PER membrane fraction, N-glycopeptide enrichment: M1, M2 (min_observed 1)	477	198	0.41509433962264153	0.2	Homo sapiens		0	6	477
sun-mcf7-xlink-gao-2021	MCF7 galactose-oxidase/hydrazide surface glycoprotein capture with in situ crosslinking	Sun et al. 2021	Sun F	2021	34163979	10.1039/d0sc06327d	held	the sample-to-condition map is unpublished	Intact-cell galactose oxidase/hydrazide capture, but the only full list pools the crosslinked arm (which deliberately adds crosslinked, partly intracellular prey) with the no-crosslinker control captures and has no per-channel values, so control-arm membership cannot be stated. Per-channel TMT reporter values from the authors would resolve it.	none (supplementary tables only)		SC-012-D0SC06327D-s002.xlsx sheet All proteins in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC8179341/supplementaryFiles>	in situ crosslinking (or none, control) then galactose oxidase + hydrazide capture on intact MCF7, TMT6	Method as described in the paper's Results (principle, TMT design) and Experimental (lysis, database searching) (full text PMC8179341).	hydrazide resin	not stated	LTQ Orbitrap Elite	LC-MS/MS, Top15 DDA	Instrument as named in the paper's Methods (full text PMC8179341).	MCF7 breast cancer cell line	ESI Table S1(a) 'All proteins' (3,271 proteins identified and quantified in the pooled TMT 6-plex). No row filter applied; the authors' fold change >2, P<0.05 'Enriched proteins' sheet not used. Membership = identified in the pooled plex, which mixes three crosslinked and three no-crosslinker control captures; no per-channel values are published.	SC-012-D0SC06327D-s002.xlsx: Uniprot ID			3223	755	0.23425380080670183	0.2	Homo sapiens		0	8	3223
lorenz-muller-2021	MIO-M1 retinal Muller glia aminooxy-biotin surfaceome	Lorenz et al. 2021	Lorenz L	2021	33806940	10.3390/cells10030711	held	conditions are pooled in one list, with no separable baseline	Intact-cell aminooxy-biotin capture, but the only table pools untreated, LPS-stimulated and no-biotin samples without per-sample values, so baseline membership cannot be separated; 76 of 507 ENSP rows could not be mapped to reviewed UniProt.	none (supplementary tables only)		Supplementary Table S1.xlsx sheet Tabelle1 in supplementaryFiles › cells-10-00711-s001.zip <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC8004686/supplementaryFiles> | uniprot_idmapping_Ensembl_Protein_to_SwissProt_2026-10-29.tsv | Supplementary Table S1.uniprot_mapped.tsv	Periodate/aniline-catalysed aminooxy-biotin labeling of intact cells, streptavidin capture, LTQ Orbitrap XL, Progenesis QI label-free quantification, Mascot search of the Ensembl human protein database (percolator FDR < 1%).	Method summarized from the paper (PMC8004686) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	LTQ Orbitrap XL			MIO-M1 human retinal Muller glia cell line	Supplementary Table S1 (507 proteins, Ensembl protein IDs), pooled across 3 unstimulated, 3 LPS-stimulated and 1 non-biotinylated flask; no per-sample abundances. ENSP mapped to reviewed human UniProt by UniProt ID mapping: 431 rows mapped to exactly one entry (423 distinct accessions), 76 rows unmapped and dropped (retired or non-canonical ENSPs plus one bovine albumin contaminant). Equine primary RMG (Table S2) not used.	Supplementary Table S1.uniprot_mapped.tsv: uniprot_mapped			423	278	0.6572104018912529	0.2	Homo sapiens		0	0	423
heider-mm1s-2021	MM.1S myeloma SILAC sulfo-NHS-SS-biotin surfaceome · DMSO solvent (inferred) (baseline)	Heider et al. 2021	Heider M	2021	33571422	10.1016/j.molcel.2020.12.046	held	the sample-to-condition map is unpublished	Intact-cell sulfo-NHS-SS-biotin capture, but neither the paper nor the deposit says which SILAC channel is DMSO. Heavy is inferred to be DMSO because the paper's lenalidomide-depleted surface proteins (SLC3A2/CD98hc, SLC7A5/LAT1, BSG/CD147) all have surface H/L of about 1.7-2.7. Hold until the mapping is confirmed; MM.1S is already covered by myeloma CSC inputs.	PRIDE	PXD018244	proteinGroups.txt	Pierce Cell Surface Protein Isolation Kit 89881: EZ-Link sulfo-NHS-SS-biotin on intact cells at 4 C for 30 min, NeutrAvidin beads, Laemmli elution under reducing conditions	Method as described in the paper's STAR Methods 'Cell surface biotinylation and extraction' and 'LC-MS/MS measurements'; experimentalDesignTemplateSurface.txt / summary.txt (Input, FT, Surface1-3).	NeutrAvidin agarose (kit)	not stated	Orbitrap Fusion Lumos; LTQ Orbitrap Velos		Instrument as listed in the ProteomeXchange record PXD018244.	MM.1S multiple myeloma cell line	PRIDE PXD018244 MQresultSurface.7z proteinGroups.txt (2,602 groups; reverse, contaminant and only-by-site removed = 2,445). Membership = heavy-channel (DMSO, inferred) Intensity > 0 in >= 2 of 3 surface injections. Light (lenalidomide) surface channel and both lysate input channels kept as measurements only; flow-through not used. The authors' >= 2 unique-peptide filter is not applied.	proteinGroups.txt: Protein IDs	drop rows flagged Reverse, Potential contaminant, Only identified by site	MM.1S multiple myeloma line / DMSO solvent, sulfo-NHS-SS-biotin surface capture (heavy channel, inferred): Intensity H Surface1, Intensity H Surface2, Intensity H Surface3 (min_observed 2) | MM.1S multiple myeloma line / lenalidomide 48 h, surface capture (light channel, inferred; not used for membership): Intensity L Surface1, Intensity L Surface2, Intensity L Surface3 (min_observed 2) | MM.1S multiple myeloma line / DMSO whole-cell lysate input (not used for membership): Intensity H Input (min_observed 1) | MM.1S multiple myeloma line / lenalidomide whole-cell lysate input (not used for membership): Intensity L Input (min_observed 1)	1398	202	0.14449213161659513	0.2	Homo sapiens		0	0	1398
heider-mm1s-2021--lenalidomide-48-h-surface-capture	MM.1S myeloma SILAC sulfo-NHS-SS-biotin surfaceome · lenalidomide 48 h (inferred)	Heider et al. 2021	Heider M	2021	33571422	10.1016/j.molcel.2020.12.046	perturbed	drug, ligand or treatment: lenalidomide 48 h (light ,)	drug, ligand or treatment arm of heider-mm1s-2021; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD018244	proteinGroups.txt	Pierce Cell Surface Protein Isolation Kit 89881: EZ-Link sulfo-NHS-SS-biotin on intact cells at 4 C for 30 min, NeutrAvidin beads, Laemmli elution under reducing conditions	Method as described in the paper's STAR Methods 'Cell surface biotinylation and extraction' and 'LC-MS/MS measurements'; experimentalDesignTemplateSurface.txt / summary.txt (Input, FT, Surface1-3).	NeutrAvidin agarose (kit)	not stated	Orbitrap Fusion Lumos; LTQ Orbitrap Velos		Instrument as listed in the ProteomeXchange record PXD018244.	MM.1S multiple myeloma line	MM.1S multiple myeloma line, lenalidomide 48 h, surface capture (light channel, inferred; not used for membership): a non-baseline state of heider-mm1s-2021, listed when observed in at least 2 of its 3 samples				1409	200	0.14194464158977999		Homo sapiens		0	0	1409
lu-molm14-2021	MOLM-14 AML sucrose-gradient plasma-membrane fraction, three instruments	Lu et al. 2021	Lu C	2021	34669412	10.1021/acs.jproteome.1c00624	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Sucrose-gradient PM fraction of lysed cells with no surface label: complementary membrane evidence only. AML is already well represented (schmidt-aml-2018 and intact-cell AML inputs); the value here is depth (24 runs, ~6,000 groups) on one line. Instruments are kept as separate groups so the replicate rule never pools platforms.	PRIDE	PXD022721	proteinGroups.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2021/12/PXD022721/proteinGroups.txt>	sucrose cushion + sucrose step-gradient enriched plasma-membrane fraction, no affinity step ('label-free, non-affinity-purified enrichment')	Method read from: PRIDE PXD022721 sample and data processing protocols; PubMed abstract (paper not open access).	none	not applicable	Q Exactive HF; Orbitrap Fusion; LTQ Orbitrap Elite		Instrument as listed in the ProteomeXchange record PXD022721.	MOLM-14 acute myeloid leukemia cell line	PRIDE PXD022721 proteinGroups.txt (6,681 protein groups, 24 runs: Elite R1-R7, Fusion R1-R9, QEHF R1-R8). Rows flagged Only identified by site, Reverse or Potential contaminant removed (6,190 remain). Membership = MaxQuant Intensity > 0 in >= 2 runs of one instrument. The authors' nine-GO-term surface selection (>2,300 'putative cell surface proteins') is not used.	proteinGroups.txt: Majority protein IDs	drop rows flagged Only identified by site, Reverse, Potential contaminant	MOLM-14 / baseline enriched plasma-membrane fraction (sucrose gradient), Orbitrap Elite runs: Intensity Elite_R1, Intensity Elite_R2, Intensity Elite_R3, Intensity Elite_R4, Intensity Elite_R5, Intensity Elite_R6, Intensity Elite_R7 (min_observed 2) | MOLM-14 / baseline enriched plasma-membrane fraction (sucrose gradient), Orbitrap Fusion runs: Intensity Fusion_R1, Intensity Fusion_R2, Intensity Fusion_R3, Intensity Fusion_R4, Intensity Fusion_R5, Intensity Fusion_R6, Intensity Fusion_R7, Intensity Fusion_R8, Intensity Fusion_R9 (min_observed 2) | MOLM-14 / baseline enriched plasma-membrane fraction (sucrose gradient), Q Exactive HF runs: Intensity QEHF_R1, Intensity QEHF_R2, Intensity QEHF_R3, Intensity QEHF_R4, Intensity QEHF_R5, Intensity QEHF_R6, Intensity QEHF_R7, Intensity QEHF_R8 (min_observed 2)	5973	637	0.10664657625983592	0.2	Homo sapiens		0	0	5973
myc-wells-2021	MYC surfaceome	Chen et al. 2021	Chen W	2021	33483421	10.1073/pnas.2018861118	held	conditions are pooled in one list, with no separable baseline	Main-text comparisons are high versus low MYC in isogenic cells. Current SILAC pooled-source baseline and supplemental processing remain incompletely reconciled. No omission-control selection can be inferred from the word control or the positive/negative MYC ratios.	MassIVE	MSV000085930;PXD020799	control_surface_proteins.tsv	Wells-lab glycan-directed cell surface capture (CSC) on intact cells: P493-6 B cells (SILAC heavy/light, high- vs low-MYC, mixed 1:1) and RWPE-1 / PrEC-LHS prostate cells (20e6 cells at 80% confluence; ReDiMe dimethyl labeling for quantification) treated with mild sodium periodate then biocytin hydrazide to biotinylate surface glycans; lysis, biotinylated glycoproteins bound to NeutrAvidin beads, washes with RIPA, 1 M NaCl PBS and 2 M urea, on-bead TCEP/IAA and trypsin digestion, formerly N-glycosylated peptides released with PNGase F; LC-MS/MS. The inventory table pools MYC conditions, which is why the row is on hold.	Method as described in the paper's Methods 'Cell Surface Capture' (PNAS 2021; full text PMC7848737).	NeutrAvidin agarose beads (vendor/catalog not stated in main text; Wells-lab protocol uses Thermo High Capacity NeutrAvidin 29204)	not reported	Q Exactive Plus		Instrument as listed in the ProteomeXchange records MSV000085930 and PXD020799.	P493-6 B cells and RWPE-1/PrEC-LHS prostate cells; mixed MYC conditions	Three human isogenic ±MYC model cell lines: (1) P493-6 -- tet-off conditional-MYC B-lymphoblastoid line (EBV-immortalized human B cell); (2) RWPE-1 -- human normal prostate epithelial cell line engineered for MYC over-expression; (3) PrEC-LHS -- human normal prostate epithelial cell line (LHS derivative) engineered for MYC over-expression.	control_surface_proteins.tsv: uniprot_accession			1243	598	0.48109412711182625	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			1229
akpinar-msc-pm-2021	Mesenchymal stem cells from dental pulp, adipose, bone marrow and hair follicle, plasma-membrane fraction	Akpinar et al. 2021	Akpinar G	2021	34230997	10.1007/s00232-021-00190-1	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Differential centrifugation of lysed cells: total-membrane enrichment, complementary only. Adds four MSC origins (including bone-marrow MSCs) with per-origin lists.	none (supplementary table only; raw data on request per Data Availability)		232_2021_190_MOESM1_ESM.xlsx sheet DP_Rep1 <https://static-content.springer.com/esm/art%3A10.1007%2Fs00232-021-00190-1/MediaObjects/232_2021_190_MOESM1_ESM.xlsx> | 232_2021_190_MOESM1_ESM.xlsx sheet hAT_Rep1 <https://static-content.springer.com/esm/art%3A10.1007%2Fs00232-021-00190-1/MediaObjects/232_2021_190_MOESM1_ESM.xlsx> | 232_2021_190_MOESM1_ESM.xlsx sheet hBM_Rep1 <https://static-content.springer.com/esm/art%3A10.1007%2Fs00232-021-00190-1/MediaObjects/232_2021_190_MOESM1_ESM.xlsx> | 232_2021_190_MOESM1_ESM.xlsx sheet HF_Rep1 <https://static-content.springer.com/esm/art%3A10.1007%2Fs00232-021-00190-1/MediaObjects/232_2021_190_MOESM1_ESM.xlsx>	differential-velocity centrifugation PM enrichment, nLC-MS/MS	Method read from: Springer abstract; ESM_1 sheet layout (Proteome Discoverer export); full text paywalled, not read.	none	n/a	not stated in accessible text		Where we looked for the instrument: Europe PMC abstract only (no free full text); publisher page via DOI blocked (refused automated access) or served no readable text; abstract says nLC-MS/MS only.	Cultured human mesenchymal stem cells (dental pulp, adipose tissue, bone marrow, hair follicle)	Supplementary file 1 (ESM_1 xlsx), one Proteome Discoverer protein sheet per MSC origin (DP_Rep1 609, hAT_Rep1 618, hBM_Rep1 2,133, HF_Rep1 330 rows). Membership per origin = listed proteins with >= 1 PSM; origins kept as separate groups, never pooled. Only one replicate sheet per origin is published.	232_2021_190_MOESM1_ESM.xlsx: Accession | 232_2021_190_MOESM1_ESM.xlsx: Accession | 232_2021_190_MOESM1_ESM.xlsx: Accession | 232_2021_190_MOESM1_ESM.xlsx: Accession		dental-pulp MSC / plasma-membrane-enriched fraction, culture baseline: Σ# PSMs (min_observed 1) | adipose-tissue MSC / plasma-membrane-enriched fraction, culture baseline: Σ# PSMs (min_observed 1) | bone-marrow MSC / plasma-membrane-enriched fraction, culture baseline: Σ# PSMs (min_observed 1) | hair-follicle MSC / plasma-membrane-enriched fraction, culture baseline: Σ# PSMs (min_observed 1)	2341	277	0.11832550192225545	0.2	Homo sapiens		0	12	2341
kaczmarczyk-h23-2021	NCI-H23 lung adenocarcinoma microsomal fractions, 2D and 3D culture	Kaczmarczyk et al. 2021	Kaczmarczyk JA	2021	34611477	10.18632/oncotarget.28072	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Ultracentrifugation microsomal pellet from sonicated cells; no surface label. The authors describe it as a crude membrane fraction including mitochondria, nuclei, ER and Golgi.	none (supplementary tables only)		oncotarget-12-2022-s002.xlsx sheet Supplementary Table 1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC8487723/supplementaryFiles> | oncotarget-12-2022-s002.xlsx sheet Supplementary Table 2 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC8487723/supplementaryFiles>	Tip sonication, debris removal, 100,000 x g for 1.5 h; pellet = enriched microsomal fraction	Method as described in the paper's Methods 'Microsomal fraction preparation' and Results first section.	none	not reported	Orbitrap Elite	EASY-nLC 1200 coupled; SCX fractions	Instrument as named in the paper's Methods (full text PMC8487723).	NCI-H23 lung adenocarcinoma (KRAS G12C) cells grown as 2D monolayers and on 3D microcarriers	oncotarget-12-2022-s002.xlsx Supplementary Table 1 (3D culture, 4,180 protein groups) and Supplementary Table 2 (2D culture, 4,444 protein groups); all rows High FDR confidence. Membership = # PSMs > 0 in that culture. HPA location columns are annotation only and select nothing; Tables 5-8 (PSORT/TMHMM integral and CSPA subsets) not used.	oncotarget-12-2022-s002.xlsx: Accession | oncotarget-12-2022-s002.xlsx: Accession #	FDR Confidence = High | Confidence = High	NCI-H23 / 3D microcarrier culture, microsomal fraction: # PSMs (min_observed 1) | NCI-H23 / 2D monolayer culture, microsomal fraction: # PSMs (min_observed 1)	4765	393	0.08247639034627492	0.2	Homo sapiens		0	0	4765
li-npc-2021	Nasopharyngeal carcinoma 6-10B / 5-8F surface biotinylation + SILAC	Li et al. 2021	Li M	2021	34178975	10.3389/fcell.2021.621810	below_screen	11% Canonical or Likely proteins, under 20%	Both untreated lines labeled on intact cells; full MaxQuant protein-group table. Columns after 'Ratio H/L variability [%]' are misaligned in the supplement, so only the peptide-count and Q-value columns are used.	none found (supplementary tables only)		Table_1.XLSX sheet proteinGroups in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC8219959/supplementaryFiles>	Sulfo-NHS-SS-biotin labeling of intact SILAC-labeled cells (6-10B light, 5-8F heavy), lysates mixed, streptavidin capture; LTQ-Orbitrap DDA, MaxQuant 1.5.8.30 against UniProt human (2019-07-06).	Method summarized from the paper (PMC8219959) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	LTQ Orbitrap			Isogenic nasopharyngeal carcinoma lines 6-10B (low metastatic) and 5-8F (high metastatic), SILAC-mixed	Supplementary Table 1 (MaxQuant proteinGroups, 3,003 groups); drop REV__/CON__ groups and Q-value > 0.01; membership = >= 1 unique peptide in >= 2 of 7 runs (3 biological replicates with 2/3/2 technical runs). Light and heavy lines share each run, so detection cannot be assigned to one line.	Table_1.XLSX: Majority protein IDs	Q-value ≤ 0.01 | drop rows where Majority protein IDs matches ^(?:REV__|CON__)	6-10B + 5-8F (SILAC light/heavy mix) / untreated, intact-cell sulfo-NHS-SS-biotin capture: Unique peptides exp11, Unique peptides exp12, Unique peptides exp21, Unique peptides exp22, Unique peptides exp23, Unique peptides exp31, Unique peptides exp32 (min_observed 2)	2473	266	0.10756166599272139	0.2	Homo sapiens		0	69	2473
ehlers-ampd2-2021--hox-sulfo-nhs-ss-biotin-pulldown	Sulfo-NHS-SS-biotin surface pulldown with no-biotin control, unstated human cell type · hypoxia (inferred)	Ehlers et al. 2021	Ehlers L	2021	34159634	10.1096/fj.202002658RR	perturbed	stress: HOX (hypoxia)	stress arm of ehlers-ampd2-2021; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD022350	proteinGroups_EV2.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2021/11/PXD022350/proteinGroups_EV2.txt>	Pierce Cell Surface Protein Isolation Kit (sulfo-NHS-SS-biotin) per PRIDE sample protocol; matched no-biotin controls	Method read from: PXD022350 sample/data processing protocols and summary_EV2.txt raw-file-to-experiment map; paper not accessible (Wiley full text not accessible, no PMC copy).	kit NeutrAvidin agarose (per kit; deposit says streptavidin-based pulldown)	not stated	Q Exactive HF; Q Exactive; Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD022350.	unstated human cells (PXD022350)	unstated human cells (PXD022350), HOX (inferred hypoxia) sulfo-NHS-SS-biotin pulldown: a non-baseline state of ehlers-ampd2-2021, listed when observed in at least 2 of its 3 samples				3827	291	0.07603867258949569		Homo sapiens		0	65	3827
ehlers-ampd2-2021	Sulfo-NHS-SS-biotin surface pulldown with no-biotin control, unstated human cell type · normoxia (inferred) (baseline)	Ehlers et al. 2021	Ehlers L	2021	34159634	10.1096/fj.202002658RR	held	the deposit can't be matched to the paper's cell type	Hold: the deposit does not state the cell type and the paper is not open access; the abstract places surface biotinylation on monocytes, yet the pulldowns and inputs lack monocyte markers (no CD14, PTPRC, ITGB2, HLA-DRA, CD74) and carry collagens, THY1, NT5E and ENG, so the deposit cannot be matched to the paper's design. NOX/HOX read as normoxia/hypoxia is inferred. Resolve the cell type and arm meaning from the paper's Methods before any admission.	PRIDE	PXD022350	proteinGroups_EV2.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2021/11/PXD022350/proteinGroups_EV2.txt>	Pierce Cell Surface Protein Isolation Kit (sulfo-NHS-SS-biotin) per PRIDE sample protocol; matched no-biotin controls	Method read from: PXD022350 sample/data processing protocols and summary_EV2.txt raw-file-to-experiment map; paper not accessible (Wiley full text not accessible, no PMC copy).	kit NeutrAvidin agarose (per kit; deposit says streptavidin-based pulldown)	not stated	Q Exactive HF; Q Exactive; Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD022350.	Unstated human cell type (paper abstract: monocytes; deposit tags blood cells and epithelial cells; the proteome is mesenchymal-like)	proteinGroups_EV2.txt (MaxQuant, 1% protein FDR): reverse, potential-contaminant and only-by-site groups removed. Membership = Intensity > 0 in >= 2 of 3 NOX biotin pulldowns. NOX no-biotin controls, all HOX pulldowns and controls, and the input (total) samples kept as non-membership measurements. EV1 (AMPD2 immunoprecipitations) and EV3 (AMPD2 antibody IPs) not read.	proteinGroups_EV2.txt: Protein IDs	drop rows flagged Reverse, Potential contaminant, Only identified by site	unstated human cells (PXD022350) / NOX (inferred normoxia) sulfo-NHS-SS-biotin pulldown: Intensity Strep_IP_NOX_biotin_1, Intensity Strep_IP_NOX_biotin_2, Intensity Strep_IP_NOX_biotin_3 (min_observed 2) | unstated human cells (PXD022350) / NOX no-biotin control pulldown (not used for membership): Intensity Strep_IP_NOX_control_1, Intensity Strep_IP_NOX_control_2, Intensity Strep_IP_NOX_control_3 (min_observed 2) | unstated human cells (PXD022350) / HOX (inferred hypoxia) sulfo-NHS-SS-biotin pulldown (not used for membership): Intensity Strep_IP_HOX_biotin_1, Intensity Strep_IP_HOX_biotin_2, Intensity Strep_IP_HOX_biotin_3 (min_observed 2) | unstated human cells (PXD022350) / HOX no-biotin control pulldown (not used for membership): Intensity Strep_IP_HOX_control_1, Intensity Strep_IP_HOX_control_2, Intensity Strep_IP_HOX_control_3 (min_observed 2) | unstated human cells (PXD022350) / NOX input lysate before pulldown (not used for membership): Intensity Input_NOX_biotin_1, Intensity Input_NOX_biotin_2, Intensity Input_NOX_biotin_3, Intensity Input_NOX_control_1, Intensity Input_NOX_control_2, Intensity Input_NOX_control_3 (min_observed 2)	3806	295	0.07750919600630583	0.2	Homo sapiens		0	71	3806
zurli-bcell-pmp-2020	B-cell line plasma membrane profiling, periodate/aminooxy-biotin (Zurli et al. 2020 deposit)	Zurli et al. 2020	Zurli V	2020	32398348	10.1126/scisignal.aaz1965	core		Intact-cell periodate/aminooxy-biotin capture of untreated B-cell targets with per-sample abundances; membership read per sample from both technical injections. No no-label control. Two samples (PS69, PS78) are not identified in the deposit and the paper (closed access) could not be read; Progenesis abundances come from cross-run feature alignment, so a value is not a per-run identification.	PRIDE	PXD013840	allproteinsindividualsamplestechnreplicates.csv <https://ftp.pride.ebi.ac.uk/pride/data/archive/2020/04/PXD013840/allproteinsindividualsamplestechnreplicates.csv>	periodate/aminooxy-biotin/aniline on intact B cells at 4 C, streptavidin agarose	Method read from: PRIDE PXD013840 sample and data processing protocols (paper is subscription-only).	high-affinity streptavidin agarose (Pierce)	not stated	Orbitrap Fusion Lumos		Instrument as listed in the ProteomeXchange record PXD013840.	B-cell lines and samples used as CTL targets: BJAB, EBV-transformed B cells (EBVB), MEC (CLL), PS69, PS78	PRIDE allproteinsindividualsamplestechnreplicates.csv (Progenesis QI export, 1,392 proteins, all Homo sapiens). No row filter beyond the export. Membership = Progenesis raw abundance > 0 in both technical injections of a sample, evaluated per sample (five samples, two injections each). Normalized-abundance and ANOVA columns not used.	allproteinsindividualsamplestechnreplicates.csv: Accession		BJAB (Burkitt lymphoma B-cell line) / baseline periodate/aminooxy-biotin surface capture: raw_BJAB_inj1, raw_BJAB_inj2 (min_observed 2) | EBVB (EBV-transformed B cells, per sample label) / baseline periodate/aminooxy-biotin surface capture: raw_EBVB_inj1, raw_EBVB_inj2 (min_observed 2) | MEC (B-CLL line, per sample label; presumed MEC-1) / baseline periodate/aminooxy-biotin surface capture: raw_MEC_inj1, raw_MEC_inj2 (min_observed 2) | PS69 B-cell sample (identity not stated in deposit) / baseline periodate/aminooxy-biotin surface capture: raw_PS69_inj1, raw_PS69_inj2 (min_observed 2) | PS78 B-cell sample (identity not stated in deposit) / baseline periodate/aminooxy-biotin surface capture: raw_PS78_inj1, raw_PS78_inj2 (min_observed 2)	1203	591	0.4912718204488778	0.2	Homo sapiens		0	0	1203
beguin-boec-2020	Blood outgrowth endothelial cell sulfo-NHS-LC-biotin site footprint under shear	Béguin et al. 2020	Béguin EP	2020	32332107	10.1074/mcp.ra120.001964	held	the sample-to-condition map is unpublished	Intact-cell sulfo-NHS-LC-biotin with site-level evidence (biotinylated peptides themselves are pulled down), on a primary normal endothelial cell. Held: static and shear-stressed cells are mixed 1:1:1 before pull-down and MaxQuant requantify was on, so baseline (static) membership cannot be separated from the flow arms; per-channel intensities exist only inside the 4 GB PRIDE IP_*_combined.zip archives (BiotinSites.txt). Leading accession is often TrEMBL (71 of 1,346 sites start with A0A).	PRIDE	PXD014526	158553_1_supp_511750_q8501x.xlsx in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC7338090/supplementaryFiles>	EZ-Link sulfo-NHS-LC-biotin, 3 mM, 30 min 4 C on intact SILAC BOECs; peptide-level streptavidin capture	Method as described in the paper's Methods 'MS Analysis of Flow-treated SILAC-labeled ECs', 'Data analysis'; Fig. 1A legend; Table S2 header.	SigmaScreen Streptavidin high capacity coated plate (Sigma-Aldrich)	not stated	Orbitrap Fusion Lumos; Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD014526.	Primary human blood outgrowth endothelial cells (BOEC), pool of 3 healthy donors	Supplementary Table S2 'Unambiguous biotin site modifications' (1,346 class I biotin sites: localization probability > 0.75, score difference > 5; MaxQuant reverse/contaminant/only-by-site removed; >= 3 valid SILAC ratios in one comparison, all by the authors). Membership = protein (leading accession of the site's Protein IDs) carrying a site with a log2 SILAC ratio observed in >= 2 of 3 replicates (A, B, C) of the 24 h/static comparison. Each replicate is one 1:1:1 mix of static, 24 h and 48 h flow cells, so identification is pooled across conditions; 48 h/static ratios kept as measurements only. Table S3 (ambiguous localizations, ~420 sites) not used.	158553_1_supp_511750_q8501x.xlsx: Protein IDs		BOEC (3-donor pool) / SILAC mix of static and flow-exposed cells, intact-cell sulfo-NHS-LC-biotin (24 h/static ratio): log2 ratio 24h/static A, log2 ratio 24h/static B, log2 ratio 24h/static C (min_observed 2; floor -1000) | BOEC (3-donor pool) / 48 h flow vs static SILAC ratio (not used for membership): log2 ratio 48h/static A, log2 ratio 48h/static B, log2 ratio 48h/static C (min_observed 2; floor -1000)	286	150	0.5244755244755245	0.2	Homo sapiens		0	8	286
ito-bbb-2020	Brain microvascular and umbilical vein endothelial sulfo-NHS surfaceome	Ito et al. 2020	Ito S	2020	32585920	10.3390/pharmaceutics12060579	held	only proteins above an enrichment cutoff are reported	Intact-cell sulfo-NHS capture with a no-biotin control, but only proteins above a label/control ratio threshold are reported, and the threshold (8 or 4) was chosen from the plasma-membrane GO-annotation fraction, so the list is partly annotation-calibrated.	none (supplementary tables only)		Supplementary Materials_Table S2-S3.xlsx sheet TableS2 in supplementaryFiles › pharmaceutics-12-00579-s001.zip <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC7356521/supplementaryFiles> | TableS2a_hCMEC-D3.tsv | TableS2b_HUVEC.tsv	EZ-Link sulfo-NHS-SS-biotin labeling of intact cells at 4 C with a PBS-only (no-biotin) control, streptavidin capture, DTT elution, SWATH-MS label-free quantification.	Method summarized from the paper (PMC7356521) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	TripleTOF 5600 (SCIEX)	SWATH-MS quantification, Dionex Ultimate 3000 RSLC nano	Instrument as named in the paper's Methods (full text PMC7356521).	hCMEC/D3 brain microvascular endothelial cell line and primary HUVEC (pooled donors)	Table S2a (hCMEC/D3, 378 proteins) and S2b (HUVEC, 225 proteins): only proteins whose Cell-surface/Control peak-area ratio exceeded 8 (hCMEC/D3) or 4 (HUVEC); 185 and 174 identified proteins below the threshold are not reported. Membership = listed with a positive Cell-surface mean peak area (n = 3, mean only). Control means kept as measurements only. Table S3 (endocytosis subset) not used.	TableS2a_hCMEC-D3.tsv: UniProt ID | TableS2b_HUVEC.tsv: UniProt ID		hCMEC/D3 / baseline sulfo-NHS-SS-biotin labeled: Cell-surface peak area mean (n=3) (min_observed 1) | hCMEC/D3 / no-biotin control (not used for membership): Control peak area mean (n=3) (min_observed 1) | HUVEC / baseline sulfo-NHS-SS-biotin labeled: Cell-surface peak area mean (n=3) (min_observed 1) | HUVEC / no-biotin control (not used for membership): Control peak area mean (n=3) (min_observed 1)	439	260	0.592255125284738	0.2	Homo sapiens		0	0	439
barua-hct116-2020	HCT116 colorectal cancer sulfo-NHS surface biotinylation with Dounce lysis	Barua et al. 2020	Barua P	2020	32030527	10.1007/s10529-020-02824-1	below_screen	13% Canonical or Likely proteins, under 20%	Intact-cell surface biotinylation of unperturbed HCT116 with a matched non-biotinylated control; Supplementary table 1 is the complete eluate list after control subtraction, which keeps non-surface hits (ribosomal proteins, chaperones). Single list, single condition; no replicate columns are reported.	none (supplementary table only)		10529_2020_2824_MOESM1_ESM.xlsx sheet Supplementary table 1 <https://static-content.springer.com/esm/art%3A10.1007%2Fs10529-020-02824-1/MediaObjects/10529_2020_2824_MOESM1_ESM.xlsx>	cell surface biotinylation of intact HCT116 cells (abstract; Springer full text paywalled, reagent not verified in methods)	Method read from: Europe PMC abstract; ESM1 table captions.	affinity beads (streptavidin, per abstract 'affinity bead-based purification')	not reported in abstract	not stated in accessible text		Where we looked for the instrument: Springer page blocked (client challenge); Europe PMC abstract has no instrument; no free full text in PubMed Central.	HCT116 colorectal carcinoma cell line	ESM1 'Supplementary table 1': 300 UniProt entries identified in the biotinylated eluate of HCT116 cells after the authors removed false positives and every protein also identified in the control eluate (label-vs-control subtraction, not an annotation filter). Membership = listed. Gold/green row highlighting (plasma-membrane/junctional; transcript-level evidence) is formatting only and selects nothing. Supplementary table 2 (whole-cell lysate, 505) and table 3 (control eluate, 89) are not used.	10529_2020_2824_MOESM1_ESM.xlsx: Entry			299	38	0.12709030100334448	0.2	Homo sapiens		0	0	299
lango-hl60-proteolysis-2020	HL60 sulfo-NHS-SS-biotin labeled-peptide surfaceome with and without partial surface proteolysis	Langó et al. 2020	Langó T	2020	32483232	10.1038/s41598-020-65831-2	core		Direct labeled-peptide (site) evidence from intact HL60 cells; membership uses the 0-min arms that are the standard sulfo-NHS protocol. Pre-digestion is a deliberate surface perturbation, so those runs are measurements only. Same group and line as lango-leukemia-2017 and lango-hl60-2022; this adds few new IDs.	none (supplementary tables only)		lango2020_labelled_psm_counts.tsv	Sulfo-NHS-SS-biotin on intact HL60 after optional surface trypsin/chymotrypsin pre-digestion; NeutrAvidin capture of labeled peptides from isolated plasma membranes	Method as described in the paper's Results ('Trypsin and chymotrypsin pre-digestion resulted in 4344 labeled peptides') and Methods (full text PMC7264363).	high-capacity NeutrAvidin agarose	not stated	Maxis II QTOF	Bruker Maxis II Q-TOF with CaptiveSpray nanoBooster, nanoLC Dionex	Instrument as named in the paper's Methods and author contributions (full text PMC7264363).	HL60 acute promyelocytic leukemia cell line	Supplementary Table 1 (MOESM2) sheets 'Trypsin' (4,344 labeled-peptide PSMs), 'Cymotrypsin' (5,594) and 'Control_unlabeled' (91), all HL60; rolled up to labeled-PSM counts per reported accession per run (Sample ID). Only peptides carrying the labeling remnant are listed; the TM column is a CCTOP annotation and never filters. Membership = labeled PSM in >= 2 of the 8 no-pre-digestion (0 min) runs. Trypsin- and chymotrypsin-pre-digested runs and the unlabeled control kept as measurements only.	lango2020_labelled_psm_counts.tsv: Acc#		HL60 / baseline intact-cell sulfo-NHS-SS-biotin labeled peptides, no surface pre-digestion: chymo|20180307_0min_chimo, chymo|20190123_0min_chimo, chymo|20190216_0min_chimo, chymo|20191029_0min_chimo, try|20170809_0min_try, try|20170828_0min_4*try, try|20180111_0min_try, try|20181128_0min_try (min_observed 2) | HL60 / surface trypsin pre-digestion 15-25 min before labeling (not used for membership): try|20170809_15min_try, try|20170809_25min_try, try|20170828_15min_4*try, try|20170828_25min_4*try, try|20180111_15min_try, try|20180111_25min_try, try|20181128_15min_try, try|20181128_25min_try (min_observed 2) | HL60 / surface chymotrypsin pre-digestion 10-20 min before labeling (not used for membership): chymo|20180307_10min_chimo, chymo|20180307_20min_chimo, chymo|20190123_10min_chimo, chymo|20190123_20min_chimo, chymo|20190123_20min_chimo_reload, chymo|20190216_10min_chimo, chymo|20190216_20min_chimo, chymo|20191029_10min_chimo, chymo|20191029_20min_chimo (min_observed 2) | HL60 / unlabeled control membrane preparation (not used for membership): ctrl|20181128_LT1_ctr, ctrl|20181128_LT2_ctr, ctrl|20181128_LT3_ctr, ctrl|20181128_LT4_ctr (min_observed 2)	61	45	0.7377049180327869	0.2	Homo sapiens		0	0	61
soh-hacat-pmp-2020	HaCaT keratinocyte plasma membrane profiling, WT vs GOPC KO	Soh et al. 2020	Soh TK	2020	33027661	10.1016/j.celrep.2020.108235	core		Uninfected WT HaCaT channel of a Weekes-lab PMP plex (same lab and aminooxy-biotin method as Depierreux, Fielding and Hunter; one cell type each). Single TMT channel, so membership is pooled-plex identification with a non-zero WT reporter.	PRIDE	PXD021351	PMP_GOPC_KO_proteins.xlsx sheet MPW_LH_GOPC_PMP_161219_run1_Try <https://ftp.pride.ebi.ac.uk/pride/data/archive/2020/10/PXD021351/PMP_GOPC_KO_proteins.xlsx>	Plasma membrane profiling (Weekes lab): live-cell sodium periodate/aniline oxidation of sialic-acid glycans and aminooxy-biotin labeling, streptavidin enrichment, on-bead trypsin digestion, TMT multiplexing, LC-MS3. Experiment 5 of PXD021351: uninfected WT HaCaT plus three GOPC-knockout clones in one TMT plex (126, 127N, 127C, 129N).	Method summarized from the paper (PMC7539533) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion Lumos; Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD021351.	HaCaT immortalized human keratinocyte line (uninfected)	PMP_GOPC_KO_proteins.xlsx (GOPC-KO PMP, 1,332 protein rows). Membership = WT HaCaT channel (129N) > 0. The three GOPC-knockout clone channels are kept as non-membership measurements. Bovine/streptavidin '_contaminant' rows and non-UniProt ORF rows dropped. The paper's SILAC PMP of mock vs HSV-1-infected HaCaT cells (Table S6) is a separate dataset, soh-hacat-silac-pmp-2020; the WCL is not used.	PMP_GOPC_KO_proteins.xlsx: Protein Id	drop rows where Protein Id matches _contaminant	HaCaT keratinocytes / baseline uninfected wild-type, PMP: WT HaCaT (min_observed 1) | HaCaT keratinocytes / GOPC knockout clones (genetic perturbation; not used for membership): GOPC 2-F6, GOPC 1-E3, GOPC 1-C8 (min_observed 1)	1255	631	0.502788844621514	0.2	Homo sapiens		0	0	1255
soh-hacat-silac-pmp-2020	HaCaT keratinocyte plasma membrane profiling, mock vs HSV-1, SILAC	Soh et al. 2020	Soh TK	2020	33027661	10.1016/j.celrep.2020.108235	provisional	within 2 points of the 20% screen (18.2%)	Second, independent PMP experiment in the same paper, pointed out by the corresponding author (C. Crump, 2026-11-17). Identification comes from the SILAC mix of mock and infected cells, but every row carries a ratio to the mock (light) channel, so it was quantified in the uninfected baseline, the same standard applied to the paper's TMT dataset and to other SILAC PMP inputs.	PRIDE	PXD021351	mmc7.xlsx sheet Data in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC7539533/supplementaryFiles>	Plasma membrane profiling (Weekes lab): live-cell sodium periodate/aniline oxidation of sialic-acid glycans and aminooxy-biotin labeling, streptavidin enrichment, on-bead trypsin digestion, SILAC (light mock, medium HSV-1, heavy HSV-1 dUL56). Table S6 of Soh et al. 2020.	Method read from: Soh et al. 2020 Cell Rep, Table S6 (mmc7, sheets 'Data' and 'SILAC labeling'), PMC7539533; corresponding-author correspondence 2026-11-17.	not recorded (capture matrix not yet audited)	not reported	Orbitrap Fusion Lumos; Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD021351.	HaCaT immortalized human keratinocyte line (uninfected)	Table S6 (supplement mmc7, sheet 'Data'; 2,257 protein groups, 2,223 human). Membership = mock-infected (SILAC light) channel: every human row has quantified peptides in the one SILAC experiment, so the mock list is the table's human list. Normalized HSV-1/mock and dUL56/mock SILAC ratios are carried as non-membership measurements. HSV-1 proteins dropped (Species = Human only).	mmc7.xlsx: Uniprot-l	Species = Human	HaCaT keratinocytes / baseline mock-infected, SILAC light, PMP: Peptides (min_observed 1) | HaCaT keratinocytes / HSV-1/mock and HSV-1 dUL56/mock SILAC ratios (not used for membership): Ratio M/L normalized, Ratio H/L normalized (min_observed 1)	2200	401	0.18227272727272728	0.2	Homo sapiens		0	0	2200
mahameed-hepg2-2020--thapsigargin-gsk414-16-h	HepG2 sulfo-NHS-SS-biotin surfaceome · thapsigargin + GSK414 (PERK inhibitor) 16 h	Mahameed et al. 2020	Mahameed M	2020	32161259	10.1038/s41467-020-15067-5	perturbed	drug, ligand or treatment: thapsigargin + GSK414 (PERK inhibitor) 16 h	drug, ligand or treatment arm of mahameed-hepg2-2020; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD014709	41467_2020_15067_MOESM4_ESM.xlsx sheet Sheet1 <https://static-content.springer.com/esm/art%3A10.1038%2Fs41467-020-15067-5/MediaObjects/41467_2020_15067_MOESM4_ESM.xlsx>	Pierce Cell Surface Protein Isolation Kit (Thermo #89881, sulfo-NHS-SS-biotin) on intact cells; MaxQuant variable mod for cleaved sulfo-NHS-SS-biotin on K (+87.998)	Method as described in the paper's Methods 'Cell surface protein isolation' and 'Quantitative proteomics of surface proteins'; Fig. 2d legend (Tg in absence and presence of GSK414).	streptavidin beads per kit instructions (kit NeutrAvidin agarose implied; not stated)	not stated	Q Exactive		Instrument as listed in the ProteomeXchange record PXD014709.	HepG2	HepG2, thapsigargin + GSK414 (PERK inhibitor) 16 h: a non-baseline state of mahameed-hepg2-2020, listed when observed in at least 2 of its 3 samples				1290	144	0.11162790697674418		Homo sapiens		0	0	1290
mahameed-hepg2-2020	HepG2 sulfo-NHS-SS-biotin surfaceome · thapsigargin alone 16 h (baseline)	Mahameed et al. 2020	Mahameed M	2020	32161259	10.1038/s41467-020-15067-5	held	every arm is treated, so there is no unperturbed baseline	Hold: the only arm that could define membership is itself thapsigargin-treated (16 h ER stress), so no unperturbed baseline exists; there is also no no-biotin control. Intact-cell sulfo-NHS-SS-biotin capture of HepG2 with per-replicate, non-imputed LFQ; the supplement is the full post-QC table, not annotation-selected. Caveat: the comparison's control arm is itself thapsigargin-treated (16 h ER stress), not unperturbed cells, and there is no no-biotin control; membership is the control arm of the authors' design.	PRIDE	PXD014709	41467_2020_15067_MOESM4_ESM.xlsx sheet Sheet1 <https://static-content.springer.com/esm/art%3A10.1038%2Fs41467-020-15067-5/MediaObjects/41467_2020_15067_MOESM4_ESM.xlsx>	Pierce Cell Surface Protein Isolation Kit (Thermo #89881, sulfo-NHS-SS-biotin) on intact cells; MaxQuant variable mod for cleaved sulfo-NHS-SS-biotin on K (+87.998)	Method as described in the paper's Methods 'Cell surface protein isolation' and 'Quantitative proteomics of surface proteins'; Fig. 2d legend (Tg in absence and presence of GSK414).	streptavidin beads per kit instructions (kit NeutrAvidin agarose implied; not stated)	not stated	Q Exactive		Instrument as listed in the ProteomeXchange record PXD014709.	HepG2 hepatocellular carcinoma cell line	Supplementary Data 1 (1,314 protein groups, log2 LFQ per replicate). The authors already removed contaminants, reverse and only-by-site rows, required >= 2 peptides (>= 1 unique), quantification in all 3 replicates of at least one condition and median LFQ >= 5e6 in one condition. 'Control' = thapsigargin (Tg) alone 16 h; 'treatment' = Tg + PERK inhibitor GSK414. Membership = log2 LFQ observed (non-blank) in >= 2 of 3 Tg-alone replicates. Tg + GSK414 replicates kept as measurements only. GO/function columns carried, never used to select rows.	41467_2020_15067_MOESM4_ESM.xlsx: Majority protein IDs		HepG2 / control arm: thapsigargin alone 16 h, intact-cell sulfo-NHS-SS-biotin: LFQ intensity control 1, LFQ intensity control 2, LFQ intensity control 3 (min_observed 2) | HepG2 / thapsigargin + GSK414 (PERK inhibitor) 16 h (not used for membership): LFQ intensity treatment 1, LFQ intensity treatment 2, LFQ intensity treatment 3 (min_observed 2)	1295	142	0.10965250965250965	0.2	Homo sapiens		0	0	1295
kong-lung-2020	Lung cancer 95C / 95D Pierce surface-kit proteome	Kong et al. 2020	Kong Y	2020	33005184	10.3389/fgene.2020.01023	below_screen	14.5% of its length-corrected amount in Canonical or Likely proteins, under 25%	Both untreated lines labeled on intact cells with the Pierce sulfo-NHS-SS-biotin kit; the deposited table is the full identification list with per-replicate iBAQ. The table has no FDR or decoy columns, so identification filtering by the authors is assumed.	PRIDE	PXD016912	search-result.xlsx sheet Sheet1 <https://ftp.pride.ebi.ac.uk/pride/data/archive/2020/08/PXD016912/search-result.xlsx>	Pierce Cell Surface Protein Isolation Kit (sulfo-NHS-SS-biotin on intact cells, NeutrAvidin capture); Bruker maXis Impact Q-TOF DDA. Paper cites MASCOT against SwissProt, while the deposited table carries MaxQuant-style iBAQ columns.	Method summarized from the paper (PMC7483668) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q-TOF; Bruker Impact/maXis			Non-small cell lung cancer lines 95C (low metastatic) and 95D (high metastatic)	PRIDE search-result.xlsx (3,279 protein groups, unique peptides and iBAQ per sample); membership = iBAQ > 0 in >= 2 of 3 biological replicates of a line. Paper Table S1 sheet 1b (annotation-filtered membrane list) not used.	search-result.xlsx: Protein IDs	drop rows where Protein IDs matches ^(?:REV__|CON__)	95C (low-metastatic NSCLC) / untreated, Pierce cell-surface kit (sulfo-NHS-SS-biotin): iBAQ 95C-1, iBAQ 95C-2, iBAQ 95C-3 (min_observed 2) | 95D (high-metastatic NSCLC) / untreated, Pierce cell-surface kit (sulfo-NHS-SS-biotin): iBAQ 95D-1, iBAQ 95D-2, iBAQ 95D-3 (min_observed 2)	2786	228	0.08183776022972003	0.2	Homo sapiens		0	116	2786
ravenhill-2020	Monocyte subsets PMP	Ravenhill et al. 2020	Ravenhill BJ	2020	32165698	10.1038/s41598-020-61356-w	annotation_selected	author pre-filtered to membrane- or surface-annotated proteins	pre-filtered by surface annotation (annotation-selected-and-sample-restricted); shown, not counted. Was provisional. provisional: threshold 43.7072%; borderline allowance 2.0%. Current PM/cell-surface/extracellular annotations approximate the historical GO/short-GO selection.	PRIDE	PXD013832	control_surface_proteins.tsv	Plasma membrane profiling (Weekes protocol) on intact primary human monocytes: classical monocytes (~1e7 cells; intermediate and non-classical 1e5 to 1e6) enriched from PBMC of three healthy donors by magnetic negative selection and FACS (CD86/CD14/CD16); cell-surface sialic acids oxidized with sodium metaperiodate (Thermo) and biotinylated with aminooxy-biotin (Biotium) on live cells, quenched; 1% Triton X-100 lysis; biotinylated glycoproteins captured on high-affinity streptavidin agarose beads (Pierce), washed extensively, on-bead DTT/IAA and trypsin digestion (3 h, HEPES pH 8.5); TMT labeling, high-pH fractionation, Orbitrap Lumos MS3. 373 classical-monocyte surface proteins quantified.	Method as described in the paper's Methods 'Plasma membrane profiling' (Sci Rep 2020; full text PMC7067879).	high-affinity streptavidin agarose beads (Pierce; catalog number not stated)	not reported	Orbitrap Fusion Lumos			Primary classical monocytes	Classical monocytes only in this frozen extraction; intermediate and nonclassical subsets remain to be extracted	control_surface_proteins.tsv: uniprot_accession			516	341	0.6608527131782945	0.43707207734365944	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			511
myeloma-csc-2020	Myeloma CSC resource	Oldham et al. 2020	Oldham RAA	2020	32771993	10.1136/jitc-2020-000915	core		Original identification and specimen caveats retained in previous_reason.	MassIVE	MSV000084858	control_surface_proteins.tsv	Wollscheid/Gundry Cell Surface Capture on live cells, ~100 million cells per biological replicate (n = 3 to 6; MM.1R, RPMI-8226, RPMI-8226/R5, U266 myeloma lines; RPMI-1788 and BLCL B-cell controls): cell-surface oligosaccharides mildly oxidized with periodate and labeled with biocytin hydrazide on live cells; hypotonic lysis, nuclei removed, membranes pelleted by ultracentrifugation (210,000 g, 18 h), membrane pellet trypsin-digested, biotinylated glycopeptides captured on immobilized streptavidin resin, stringently washed, released with PNGase F; Q Exactive LC-MS/MS, Proteome Discoverer 2.2; proteins kept only with >=1 peptide carrying a deamidated Asn in an N-X-S/T/C sequon (experimental surface N-glycosite evidence).	Method as described in the paper's Methods 'CSC for discovery of cell surface N-glycoproteins' (J Immunother Cancer 2020; full text PMC7418848).	immobilized streptavidin resin (product not stated)	not reported	Q Exactive			MM.1R, RPMI-8226, RPMI-8226/R5 and U266 myeloma lines; RPMI-1788 and BLCL B-cell controls	Human cell lines (discovery CSC): 4 multiple myeloma lines -- MM.1R (MM1R), RPMI-8226, RPMI-8226/R5 (bortezomib-resistant subline of RPMI-8226), and U266 -- plus 2 non-malignant B-lymphoblastoid control lines RPMI-1788 and BLCL (a patient-derived B-lymphoblastoid line). Targeted-PRM validation arm additionally used 6 primary MM patient bone-marrow samples (CD138+ plasma cells) vs controls -- not part of this control surface list.	control_surface_proteins.tsv: uniprot_accession			696	360	0.5172413793103449	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			676
wojdyla-2020	Naive/primed PMP	Wojdyla et al. 2020	Wojdyla K	2020	32302559	10.1016/j.stemcr.2020.03.017	core		Original identification and specimen caveats retained in previous_reason.	PRIDE	PXD015359	mmc2_TableS1_full_surface_proteome.xlsx sheet ALL <https://pubmed.ncbi.nlm.nih.gov/32302559/>	Plasma membrane profiling (PMP; Weekes et al. 2012 protocol, performed with the Lehner/Williamson lab) on intact primed and naive H9 human pluripotent stem cells grown feeder-free (primed in TeSR-E8 on vitronectin; naive in t2iLGo on Matrigel; two culture replicates across two media for the primed arm used here): cell-surface sialoglycans periodate-oxidized and aminooxy-biotinylated on live cells, lysis, biotinylated glycoproteins captured on streptavidin beads, on-bead trypsin digestion, TMT labeling, offline fractionation and LC-MS/MS (MS3); >1,700 plasma-membrane proteins identified. Reagent concentrations and bead product are in the Supplemental Experimental Procedures, not the PMC main text.	Method as described in the paper's Results 'Cell-Surface Proteomes of Human Pluripotent States' and Figure 1A (Stem Cell Reports 2020; full text PMC7220956).	streptavidin beads (product in Supplemental Experimental Procedures; PMP protocol uses high-affinity streptavidin agarose)	not reported	Orbitrap Fusion Lumos		Instrument as listed in the ProteomeXchange record PXD015359.	Primed human pluripotent stem cells; two culture replicates across two media	Primed P1A/P2A/P1E/P2E channels from ALL, >=2 observed; naive N channels not used for baseline membership	mmc2_TableS1_full_surface_proteome.xlsx: UniProt accession		primed hPSC / primed baseline: P1A, P2A, P1E, P2E (min_observed 2)	5870	913	0.1555366269165247	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			5865
leung-2020	Oncogene surfaceome	Leung et al. 2020	Leung KK	2020	32205440	10.1073/pnas.1917947117	held	only biological comparisons are published, not a baseline list	Oncogene-dependent SILAC and glycosylation comparisons are biological contrasts, not no-label enrichment. The paper includes intact-glycopeptide and surface-proteome analyses; current frozen input-to-arm and baseline assignment remain unresolved.	supplement	PXD017039 (PRIDE; holds ONLY raw .raw + search-engine output .mgf.byrslt/.byspec2/.pep.xml/.fasta - no processed protein tables);PMC7148585 (PNAS Supporting Information; source of the protein-level CSC table used here)	control_surface_proteins.tsv	Wells-lab glycan-directed cell surface capture (CSC) with SILAC quantification on intact MCF10A cells: each oncogene-transformed line (KRAS G12V, HER2, EGFR L858R, BRAF V600E, phosphomimetic MEK, myristoylated AKT) compared to the empty-vector control; live cells periodate-oxidized and labeled with biocytin hydrazide, lysed, glycoproteins captured on NeutrAvidin beads, on-bead trypsin digestion and PNGase F release of N-glycopeptides; LC-MS/MS; 654 surface proteins quantified across six lines. The main text gives only this summary; reagent concentrations and bead product are in the SI Appendix Materials and Methods. The inventory table pools conditions, hence the hold.	Method as described in the paper's Results and Materials and Methods (summary; details in SI Appendix) (PNAS 2020; full text PMC7148585).	NeutrAvidin agarose (per Wells-lab CSC protocol; product in SI Appendix)	not reported	Orbitrap Fusion Lumos; Q Exactive		Instrument as listed in the ProteomeXchange record PXD017039.	MCF10A breast epithelial isogenic oncogene panel; condition mixture unresolved	Human breast epithelial cell line MCF10A, isogenic panel. Control = MCF10A empty-vector (MCF10A-EV, puromycin-resistant). Oncogene lines: EGFR(L858R), HER2/ERBB2, KRAS(G12V), BRAF(V600E), MEK(MEKDD, constitutively active), and myristoylated AKT (AKTmyr / mAKT). All human.	control_surface_proteins.tsv: uniprot_accession			653	437	0.669218989280245	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			648
beguin-mdm-2019	Primary monocyte-derived macrophage and U87MG sulfo-NHS-LC-biotin surface peptidome	Béguin et al. 2020	Béguin EP	2020	31248969	10.3324/haematol.2018.210682	core		Intact-cell sulfo-NHS-LC-biotin with biotinylated-peptide capture, so every site carries the label; untreated MDMs from three donors and U87MG cells, no perturbation arms. No no-label control. Same lab and protocol as beguin-boec-2020 and beguin-boec-inflam-2019.	PRIDE	PXD011490	BiotinSites.txt	3 mM EZ-link sulfo-NHS-LC-biotin 30 min on MDMs and U87MG, streptavidin peptide pull-down	Method read from: Online Supplementary methods ('Culture of MDMs and U87MG cells', surface labeling) and Table S1 legend: 'MDMs (M1-3) and U87MG cells (U1-3)'; PRIDE summary.txt raw-file map.	SigmaScreen Streptavidin High Capacity coated plates	not stated	Orbitrap Fusion ETD		Instrument as listed in the ProteomeXchange record PXD011490.	Primary human monocyte-derived macrophages (3 healthy donors); U87MG glioblastoma line	PRIDE IPtxt.zip member txt/BiotinSites.txt (MaxQuant biotin-lysine site table, 6,319 rows; range-fetched by the derive script). Reverse and potential-contaminant sites dropped; class I sites (Localization prob >= 0.75, Score diff >= 5; 5,247 sites). Membership = protein (first accession of 'Leading proteins') carrying a site with Intensity > 0 in >= 2 of 3 MDM donors (experiments M0, M7, M8 = MDM 1-3 of Supplementary Table S1) or >= 2 of 3 U87MG replicates (U1-U3). Each experiment pools two injections. The whole-cell proteome (proteomestxt.zip, 3.1 GB) is not read.	BiotinSites.txt: Leading proteins	Localization prob ≥ 0.75 | Score diff ≥ 5 | drop rows flagged Reverse, Potential contaminant	Monocyte-derived macrophages / baseline sulfo-NHS-LC-biotin labeled: Intensity M0, Intensity M7, Intensity M8 (min_observed 2) | U87MG / baseline sulfo-NHS-LC-biotin labeled: Intensity U1, Intensity U2, Intensity U3 (min_observed 2)	1096	430	0.39233576642335766	0.2	Homo sapiens		0	28	1096
beguin-boec-inflam-2019	Blood outgrowth endothelial cell sulfo-NHS-LC-biotin site footprint, mock/TNF/IL-1 SILAC	Béguin et al. 2019	Béguin EP	2019	30153514	10.1016/j.jprot.2018.08.011	held	the sample-to-condition map is unpublished	Intact-cell sulfo-NHS-LC-biotin with site-level (biotinylated peptide) evidence on a primary endothelial cell. Held: mock and cytokine-treated cells are mixed before capture and labels are switched between replicates without a deposited label-to-condition key (the J Proteomics paper is not open access), so baseline membership cannot be separated; per-channel L/M/H intensities exist but cannot be assigned to mock. A key from the authors would allow a mock-only membership from the same file.	PRIDE	PXD009174	Sulfo biotin label EelkeSites.txt in SurfacePeptidome.zip <https://ftp.pride.ebi.ac.uk/pride/data/archive/2018/09/PXD009174/SurfacePeptidome.zip>	3 mM EZ-link sulfo-NHS-LC-biotin, 30 min 4 C on intact SILAC BOECs, glycine quench; biotinylated-peptide capture after FASP	Method read from: PRIDE PXD009174 sample and data processing protocols (paper not open access); MaxQuant summary.txt in the zip (experiments 1510IP_1-3, 2 pull-down fractions each).	SigmaScreen streptavidin coated 96-well plate (Sigma-Aldrich), two rounds	not stated	Orbitrap Fusion ETD		Instrument as listed in the ProteomeXchange record PXD009174.	Primary human blood outgrowth endothelial cells (BOEC)	PRIDE PXD009174 SurfacePeptidome.zip member 'Sulfo biotin label EelkeSites.txt' (MaxQuant biotin-lysine site table, 3,000 sites). Reverse and potential-contaminant sites removed; class I sites as the authors define them (localization probability >= 0.75, score difference >= 5; the authors use strict >). Membership = protein (leading accession of 'Leading proteins') carrying a site with summed SILAC intensity > 0 in >= 2 of the 3 IP replicates (1,822 sites, 505 accessions). Each replicate mixes mock, TNF and IL-1 cells 1:1:1 with label switching, so membership pools the three conditions. proteinGroups.txt (all captured peptides) not used.	Sulfo biotin label EelkeSites.txt: Leading proteins	Localization prob ≥ 0.75 | Score diff ≥ 5 | drop rows flagged Reverse, Potential contaminant	BOEC / SILAC mix of mock, TNFalpha and IL-1beta 24 h cells (pooled), intact-cell sulfo-NHS-LC-biotin: Intensity 1510IP_1, Intensity 1510IP_2, Intensity 1510IP_3 (min_observed 2)	485	182	0.3752577319587629	0.2	Homo sapiens		0	14	485
matta-2019	Chondroprogenitor/MSC PMP	Matta et al. 2019	Matta C	2019	31227739	10.1038/s41598-019-44957-y	annotation_selected	author pre-filtered to transmembrane or signal-peptide proteins	pre-filtered by surface annotation (annotation-selected); shown, not counted. Was provisional. provisional: threshold 47.0851%; borderline allowance 2.0%. Current topology proxy is not the original PEAKS identification or annotation universe.	supplement	PMID:31227739	control_surface_proteins.tsv	Aminooxy-biotin plasma-membrane profiling (Weekes protocol) on intact cells: ~90% confluent osteoarthritic-cartilage chondroprogenitor cells and hTERT-immortalized bone-marrow MSCs (175 cm2 flasks, serum-starved 1 h) washed in ice-cold PBS and incubated 1 h at 4 C in the dark with 1 mM sodium metaperiodate, 100 mM aminooxy-biotin (Biotium) and 10 mM aniline in PBS pH 6.7; quenched with 1 mM glycerol; scraped, lysed in 1% Triton X-100 with 5 mM iodoacetamide; nuclei/debris removed; biotinylated glycoproteins bound 2 h at 4 C to 250 uL Pierce NeutrAvidin agarose in Snap Cap spin columns, washed 20x each with lysis buffer, PBS/0.5% SDS (+100 mM DTT step), 6 M urea and further buffers, on-bead trypsin digestion; nanoLC-MS/MS on a Bruker Impact II, PEAKS Studio 8.5 LFQ (1 peptide minimum at 1% protein FDR); three biological replicates per cell type.	Method as described in the paper's Methods 'Sample preparation and enrichment of cell surface glycoproteins using aminooxy-biotin labeling' (Sci Rep 2019; full text PMC6588563).	Pierce NeutrAvidin Agarose (Life Technologies/Thermo; catalog number not stated); aminooxy-biotin (Biotium)	not reported	Bruker Impact II	nanoLC-MS/MS of peptides, CaptiveSpray nanoBooster source	Instrument as named in the paper's Methods LC-MS/MS (full text PMC6588563).	Osteoarthritic-cartilage chondroprogenitors and bone-marrow mesenchymal stromal cells	Primary human cells: osteoarthritic-cartilage-derived migratory chondroprogenitors (CPC) and bone-marrow-derived mesenchymal stem cells (MSC). Both cell types are baseline/untreated primary isolates -- this is a CPC-vs-MSC cell-type comparison, not a perturbation experiment, so both arms are treated as CONTROL per protocol.	control_surface_proteins.tsv: uniprot_accession			789	405	0.5133079847908745	0.47085130205355774	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			780
suttapitugsakul-8lines-2019	Eight human cell lines, GalNAz metabolic labeling + DBCO-biotin click surface N-glycoproteomics	Suttapitugsakul et al. 2019	Suttapitugsakul S	2019	31025852	10.1021/acs.analchem.9b01447	core		Intact-cell click tagging of metabolically azide-labeled glycans (same Wu-lab method as smeekens-hek293t-galnaz-2015); unperturbed cells in standard media; Table S1 is the full site identification list per cell line before any annotation, with both biological experiments kept as separate columns.	none (supplementary tables only)		ac9b01447_si_002.xlsx sheet HEK293T <https://pmc.ncbi.nlm.nih.gov/articles/PMC6584960/> | suttapitugsakul_site_counts_by_cell_type.tsv	Ac4GalNAz metabolic labeling 24 h, DBCO-biotin click on live cells in flask 1 h, DTT quench; NeutrAvidin glycopeptide enrichment; PNGase F/H2(18)O	Method read from: PMC6584960 Experimental Section (Cell Culture, Metabolic Labeling, and Click-Chemistry Reaction; Glycopeptide enrichment; Database search).	NeutrAvidin agarose (peptide level)	not stated	LTQ Orbitrap Elite	LC-MS/MS Top20 DDA	Instrument as named in the paper's Methods (full text PMC6584960).	Eight human cell lines: HEK293T embryonic kidney, HeLa cervical carcinoma, HepG2 hepatocellular carcinoma, Jurkat T-cell leukemia, K562 chronic myeloid leukemia, MCF7 breast carcinoma, PANC-1 pancreatic carcinoma, U266B1 multiple myeloma	Table S1A-H (ac9b01447_si_002.xlsx), one sheet per cell line, every identified N-glycosylation site (sequon-filtered, 1% FDR) with the glycopeptide seen in biological experiment 1 and/or 2; derived to one row per accession with per-cell-line, per-experiment site counts (1,047 accessions, matching the paper's 1,047 surface glycoproteins). Membership = identified in >= 1 of the two experiments within a cell line. No further filter. Table S4 (LFQ of the 784 quantified glycoproteins) not used. The Annotation column is a protein name, not a selection.	suttapitugsakul_site_counts_by_cell_type.tsv: uniprot_accession		HEK293T / baseline Ac4GalNAz-labeled, DBCO-biotin clicked on intact cells: HEK293T_exp1_sites, HEK293T_exp2_sites (min_observed 1) | HeLa / baseline Ac4GalNAz-labeled, DBCO-biotin clicked on intact cells: HeLa_exp1_sites, HeLa_exp2_sites (min_observed 1) | HepG2 / baseline Ac4GalNAz-labeled, DBCO-biotin clicked on intact cells: HepG2_exp1_sites, HepG2_exp2_sites (min_observed 1) | Jurkat / baseline Ac4GalNAz-labeled, DBCO-biotin clicked on intact cells: Jurkat_exp1_sites, Jurkat_exp2_sites (min_observed 1) | K562 / baseline Ac4GalNAz-labeled, DBCO-biotin clicked on intact cells: K562_exp1_sites, K562_exp2_sites (min_observed 1) | MCF7 / baseline Ac4GalNAz-labeled, DBCO-biotin clicked on intact cells: MCF7_exp1_sites, MCF7_exp2_sites (min_observed 1) | PANC1 / baseline Ac4GalNAz-labeled, DBCO-biotin clicked on intact cells: PANC1_exp1_sites, PANC1_exp2_sites (min_observed 1) | U266B1 / baseline Ac4GalNAz-labeled, DBCO-biotin clicked on intact cells: U266B1_exp1_sites, U266B1_exp2_sites (min_observed 1)	1031	633	0.6139670223084384	0.2	Homo sapiens		0	0	1031
li-hela-biotin-2019	HeLa optimized sulfo-NHS-SS-biotin surfaceome, new protocol	Li et al. 2019	Li Y	2019	30707948	10.1016/j.jprot.2019.01.015	below_screen	15% Canonical or Likely proteins, under 20%	Intact-cell amine biotinylation of unperturbed HeLa; the deposited list is the authors' full identification list for the new protocol with annotation shown as flags rather than used as a filter.	jPOST / ProteomeXchange	PXD039794;JPST002017	Supplementary Table S4.xlsx sheet Sheet1	amine-reactive cleavable biotin on intact HeLa (CAMthiopropanoyl lysine remnants in S9/S10 confirm the SS-biotin chemistry); exact reagent name not read	Method read from: PubMed abstract 30707948; table titles in the jPOST JPST002017 supplementary xlsx files (paper not in PMC; ScienceDirect full text not accessible).	streptavidin (type not verified)	not stated	Q Exactive		Instrument as listed in the ProteomeXchange record PXD039794.	HeLa cervical carcinoma cell line	Deposited 'Supplementary Table S4.xlsx' (Sheet1, header row 2): 'List of the identified proteins by the new protocol of cell surface biotinylation method' in HeLa, 2,932 proteins. One pooled identification list for a single unperturbed condition (no per-replicate columns). The CD/transmembrane/secretory/surface-annotation columns are flags only and are not used to select rows (1,401 of 2,932 flagged surface-associated). Not used: S2 (per-replicate experimental vs negative-control sheets), S9/S10 (biotin-site peptides), S11/S12 (CD subsets), S13 (BT474 vs MCF7 proteins with p < 0.01, a statistically selected list).	Supplementary Table S4.xlsx: Protein ID			2919	448	0.15347721822541965	0.2	Homo sapiens		0	0	2919
vit-lymphoma-hptc-2019	Human B-cell lymphoma cell carbonate-washed membrane proteome by hpTC (Vit et al. 2019, Pitchfork)	Vit et al. 2019	Vit O	2019	31176011	10.1016/j.jprot.2019.103411	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis then carbonate-washed membrane pellet, so complementary by family policy; captures all cellular membranes, not only plasma membrane. Untreated cells, one condition.	PRIDE	PXD012647	proteinGroups.txt	carbonate-washed membranes, trypsin shave + CNBr (hpTC)	Method read from: PRIDE PXD012647 sample processing protocol and PubMed abstract (full text not open access; not read).	none	not stated	Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD012647.	Human B-cell lymphoma cells (line not named in the deposit)	PRIDE PXD012647 hptctxt.zip member proteinGroups.txt (MaxQuant search of 3 replicate runs, one pooled Intensity column). Reverse, contaminant and only-by-site groups removed (2,298 groups). Membership = pooled Intensity > 0 (1,720 groups; groups identified without a quantified feature drop out). No annotation filter.	proteinGroups.txt: Protein IDs	drop rows flagged Reverse, Potential contaminant, Only identified by site	B-cell lymphoma cells / untreated, carbonate-washed membranes, hpTC: Intensity (min_observed 1)	1717	187	0.10891089108910891	0.2	Homo sapiens		0	0	1717
leung-2019	Leung 2019 (Veneer reanalysis)	Leung et al. 2019	Leung KK	2019	30584089	10.1073/pnas.1813666116	annotation_selected	author pre-filtered to annotated surface proteins	pre-filtered by surface annotation (annotation-selected); shown, not counted. Was hold. hold: threshold 20.0000%; borderline allowance 0.0%. Current Veneer table is restricted to the original 875 surface-membrane proteins and pools conditions. Oncogene-related abundance comparisons are not established no-label contrasts. Original complete supplemental/control chain remains unresolved; do not treat all tiers as unrestricted.			pr3c00800_si_002.xlsx sheet Table S10 <https://doi.org/10.1021/acs.jproteome.3c00800>	Wells-lab glycan-directed cell surface capture (CSC) with SILAC quantification on intact AML cells: AML193, HL60, KG1a and HNT34 grown in SILAC RPMI, treated daily for 3 d with vehicle or 0.5 uM azacitidine then 4 d drug-free before harvest; live cells periodate-oxidized and biocytin-hydrazide labeled, lysed, glycoproteins captured on NeutrAvidin beads, on-bead trypsin digestion and PNGase F release of N-glycopeptides, LC-MS/MS. Main text states only the design; reagent concentrations and bead product are in the SI Appendix. The inventory table pools vehicle and azacitidine conditions, hence the hold.	Method as described in the paper's Materials and Methods (summary; details in SI Appendix) (PNAS 2019; full text PMC6329958).	NeutrAvidin agarose (per Wells-lab CSC protocol; product in SI Appendix)	not reported	not stated in accessible text		Where we looked for the instrument: PMC6329958 main text has no MS methods (in SI Appendix, not accessed).	AML lines KG1a, HL60, HNT34 and AML193; vehicle/azacitidine conditions pooled in reanalysis	All reanalysis tiers; pooled conditions. Baseline membership unresolved	pr3c00800_si_002.xlsx: Protein accessions			875	565	0.6457142857142857	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			862
giovani-pdl-2019	Periodontal-ligament fibroblast membrane-enriched fraction	Giovani et al. 2019	Giovani PA	2019	30499115	10.1002/jper.18-0217	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Carbonate-washed total membrane from primary cells; low weight, complementary only. Deciduous vs permanent assignment of the donor codes is not in the deposited files.	PRIDE	PXD010226	giovani_prt_by_donor.tsv	Sucrose homogenisation, crude membrane pellet washed in 0.1 M Na2CO3 pH 11; LTQ Orbitrap Velos, SEQUEST non-specific-enzyme search, Scaffold (protein probability >= 0.99).	Method summarized from the paper (10.1002/jper.18-0217) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	LTQ Orbitrap Velos			Primary periodontal ligament fibroblasts from deciduous and permanent teeth (6 donors: BCL, JAS, MCDS, MS, VRP, YSB)	PRT sections of the six per-donor RESULT mzTab files; ambiguity groups collapsed to one row; membership = PSMs > 0 in a donor (one run per donor).	giovani_prt_by_donor.tsv: protein_group		PDL fibroblasts donor BCL / membrane-enriched fraction: psms_BCL (min_observed 1) | PDL fibroblasts donor JAS / membrane-enriched fraction: psms_JAS (min_observed 1) | PDL fibroblasts donor MCDS / membrane-enriched fraction: psms_MCDS (min_observed 1) | PDL fibroblasts donor MS / membrane-enriched fraction: psms_MS (min_observed 1) | PDL fibroblasts donor VRP / membrane-enriched fraction: psms_VRP (min_observed 1) | PDL fibroblasts donor YSB / membrane-enriched fraction: psms_YSB (min_observed 1)	925	152	0.1643243243243243	0.2	Homo sapiens		0	3	925
higginbotham-adbrain-2019	Post-mortem frontal cortex membrane-enriched fraction, control/AsymAD/AD	Higginbotham et al. 2019	Higginbotham L	2019	31461916	10.3390/proteomes7030030	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Ultracentrifugation/carbonate-washed total membrane pellet from brain tissue, not a surface label; organelle membranes co-sediment. RefSeq identifiers joined to UniProt by idmapping.	PRIDE	PXD014376	higginbotham_top_members_uniprot.tsv	sucrose homogenisation, 180,000 g pellet, sodium carbonate pH 11 wash	Method as described in the paper's Methods 2.2 'Membrane Enrichment', 2.3 MS; Table S1 case list; Results 3.2 (1808 protein groups).	none	n/a	LTQ Orbitrap		Instrument as listed in the ProteomeXchange record PXD014376.	Post-mortem human dorsolateral prefrontal / middle frontal gyrus cortex (6 control, 6 asymptomatic AD, 6 AD cases)	PRIDE Higginbotham2019-idsum.dquan.xlsx (= paper Table S3; 3,995 protein rows). Derived table keeps the 1,808 protein-group top members (rows with a 'Groups' number: the paper's analysed set), removes 8 cRAP contaminant rows and maps RefSeq protein IDs to UniProtKB (1,800 rows; 1,753 mapped, 47 unmapped or ambiguous left blank). Membership = signal/noise > 0 in >= 2 of the 6 pathology-free control cases (UWA420, UWA431, UWA479, UWA506, UWA531, UWA623 per Table S1); AsymAD and AD cases kept as non-membership measurements. Values are complete for all rows, so membership equals the pooled identification list.	higginbotham_top_members_uniprot.tsv: uniprot_accession_mapped		frontal cortex membrane fraction / pathology-free control cases: UWA420, UWA431, UWA479, UWA506, UWA531, UWA623 (min_observed 2) | frontal cortex membrane fraction / asymptomatic AD cases (not used for membership): UWA419, UWA422, UWA556, UWA558, UWA596, UWA626 (min_observed 2) | frontal cortex membrane fraction / symptomatic AD cases (not used for membership): UWA530, UWA576, UWA579, UWA580, UWA612, UWA614 (min_observed 2)	1739	232	0.13341000575043127	0.2	Homo sapiens		0	0	1739
ravenhill-rbc-pmp-2019	Primary erythrocyte plasma membrane profiling, UK and Senegalese donors	Ravenhill et al. 2019	Ravenhill BJ	2019	31552303	10.1038/s42003-019-0596-y	core		Intact-cell periodate/aminooxy-biotin PMP on unperturbed primary erythrocytes; Data 2F is the full quantified list before the authors' UniProt-location/TMHMM filter. No no-label control; the authors note residual hemoglobin and serum-protein carryover, and trace platelet markers (ITGB3, ITGA2B), which remain in the list.	PRIDE	PXD013852	42003_2019_596_MOESM6_ESM.xlsx sheet Data S2F in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6754445/supplementaryFiles>	sodium meta-periodate (Thermo) oxidation then aminooxy-biotin (Biotium) on ~1.5e9 intact RBC, quench, Triton X-100 lysis	Method as described in the paper's Methods 'Plasma membrane profiling'; Supplementary Data legends (MOESM2 docx).	high-affinity streptavidin agarose (Pierce)	not stated	Orbitrap Fusion Lumos; Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD013852.	Primary human erythrocytes (9 UK donors, 9 Senegalese donors)	Supplementary Data 2F ('All quantified and unfiltered proteins, raw signal:noise'; 1,323 rows). Decoy rows ('##' prefix) fail the accession pattern; search-database contaminant entries ('_contaminant') excluded, leaving 1,260 proteins (the paper's stated total). Membership = TMT signal:noise > 0 in >= 2 of 9 donor channels within one population multiplex (Senegal 1,170, UK 877). Supplementary Data 2A-2E (filtered to the annotation-based 'sensitive' RBC surface list) and Data 3 not used. The PRIDE RBCProteins.xlsx is the same table plus 181 all-zero rows.	42003_2019_596_MOESM6_ESM.xlsx: Protein Id	drop rows where Protein Id matches contaminant	erythrocytes (Senegalese donors) / baseline, PMP (Senegal multiplex): Senegal Donor 1, Senegal Donor 2, Senegal Donor 3, Senegal Donor 4, Senegal Donor 5, Senegal Donor 6, Senegal Donor 7, Senegal Donor 8, Senegal Donor 9 (min_observed 2) | erythrocytes (UK donors) / baseline, PMP (UK multiplex): UK Donor 1, UK Donor 2, UK Donor 3, UK Donor 4, UK Donor 5, UK Donor 6, UK Donor 7, UK Donor 8, UK Donor 9 (min_observed 2)	1245	236	0.1895582329317269	0.2	Homo sapiens		0	0	1245
wang-bcell-pmp-2019--ebv-infected-2-14-dpi	Primary human CD19+ B cell plasma membrane profiling · EBV-infected 2-14 dpi	Wang et al. 2019	Wang LW	2019	31257153	10.1016/j.cmet.2019.06.003	perturbed	infection: EBV-infected 2-14 dpi	infection arm of wang-bcell-pmp-2019; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD013034	mmc2.xlsx sheet Data in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6720460/supplementaryFiles>	periodate/aminooxy-biotin PMP on live cells (Weekes et al. 2014 protocol), STAR Methods	Method as described in the paper's STAR Methods 'Plasma membrane profiling'; PRIDE PXD013034 sample protocol (full text PMC6720460).	high-affinity streptavidin agarose	not stated	Orbitrap Fusion Lumos		Instrument as listed in the ProteomeXchange record PXD013034.	primary CD19+ B cells	primary CD19+ B cells, EBV-infected 2-14 dpi: a non-baseline state of wang-bcell-pmp-2019, listed when observed in at least 1 of its 4 samples				674	294	0.4362017804154303		Homo sapiens	Search included EBV proteins (Species EBVB9/EBV_ORF); only HUMAN rows are read.	0	1	674
wang-bcell-pmp-2019	Primary human CD19+ B cell plasma membrane profiling · resting uninfected (PM1) (baseline)	Wang et al. 2019	Wang LW	2019	31257153	10.1016/j.cmet.2019.06.003	core		Weekes-lab PMP on primary resting human B cells, an immune cell type otherwise represented mainly by lines; membership rests on the uninfected channel of the single PMP multiplex. TMT channel values reflect quantification of proteins identified in the pooled run, so a one-channel rule is an identification of the pooled multiplex filtered to signal in the resting channel.	PRIDE	PXD013034	mmc2.xlsx sheet Data in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6720460/supplementaryFiles>	periodate/aminooxy-biotin PMP on live cells (Weekes et al. 2014 protocol), STAR Methods	Method as described in the paper's STAR Methods 'Plasma membrane profiling'; PRIDE PXD013034 sample protocol (full text PMC6720460).	high-affinity streptavidin agarose	not stated	Orbitrap Fusion Lumos		Instrument as listed in the ProteomeXchange record PXD013034.	Primary human peripheral blood CD19+ B cells (resting)	Table S1 (mmc2.xlsx) 'Data' sheet, which merges whole-cell-lysate (WCL1-3) and PMP (PM1) rows; Species = HUMAN only (29 EBV rows dropped). Membership = 'PM1 uninfected' reporter > 0 (resting B cells). The four EBV-infected PM1 time points are kept as non-membership measurements; WCL columns are not read. No annotation column selects rows (the sheet carries none).	mmc2.xlsx: Uniprot-s	Species = HUMAN	primary CD19+ B cells / baseline resting uninfected, PMP (PM1): PM1     uninfected (min_observed 1) | primary CD19+ B cells / EBV-infected 2-14 dpi (not used for membership): PM1        d2, PM1        d4, PM1        d7, PM1        d14 (min_observed 1)	661	287	0.4341906202723147	0.2	Homo sapiens	Search included EBV proteins (Species EBVB9/EBV_ORF); only HUMAN rows are read.	0	1	661
autocsc-2019	autoCSC	van Oostrum et al. 2019	van Oostrum M	2019	31844046	10.1038/s41467-019-13418-5	core		Original identification and specimen caveats retained in previous_reason.	PRIDE	PXD013627	control_surface_proteins.tsv	autoCSC (automated, miniaturised Cell Surface Capture) on live cells: surface glycans gently oxidized with 2 mM NaIO4 (20 min, 4 C, PBS pH 6.5), then 5 mM biocytin hydrazide (Pitsch Nucleic Acids) + 5 mM 5-methoxyanthranilic acid catalyst for 1 h at 4 C; lysis in Tris/1% sodium deoxycholate/TCEP/chloroacetamide by VialTweeter sonication and 95 C; trypsin (or LysC + trypsin) digestion; ~1 mg peptide per sample (11 human cancer cell lines) processed on a liquid-handling robot by repeated aspiration through filter tips packed with streptavidin resin, extensive washing, and PNGase F release in a heated 96-well plate; manual comparison used 80 uL Streptavidin Plus UltraLink Resin (Pierce). Identification requires deamidated Asn in an N-X-S/T sequon; DIA-MS quantification. Mouse B-cell populations in the same paper are excluded here.	Method as described in the paper's Methods 'Cell surface capture - labeling and digestion' and automated enrichment (Nat Commun 2019; full text PMC6915781).	streptavidin resin in filter tips for the automated workflow (Streptavidin Plus UltraLink Resin, Pierce, named for the manual comparison); biocytin hydrazide (Pitsch Nucleic Acids)	not reported	Orbitrap Fusion Lumos; Orbitrap Fusion; Q Exactive		Instrument as listed in the ProteomeXchange record PXD013627.	11 cell lines: A549, HBE, A431, Caco-2, HEK293, HeLa, HT29, HepG2, Huh7, MDA-MB-231 and U87	11 human cell lines (steady-state, unperturbed): A549 (lung), 16HBE14o- (labeled 'HBE', bronchial epithelial), A431 (epidermoid), Caco-2 (colon), HEK-293 (embryonic kidney), HeLa Kyoto (cervical), HT-29 (colon), HepG2 (hepatoma), Huh-7 (hepatoma), MDA-MB-231 (labeled 'MDA', breast), U87 (glioblastoma). All human. (The developmental B-cell panel in the same paper is MOUSE and was excluded.)	control_surface_proteins.tsv: uniprot_accession			892	691	0.7746636771300448	0.2	Homo sapiens	Paper includes mouse data; only the documented human cell/column subset is retained.			884
jpst000531-bbb-pm-2019	hCMEC/D3 and HBMEC/cib brain microvascular endothelial plasma membrane fraction (jPOST JPST000531)			2019			comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Density/differential fractionation after homogenisation, so complementary evidence only. Adds the first brain microvascular endothelial (blood-brain barrier) membrane data; deposit has no linked publication.	jPOST	JPST000531;PXD012021	TableS2_BBB.xlsx sheet Protein	plasma membrane enrichment (jPOST Fractionation term) after crude membrane preparation; SWATH	Method read from: jPOST JPST000531 project XML and TableS2_BBB.xlsx headers.	none	not applicable	TripleTOF 5600		Instrument as listed in the ProteomeXchange record PXD012021.	hCMEC/D3 and HBMEC/cib immortalized human brain microvascular endothelial cells	Deposited TableS2_BBB.xlsx 'Protein' sheet (2,365 proteins; header on row 4; the 12 peak-area columns renamed by position because the sheet labels them only 1/2/3 under merged headers). Membership = PM peak area > 0 in >= 2 of 3 runs, separately per line. Crude-membrane columns kept as non-membership measurements. The TMD and CD# annotation columns are carried but do not select rows (1,648 rows have TMD = 0). Every row carries a value in all 12 columns, so the table is already restricted to proteins quantified in every run.	TableS2_BBB.xlsx: AcNum		hCMEC/D3 / baseline plasma-membrane-enriched fraction: D3_PM_1, D3_PM_2, D3_PM_3 (min_observed 2) | HBMEC/cib / baseline plasma-membrane-enriched fraction: HBMEC_PM_1, HBMEC_PM_2, HBMEC_PM_3 (min_observed 2) | hCMEC/D3 / crude membrane fraction (not used for membership): D3_CM_1, D3_CM_2, D3_CM_3 (min_observed 2) | HBMEC/cib / crude membrane fraction (not used for membership): HBMEC_CM_1, HBMEC_CM_2, HBMEC_CM_3 (min_observed 2)	2356	331	0.14049235993208828	0.2	Homo sapiens		0	3	2356
schmidt-aml-2018	AML and donor CD34+CD123+ progenitor Mem-PER Plus membranes	Schmidt et al. 2018	Schmidt JR	2018	29439554	10.3390/proteomes6010011	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Mem-PER Plus detergent membrane extraction of primary sorted progenitors; no surface label. Abundances are reported per person; membership needs one.	PRIDE	PXD008378	Supplemental_Table_S1.xlsx sheet Suppl table 1 in supplementaryFiles › proteomes-06-00011-s001.zip <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5874770/supplementaryFiles>	Thermo Mem-PER Plus membrane and cytosol fractions of sorted CD34+CD123+ cells; TMT-free label-free LC-MS/MS, Proteome Discoverer (Sequest HT, MS Amanda), protein FDR < 1%.	Method summarized from the paper (PMC5874770) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive		Instrument as listed in the ProteomeXchange record PXD008378.	Primary CD34+CD123+ progenitor cells from 5 AML patients and 5 healthy donors	Supplemental Table S1 (all 2,071 identified proteins); membership = membrane-fraction abundance reported in >= 1 person; cytosol columns not used	Supplemental_Table_S1.xlsx: Accession		DON_004 / membrane fraction: Abundance: DON_004_membrane (min_observed 1) | DON_005 / membrane fraction: Abundance: DON_005_membrane (min_observed 1) | DON_012 / membrane fraction: Abundance: DON_012_membrane (min_observed 1) | DON_013 / membrane fraction: Abundance: DON_013_membrane (min_observed 1) | DON_011 / membrane fraction: Abundance: DON_011_membrane (min_observed 1) | AML_037 / membrane fraction: Abundance: AML_037_membrane (min_observed 1) | AML_033 / membrane fraction: Abundance: AML_033_membrane (min_observed 1) | AML_036 / membrane fraction: Abundance: AML_036_membrane (min_observed 1) | AML_044 / membrane fraction: Abundance: AML_044_membrane (min_observed 1) | AML_049 / membrane fraction: Abundance: AML_049_membrane (min_observed 1)	966	80	0.08281573498964803	0.2	Homo sapiens		0	0	966
egan-rbc-pmp-2018	Erythrocyte plasma membrane profiling, Lan-null and control donors pooled	Egan et al. 2018	Egan ES	2018	30271928	10.1038/s42003-018-0046-2	held	the sample-to-condition map is unpublished	Intact-cell periodate/aminooxy-biotin capture, but the only unfiltered public list is the pooled 10-plex identification list, which mixes ABCB6-null (perturbed) and control donors with no per-channel values; the per-channel table (Table S1) is GO-annotation-filtered. Control-donor membership cannot be stated cleanly. A full per-channel protein table from the authors would resolve it.	PRIDE	PXD008752	ABCB6_peptides.xlsx <https://ftp.pride.ebi.ac.uk/pride/data/archive/2018/10/PXD008752/ABCB6_peptides.xlsx>	periodate/aminooxy-biotin PMP on intact erythrocytes, TMT10	Method read from: PRIDE PXD008752 sample processing protocol (Egan 2015 / Weekes 2014 method).	high-affinity streptavidin agarose (Pierce)	not stated	Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD008752.	Primary human erythrocytes (5 Lan-null and 5 Lan-positive donors)	PRIDE ABCB6_peptides.xlsx: the full peptide identification list of the pooled TMT 10-plex across all six SCX fractions (6,102 peptide rows, 740 protein accessions, no reporter values). Decoys (gene symbol prefixed '##') and labeled contaminants dropped. Membership = protein identified in the pooled plex, which mixes the five Lan-null and five control donors; no per-channel values exist for the full list. Table S1 (265 rows, GOCC 'plasma membrane'-filtered) not used.	ABCB6_peptides.xlsx: Uniprot	drop rows where GeneSymbol matches ## | drop rows where Description matches contaminant		684	305	0.44590643274853803	0.2	Homo sapiens		0	0	684
gu-tumorlines-2018	Five tumor lines, native membrane protein extraction kit fractions	Gu et al. 2018	Gu X	2018	29719786	10.1016/j.apsb.2017.10.002	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Native membrane protein extraction kit fraction of lysed cells; no surface label. Missing values were imputed with one constant, which is used as the detection floor.	none (supplementary tables only)		mmc1.xlsx sheet table 1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5925393/supplementaryFiles> | mmc1.uniprot_mapped.tsv	ProteoExtract Native Membrane Protein Extraction Kit (EMD Millipore/Calbiochem) on >= 20 million cells, then ProteoExtract precipitation to remove detergent	Method as described in the paper's Methods 2.3-2.4 and 2.8 (imputation: 'global minimum of all protein intensities divided by an arbitrary factor of 3').	none	not reported	Q Exactive (Thermo)		Instrument as named in the paper's Methods (full text PMC5925393).	NCI-H226 lung squamous/mesothelioma, Hep3B2 and HepG2 hepatocellular carcinoma, NCI-N87 gastric carcinoma, OVCAR-3 ovarian carcinoma lines	mmc1 'table 1' (6,028 protein groups, MaxQuant intensity per line; the authors imputed missing intensities with the global minimum/3 = 8,577). Membership per line = intensity above the 8,577 imputation constant (one pooled measurement per line). Symbols from the 'Symbol' column (first symbol of multi-gene groups); 20 rows without a symbol and descriptive pseudo-symbols are left unmapped. GO-annotated membrane subsets in the paper are not used.	mmc1.uniprot_mapped.tsv: uniprot_mapped		H226 / membrane fraction: Intensity H226 (min_observed 1; floor 8577) | Hep3B2 / membrane fraction: Intensity Hep3B2 (min_observed 1; floor 8577) | HepG2 / membrane fraction: Intensity HepG2 (min_observed 1; floor 8577) | N87 / membrane fraction: Intensity N87 (min_observed 1; floor 8577) | Ovcar3 / membrane fraction: Intensity Ovcar3 (min_observed 1; floor 8577)	5746	753	0.13104768534632788	0.2	Homo sapiens		0	0	5746
furniss-hela-pmp-2018	HeLa plasma membrane profiling, uninfected vs EHEC, spike-in SILAC	Furniss et al. 2018	Furniss RCD	2018	30190327	10.1074/jbc.RA118.005114	core		Intact-cell periodate/aminooxy-biotin PMP; the full quantified table is given before any annotation, and every row has light-channel ratios in at least two uninfected plates, so membership rests on uninfected cells. No no-label control; the heavy standard is itself a PMP sample, so a ratio confirms detection in the light uninfected sample.	PRIDE	PXD010361	supp_RA118.005114_139760_1_supp_193480_pq7qm0.xlsx sheet Full CS Dataset in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC6222108/supplementaryFiles>	sodium metaperiodate 1 mM on ice 30 min, then aminooxy-biotin 250 uM + 10 mM aniline, pH 6.7, 4 C	Method as described in the paper's Experimental procedures 'Plasma membrane profiling' and 'MaxQuant analysis'; Fig. 1A legend.	streptavidin (immunoprecipitation step per Fig 1A)	aminooxy-biotin (Biotium); lot not stated	Q Exactive		Instrument as listed in the ProteomeXchange record PXD010361.	HeLa cervical adenocarcinoma cell line	File S1 (supp_..._193480_pq7qm0.xlsx) sheet 'Full CS Dataset' (997 protein groups; authors' filters: >= 2 unique peptides and >= 2 valid L/H ratios in a condition). Membership = normalised log2 L/H ratio present in >= 2 of 3 uninfected light samples (all 997 rows pass). EHEC-infected ratios kept as non-membership measurements. 'Reduced on CS' and 'Increased on CS' sheets (subsets) not used. EHEC proteins in the combined search are removed by the pipeline's species filter.	supp_RA118.005114_139760_1_supp_193480_pq7qm0.xlsx: Majority protein IDs (accession no.)		HeLa / baseline uninfected, PMP light channel: Normalised L/H ratio uninfected sample 1, Normalised L/H ratio uninfected sample 2, Normalised L/H ratio uninfected sample 3 (min_observed 2) | HeLa / EHEC EDL933-infected 5 h (not used for membership): Normalised L/H ratio EHEC infected sample 1, Normalised L/H ratio EHEC infected sample 2, Normalised L/H ratio EHEC infected sample 3 (min_observed 2)	959	353	0.3680917622523462	0.2	Homo sapiens	Combined UniProt human + EHEC O157:H7 EDL933 search; only human accessions are kept.	0	36	959
liu-hela-pda-2018	HeLa plasma-membrane fragments from polydopamine-encapsulated, magnetically captured cells	Liu et al. 2018	Liu Y	2018	29051082	10.1016/j.jprot.2017.10.009	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Plasma-membrane fragments isolated after cell disruption (PDA-encapsulation and magnetic capture): membrane fractionation, complementary by family policy. Unperturbed HeLa; a methods paper with one pooled identification list.	none (supplementary table only)		1-s2.0-S1874391917303664-mmc3.xlsx sheet Table S1 <https://ars.els-cdn.com/content/image/1-s2.0-S1874391917303664-mmc3.xlsx>	PDA encapsulation of intact cells is a physical coating used to recover plasma-membrane fragments after sonication; no covalent surface label is read out	Method read from: Europe PMC abstract; Supporting Information mmc2.docx (figure legends); Elsevier full text not accessible.	amine-functionalised Fe3O4 magnetic nanoparticles	not stated in the available supplement	not stated in accessible text		Where we looked for the instrument: Europe PMC abstract only (no free full text); publisher page via DOI blocked (refused automated access) or served no readable text; abstract says shotgun proteomics only.	HeLa cervical adenocarcinoma cell line	Supplementary mmc3.xlsx sheet 'Table S1. Total identified proteins': all 1,796 proteins identified from the magnetically enriched plasma-membrane fragments (paper: 385 PMPs + 1,411 non-PMPs = 1,796). The GO cellular component, hydrophobicity and TMD columns are annotations of the full list, not a selection. One pooled identification list; no per-replicate columns, no filter applied beyond the authors' identification criteria.	1-s2.0-S1874391917303664-mmc3.xlsx: Accession			1795	126	0.0701949860724234	0.2	Homo sapiens		0	0	1795
weldemariam-hesc-membrane-2018	Human embryonic stem cell sucrose-centrifugation membrane fraction, two batches	Weldemariam et al. 2018	Weldemariam MM	2018	30203655	10.1021/acs.jproteome.8b00407	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis then sucrose-centrifugation membrane fraction, so complementary evidence only. Adds a deep hESC membrane proteome; the two batches are separate preparations of the same cells and are combined as one list because the tables carry no per-run columns.	jPOST	JPST000421;PXD009840	20170417_ESC_mem_F1-7-cons-comb-new_Proteins.txt | ESC_2ndba_mem_24FsCons-comb_Proteins.txt	two-step sucrose centrifugation subcellular fractionation (membrane fraction), high-pH RP fractionation, PD 2.1 three-engine consensus	Method read from: ProteomeCentral PXD009840 sample/data processing protocols; jPOST JPST000421 file listing; Europe PMC abstract.	none	not stated	LTQ Orbitrap		Instrument as listed in the ProteomeXchange record PXD009840.	Human embryonic stem cells (line not named in the deposit)	Two deposited Proteome Discoverer consensus protein tables of the membrane fraction: batch 1 '20170417_ESC_mem_F1-7-cons-comb-new_Proteins.txt' (6,965 master proteins) and batch 2 'ESC_2ndba_mem_24FsCons-comb_Proteins.txt' (8,327). Filters: Master = IsMasterProtein and Protein FDR Confidence = High (6,221 and 7,549 rows); membership = union of the two batch lists. No per-run or abundance columns exist, so no replicate requirement can be applied. Nuclear and cytosolic tables in the same deposit are not used. All rows are Homo sapiens entries (no contaminant entries present).	20170417_ESC_mem_F1-7-cons-comb-new_Proteins.txt: Accession | ESC_2ndba_mem_24FsCons-comb_Proteins.txt: Accession	Master = IsMasterProtein | Protein FDR Confidence = High | Master = IsMasterProtein | Protein FDR Confidence = High		7796	1035	0.1327603899435608	0.2	Homo sapiens		0	0	7796
murphy-mdamb468-pmp-2018--fk866-nmn-fk866-nmn-or-azaserine-24-h	MDA-MB-468 breast cancer plasma membrane profiling · FK866, NMN, FK866+NMN or azaserine 24 h	Murphy et al. 2018	Murphy JP	2018	30157431	10.1016/j.celrep.2018.07.086	perturbed	drug, ligand or treatment: FK866, NMN, FK866+NMN or azaserine 24 h	drug, ligand or treatment arm of murphy-mdamb468-pmp-2018; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE; Mendeley Data	PXD007791;10.17632/ptm7dzc25y.2	Supplementary Data 1.xlsx sheet Cell Surface Quant <https://data.mendeley.com/public-files/datasets/ptm7dzc25y/files/e9b9cd20-8828-4745-b46b-3125cb520f4d/file_downloaded>	1 mM NaIO4 + 100 uM aminooxy-biotin + 10 mM aniline, 2 h 4 C dark, on intact cells; glycerol quench	Method read from: PRIDE PXD007791 sample processing protocol; STAR Methods (author manuscript PMC6402325); Mendeley 'Information' sheet.	streptavidin-agarose (Thermo 20347)	Biotium 90113 aminooxy-biotin; lot not stated	LTQ Orbitrap Velos		Instrument as listed in the ProteomeXchange record PXD007791.	MDA-MB-468	MDA-MB-468, FK866, NMN, FK866+NMN or azaserine 24 h: a non-baseline state of murphy-mdamb468-pmp-2018, listed when observed in at least 1 of its 8 samples				1316	549	0.41717325227963525		Homo sapiens		0	1	1316
murphy-mdamb468-pmp-2018	MDA-MB-468 breast cancer plasma membrane profiling · PBS vehicle 24 h (baseline)	Murphy et al. 2018	Murphy JP	2018	30157431	10.1016/j.celrep.2018.07.086	core		Intact-cell periodate/aminooxy-biotin PMP with PBS vehicle channels in the multiplex; the deposited table is the full 1%-FDR protein list with annotation columns appended, not selected by them. No no-label control. Two PBS channels in one multiplex are not independent identifications.	PRIDE; Mendeley Data	PXD007791;10.17632/ptm7dzc25y.2	Supplementary Data 1.xlsx sheet Cell Surface Quant <https://data.mendeley.com/public-files/datasets/ptm7dzc25y/files/e9b9cd20-8828-4745-b46b-3125cb520f4d/file_downloaded>	1 mM NaIO4 + 100 uM aminooxy-biotin + 10 mM aniline, 2 h 4 C dark, on intact cells; glycerol quench	Method read from: PRIDE PXD007791 sample processing protocol; STAR Methods (author manuscript PMC6402325); Mendeley 'Information' sheet.	streptavidin-agarose (Thermo 20347)	Biotium 90113 aminooxy-biotin; lot not stated	LTQ Orbitrap Velos		Instrument as listed in the ProteomeXchange record PXD007791.	MDA-MB-468 triple-negative breast cancer cell line	Mendeley Data ptm7dzc25y v2 'Supplementary Data 1.xlsx', sheet 'Cell Surface Quant' (1,342 proteins, 1% protein FDR; MDA MB 468 per the 'Information' sheet). Membership = relative intensity > 0 in >= 1 of the 2 PBS control channels. FK866, NMN, FK866+NMN and azaserine channels (24 h) kept as non-membership measurements. GO/membrane/glycosylation annotation columns are not used for selection. 'Complex I Protein Quant' (SH-SY5Y whole-cell) not used.	Supplementary Data 1.xlsx: Uniprot Protein Id		MDA-MB-468 / baseline PBS vehicle 24 h, PMP: PBS 1, PBS 2 (min_observed 1) | MDA-MB-468 / FK866, NMN, FK866+NMN or azaserine 24 h (not used for membership): FK866 1, FK866 2, NMN 1, NMN 2, FK NMN 1, FK NMN 2, Azaserine 1, Azaserine 2 (min_observed 1)	1314	549	0.4178082191780822	0.2	Homo sapiens		0	1	1314
perna-2017	AML CAR-target	Perna et al. 2017	Perna F	2017	29017060	10.1016/j.ccell.2017.09.004	below_screen	8% Canonical or Likely proteins, under 20%	Original identification and specimen caveats retained in previous_reason.	PRIDE	PXD007552	control_surface_proteins.tsv	Cell-surface biotinylation of six intact AML cell lines (THP-1, Mono-Mac, Kasumi-1, MOLM-13, OCI-AML3, TF-1; 6e6 cells per 75 cm2 flask) with the Pierce Cell Surface Protein Isolation Kit (Thermo Scientific 89881): 0.25 mg/mL Sulfo-NHS-SS-Biotin in ice-cold PBS, 30 min at 4 C, kit quenching solution; kit lysis buffer with protease inhibitors; clarified lysate bound 2 h at RT to 500 uL NeutrAvidin Agarose slurry in the kit column, washed with kit wash buffer, ammonium bicarbonate and Tris/CaCl2 digestion buffer; on-bead trypsin digestion overnight, StageTip desalting, nanoLC-MS/MS. Protein-level biotin capture with no biotin-site evidence; the list was later filtered by the authors for surface annotation and expression.	Method as described in the paper's STAR Methods 'Surface Proteomics' (Cancer Cell 2017; full text PMC7025434).	NeutrAvidin Agarose from the Pierce Cell Surface Protein Isolation Kit (Thermo Scientific 89881)	not reported	Q Exactive		Instrument as listed in the ProteomeXchange record PXD007552.	AML lines THP-1, Mono-Mac, Kasumi-1, MOLM-13, OCI-AML3 and TF-1	6 AML cell lines: THP-1, Mono-Mac(-6), Kasumi-1, MOLM-13, OCI-AML3, TF-1	control_surface_proteins.tsv: uniprot_accession			3309	255	0.0770625566636446	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			3308
ghosh-gbm-2017	Glioblastoma lines, GBM stem cells and neural stem cells sulfo-NHS surfaceome	Ghosh et al. 2017	Ghosh D	2017	28365151	10.1016/j.cels.2017.03.004	below_screen	16% Canonical or Likely proteins, under 20%	Intact-cell sulfo-NHS-SS-biotin capture of four unperturbed populations; Table S1 is the full per-run identification list before the TMHMM/transcriptome filters. No no-biotin control was reported, so the list carries the usual intracellular background; technical runs only (one capture per population).	GPM (thegpm.org model IDs; no PRIDE/ProteomeXchange deposit)		mmc2.xlsx sheet List of Proteins <https://doi.org/10.1016/j.cels.2017.03.004> | ghosh_table_s1_by_run.tsv	EZ-Link sulfo-NHS-SS-biotin kit on intact cells, NeutrAvidin beads (STAR Methods 'Cell-Surface Labeling and Mass Spectrometry')	Method read from: PMC5512565 Europe PMC full text (Results, STAR Methods, Table S1 legend).	NeutrAvidin agarose (kit)	not reported	LTQ Orbitrap (Thermo; exact model suffix not given)	Agilent HP1100 LC	Instrument as named in the paper's Methods (full text PMC5512565).	U87MG and T98G glioblastoma lines, CD133+ GBM cancer stem cells, neural stem cells	Table S1 'List of Proteins' (mmc2.xlsx): 7,232 per-run identifications over 4 populations x 3 technical runs, before the authors' TMHMM filter. Rolled up to one row per Ensembl/Swiss-Prot identifier with -log10(e) per run; membership = log(e) < -3 (the paper's validity cut) in >= 1 of the population's 3 runs. Gives 897/812/564/366 identifiers for U87MG/T98G/CSC/NSC (paper: 868/813/564/541). ENSP -> UniProt by a frozen mapping (1,481 reviewed, 249 single unreviewed, 229 unmapped incl. contaminants).	ghosh_table_s1_by_run.tsv: uniprot_accession		U87MG glioblastoma cell line / baseline sulfo-NHS-SS-biotin labeled: U87MG_run1, U87MG_run2, U87MG_run3 (min_observed 1; floor 3) | T98G glioblastoma cell line / baseline sulfo-NHS-SS-biotin labeled: T98G_run1, T98G_run2, T98G_run3 (min_observed 1; floor 3) | CD133+ GBM cancer stem cells (Celprogen) / baseline sulfo-NHS-SS-biotin labeled: GBM_CSC_run1, GBM_CSC_run2, GBM_CSC_run3 (min_observed 1; floor 3) | neural stem cells (Millipore) / baseline sulfo-NHS-SS-biotin labeled: NSC_run1, NSC_run2, NSC_run3 (min_observed 1; floor 3)	1178	189	0.16044142614601017	0.2	Homo sapiens		0	0	1178
fielding-hfff-us12-2017--hcmv-merlin-or-us12-family-mutant-infected-72-h-pmp	HF-TERT fibroblast plasma membrane profiling · HCMV Merlin or US12-family mutant infected 72 h, Series 1	Fielding et al. 2017	Fielding CA	2017	28186488	10.7554/eLife.22206	perturbed	infection: HCMV Merlin or US12-family mutant infected 72 h, Series 1	infection arm of fielding-hfff-us12-2017; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD005883	elife-22206-supp1.xlsx sheet Data in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5367895/supplementaryFiles>	PMP (periodate/aminooxy-biotin on live cells) with TMT 10-plex MS3, as in Weekes 2014; paper describes PM fractions from TMT series 1-3	Method as described in the paper's Results ('The US12 family targets plasma membrane proteins'), Figure 4/8 workflows, Supplementary file 1 (full text PMC5367895).	streptavidin agarose (Weekes PMP protocol)	not stated	LTQ Orbitrap		Instrument as listed in the ProteomeXchange record PXD005883.	HF-TERT fibroblasts	HF-TERT fibroblasts, HCMV Merlin or US12-family mutant infected 72 h, PMP Series 1: a non-baseline state of fielding-hfff-us12-2017, listed when observed in at least 1 of its 6 samples				2591	732	0.28251640293323044		Homo sapiens		0	1	2591
fielding-hfff-us12-2017--hcmv-infected-with-or-without-leupeptin-pmp-series-3	HF-TERT fibroblast plasma membrane profiling · HCMV infected with or without leupeptin, Series 3	Fielding et al. 2017	Fielding CA	2017	28186488	10.7554/eLife.22206	perturbed	infection: HCMV infected with or without leupeptin, Series 3	infection arm of fielding-hfff-us12-2017; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD005883	elife-22206-supp1.xlsx sheet Data in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5367895/supplementaryFiles>	PMP (periodate/aminooxy-biotin on live cells) with TMT 10-plex MS3, as in Weekes 2014; paper describes PM fractions from TMT series 1-3	Method as described in the paper's Results ('The US12 family targets plasma membrane proteins'), Figure 4/8 workflows, Supplementary file 1 (full text PMC5367895).	streptavidin agarose (Weekes PMP protocol)	not stated	LTQ Orbitrap		Instrument as listed in the ProteomeXchange record PXD005883.	HF-TERT fibroblasts	HF-TERT fibroblasts, HCMV infected with or without leupeptin, PMP Series 3: a non-baseline state of fielding-hfff-us12-2017, listed when observed in at least 1 of its 5 samples				2524	738	0.29239302694136293		Homo sapiens		0	1	2524
fielding-hfff-us12-2017	HF-TERT fibroblast plasma membrane profiling · mock-infected (Proteomic Series 1) (baseline)	Fielding et al. 2017	Fielding CA	2017	28186488	10.7554/eLife.22206	core		Weekes-lab PMP (same lab and method as Depierreux, Hunter, Soh and Fielding 2022) on uninfected fibroblasts; membership rests on the mock channels of two independent TMT series. Same cell type as depierreux-hfff-pmp-2022 and hunter-hfff-pmp-2024, so not an independent cell type.	PRIDE	PXD005883	elife-22206-supp1.xlsx sheet Data in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5367895/supplementaryFiles>	PMP (periodate/aminooxy-biotin on live cells) with TMT 10-plex MS3, as in Weekes 2014; paper describes PM fractions from TMT series 1-3	Method as described in the paper's Results ('The US12 family targets plasma membrane proteins'), Figure 4/8 workflows, Supplementary file 1 (full text PMC5367895).	streptavidin agarose (Weekes PMP protocol)	not stated	LTQ Orbitrap		Instrument as listed in the ProteomeXchange record PXD005883.	HF-TERT telomerase-immortalized human foreskin fibroblasts	Supplementary file 1 'Data' sheet (merged PM and WCL rows, normalised so each protein's highest channel = 1). Species = HUMAN only (164 HCMV rows dropped). Membership = either Series 1 mock PM channel > 0 (min_observed 1 of 2) or the Series 3 mock PM channel > 0. HCMV-infected PM channels of Series 1 and 3 kept as non-membership measurements; Series 2 (no mock) and all WCL channels not read. The sheet's GO flag columns (M, PM, IPM, CS, XC) are not applied.	elife-22206-supp1.xlsx: Uniprot-l	Species = HUMAN	HF-TERT fibroblasts / baseline mock-infected, PMP (Proteomic Series 1): Mock PM_1, Mock PM_1.1 (min_observed 1) | HF-TERT fibroblasts / baseline mock-infected, PMP (Proteomic Series 3): Mock PM_3 (min_observed 1) | HF-TERT fibroblasts / HCMV Merlin or US12-family mutant infected 72 h, PMP Series 1 (not used for membership): Merlin PM_1, Merlin PM_1.1, US12-21 PM_1, US18 PM_1, US19 PM_1, US20 PM_1 (min_observed 1) | HF-TERT fibroblasts / HCMV infected with or without leupeptin, PMP Series 3 (not used for membership): Merlin_24 PM_3, Merlin_48 PM_3, Merlin_72 PM_3, US12_21_72h PM_3, Merlin_72_Leu PM_3 (min_observed 1)	2948	785	0.2662822252374491	0.2	Homo sapiens		0	1	2948
tharkeshwar-hela-pm-2017--hela-npc1-ko-clone-1-npc1-knockout-spion-plasma-membrane-isolate	HeLa plasma membrane isolated with aminolipid-coated magnetic nanoparticles · NPC1 knockout, clone 1	Tharkeshwar et al. 2017	Tharkeshwar AK	2017	28134274	10.1038/srep41408	perturbed	genetic perturbation: NPC1 knockout	genetic perturbation arm of tharkeshwar-hela-pm-2017; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD004273;PXD001225	MQproteinGroups-LFQ.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/02/PXD004273/MQproteinGroups-LFQ.txt>	Aminolipid-SPIONs adsorbed to intact cells (4 °C, 15 min, non-covalent), homogenisation, magnetic isolation of PM from post-nuclear supernatant	Method read from: Results 'magnetic isolation of LE/LYS and PMs'; Methods 'PEGylated phospholipid functionalization', 'Gel-free proteomics', 'Perseus' paragraphs (PMC5278418).	aminolipid-coated SPIONs (in-house)	not stated	Q Exactive; Q Exactive HF		Instrument as listed in the ProteomeXchange records PXD001225 and PXD004273.	HeLa NPC1-KO clone 1	HeLa NPC1-KO clone 1, NPC1 knockout SPION plasma-membrane isolate: a non-baseline state of tharkeshwar-hela-pm-2017, listed when observed in at least 2 of its 2 samples				2313	338	0.1461305663640294		Homo sapiens		0	0	2313
tharkeshwar-hela-pm-2017--hela-npc1-ko-clone-2-npc1-knockout-spion-plasma-membrane-isolate	HeLa plasma membrane isolated with aminolipid-coated magnetic nanoparticles · NPC1 knockout, clone 2	Tharkeshwar et al. 2017	Tharkeshwar AK	2017	28134274	10.1038/srep41408	perturbed	genetic perturbation: NPC1 knockout	genetic perturbation arm of tharkeshwar-hela-pm-2017; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD004273;PXD001225	MQproteinGroups-LFQ.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/02/PXD004273/MQproteinGroups-LFQ.txt>	Aminolipid-SPIONs adsorbed to intact cells (4 °C, 15 min, non-covalent), homogenisation, magnetic isolation of PM from post-nuclear supernatant	Method read from: Results 'magnetic isolation of LE/LYS and PMs'; Methods 'PEGylated phospholipid functionalization', 'Gel-free proteomics', 'Perseus' paragraphs (PMC5278418).	aminolipid-coated SPIONs (in-house)	not stated	Q Exactive; Q Exactive HF		Instrument as listed in the ProteomeXchange records PXD001225 and PXD004273.	HeLa NPC1-KO clone 2	HeLa NPC1-KO clone 2, NPC1 knockout SPION plasma-membrane isolate: a non-baseline state of tharkeshwar-hela-pm-2017, listed when observed in at least 2 of its 2 samples				2365	342	0.14460887949260043		Homo sapiens		0	0	2365
tharkeshwar-hela-pm-2017	HeLa plasma membrane isolated with aminolipid-coated magnetic nanoparticles · wild-type (baseline)	Tharkeshwar et al. 2017	Tharkeshwar AK	2017	28134274	10.1038/srep41408	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Plasma membranes are pulled out of a lysate by nanoparticles that coated the intact cells, so the fraction is defined by physical attachment rather than a covalent surface label; no residue is shown to be extracellular. Complementary membrane-fractionation evidence (the first cell-coating PM isolation in the compendium). HeLa is already well covered.	PRIDE	PXD004273;PXD001225	MQproteinGroups-LFQ.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/02/PXD004273/MQproteinGroups-LFQ.txt>	Aminolipid-SPIONs adsorbed to intact cells (4 °C, 15 min, non-covalent), homogenisation, magnetic isolation of PM from post-nuclear supernatant	Method read from: Results 'magnetic isolation of LE/LYS and PMs'; Methods 'PEGylated phospholipid functionalization', 'Gel-free proteomics', 'Perseus' paragraphs (PMC5278418).	aminolipid-coated SPIONs (in-house)	not stated	Q Exactive; Q Exactive HF		Instrument as listed in the ProteomeXchange records PXD001225 and PXD004273.	HeLa cervical adenocarcinoma cells (wild type and two CRISPR NPC1-knockout clones)	PRIDE PXD004273 MQproteinGroups-LFQ.txt (MaxQuant proteinGroups before Perseus imputation; 4,564 groups). Rows flagged Only identified by site, Reverse or Potential contaminant removed (4,383 left). Membership = raw MaxQuant LFQ intensity > 0 in both WT PM duplicates (2 of 2). NPC1-KO1 and NPC1-KO2 PM isolates and WT total cell lysate kept as non-membership measurements; lysosome (Lys) fractions not read. The paper's Supplementary Table S4 (srep41408-s5.xls) holds Perseus-imputed LFQ values and is not used.	MQproteinGroups-LFQ.txt: Majority protein IDs	drop rows flagged Only identified by site, Reverse, Potential contaminant	HeLa wild type / baseline SPION plasma-membrane isolate: LFQ intensity WT PM 1, LFQ intensity WT PM 2 (min_observed 2) | HeLa NPC1-KO clone 1 / NPC1 knockout SPION plasma-membrane isolate (not used for membership): LFQ intensity KO1 PM 1, LFQ intensity KO1 PM 2 (min_observed 2) | HeLa NPC1-KO clone 2 / NPC1 knockout SPION plasma-membrane isolate (not used for membership): LFQ intensity KO2 PM 1, LFQ intensity KO2 PM 2 (min_observed 2) | HeLa wild type / total cell lysate (not used for membership): LFQ intensity WT TCL 1, LFQ intensity WT TCL 2 (min_observed 2)	2360	333	0.14110169491525423	0.2	Homo sapiens		0	0	2360
hepatic-endoderm-2017	Hepatic endoderm CSC	Mallanna et al. 2017	Mallanna SK	2017	27966262	10.1002/pmic.201600397	core		Original identification and specimen caveats retained in previous_reason.	supplement		control_surface_proteins.tsv	Cell Surface Capture Technology (Wollscheid/Gundry CSC) on live hiPSC-derived specified hepatic endoderm cells: extracellular oligosaccharides on live cells biotinylated with membrane-impermeable reagents (periodate oxidation + biocytin hydrazide per the Gundry protocol), tryptic digestion, biotinylated glycopeptides captured on immobilized streptavidin, PNGase F release of formerly N-glycosylated peptides, high-mass-accuracy LC-MS/MS; identifications require a deamidated Asn in an N-glycosylation sequon. Reagent-level details are in the Supporting Information.	Method as described in the paper's Introduction and Methods summary (Proteomics 2017; full text PMC5340625).	immobilized streptavidin (product per Gundry-lab CSC protocol; not stated in main text)	not reported	not stated in accessible text		Where we looked for the instrument: PMC5340625 page: no instrument named in accessible text; Wiley DOI page refused automated access.	iPSC-derived hepatic endoderm	iPSC-derived hepatic endoderm	control_surface_proteins.tsv: uniprot_accession			395	331	0.8379746835443038	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			395
temme-asc-2017	Human atrial stromal cell sulfo-NHS-SS-biotin surfaceome	Temme et al. 2017	Temme S	2017	29156374	10.1016/j.scr.2017.11.006	core		Intact-cell amine biotinylation of untreated primary human atrial stromal cells; the deposited MaxQuant table is the full identification list before the authors' GO plasma-membrane selection. No no-biotin control. Sample 1 carries most identifications (1,225 groups with MS/MS vs 658 in >= 2 samples), so the 2-of-3 rule leans on match-between-runs in samples 2-3.	PRIDE	PXD005013	proteinGroups.txt	Cell surface biotinylation, sulfo-NHS-SS-biotin (linker remnant +145.0197 on K in the search), streptavidin isolation	Method read from: PubMed abstract; PRIDE PXD005013 sample/data processing protocols; MaxQuant site table 'S SS NHS Biotin IAA'. Full text is subscription-only and was not read.	not stated in the abstract/PRIDE record	not stated	Q Exactive; LTQ Orbitrap Elite		Instrument as listed in the ProteomeXchange record PXD005013.	Primary human atrial stromal cells (epicardium-derived-cell-like) cultured from atrial tissue biopsies	PRIDE PXD005013 txt_humanEPDCs.zip member txt/proteinGroups.txt (1,309 groups; samples 'h EPDCS 1-3'). Rows flagged Only identified by site, Reverse or Potential contaminant removed (1,248 left); Peptides >= 2 (the authors' identification rule). Membership = razor+unique peptides > 0 in >= 2 of the 3 samples (counts include match-between-runs). The paper's 239 'plasma membrane proteins' are a GO-selected subset and are not used.	proteinGroups.txt: Majority protein IDs	Peptides ≥ 2 | drop rows flagged Only identified by site, Reverse, Potential contaminant	human atrial stromal cells / baseline intact-cell sulfo-NHS-SS-biotin labeled: Razor + unique peptides h EPDCS 1, Razor + unique peptides h EPDCS 2, Razor + unique peptides h EPDCS 3 (min_observed 2)	810	228	0.2814814814814815	0.2	Homo sapiens		0	0	810
lango-leukemia-2017	K562 and HL60 labeled extracellular lysine peptides, sulfo-NHS-SS-biotin	Langó et al. 2017	Langó T	2017	28211907	10.1038/srep42610	core		Site-level evidence: only peptides carrying the membrane-impermeable label on a lysine are reported, so each accession has a directly labeled extracellular residue in untreated cells. No unlabeled control is reported, and replicates are pooled into one list per line. Small lists (HL60 ~320, K562 ~210 accessions), and many accessions are TrEMBL entries, which depresses reference overlap.	none (spectra on a Protein Prospector server; no ProteomeXchange deposit)		srep42610-s3.xls sheet LTQ-Orbitrap Elite in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5304180/supplementaryFiles>	Sulfo-NHS-SS-biotin on intact cells, 4 °C 20 min, quenched with Tris; labeled-peptide capture on neutravidin agarose	Method as described in the paper's Methods 'Cell surface labeling', 'Biotinylated peptide isolation', 'Processing of the MS results' (PMC5304180).	neutravidin agarose (Pierce), saturation checked by dot blot	not stated	LTQ-Orbitrap Elite	UPLC-coupled; CID in trap or HCD	Instrument as named in the paper's Methods (full text PMC5304180).	HL60 acute promyelocytic leukemia and K562 chronic myelogenous leukemia cell lines	Supplementary Table 2 (srep42610-s3.xls) sheet 'LTQ-Orbitrap Elite': 3,381 labeled-peptide matches with cell line, UniProt accession and a TM/nonTM column (both kept; the TM column never filters). The 'Bruker Maxis II Q-TOF' sheet is an identical copy and is not read twice. Membership = every reported labeled peptide, per cell line (HL60 2,765 rows, K562 616 rows). RBC peptides are not in this sheet; Supplementary Table 3 (s4.xls, 730 labeled positions) is restricted to CCTOP-predicted transmembrane proteins seen in >= 3 replicates and is not used. Accessions are those reported (many TrEMBL entries).	srep42610-s3.xls: Acc# | srep42610-s3.xls: Acc#	Cell line = HL60 | Cell line = K562	HL60 / baseline intact-cell sulfo-NHS-SS-biotin labeled peptides: Score (min_observed 1) | K562 / baseline intact-cell sulfo-NHS-SS-biotin labeled peptides: Score (min_observed 1)	360	137	0.38055555555555554	0.2	Homo sapiens		0	23	360
kalxdorf-2017	Kalxdorf 2017 (Veneer reanalysis)	Kalxdorf et al. 2017	Kalxdorf M	2017	28336715	10.1074/mcp.M116.063859	annotation_selected	author pre-filtered to annotated surface proteins	pre-filtered by surface annotation (annotation-selected); shown, not counted. Was hold. hold: threshold 20.0000%; borderline allowance 0.0%. Differentiation/time-zero and inhibitor comparisons are biological; CRAPome supplies external bead-background annotations, not matched negative runs. Current Veneer reanalysis only covers original PM-selected proteins and pools conditions. All-tier reanalysis does not recover excluded proteins.			pr3c00800_si_002.xlsx sheet Table S9 <https://doi.org/10.1021/acs.jproteome.3c00800>	Alkoxyamine-PEG4-biotin cell-surface glycan labeling on intact cells (suspension cells or a 15 cm dish of adherent cells at 70 to 80% confluency): carbohydrates oxidized with 1 mM sodium metaperiodate in PBS pH 6.5 for 10 min at 4 C in the dark, then 1 mM alkoxyamine-PEG4-biotin + 10 mM aniline for 10 min at 4 C; pellets frozen. Lysis by boiling in 4% SDS / 50 mM DTT, sonication, 1:10 dilution; biotinylated PROTEINS captured on 15 uL high-capacity streptavidin agarose resin per sample in deep 96-well filter plates (60 min, 25 C), washed 3x 0.4% SDS/400 mM NaCl, 8x 400 mM NaCl, 8x 2 M urea/TEAB; on-resin DTT/IAA and overnight trypsin digestion (all tryptic peptides analysed; PNGase F elution tested and dropped). Orbitrap Q Exactive, label-free (Top3) quantification; monocyte-to-macrophage differentiation and kinase-inhibitor comparisons, 11 cell lines/primary cells; bead background annotated from CRAPome streptavidin-agarose entries. The inventory table is the Veneer 2024 re-report (Table S9) of these proteins.	Method as described in the paper's Experimental Procedures 'Plasma membrane protein enrichment' and Results (Mol Cell Proteomics 2017; full text PMC5417820).	high-capacity streptavidin agarose resin (vendor/catalog not stated); alkoxyamine-PEG4-biotin	not reported	Q Exactive			Monocyte/macrophage differentiation and primary hematopoietic-cell comparisons; pooled reanalysis conditions	All reanalysis tiers; pooled conditions. Baseline membership unresolved	pr3c00800_si_002.xlsx: Protein accessions			1390	1004	0.7223021582733813	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			1388
haverland-2017	Lymphoid CSC	Haverland et al. 2017	Haverland NA	2017	28834292	10.1002/pmic.201700156	core		Original identification and specimen caveats retained in previous_reason.	supplement		control_surface_proteins.tsv	Cell Surface Capture Technology (Wollscheid/Gundry CSC) on viable human lymphoid cell lines (Ramos, HG-3, RCH-ACV, Jurkat; 3 biological replicates per line defined as separately passaged cultures, 3 technical replicates each): extracellular oligosaccharides on live cells biotinylated with membrane-impermeable reagents (periodate oxidation + biocytin hydrazide per the cited Gundry protocol), glycoproteins digested, biotinylated glycopeptides captured on immobilized streptavidin, formerly N-glycosylated peptides released with PNGase F; Dionex UltiMate 3000 RSLCnano + Velos Orbitrap; Proteome Discoverer 2.1 (Sequest HT, MS Amanda, Mascot); proteins kept only with >=1 peptide carrying a deamidated Asn in an N-X-S/T/C sequon. 404 cell-surface N-glycoproteins across the four lines. Reagent-level details are in the cited protocol papers and Supporting Information.	Method as described in the paper's Introduction and Methods paragraph (Proteomics 2017; full text PMC5633517).	immobilized streptavidin (product per Gundry-lab CSC protocol; not stated in main text)	not reported	Velos Orbitrap	N-glycopeptide analysis (Dionex UltiMate 3000 RPLCnano)	Instrument as named in the paper's Methods (full text PMC5633517).	Lymphoid lines HG3, Ramos, RCH-ACV and Jurkat	4 human lymphoid cell lines (HG3, Ramos, RCH-ACV, Jurkat)	control_surface_proteins.tsv: uniprot_accession			401	296	0.7381546134663342	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			390
xiao-mcf7-2017	MCF-7 metabolic-labeling surface glycoproteins, Veneer reanalysis	Xiao and Wu 2017	Xiao H	2017	28616130	10.1039/c6sc01814a	annotation_selected	author pre-filtered to annotated surface proteins	Intact-cell metabolic glycan labeling with a membrane-impermeable click reagent, but the only machine-readable list is the authors' reported surface set as republished by Veneer (the original supplements are PDFs); held like kalxdorf-2017 and leung-2019.	none (list from the Veneer reanalysis, Table S1 of Gundry lab JPR 2024)		pr3c00800_si_002.xlsx sheet Table S12 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11301670/supplementaryFiles>	Metabolic azido-sugar labeling then DBCO-sulfo-biotin click on intact cells, NeutrAvidin capture; protein list as reported in the original study, with Veneer surface-assignment tiers.	Method summarized from the paper (PMC5458730) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	LTQ Orbitrap Elite	Top15 DDA, Xcalibur 3.0.63	Instrument as named in the paper's Methods (full text PMC5458730).	MCF-7 breast cancer cells (surface glycoprotein turnover time course)	Veneer (PMID 38412263) Supplementary Table S12: the 265 cell-surface proteins reported in the original study, all tiers; time points pooled	pr3c00800_si_002.xlsx: Protein accessions			265	227	0.8566037735849057	0.2	Homo sapiens		0	0	265
glisovic-molm14-pm-2017	MOLM-14 AML sucrose-gradient plasma membrane fraction, label-free	Glisovic-Aplenc et al. 2017	Glisovic-Aplenc T	2017	28116781	10.1002/pmic.201600344	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Density-gradient plasma-membrane flotation from lysed cells, no surface label; the authors then selected 'surfaceome' members by GO terms, which is not used here. Pooling 14 preparation variants gives a larger list than any single workflow in the paper.	PRIDE	PXD004801	proteinGroups.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/01/PXD004801/proteinGroups.txt>	sucrose cushion + step-gradient flotation of PM, label-free	Method read from: PRIDE PXD004801 sample/data processing protocol; paper Results (author manuscript PMC5518111).	none	n/a	LTQ Orbitrap Elite		Instrument as listed in the ProteomeXchange record PXD004801.	MOLM-14 acute myeloid leukemia cell line	PRIDE PXD004801 proteinGroups.txt (one MaxQuant search over 18 experiments; 5,876 groups). Reverse, potential-contaminant and only-by-site groups removed (5,471). Membership = MS/MS count > 0 in >= 2 of the 14 label-free MOLM-14 plasma-membrane-fraction experiments (in-solution PPM_IS_*, in-gel RA927*, SG1070_*, SG976_Heated*); the 4 sulfo-NHS-SS-biotin experiments kept as non-membership measurements. MS/MS count rather than intensity so that match-between-runs transfers do not count.	proteinGroups.txt: Majority protein IDs	drop rows flagged Reverse, Potential contaminant, Only identified by site	MOLM-14 / untreated, label-free sucrose-gradient plasma membrane fraction: MS/MS Count PPM_IS_RG, MS/MS Count PPM_IS_SDC, MS/MS Count PPM_IS_SDC_PT, MS/MS Count RA927_50KA, MS/MS Count RA927_50KB, MS/MS Count RA927_50uL_tech, MS/MS Count RA927igd3, MS/MS Count RA927igd3_DC, MS/MS Count SG1070_002, MS/MS Count SG1070_004, MS/MS Count SG1070_005, MS/MS Count SG976_Heated1, MS/MS Count SG976_Heated2, MS/MS Count SG976_Heated3 (min_observed 2) | MOLM-14 / sulfo-NHS-SS-biotin streptavidin arm (not used for membership): MS/MS Count BiotinylatedPPM_IS_RG1, MS/MS Count BiotinylatedPPM_IS_RG2, MS/MS Count BiotinylatedPPM_IS_SDC1, MS/MS Count BiotinylatedPPM_IS_SDC2 (min_observed 2)	5265	598	0.11358024691358025	0.2	Homo sapiens		0	0	5265
glisovic-molm14-biotin-2017	MOLM-14 AML sulfo-NHS-SS-biotin surface capture arm	Glisovic-Aplenc et al. 2017	Glisovic-Aplenc T	2017	28116781	10.1002/pmic.201600344	held	the run design is only in a supplement we couldn't retrieve	Intact-cell amine biotinylation on untreated cells, but the experimental design of the four biotin runs (what RG vs SDC denotes, whether the biotin pull-down followed the sucrose PM prep, as the 'BiotinylatedPPM' name suggests) is only in the Supporting Information, which is not openly retrievable; no no-biotin control. The 968-group list could not be reproduced exactly from the deposit.	PRIDE	PXD004801	proteinGroups.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2017/01/PXD004801/proteinGroups.txt>	sulfo-NHS-SS-biotin lysine labeling (CAMthiopropanoyl +87.998 Da searched); details in inaccessible Supporting Information	Method read from: paper Results ('captured via lysine biotinylation, following a published protocol [14]'); PRIDE data processing protocol.	streptavidin (not specified in accessible text)	not stated	LTQ Orbitrap Elite		Instrument as listed in the ProteomeXchange record PXD004801.	MOLM-14 acute myeloid leukemia cell line	PRIDE PXD004801 proteinGroups.txt; reverse, contaminant and only-by-site groups removed. Membership = MS/MS count > 0 in >= 2 of the 4 'BiotinylatedPPM_IS_*' experiments (RG1, RG2, SDC1, SDC2); label-free fraction experiments kept as non-membership measurements. Paper reports 968 protein groups for this arm.	proteinGroups.txt: Majority protein IDs	drop rows flagged Reverse, Potential contaminant, Only identified by site	MOLM-14 / untreated, sulfo-NHS-SS-biotin streptavidin capture: MS/MS Count BiotinylatedPPM_IS_RG1, MS/MS Count BiotinylatedPPM_IS_RG2, MS/MS Count BiotinylatedPPM_IS_SDC1, MS/MS Count BiotinylatedPPM_IS_SDC2 (min_observed 2) | MOLM-14 / label-free plasma membrane fraction (not used for membership): MS/MS Count PPM_IS_RG, MS/MS Count PPM_IS_SDC, MS/MS Count PPM_IS_SDC_PT, MS/MS Count RA927_50KA, MS/MS Count RA927_50KB, MS/MS Count RA927_50uL_tech, MS/MS Count RA927igd3, MS/MS Count RA927igd3_DC, MS/MS Count SG1070_002, MS/MS Count SG1070_004, MS/MS Count SG1070_005, MS/MS Count SG976_Heated1, MS/MS Count SG976_Heated2, MS/MS Count SG976_Heated3 (min_observed 2)	618	220	0.3559870550161812	0.2	Homo sapiens		0	0	618
ersing-p3hr1-pmp-2017	P3HR1 Burkitt lymphoma plasma membrane profiling, uninduced vs EBV lytic	Ersing et al. 2017	Ersing I	2017	28514666	10.1016/j.celrep.2017.04.062	core		Weekes-lab PMP on a Burkitt lymphoma B cell line; membership rests on the two uninduced channels of the single PMP multiplex. Adds a lymphoma B cell surface to the compendium; the induced arms are perturbations.	PRIDE	PXD006317	mmc2.xlsx sheet Data in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5446956/supplementaryFiles>	periodate/aminooxy-biotin PMP on FACS-sorted live cells	Method as described in the paper's Experimental Procedures; PRIDE PXD006317 sample protocol (full text PMC5446956).	streptavidin agarose	not stated	Orbitrap Fusion Lumos; Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD006317.	P3HR1 EBV+ Burkitt lymphoma B cell line (P3HR1-ZHT/RHT and parental)	Table S1 (mmc2.xlsx) 'Data' sheet, which merges WCL1-3, Akata WCL and PM1 rows; Species = HUMAN only (64 viral rows dropped). Membership = reporter > 0 in either uninduced PM1 channel (P3HR1-ZHT/RHT uninduced, parental P3HR1 uninduced). 4-HT-treated parental and induced gp350+/- channels kept as non-membership measurements. The subcellular annotation columns (M, PM, IPM, CS, XC, Nuc, ShG) are carried but never filter rows; the paper's 550 'PM proteins' is that annotation subset and is not used.	mmc2.xlsx: Uniprot	Species = HUMAN	P3HR1 Burkitt lymphoma / baseline uninduced (ZHT/RHT and parental), PMP (PM1): PM1 Uninduced, PM1 P3HR1 parental Uninduced (min_observed 1) | P3HR1 Burkitt lymphoma / 4-HT treated / EBV lytic induction (not used for membership): PM1 P3HR1 parental 24h, PM1 P3HR1 parental 72h, PM1 24h gp350-, PM1 48h gp350-, PM1 72h gp350-, PM1 24h gp350+, PM1 48h gp350+, PM1 72h gp350+ (min_observed 1)	1000	304	0.304	0.2	Homo sapiens	Search included EBV strain proteomes (P3HR1, AG876, Akata); only HUMAN rows are read.	0	2	1000
kim-wi38-mempn-2017	WI-38 fibroblast Mem-PER Plus membrane fraction · proliferating (baseline)	Kim et al. 2017	Kim KM	2017	28877934	10.1101/gad.302570.117	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Detergent kit total-membrane extract (the paper notes it includes ER, mitochondria and other internal membranes); complementary only. Adds a normal diploid fibroblast line.	none (supplementary table only)		supp_gad.302570.117_Supplemental_Table_S1.xlsx sheet Table1A_membrane fraction in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5630018/supplementaryFiles>	Mem-PER Plus Membrane Protein Extraction Kit (Thermo) on lysed cells	Method read from: Supplemental Material PDF, 'Isolation of cell membrane and cell surface proteins, and mass spectrometry and Western blot analyses'; main text Results (PMC5630018).	none	not stated	not stated in accessible text		Where we looked for the instrument: PMC5630018 MS methods deferred to Supplemental Material (not accessible); genesdev page gave no text.	WI-38 human diploid fetal lung fibroblasts, proliferating (PDL23) and replicatively senescent (PDL59)	Supplementary Table S1 sheet 'Table1A_membrane fraction' (1,414 proteins, Proteome Discoverer export with GI 'Accession' and UniProt 'SP' columns; UniProt annotation columns such as Transmembrane are carried but never filter rows). Membership = PSM count > 0 in >= 1 of the 2 proliferating (MP-23) runs; 841 proteins have PSMs in both. Senescent (MP-59) runs kept as non-membership measurements. The sheet appears to list proteins detected in the senescent runs (1,410 of 1,414 rows have senescent PSMs; only 3 rows are proliferating-only), so proliferating membership is effectively truncated to proteins also seen in senescent cells.	supp_gad.302570.117_Supplemental_Table_S1.xlsx: SP		WI-38 fibroblasts, proliferating (PDL23) / baseline proliferating, Mem-PER Plus membrane fraction: # PSM MP-23-1, # PSM MP-23-2 (min_observed 1) | WI-38 fibroblasts, replicative senescent (PDL59) / replicative senescence, Mem-PER Plus membrane fraction (not used for membership): # PSM MP-59-1, # PSM MP-59-2 (min_observed 1)	1100	138	0.12545454545454546	0.2	Homo sapiens		0	0	1100
kim-wi38-mempn-2017--replicative-senescence-mem-per-plus-membrane-fraction	WI-38 fibroblast Mem-PER Plus membrane fraction · replicative senescence	Kim et al. 2017	Kim KM	2017	28877934	10.1101/gad.302570.117	perturbed	replicative senescence	senescence arm of kim-wi38-mempn-2017; shown, not counted. Membership follows the parent recipe's rule for this sample group.	none (supplementary table only)		supp_gad.302570.117_Supplemental_Table_S1.xlsx sheet Table1A_membrane fraction in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5630018/supplementaryFiles>	Mem-PER Plus Membrane Protein Extraction Kit (Thermo) on lysed cells	Method read from: Supplemental Material PDF, 'Isolation of cell membrane and cell surface proteins, and mass spectrometry and Western blot analyses'; main text Results (PMC5630018).	none	not stated	not stated in accessible text		Where we looked for the instrument: PMC5630018 MS methods deferred to Supplemental Material (not accessible); genesdev page gave no text.	WI-38 fibroblasts, replicative senescent (PDL59)	WI-38 fibroblasts, replicative senescent (PDL59), replicative senescence, Mem-PER Plus membrane fraction: a non-baseline state of kim-wi38-mempn-2017, listed when observed in at least 1 of its 2 samples				1399	188	0.1343817012151537		Homo sapiens		0	0	1399
kim-wi38-surface-2017	WI-38 fibroblast Pierce Cell Surface Protein Isolation (sulfo-NHS-SS-biotin) · proliferating (baseline)	Kim et al. 2017	Kim KM	2017	28877934	10.1101/gad.302570.117	held	the published table keeps only proteins detected in the other condition, so the baseline list is cut short	Intact-cell amine biotinylation with the Pierce kit on proliferating normal fibroblasts. Held: the published sheet appears to be defined by detection in the senescent (perturbed-state) runs (0 of 1,501 rows are proliferating-only), so baseline membership is truncated by the non-baseline arm; there is no no-biotin control, the two runs per state are not described as biological replicates, and the list is barely surface-enriched (11.9% canonical+likely, below the 14.8% proteome background).	none (supplementary table only)		supp_gad.302570.117_Supplemental_Table_S1.xlsx sheet Table1B_surface fraction in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5630018/supplementaryFiles>	Pierce Cell Surface Protein Isolation Kit (sulfo-NHS-SS-biotin on intact cells, NeutrAvidin agarose)	Method read from: Supplemental Material PDF, 'Isolation of cell membrane and cell surface proteins...' (PMC5630018).	NeutrAvidin agarose (kit)	not stated	not stated in accessible text		Where we looked for the instrument: PMC5630018 MS methods deferred to Supplemental Material (not accessible); genesdev page gave no text.	WI-38 human diploid fetal lung fibroblasts, proliferating (PDL23) and replicatively senescent (PDL59)	Supplementary Table S1 sheet 'Table1B_surface fraction' (1,501 proteins; UniProt 'SP' accession column; annotation columns carried but never filter rows). Membership = PSM count > 0 in >= 1 of the 2 proliferating (SP-23) runs (1,285 proteins; 1,070 in both). Senescent (SP-59) runs kept as non-membership measurements. Every one of the 1,501 rows has senescent PSMs and none is proliferating-only, so the sheet appears restricted to proteins detected in senescent cells.	supp_gad.302570.117_Supplemental_Table_S1.xlsx: SP		WI-38 fibroblasts, proliferating (PDL23) / baseline proliferating, Pierce cell-surface biotinylation: # PSM SP-23-1, # PSM SP-23-2 (min_observed 1) | WI-38 fibroblasts, replicative senescent (PDL59) / replicative senescence, Pierce cell-surface biotinylation (not used for membership): # PSM SP-59-1, # PSM SP-59-2 (min_observed 1)	1275	156	0.1223529411764706	0.2	Homo sapiens		0	0	1275
kim-wi38-surface-2017--replicative-senescence-pierce-cell-surface-biotinylation	WI-38 fibroblast Pierce Cell Surface Protein Isolation (sulfo-NHS-SS-biotin) · replicative senescence	Kim et al. 2017	Kim KM	2017	28877934	10.1101/gad.302570.117	perturbed	replicative senescence	senescence arm of kim-wi38-surface-2017; shown, not counted. Membership follows the parent recipe's rule for this sample group.	none (supplementary table only)		supp_gad.302570.117_Supplemental_Table_S1.xlsx sheet Table1B_surface fraction in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5630018/supplementaryFiles>	Pierce Cell Surface Protein Isolation Kit (sulfo-NHS-SS-biotin on intact cells, NeutrAvidin agarose)	Method read from: Supplemental Material PDF, 'Isolation of cell membrane and cell surface proteins...' (PMC5630018).	NeutrAvidin agarose (kit)	not stated	not stated in accessible text		Where we looked for the instrument: PMC5630018 MS methods deferred to Supplemental Material (not accessible); genesdev page gave no text.	WI-38 fibroblasts, replicative senescent (PDL59)	WI-38 fibroblasts, replicative senescent (PDL59), replicative senescence, Pierce cell-surface biotinylation: a non-baseline state of kim-wi38-surface-2017, listed when observed in at least 1 of its 2 samples				1490	182	0.1221476510067114		Homo sapiens		0	0	1490
niehage-dpsc-2016	Dental pulp MSC sulfo-NHS-SS-biotin surfaceome	Niehage et al. 2016	Niehage C	2016	27490675	10.1371/journal.pone.0159824	held	the pull-downs are barely enriched over total lysate	Live-cell sulfo-NHS-SS-biotin capture of primary normal stromal cells; S5 is the full MaxQuant table before the authors' GO-based surface selection. Held: the pull-downs are barely enriched (16.7% of the 3,348 members are in the canonical+likely surfaceome vs 13.5% of total-lysate detections) and the no-biotin controls recover 2,691 of the 3,348 members at >= 2 of 3; membership is not control-subtracted. Controls and lysates are carried as measurements for a later enrichment rule.	none found		niehage_S5_leading_accession.tsv	Sulfo-NHS-SS-biotin on intact cells, streptavidin pull-down, SDS-PAGE fractionation; label-free LC-MS/MS, MaxQuant. No-biotin pull-down controls and total lysates run in parallel.	Method summarized from the paper (PMC4973913) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	LTQ Orbitrap XL	label-free LC-MS/MS	Instrument as named in the paper's Methods (full text PMC4973913).	Primary human dental pulp mesenchymal stromal cells, expanded in 10% FCS or 2% serum basic expansion medium	S5 Table 'ProteinGroups' (4,091 groups); rows flagged Only identified by site, Reverse or Contaminant removed; membership = razor+unique peptides > 0 in >= 2 of 3 biotin pull-downs of a medium. No-biotin controls and total lysates kept as measurements only.	niehage_S5_leading_accession.tsv: leading_accession	drop rows flagged Only identified by site, Reverse, Contaminant	dental pulp MSC (10% FCS) / baseline intact-cell surface biotinylation: Razor + unique Peptides B10D, Razor + unique Peptides B10H, Razor + unique Peptides B10L (min_observed 2) | dental pulp MSC (2% serum) / baseline intact-cell surface biotinylation: Razor + unique Peptides B2C, Razor + unique Peptides B2G, Razor + unique Peptides B2K (min_observed 2) | dental pulp MSC (10% FCS) / no-biotin pull-down control: Razor + unique Peptides C10B, Razor + unique Peptides C10F, Razor + unique Peptides C10J (min_observed 2) | dental pulp MSC (2% serum) / no-biotin pull-down control: Razor + unique Peptides C2A, Razor + unique Peptides C2E, Razor + unique Peptides C2I (min_observed 2) | dental pulp MSC (10% FCS) / total lysate: Razor + unique Peptides T10F, Razor + unique Peptides T10G, Razor + unique Peptides T10H, Razor + unique Peptides T10I, Razor + unique Peptides T10J (min_observed 2) | dental pulp MSC (2% serum) / total lysate: Razor + unique Peptides T2A, Razor + unique Peptides T2B, Razor + unique Peptides T2C, Razor + unique Peptides T2D, Razor + unique Peptides T2E (min_observed 2)	3326	562	0.16897173782321107	0.2	Homo sapiens		0	0	3326
chhuon-hela-raft-2016	HeLa (wt/F508del CFTR) detergent-resistant lipid-raft microdomains, SILAC	Chhuon et al. 2016	Chhuon C	2016	27626054	10.1016/j.dib.2016.08.012	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Detergent-resistant membrane (lipid raft) fraction from lysed cells; complementary only. The list is restricted to proteins SILAC-quantified in all four experiments, so it is a quantified core rather than every identification.	none (supplementary tables only)		mmc3.xlsx sheet Table II in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5011161/supplementaryFiles>	Detergent-resistant LRM from sucrose density gradient after lysis	Method read from: Data Brief sections 1, 2.1 and Fig. 1 (PMC5011161); detergent and gradient details deferred to Chhuon 2016 J Proteomics.	none	not stated	LTQ Orbitrap Velos	DDA, nanoUPLC RSLC U3000	Instrument as named in the paper's Data acquisition table (full text PMC5011161).	HeLa cells with inducible wt-CFTR or F508del-CFTR (pooled by SILAC mixing)	Supplementary Table II (mmc3.xlsx) 'Total LRM proteins', 332 protein groups; header row 5 with columns renamed by position. Every row is quantified in both untreated and both TNF-alpha experiments. Membership = quantified peptides > 0 in both untreated experiments (2 of 2). TNF-alpha arm kept as non-membership measurements. wt-CFTR and F508del-CFTR cells are mixed before fractionation and cannot be separated. Table I (mmc2, subcellular-fraction total proteome) not used.	mmc3.xlsx: Accession		HeLa wt-CFTR + F508del-CFTR (SILAC pool) / baseline untreated lipid-raft microdomains: Peptides untreated n1, Peptides untreated n2 (min_observed 2) | HeLa wt-CFTR + F508del-CFTR (SILAC pool) / TNF-alpha 10 min lipid-raft microdomains (not used for membership): Peptides TNF10 n1, Peptides TNF10 n2 (min_observed 2)	331	79	0.23867069486404835	0.2	Homo sapiens		0	0	331
sun-hela-seel-chase-2016	HeLa one-step SEEL with no-enzyme controls, 0 h and 16 h chase	Sun et al. 2016	Sun T	2016	27541995	10.1021/jacs.6b04049	core		Intact-cell one-step SEEL on unperturbed HeLa at time zero defines membership; the no-enzyme control is kept as measurements so the label-vs-control contrast can be read (204 accessions in the 0 h control). Chase and chloroquine arms are perturbed and excluded from membership.	none (supporting information PDF only)		ja6b04049_si_001.pdf <https://pubs.acs.org/doi/suppl/10.1021/jacs.6b04049/suppl_file/ja6b04049_si_001.pdf> | sun_table_s7_by_condition.tsv	recombinant ST6Gal1 with CMP-Neu5Ac-9-biotin (one-step) or CMP-Neu5Ac-9N3 then S-DIBO-biotin (two-step) on live adherent HeLa cells; RIPA lysis; streptavidin capture; on-bead trypsin; LC-MS/MS, ProteoIQ 1% protein FDR; proteins detected in no-enzyme negative controls removed from the final lists	Method read from: PMC5067740 Europe PMC full text (Results, Experimental section) and SI Tables S1, S7, S8.	streptavidin agarose	not reported	Orbitrap Fusion Tribrid	180-min gradient, Top-Speed, ion-trap MS2	Instrument as named in the paper's Methods (full text PMC5067740).	HeLa cervical adenocarcinoma cell line	SI Table S7 (PDF pages S44-S92, 'negative controls included'): 2,122 records over 3 conditions x SEEL/Control; rolled up to one row per accession (max total spectra and record count per condition x label). Membership = detected in the 0 h SEEL sample (471 accessions; paper's control-subtracted time-zero list is 282). 0 h control, 16 h chase and 16 h chase + chloroquine samples (SEEL and control) are measurements only.	sun_table_s7_by_condition.tsv: uniprot_accession		HeLa / baseline one-step SEEL, 0 h: spectra_0h_SEEL (min_observed 1) | HeLa / no-enzyme control, 0 h (not used for membership): spectra_0h_Control (min_observed 1) | HeLa / 16 h chase after labeling, SEEL and control (not used for membership): spectra_16h_chase_SEEL, spectra_16h_chase_Control (min_observed 1) | HeLa / 16 h chase with chloroquine, SEEL and control (not used for membership): spectra_16h_chase_chloroquine_SEEL, spectra_16h_chase_chloroquine_Control (min_observed 1)	456	241	0.5285087719298246	0.2	Homo sapiens		0	10	456
sun-hela-seel-2016	HeLa one-step and two-step SEEL sialoglycoprotein surfaceome	Sun et al. 2016	Sun T	2016	27541995	10.1021/jacs.6b04049	core		Intact-cell enzymatic tagging of surface sialylation sites on live, unperturbed HeLa cells; Table S1 is the complete list per method after the no-enzyme control subtraction (an experimental control, not an annotation filter), including non-surface hits (UTP20, PES1).	none (supporting information PDF only)		ja6b04049_si_001.pdf <https://pubs.acs.org/doi/suppl/10.1021/jacs.6b04049/suppl_file/ja6b04049_si_001.pdf> | sun_table_s1_seel.tsv	recombinant ST6Gal1 with CMP-Neu5Ac-9-biotin (one-step) or CMP-Neu5Ac-9N3 then S-DIBO-biotin (two-step) on live adherent HeLa cells; RIPA lysis; streptavidin capture; on-bead trypsin; LC-MS/MS, ProteoIQ 1% protein FDR; proteins detected in no-enzyme negative controls removed from the final lists	Method read from: PMC5067740 Europe PMC full text (Results, Experimental section) and SI Tables S1, S7, S8.	streptavidin agarose	not reported	Orbitrap Fusion Tribrid	180-min gradient, Top-Speed, ion-trap MS2	Instrument as named in the paper's Methods (full text PMC5067740).	HeLa cervical adenocarcinoma cell line	SI Table S1 (PDF pages S4-S10): 320 proteins, of which 294 one-step SEEL and 180 two-step SEEL (paper text: 294 and 174), after the authors removed proteins detected in the no-enzyme negative controls (label-vs-control subtraction, not annotation). Membership = spectral count reported for the method. Table S8 (HEK293F SEEL vs sulfo-NHS-LC-biotin) lists only proteins annotated 'Cell surface protein' and is not used.	sun_table_s1_seel.tsv: uniprot_accession		HeLa / baseline one-step SEEL (ST6Gal1, CMP-Neu5Ac-9-biotin): spectral_count_one_step (min_observed 1) | HeLa / baseline two-step SEEL (ST6Gal1, CMP-Neu5Ac-9-azide then S-DIBO-biotin): spectral_count_two_step (min_observed 1)	315	224	0.7111111111111111	0.2	Homo sapiens		0	3	315
xiao-hepg2-galnaz-2016	HepG2 metabolic GalNAz click surface N-glycosites	Xiao et al. 2016	Xiao H	2016	26894747	10.1021/acs.analchem.5b04871	core		Same Wu-lab metabolic-labeling plus copper-free click design as smeekens-hek293t-galnaz-2015: the azide is tagged on living cells so only surface-exposed glycans are captured; untreated HepG2, full site identification list for the GalNAz arm, not selected by annotation. The three sugar arms are separate labeling experiments on the same line and are recorded as separate studies.	none (supplementary tables only)		ac5b04871_si_002.xlsx sheet Total Sites <https://pubs.acs.org/doi/10.1021/acs.analchem.5b04871>	metabolic GalNAz labeling then copper-free click on cell-surface azido-glycans, streptavidin glycopeptide enrichment, PNGase F release	Method read from: Europe PMC abstract and the Supporting Table titles ('N-glycosylation sites on cell-surface proteins'); full text paywalled (ACS) and not read, the click-on-live-cells step is inferred from the abstract and the same lab's protocol (Smeekens 2015).	streptavidin	not stated	not stated in accessible text		Where we looked for the instrument: ACS refused automated access; Europe PMC abstract has no instrument; no free full text in PubMed Central.	HepG2 hepatocellular carcinoma cell line	Supporting Table S1 (ac5b04871_si_002.xlsx, sheet 'Total Sites'): all 590 N-glycosylation sites identified on the cell surface of untreated HepG2 cells labeled with GalNAz, one protein per site row, with Y/N identification flags for the two biological experiments. Membership = site identified in either experiment (the Y/N flags are not numeric, so per-experiment replicate counting is not applied). Tables S4-S5 (atorvastatin vs control SILAC ratios) not used. No annotation filter.	ac5b04871_si_002.xlsx: UniProt name			274	184	0.6715328467153284	0.2	Homo sapiens		0	0	274
xiao-hepg2-glcnaz-2016	HepG2 metabolic GlcNAz click surface N-glycosites	Xiao et al. 2016	Xiao H	2016	26894747	10.1021/acs.analchem.5b04871	core		Same Wu-lab metabolic-labeling plus copper-free click design as smeekens-hek293t-galnaz-2015: the azide is tagged on living cells so only surface-exposed glycans are captured; untreated HepG2, full site identification list for the GlcNAz arm, not selected by annotation. The three sugar arms are separate labeling experiments on the same line and are recorded as separate studies.	none (supplementary tables only)		ac5b04871_si_004.xlsx sheet Total Sites <https://pubs.acs.org/doi/10.1021/acs.analchem.5b04871>	metabolic GlcNAz labeling then copper-free click on cell-surface azido-glycans, streptavidin glycopeptide enrichment, PNGase F release	Method read from: Europe PMC abstract and the Supporting Table titles ('N-glycosylation sites on cell-surface proteins'); full text paywalled (ACS) and not read, the click-on-live-cells step is inferred from the abstract and the same lab's protocol (Smeekens 2015).	streptavidin	not stated	not stated in accessible text		Where we looked for the instrument: ACS refused automated access; Europe PMC abstract has no instrument; no free full text in PubMed Central.	HepG2 hepatocellular carcinoma cell line	Supporting Table S3 (ac5b04871_si_004.xlsx, sheet 'Total Sites'): all 117 N-glycosylation sites identified on the cell surface of untreated HepG2 cells labeled with GlcNAz, one protein per site row, with Y/N identification flags for the two biological experiments. Membership = site identified in either experiment (the Y/N flags are not numeric, so per-experiment replicate counting is not applied). Tables S4-S5 (atorvastatin vs control SILAC ratios) not used. No annotation filter.	ac5b04871_si_004.xlsx: UniProt name			91	35	0.38461538461538464	0.2	Homo sapiens		0	0	91
xiao-hepg2-mannaz-2016	HepG2 metabolic ManNAz click surface N-glycosites	Xiao et al. 2016	Xiao H	2016	26894747	10.1021/acs.analchem.5b04871	core		Same Wu-lab metabolic-labeling plus copper-free click design as smeekens-hek293t-galnaz-2015: the azide is tagged on living cells so only surface-exposed glycans are captured; untreated HepG2, full site identification list for the ManNAz arm, not selected by annotation. The three sugar arms are separate labeling experiments on the same line and are recorded as separate studies.	none (supplementary tables only)		ac5b04871_si_003.xlsx sheet Total Sites <https://pubs.acs.org/doi/10.1021/acs.analchem.5b04871>	metabolic ManNAz labeling then copper-free click on cell-surface azido-glycans, streptavidin glycopeptide enrichment, PNGase F release	Method read from: Europe PMC abstract and the Supporting Table titles ('N-glycosylation sites on cell-surface proteins'); full text paywalled (ACS) and not read, the click-on-live-cells step is inferred from the abstract and the same lab's protocol (Smeekens 2015).	streptavidin	not stated	not stated in accessible text		Where we looked for the instrument: ACS refused automated access; Europe PMC abstract has no instrument; no free full text in PubMed Central.	HepG2 hepatocellular carcinoma cell line	Supporting Table S2 (ac5b04871_si_003.xlsx, sheet 'Total Sites'): all 446 N-glycosylation sites identified on the cell surface of untreated HepG2 cells labeled with ManNAz, one protein per site row, with Y/N identification flags for the two biological experiments. Membership = site identified in either experiment (the Y/N flags are not numeric, so per-experiment replicate counting is not applied). Tables S4-S5 (atorvastatin vs control SILAC ratios) not used. No annotation filter.	ac5b04871_si_003.xlsx: UniProt name			218	166	0.7614678899082569	0.2	Homo sapiens		0	1	218
szklanna-platelet-drm-2016--agonist-activated-platelet-detergent-resistant-membranes	Human platelet detergent-resistant membranes, label-free · agonist-activated platelet detergent-resistant membranes	Szklanna et al. 2016	Szklanna PB	2016	27329341	10.1002/pmic.201500309	perturbed	differentiation or activation: agonist-activated platelet detergent-resistant membranes	differentiation or activation arm of szklanna-platelet-drm-2016; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD002554	szklanna_drm_donor_lfq.tsv	Triton X-100 lysis, sucrose density gradient DRM (flotillin-1) fractions, MaxQuant LFQ	Method read from: PubMed abstract and PRIDE PXD002554 protocol (full text not open access; not read); design read from the MaxQuant summary.txt experiment names (R_/A_ donor.replicate).	none	not stated	Q Exactive		Instrument as listed in the ProteomeXchange record PXD002554.	platelet	platelet, agonist-activated platelet detergent-resistant membranes: a non-baseline state of szklanna-platelet-drm-2016, listed when observed in at least 2 of its 3 samples				145	30	0.20689655172413793		Homo sapiens		0	3	145
szklanna-platelet-drm-2016	Human platelet detergent-resistant membranes, label-free · resting platelet detergent-resistant membranes (baseline)	Szklanna et al. 2016	Szklanna PB	2016	27329341	10.1002/pmic.201500309	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Detergent lysis then sucrose-gradient DRM isolation, so complementary by family policy (plasma and internal membrane rafts). Resting platelets are the unperturbed baseline; activation is an agonist perturbation. First platelet input.	PRIDE	PXD002554	szklanna_drm_donor_lfq.tsv	Triton X-100 lysis, sucrose density gradient DRM (flotillin-1) fractions, MaxQuant LFQ	Method read from: PubMed abstract and PRIDE PXD002554 protocol (full text not open access; not read); design read from the MaxQuant summary.txt experiment names (R_/A_ donor.replicate).	none	not stated	Q Exactive		Instrument as listed in the ProteomeXchange record PXD002554.	Primary human platelets from healthy donors	PRIDE SEARCHRESULTStxt.rar member 'SEARCH RESULTStxt/proteinGroups.txt' (MaxQuant; 418 groups, 18 runs = 3 donors x 3 technical replicates x resting/activated). Reverse, contaminant and only-by-site groups removed (318). Technical replicates collapsed per donor (LFQ intensity > 0 in >= 2 of 3). Membership = resting-platelet DRM observed in >= 2 of 3 donors: 141 groups, equal to the paper's 141 proteins. Activated platelets kept as measurements only. proteinGroups2.txt (same groups) not used.	szklanna_drm_donor_lfq.tsv: Protein IDs		platelet / resting platelet detergent-resistant membranes: resting donor 1, resting donor 2, resting donor 3 (min_observed 2) | platelet / agonist-activated platelet detergent-resistant membranes (not used for membership): activated donor 1, activated donor 2, activated donor 3 (min_observed 2)	136	26	0.19117647058823528	0.2	Homo sapiens		0	4	136
hoare-imr90-pmp-2016	IMR90 fibroblast plasma membrane profiling, growing vs HRAS-G12V senescent, SILAC	Hoare et al. 2016	Hoare M	2016	27525720	10.1038/ncb3397	core		Weekes-lab PMP (same chemistry as Depierreux, Soh, Hunter) on normal diploid fibroblasts. Identification comes from the SILAC mix of growing and senescent cells, but every member carries an RIS/Growing ratio, so it was quantified in the untreated growing channel, the same standard applied to TMT mock channels. Rebuilt on 2026-11-18 from the authors' compiled results, which the corresponding author identified as the final dataset.	PRIDE	PXD004168	All_4_SILAC_Final.xlsx sheet Compiled results | All_4_SILAC_Final.uniprot_mapped.tsv	Live-cell sodium periodate / aminooxy-biotin (PMP), streptavidin agarose	Method as described in the paper's Methods 'Plasma membrane proteomics', 'Proteomic Analysis' (PMC5008465); table: the authors' compiled results (All_4_SILAC_Final.xlsx), provided by M. Hoare 2026-11-17.	high-affinity streptavidin agarose (Pierce)	not stated	LTQ Orbitrap		Instrument as listed in the ProteomeXchange record PXD004168.	IMR90 human fetal lung diploid fibroblasts expressing 4OHT-inducible ER:HRAS-G12V	Authors' compiled results ('Compiled results' sheet of All_4_SILAC_Final.xlsx, provided by M. Hoare on 2026-11-17 as the final growing-vs-senescent dataset; 1,504 protein groups across four independent SILAC experiments A-D, of which the published Supplementary Table 1 is the 'high-confidence' subset). Membership = peptides > 0 in >= 2 of the 4 experiments, the compendium's usual replicate rule. The ER:HRAS-G12V construct protein groups (ESR1; HRAS;NRAS;KRAS) are set aside because the construct's own expression cannot be told apart from the endogenous proteins. Per-experiment log2 RIS/growing ratios and experiment B's log2 etoposide/growing ratio are carried as non-membership measurements. Intensities are each experiment's combined-channel (SILAC mix) intensity, log10. Raw data: PRIDE PXD004168. Proteins are mapped by their first reported gene symbol through HGNC (as for Buhl 2026), because the compiled sheet's leading accessions include unreviewed TrEMBL fragments the pinned UniProt table does not carry.	All_4_SILAC_Final.uniprot_mapped.tsv: uniprot_mapped	drop rows where Gene Names matches ^(?:ESR1|HRAS;NRAS;KRAS)$	IMR90 ER:HRAS-G12V fibroblasts / growing and RIS cells SILAC-mixed; growing channel quantified (RIS/Growing ratio present): Pep H/M MattA, Pep M/L MattB, Pep H/L MattC, Pep H/L MattD (min_observed 2) | IMR90 ER:HRAS-G12V fibroblasts / log2 RIS/Growing SILAC ratio (not used for membership): Ratio H/M MattA, Ratio M/L MattB, Ratio H/L MattC, Ratio H/L MattD (min_observed 1) | IMR90 ER:HRAS-G12V fibroblasts / log2 etoposide-induced senescence/Growing SILAC ratio, experiment B (not used for membership): Matt B Ratio H/L norm (min_observed 1)	591	338	0.571912013536379	0.2	Homo sapiens		0	0	591
ye-mcf10a-membrane-2016	MCF10A carbonate-washed crude membrane shotgun proteome · empty-vector control (baseline)	Ye et al. 2016	Ye X	2016	27894102	10.18632/oncotarget.13566	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Carbonate-washed crude ultracentrifugation membrane from lysed cells, not a surface label; complementary only.	none (supplementary tables only)		oncotarget-07-86948-s002.xlsx sheet Table S-6 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5341332/supplementaryFiles> | oncotarget-07-86948-s002.xlsx sheet Table S-5 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5341332/supplementaryFiles>	lysis + ultracentrifugation crude membrane, carbonate wash	Method as described in the paper's Methods 'SGM proteomics: sample preparation' (full text PMC5341332).	none	n/a	Orbitrap Elite	LC-MS of CSC and membrane fractions; LTQ Orbitrap Elite also used for PRM of XPR1	Instrument as named in the paper's Methods (full text PMC5341332).	MCF10A non-transformed breast epithelial cells transduced with empty vector (control) or KRasG12V	Supplementary Tables S5A (MCF10A-KRasG12V, 4,869 proteins) and S6A (MCF10A-EV, 4,287 proteins); authors exclude single-PSM proteins. Membership = the EV list; KRasG12V kept as a non-membership measurement. MP/CSP/G-CSP/CD columns are annotations only and do not select rows.	oncotarget-07-86948-s002.xlsx: Acc #2 | oncotarget-07-86948-s002.xlsx: Acc #2		MCF10A-EV / baseline empty-vector control, crude membrane: # PSMs4 (min_observed 1) | MCF10A-KRasG12V / oncogenic KRasG12V transduced (not used for membership): # PSMs4 (min_observed 1)	4278	356	0.08321645628798503	0.2	Homo sapiens		0	0	4278
ye-mcf10a-membrane-2016--oncogenic-krasg12v-transduced	MCF10A carbonate-washed crude membrane shotgun proteome · oncogenic KRasG12V transduced	Ye et al. 2016	Ye X	2016	27894102	10.18632/oncotarget.13566	perturbed	genetic perturbation: oncogenic KRasG12V transduced	genetic perturbation arm of ye-mcf10a-membrane-2016; shown, not counted. Membership follows the parent recipe's rule for this sample group.	none (supplementary tables only)		oncotarget-07-86948-s002.xlsx sheet Table S-6 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5341332/supplementaryFiles> | oncotarget-07-86948-s002.xlsx sheet Table S-5 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5341332/supplementaryFiles>	lysis + ultracentrifugation crude membrane, carbonate wash	Method as described in the paper's Methods 'SGM proteomics: sample preparation' (full text PMC5341332).	none	n/a	Orbitrap Elite	LC-MS of CSC and membrane fractions; LTQ Orbitrap Elite also used for PRM of XPR1	Instrument as named in the paper's Methods (full text PMC5341332).	MCF10A-KRasG12V	MCF10A-KRasG12V, oncogenic KRasG12V transduced: a non-baseline state of ye-mcf10a-membrane-2016, listed when observed in at least 1 of its 1 samples				4855	452	0.09309989701338826		Homo sapiens		0	0	4855
ye-mcf10a-csc-2016	MCF10A hydrazide cell surface capture · empty-vector control (baseline)	Ye et al. 2016	Ye X	2016	27894102	10.18632/oncotarget.13566	core		Intact-cell hydrazide CSC with observed per-line identification lists; membership rests on the empty-vector control line, KRasG12V carried as a perturbed arm. Per-replicate detection is not reported (PSMs summed over two preparations), and there is no no-label control.	none (supplementary tables only)		oncotarget-07-86948-s002.xlsx sheet Table S-2 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5341332/supplementaryFiles> | oncotarget-07-86948-s002.xlsx sheet Table S-1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5341332/supplementaryFiles>	hydrazide CSC (periodate, biocytin hydrazide, PNGase F glycopeptide release) on suspended live cells	Method as described in the paper's Methods 'CSC technology: sample preparation' and Results; Tables S1A/S2A (full text PMC5341332).	Streptavidin Plus UltraLink Resin (Pierce)	not stated	Orbitrap Elite	LC-MS of CSC and membrane fractions; LTQ Orbitrap Elite also used for PRM of XPR1	Instrument as named in the paper's Methods (full text PMC5341332).	MCF10A non-transformed breast epithelial cells transduced with empty vector (control) or KRasG12V	Supplementary Tables S1A (MCF10A-KRasG12V, 148 glycoproteins) and S2A (MCF10A-EV, 122 glycoproteins) protein lists; authors already require >= 2 PSMs and a deamidated NxS/T glycopeptide. Membership = the EV (empty-vector control) list; the KRasG12V list is kept as a non-membership measurement. CSPA/CD columns are annotations only and do not select rows (3 non-CSPA rows retained).	oncotarget-07-86948-s002.xlsx: Acc #2 | oncotarget-07-86948-s002.xlsx: Acc #2		MCF10A-EV / baseline empty-vector control, CSC: # PSMs4 (min_observed 1) | MCF10A-KRasG12V / oncogenic KRasG12V transduced (not used for membership): # PSMs4 (min_observed 1)	122	98	0.8032786885245902	0.2	Homo sapiens		0	0	122
ye-mcf10a-csc-2016--oncogenic-krasg12v-transduced	MCF10A hydrazide cell surface capture · oncogenic KRasG12V transduced	Ye et al. 2016	Ye X	2016	27894102	10.18632/oncotarget.13566	perturbed	genetic perturbation: oncogenic KRasG12V transduced	genetic perturbation arm of ye-mcf10a-csc-2016; shown, not counted. Membership follows the parent recipe's rule for this sample group.	none (supplementary tables only)		oncotarget-07-86948-s002.xlsx sheet Table S-2 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5341332/supplementaryFiles> | oncotarget-07-86948-s002.xlsx sheet Table S-1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5341332/supplementaryFiles>	hydrazide CSC (periodate, biocytin hydrazide, PNGase F glycopeptide release) on suspended live cells	Method as described in the paper's Methods 'CSC technology: sample preparation' and Results; Tables S1A/S2A (full text PMC5341332).	Streptavidin Plus UltraLink Resin (Pierce)	not stated	Orbitrap Elite	LC-MS of CSC and membrane fractions; LTQ Orbitrap Elite also used for PRM of XPR1	Instrument as named in the paper's Methods (full text PMC5341332).	MCF10A-KRasG12V	MCF10A-KRasG12V, oncogenic KRasG12V transduced: a non-baseline state of ye-mcf10a-csc-2016, listed when observed in at least 1 of its 1 samples				148	134	0.9054054054054054		Homo sapiens		0	0	148
tyleckova-npc-2016	Neural precursor and hNT neuron CSC surfaceome, Veneer reanalysis	Tyleckova et al. 2016	Tyleckova J	2016	26581640	10.1016/j.jprot.2015.11.008	annotation_selected	author pre-filtered to annotated surface proteins	Intact-cell CSC, but the only public list is the authors' reported surface set as republished by Veneer, pooled across differentiation stages; held like kalxdorf-2017 and leung-2019 (Veneer S9/S10). The original paper has no deposited or supplementary protein table.	none (list from the Veneer reanalysis, Table S1 of Gundry lab JPR 2024)		pr3c00800_si_002.xlsx sheet Table S11 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC11301670/supplementaryFiles>	Cell surface capture (biocytin hydrazide on intact cells); protein list as reported in the original study, with Veneer surface-assignment tiers.	Method summarized from the paper (10.1016/j.jprot.2015.11.008) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	not stated in accessible text		Where we looked for the instrument: Europe PMC abstract only (no free full text); publisher page via DOI blocked (refused automated access) or served no readable text.	Pluripotent-stem-cell-derived (NTERA-2) neural precursors across neuronal differentiation and post-mitotic hNT neurons	Veneer (PMID 38412263) Supplementary Table S11: the 522 cell-surface proteins reported in the original study, all tiers; conditions pooled	pr3c00800_si_002.xlsx: Protein accessions			521	302	0.5796545105566219	0.2	Homo sapiens		0	0	521
mallanna-2016	Primary hepatocyte CSC	Mallanna et al. 2016	Mallanna SK	2016	27569060	10.1016/j.stemcr.2016.07.016	core		Original identification and specimen caveats retained in previous_reason.	supplement		control_surface_proteins.tsv	Cell Surface Capture Technology (Wollscheid/Gundry CSC) on live primary human hepatocytes (~100 million cryopreserved primary hepatocytes, lots Hu8176, Hu1443, Hu1460 and Hu1736 from Life Technologies): oligosaccharides on extracellular domains of surface glycoproteins biotinylated on live cells (periodate oxidation + biocytin hydrazide per the Gundry protocol), tryptic digestion, biotinylated glycopeptides enriched on immobilized streptavidin, formerly N-glycosylated peptides released with PNGase F and identified by high-mass-accuracy LC-MS/MS (deamidated-Asn sequon evidence). Reagent-level details are in the Supplemental Experimental Procedures.	Method as described in the paper's Results 'Cell-Surface N-Glycoproteins on Primary Human Hepatocytes' and Figure 2A (Stem Cell Reports 2016; full text PMC5032032).	immobilized streptavidin (product per Gundry-lab CSC protocol; not stated in main text)	not reported	not stated in accessible text		Where we looked for the instrument: PMC5032032 text says only MS data acquisition by co-author; methods in supplement not accessible; Cell Press refused automated access.	Primary hepatocytes	primary human hepatocytes	control_surface_proteins.tsv: uniprot_accession			300	198	0.66	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			300
wang-aml-surface-2015	AML patient leukemia cell surface sulfo-NHS-SS-biotin capture, absolute quantification	Wang and Hanash 2015	Wang H	2015	25794949	10.1016/j.ymeth.2015.03.007	held	the total-lysate table needed to remove contaminants isn't public	Intact-cell sulfo-NHS-SS-biotin capture on untreated primary AML cells, full quantified list before any annotation. The authors state that proteins not enriched over the total cell extract are contaminants from lysed cells and circulating proteins, and that TCE table is not public, so the list is the raw capture (5,340 forms) with known lysis carry-over (6.9% canonical+likely). Held: the authors' own surface membership needs the surface-vs-TCE enrichment comparison, which cannot be made from the public file; an author request for the TCE sheet would resolve it.	none (supplementary tables only)		NIHMS742214-supplement-Supplementary_Table_1.xlsx sheet IPAS_575_Surface_Quantified <https://pmc.ncbi.nlm.nih.gov/articles/PMC4678004/>	sulfo-NHS-SS-biotin 0.25 mg/mL in PBS 10 min RT on cells, lysine quench, OG lysis, avidin capture	Method read from: PMC4678004 sections 2.1, 2.3 ('In vitro labeling for cell-surface protein isolation'), 2.8, 3.1-3.2.	avidin affinity chromatography	not stated	SYNAPT G2-S	Waters nanoAcquity UPLC coupled to SYNAPT G2-S, LC-HDMSE ion mobility label-free quantification	Instrument as named in the paper's Methods 2.6-2.7 (full text PMC4678004).	Primary acute myeloid leukemia cell population from one patient (sample IPAS_575)	Supplementary Table 1 sheet 'IPAS_575_Surface_Quantified': all 5,340 protein forms quantified (Hi3 fmol, <= 5% FDR) in the cell-surface (avidin-captured) compartment of one AML leukemia cell population. Membership = fmol > 0 (every row). The TCE comparison the authors use to flag contaminants is not in the public file, so no enrichment filter can be applied; Supplementary Table 2 (CD/HLA subsets) not used. Accessions include TrEMBL entries. No annotation filter.	NIHMS742214-supplement-Supplementary_Table_1.xlsx: Accession		AML patient leukemia cells (IPAS_575) / baseline sulfo-NHS-SS-biotin cell-surface capture: fmol (min_observed 1)	4176	379	0.09075670498084291	0.2	Homo sapiens		0	185	4176
ross-arpe19-2015--a-769662-ampk-activator-90-min	ARPE-19 retinal pigment epithelium sulfo-NHS-SS-biotin surfaceome · A-769662 AMPK activator 90 min	Ross et al. 2015	Ross E	2015	26010094	10.1371/journal.pone.0128013	perturbed	drug, ligand or treatment: A-769662 AMPK activator 90 min	drug, ligand or treatment arm of ross-arpe19-2015; shown, not counted. Membership follows the parent recipe's rule for this sample group.	none (supplementary tables only)		ross_s1_stacked.tsv | ross_s1_stacked.uniprot_mapped.tsv	sulfo-NHS-SS-biotin on intact cells, 4 C	Method as described in the paper's Results ('838 proteins', background subtraction) and Methods (mass spectrometry); S1 Table (full text PMC4444004).	streptavidin (not named in text)	not stated	LTQ XL ion trap (Thermo)	LC-MS/MS with Agilent 1100 HPLC	Instrument as named in the paper's Methods (full text PMC4444004).	ARPE-19	ARPE-19, A-769662 AMPK activator 90 min: a non-baseline state of ross-arpe19-2015, listed when observed in at least 1 of its 1 samples				142	16	0.11267605633802817		Homo sapiens		0	0	142
ross-arpe19-2015	ARPE-19 retinal pigment epithelium sulfo-NHS-SS-biotin surfaceome · untreated (baseline)	Ross et al. 2015	Ross E	2015	26010094	10.1371/journal.pone.0128013	below_screen	11% Canonical or Likely proteins, under 20%	Intact-cell sulfo-NHS-SS-biotin capture with a no-biotin background pull-down; S1 is the complete identification list with per-condition peptide counts, so membership rests on untreated cells. Caveats: low-resolution ion-trap federated search with no stated protein FDR (list includes implausible IDs such as ADAM3A, AICDA), membership already control-subtracted by the authors, and per-replicate detection is not reported.	none (supplementary tables only)		ross_s1_stacked.tsv | ross_s1_stacked.uniprot_mapped.tsv	sulfo-NHS-SS-biotin on intact cells, 4 C	Method as described in the paper's Results ('838 proteins', background subtraction) and Methods (mass spectrometry); S1 Table (full text PMC4444004).	streptavidin (not named in text)	not stated	LTQ XL ion trap (Thermo)	LC-MS/MS with Agilent 1100 HPLC	Instrument as named in the paper's Methods (full text PMC4444004).	ARPE-19 retinal pigment epithelial cell line	S1 Table, all three sheets stacked (838 proteins: 653 depleted, 93 enriched, 92 unchanged by A-769662), already background-subtracted by the authors (no-biotin pull-down peptides = 0 for every row). Membership = basal (untreated) peptide count > 0 (745 proteins); A-769662-treated counts kept as a non-membership measurement. Gene symbols mapped through gene_resolver; 84 Ensembl-only cells use the symbol printed in the description.	ross_s1_stacked.uniprot_mapped.tsv: uniprot_mapped		ARPE-19 / baseline untreated, sulfo-NHS-SS-biotin: basal_peptides (min_observed 1) | ARPE-19 / A-769662 AMPK activator 90 min (not used for membership): a769662_peptides (min_observed 1)	554	61	0.11010830324909747	0.2	Homo sapiens		0	0	554
holley-msc-2015	Bone-marrow MSC and perivascular-cell membrane fraction	Holley et al. 2015	Holley RJ	2015	25684225	10.1016/j.stemcr.2015.01.007	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Membrane-enriched subcellular fraction, not a surface label. Ensembl protein IDs are joined through the reported gene symbol. iTRAQ pools samples in each plex, so per-cell-type detection is not recoverable.	not verified		mmc2.xlsx sheet TABLE S1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4375938/supplementaryFiles> | mmc2.uniprot_mapped.tsv	Subcellular fractionation to a membrane-enriched fraction, 8-plex iTRAQ, ProteinPilot against Ensembl human.	Method summarized from the paper (PMC4375938) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	not stated in accessible text		Where we looked for the instrument: PMC4375938 main text; PMC supplement not read.	Bone-marrow mesenchymal stromal cells and umbilical-cord perivascular cells (3 donors each) with adult dermal fibroblasts	Table S1 full membrane-enriched iTRAQ dataset; ProteinPilot Unused >= 1.3 (95% protein confidence); identifications pooled across the plexed MSC, HUCPVC and fibroblast samples	mmc2.uniprot_mapped.tsv: uniprot_mapped	Species = Homo sapiens | all Unused ≥ 1.3		5462	661	0.12101794214573416	0.2	Homo sapiens		0	0	5462
matheson-cemt4-pmp-2015	CEM-T4 T-cell plasma membrane profiling, HIV-1 time course	Matheson et al. 2015	Matheson NJ	2015	26439863	10.1016/j.chom.2015.09.003	core		Lehner/Weekes-lab PMP on a T-cell line in one 6-plex with a single uninfected channel; the deposited sheet gives ratios to that channel, finite for all 2,320 rows, so every listed protein had uninfected reporter signal. Membership is the pooled-plex identification list (as for soh-hacat-pmp-2020), not a per-channel detection; no no-label control.	PRIDE	PXD002934	mmc2.xlsx sheet Complete TMT timecourse data in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4608997/supplementaryFiles>	PMP as in Weekes 2013/2014 with 2e7 viable cells per condition; 'one pot' periodate oxidation and aminooxy-biotinylation of live cells, streptavidin bead pulldown, on-bead trypsin; each condition processed separately and TMT-labeled before pooling (6-plex). Dead cells removed by immunomagnetic depletion before PMP.	Method as described in the paper's Experimental Procedures 'Plasma Membrane Enrichment and Peptide Labeling'; Results first section; Figure 1A (full text PMC4608997).	streptavidin beads (product in Supplemental Experimental Procedures, not opened)	not reported	LTQ Orbitrap		Instrument as listed in the ProteomeXchange record PXD002934.	CEM-T4 CD4+ T-lymphoblastoid cell line	Table S1 (mmc2.xlsx) sheet 'Complete TMT timecourse data': all 2,320 proteins quantified in the 6-plex PMP time course (paper: 2,320). Only rows whose UniProt description is Homo sapiens (3 HIV-1 and 1 VSV rows dropped). The sheet reports only ratios to the uninfected 0 h channel; every row has finite ratios, so the uninfected reporter was quantified for every row, but the 0 h channel itself is not tabulated and membership is the pooled-plex identification list. Ratio columns kept as non-membership measurements. GOCC columns not used.	mmc2.xlsx: Accession	drop rows where Description matches OS=(?!Homo sapiens)		2183	493	0.22583600549702246	0.2	Homo sapiens		0	110	2183
cspa-2015	CSPA	Bausch-Fluck et al. 2015	Bausch-Fluck D	2015	25894527	10.1371/journal.pone.0121314	core		Original identification and specimen caveats retained in previous_reason.	PRIDE	PXD000589	S1_File.xlsx sheet Table_B <https://pubmed.ncbi.nlm.nih.gov/25894527/>	Wollscheid Cell Surface Capture across the Cell Surface Protein Atlas cohort (47 human cell types/samples; 1e8 suspension cells, five 15 cm dishes of adherent cells, or 200 mg to 1 g tissue per experiment): live cells treated with 2 mM sodium metaperiodate (Pierce) in PBS pH 6.5 for 15 min at 4 C in the dark, then 6.5 mM biocytin hydrazide (Biotium) for 60 min; Dounce homogenization in hypotonic buffer with iodoacetamide, nuclei removed, membranes pelleted at ~150,000 g; membrane proteins reduced/alkylated and trypsin-digested, biotinylated glycopeptides bound to Streptavidin Plus UltraLink Resin (Pierce), extensively washed, N-glycopeptides released with PNGase F (NEB); LTQ-FT-ICR / LTQ Orbitrap XL, 385 LC-MS/MS runs; only the N-glycopeptide fraction (deamidated sequon) enters the atlas. Some lymphoma lines used a variant with a reductive pre-elution before PNGase F. Table B lists all 1,492 human proteins including category 3 (lower-confidence) entries.	Method as described in the paper's Methods 'Cell Surface Capture' (PLoS One 2015; full text PMC4404347).	Streptavidin Plus UltraLink Resin (Pierce; catalog number not stated); biocytin hydrazide (Biotium)	not reported	LTQ Orbitrap XL; LTQ FT / FT-ICR			Multi-cell-type human atlas: 47 human cell-type/sample summaries, Table B	All 1492 human Table_B proteins, including category 3; 47 cell-type/sample summaries, not 47 biological replicates	S1_File.xlsx: ID_link	Organisme = Human	786-O / steady-state atlas: 786-O (min_observed 1) | A431 / steady-state atlas: A431 (min_observed 1) | Adipocytes / steady-state atlas: Adipocytes (min_observed 1) | B-ALL / steady-state atlas: B-ALL (min_observed 1) | Braintumor / steady-state atlas: Braintumor (min_observed 1) | CaLu3 / steady-state atlas: CaLu3 (min_observed 1) | CD4+CD25-Tcells / steady-state atlas: CD4+CD25-Tcells (min_observed 1) | Glioblastoma / steady-state atlas: Glioblastoma (min_observed 1) | HBL-1 / steady-state atlas: HBL-1 (min_observed 1) | HCC4012 / steady-state atlas: HCC4012 (min_observed 1) | HDLM-2 / steady-state atlas: HDLM-2 (min_observed 1) | HEK / steady-state atlas: HEK (min_observed 1) | HeLa / steady-state atlas: HeLa (min_observed 1) | HL-60 / steady-state atlas: HL-60 (min_observed 1) | hMSC / steady-state atlas: hMSC (min_observed 1) | IMR-32 / steady-state atlas: IMR-32 (min_observed 1) | Jurkat / steady-state atlas: Jurkat (min_observed 1) | KMH2 / steady-state atlas: KMH2 (min_observed 1) | L428 / steady-state atlas: L428 (min_observed 1) | L540 / steady-state atlas: L540 (min_observed 1) | LN18 / steady-state atlas: LN18 (min_observed 1) | LN229 / steady-state atlas: LN229 (min_observed 1) | LNT229 / steady-state atlas: LNT229 (min_observed 1) | Lymphoma / steady-state atlas: Lymphoma (min_observed 1) | MedB1 / steady-state atlas: MedB1 (min_observed 1) | MelanomaAdh / steady-state atlas: MelanomaAdh (min_observed 1) | Melanoma NSph / steady-state atlas: Melanoma NSph (min_observed 1) | NB4 / steady-state atlas: NB4 (min_observed 1) | NK cells / steady-state atlas: NK cells (min_observed 1) | P493-6 / steady-state atlas: P493-6 (min_observed 1) | PASMC / steady-state atlas: PASMC (min_observed 1) | RD / steady-state atlas: RD (min_observed 1) | Rh28 / steady-state atlas: Rh28 (min_observed 1) | RH4 / steady-state atlas: RH4 (min_observed 1) | Ruch-2 / steady-state atlas: Ruch-2 (min_observed 1) | SDM104 / steady-state atlas: SDM104 (min_observed 1) | SDM34 / steady-state atlas: SDM34 (min_observed 1) | SDM4 / steady-state atlas: SDM4 (min_observed 1) | SDM5 / steady-state atlas: SDM5 (min_observed 1) | SU-DHL-6 / steady-state atlas: SU-DHL-6 (min_observed 1) | SU4 (SU-DHL-4) / steady-state atlas: SU4 (SU-DHL-4) (min_observed 1) | T98G / steady-state atlas: T98G (min_observed 1) | U-2 OS / steady-state atlas: U-2 OS (min_observed 1) | U-251 MG / steady-state atlas: U-251 MG (min_observed 1) | U-87 MG / steady-state atlas: U-87 MG (min_observed 1) | U2932 / steady-state atlas: U2932 (min_observed 1) | ZL55 MPM / steady-state atlas: ZL55 MPM (min_observed 1)	1490	918	0.6161073825503356	0.2	Homo sapiens	Paper includes mouse data; only the documented human cell/column subset is retained.			1444
gao-gastric-pm-2015	Gastric cancer and adjacent normal tissue plasma-membrane fraction, TMT	Gao et al. 2015	Gao W	2015	25948494	10.1186/s12885-015-1343-5	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Ultracentrifugation/sucrose plasma-membrane fraction of whole tissue after lysis: total-membrane enrichment, complementary only. Only primary gastric tissue membrane list in the family; tumor and normal pools are not separable in the public table.	none (supplementary tables only)		12885_2015_1343_MOESM1_ESM.xlsx sheet Sheet1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4525731/supplementaryFiles>	hypotonic lysis, 100,000 x g pellet, sucrose-gradient plasma membrane; TMT tumor vs normal pools	Method as described in the paper's Methods 'Plasma membrane purification and protein lysis', 'Patient samples' (pooled separately) (full text PMC4525731).	none	n/a	LTQ Orbitrap Velos	TMT-labeled peptides, nanoACQUITY UPLC	Instrument as named in the paper's Methods, MS analysis (full text PMC4525731).	Gastric adenocarcinoma and adjacent normal gastric tissue (surgical, pooled)	Additional file 1 Table S1 'All of identified proteins' (501 protein groups, MaxQuant, 1% FDR) from one TMT experiment comparing a pooled tumor sample with a pooled adjacent-normal sample. Membership = every listed group (one pooled list; the table gives a single combined Intensity, no per-channel values). The 'Location' (IPA/GO) column is carried and never used to select rows. Table S2 (differential subset) not used.	12885_2015_1343_MOESM1_ESM.xlsx: First protein ID		gastric tissue (tumor + adjacent-normal pools) / plasma-membrane fraction, TMT-pooled tumor and normal: Intensity (min_observed 1)	490	89	0.1816326530612245	0.2	Homo sapiens		0	9	490
smeekens-hek293t-galnaz-2015	HEK293T metabolic GalNAz click surface N-glycosites	Smeekens et al. 2015	Smeekens JM	2015	25425172	10.1007/s13361-014-1016-7	core		Intact-cell click tagging of metabolically azide-labeled glycans with membrane-impermeant DBCO-sulfo-biotin on living cells at 4 C; baseline, unperturbed HEK293T; the table is the full site identification list, not selected by annotation.	none (supplementary tables only)		13361_2014_1016_MOESM1_ESM.xlsx sheet Sheet1 <https://static-content.springer.com/esm/art%3A10.1007%2Fs13361-014-1016-7/MediaObjects/13361_2014_1016_MOESM1_ESM.xlsx>	HEK293T grown with 50 uM GalNAz for 3 d; washed in PBS; 100 uM DBCO-sulfo-biotin in PBS added to the flasks for 1 h at 4 C; cells scraped, hypotonically lysed, membrane pellet digested; biotinylated glycopeptides on NeutrAvidin; PNGase F in H2(18)O. No unlabeled-cell control described in the main text.	Method read from: Springer full text (link.springer.com/article/10.1007/s13361-014-1016-7): Experimental 2.1 Cell Culture and Labeling, Results; ESM 1 header row.	NeutrAvidin agarose (peptide-level enrichment)	not reported	not stated in accessible text		Where we looked for the instrument: No free full text; abstract has no instrument; publisher DOI page refused automated access.	HEK293T embryonic kidney cell line	ESM 1 Table S1 (Sheet1): all 152 N-glycosylation sites identified on the cell surface of unperturbed HEK293T cells (paper: 144 N-glycopeptides, 152 sites, 110 proteins); site-level rows, one protein per row. No further filter. ESM 2 (Table S2, CD-protein subset of S1) not used.	13361_2014_1016_MOESM1_ESM.xlsx: Reference			110	78	0.7090909090909091	0.2	Homo sapiens		0	0	110
chen-hek293t-sialo-2015	HEK293T metabolic-azide click surface N-sialoglycosites	Chen et al. 2015	Chen W	2015	29142707	10.1039/c5sc01124h	core		Intact-cell click tagging of metabolically azide-labeled sialoglycans with a membrane-impermeant DBCO-sulfo-biotin; unlabeled cells processed in parallel yielded no sites. Baseline, unperturbed cells; the table is the full identification list.	none (supplementary tables only)		SC-006-C5SC01124H-s002.xlsx sheet Surface in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5667505/supplementaryFiles>	HEK293T cultured with Ac4ManNAz; azido-sialoglycoproteins on living cells reacted with DBCO-sulfo-biotin (cell-impermeant; imaging shows surface signal); cells lysed, proteins digested, biotinylated peptides enriched on NeutrAvidin, PNGase F in H2(18)O. Unlabeled-cell control: no N-sialoglycosites identified.	Method as described in the paper's Results ('The principle...', Fig. 1; gel and imaging controls Fig. 2-3; identification Fig. 4; SILAC Fig. 5); detailed protocol is in ESI PDF (s001), not opened beyond the main text (full text PMC5667505).	NeutrAvidin (peptide-level enrichment)	not reported	not stated in accessible text		Where we looked for the instrument: PMC5667505 main text names no instrument; methods in ESI supplement not accessible.	HEK293T embryonic kidney cell line	Table S1 (s002, sheet 'Surface'): all 395 localised N-sialoglycosites on cell-surface proteins of HEK293T (paper: 395 sites, 213 protein families / 248 proteins including isoforms); site-level rows, one protein per row. No further filter. The Annotation column is a protein name, not a selection.	SC-006-C5SC01124H-s002.xlsx: UniProt name			196	143	0.7295918367346939	0.2	Homo sapiens		0	23	196
kopecka-ht29-csc-2015--doxorubicin-selected-resistant-subline	HT29 colon carcinoma hydrazide cell surface capture · doxorubicin-selected resistant subline	Kopecka et al. 2015	Kopecka J	2015	25686827	10.18632/oncotarget.2882	perturbed	drug-resistant derivative: doxorubicin-selected resistant subline	drug-resistant derivative arm of kopecka-ht29-csc-2015; shown, not counted. Membership follows the parent recipe's rule for this sample group.	none (supplementary tables only)		oncotarget-06-6776-s002.xlsx sheet Sheet1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4466649/supplementaryFiles>	periodate + biocytin hydrazide CSC on intact cells	Method as described in the paper's Methods 'Surface glycoprotein identification via CSC technology'; Supplemental Table 1 (full text PMC4466649).	streptavidin (per ref 52 protocol; not named)	not stated	LTQ Orbitrap XL	MS/MS spectra acquisition	Instrument as named in the paper's Methods (full text PMC4466649).	HT29/dx	HT29/dx, doxorubicin-selected resistant subline: a non-baseline state of kopecka-ht29-csc-2015, listed when observed in at least 1 of its 1 samples				372	228	0.6129032258064516		Homo sapiens		0	0	372
kopecka-ht29-csc-2015	HT29 colon carcinoma hydrazide cell surface capture · untreated parental (baseline)	Kopecka et al. 2015	Kopecka J	2015	25686827	10.18632/oncotarget.2882	core		Intact-cell hydrazide CSC; the supplemental table is the full quantified glycoprotein list before annotation. Membership is the parental HT29 line. Per-line values are aligned label-free abundances (not per-line identifications), the identification list is shared between the two lines, and there is no no-label control.	none (supplementary tables only)		oncotarget-06-6776-s002.xlsx sheet Sheet1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4466649/supplementaryFiles>	periodate + biocytin hydrazide CSC on intact cells	Method as described in the paper's Methods 'Surface glycoprotein identification via CSC technology'; Supplemental Table 1 (full text PMC4466649).	streptavidin (per ref 52 protocol; not named)	not stated	LTQ Orbitrap XL	MS/MS spectra acquisition	Instrument as named in the paper's Methods (full text PMC4466649).	HT29 colorectal adenocarcinoma cells (chemosensitive parental) and doxorubicin-selected HT29/dx	Supplemental Table 1 (378 quantified glycoproteins; paper text says 380). Membership = normalized abundance in untreated parental HT29 above 0 (all 378 rows); HT29/dx (doxorubicin-selected) abundance kept as a non-membership measurement, with its 9.976 minimum placeholder treated as not detected. Surfaceome/Phobius columns are annotations only and do not select rows.	oncotarget-06-6776-s002.xlsx: Accession		HT29 / baseline untreated parental, CSC: norm_abundance_HT_untreated (min_observed 1) | HT29/dx / doxorubicin-selected resistant subline (not used for membership): norm_abundance_DX_untreated (min_observed 1; floor 9.98)	375	229	0.6106666666666667	0.2	Homo sapiens		0	0	375
ozlu-hela-mitosis-2015	HeLa SILAC sulfo-NHS-SS-biotin surfaceome · interphase (thymidine-arrested) (baseline)	Özlü et al. 2015	Özlü N	2015	25476450	10.15252/embj.201385162	core		Intact-cell sulfo-NHS-SS-biotin on attached cells; the full per-replicate proteinGroups are public before the authors' surface-annotation step. Membership uses the interphase comparator arm only; both arms are drug-synchronised (thymidine vs S-trityl-L-cysteine), and the paper notes actin carry-over (labeling permeation), so the list is broad (~47% membrane by the authors' estimate).	none (supplementary tables only)		ozlu_tableIV_by_protein.tsv	Sulfo-NHS-SS-biotin on plate-attached SILAC HeLa, separate labeling per state then pooled lysates, streptavidin capture	Method read from: Springer full-text page (Results 'Identification of surface-exposed proteins', 'Quantitative comparison ...'); Supplementary Table I label assignment.	streptavidin (immobilised; DTT release)	not stated	LTQ Orbitrap (Thermo; exact model not given)	Eksigent 2D nanoLC	Instrument as named in the paper's Methods (full text PMC4337065).	HeLa cervical adenocarcinoma cell line (interphase and mitotic arrest)	Supplementary Table IV (MOESM6): the stacked MaxQuant proteinGroups of all five surface-isolation replicates (2,005 / 1,395 / 1,187 / 1,985 / 3,205 groups, matching Supplementary Table I 'All Identified Proteins'), pivoted to one row per first reviewed UniProt entry. Only-by-site rows dropped. Membership = interphase-channel (light in replicates 1-3, heavy in 4-5) intensity > 0 in >= 2 of 5 replicates. Mitosis channel kept as measurements only. The authors' 'Included in the Analysis' flag (surface-annotated subset behind the 628-protein Table III) is carried as a count and never used.	ozlu_tableIV_by_protein.tsv: uniprot_accession		HeLa / interphase (thymidine-arrested) sulfo-NHS-SS-biotin labeled: interphase_intensity_rep1, interphase_intensity_rep2, interphase_intensity_rep3, interphase_intensity_rep4, interphase_intensity_rep5 (min_observed 2) | HeLa / mitotic arrest (S-trityl-L-cysteine) labeled (not used for membership): mitosis_intensity_rep1, mitosis_intensity_rep2, mitosis_intensity_rep3, mitosis_intensity_rep4, mitosis_intensity_rep5 (min_observed 2)	2268	356	0.15696649029982362	0.2	Homo sapiens		0	4	2268
ozlu-hela-mitosis-2015--mitotic-arrest-labelled	HeLa SILAC sulfo-NHS-SS-biotin surfaceome · mitotic arrest (S-trityl-L-cysteine)	Özlü et al. 2015	Özlü N	2015	25476450	10.15252/embj.201385162	perturbed	drug, ligand or treatment: mitotic arrest (S-trityl-L-cysteine)	drug, ligand or treatment arm of ozlu-hela-mitosis-2015; shown, not counted. Membership follows the parent recipe's rule for this sample group.	none (supplementary tables only)		ozlu_tableIV_by_protein.tsv	Sulfo-NHS-SS-biotin on plate-attached SILAC HeLa, separate labeling per state then pooled lysates, streptavidin capture	Method read from: Springer full-text page (Results 'Identification of surface-exposed proteins', 'Quantitative comparison ...'); Supplementary Table I label assignment.	streptavidin (immobilised; DTT release)	not stated	LTQ Orbitrap (Thermo; exact model not given)	Eksigent 2D nanoLC	Instrument as named in the paper's Methods (full text PMC4337065).	HeLa	HeLa, mitotic arrest (S-trityl-L-cysteine) labeled: a non-baseline state of ozlu-hela-mitosis-2015, listed when observed in at least 2 of its 5 samples				2239	348	0.15542652970075926		Homo sapiens		0	4	2239
gomesalves-hcsc-2015	Human cardiac stem cell plasma-membrane-enriched fraction	Gomes-Alves et al. 2015	Gomes-Alves P	2015	25504917	10.1002/pmic.201400318	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis-then-centrifugation plasma-membrane enrichment, not a surface label; complementary only.	PRIDE	PXD001117	gomesalves_protxml_by_replicate.tsv	lysis + differential centrifugation PM enrichment (Dormeyer protocol)	Method read from: PRIDE PXD001117 sample/data processing protocols; PubMed abstract (paper not open access).	none	n/a	LTQ Orbitrap Elite		Instrument as listed in the ProteomeXchange record PXD001117.	Human cardiac stem cells (hCSC, primary-derived)	PRIDE JA_Toran_R1g/R2g/R3g.prot.xml (Proteome Discoverer exports, ~3,750-4,020 groups each), merged by a deterministic group representative. Membership = >= 2 distinct peptide sequences in >= 2 of 3 replicate runs (3,010 groups). The exports carry PD scores, not FDR-calibrated probabilities, so the >= 2-peptide rule stands in for the authors' FDR filters (5% peptide FDR, 1% for single-peptide proteins).	gomesalves_protxml_by_replicate.tsv: accession		human cardiac stem cells / baseline, plasma-membrane-enriched fraction: distinct_peptides_R1, distinct_peptides_R2, distinct_peptides_R3 (min_observed 2; floor 1)	2971	487	0.16391787277011108	0.2	Homo sapiens		1	16	2971
sharma-fetal-cm-2015	Human fetal ventricular cardiomyocyte cationic-silica membrane fraction	Sharma et al. 2015	Sharma P	2015	26403541	10.1038/ncomms9391	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Cationic colloidal silica coats the cell before lysis, but it labels no protein and the pellet carries co-sedimenting organelle membranes; FRACTIONATION.md (2026-10-28) places silica-coating isolation in the membrane-fractionation family, so this is complementary with no surface vote. First input of the 'silica-bead or other cell-coating PM isolation' row, and the first human cardiomyocyte input.	PRIDE (deposited with Lee 2020 Sci Data, PMID 33262348)	PXD017732	41467_2015_BFncomms9391_MOESM88_ESM.xlsx sheet Sheet1 <https://ftp.pride.ebi.ac.uk/pride/data/archive/2020/11/PXD017732/41467_2015_BFncomms9391_MOESM88_ESM.xlsx>	Cationic colloidal silica membrane enrichment of human fetal and mouse neonatal ventricular cardiomyocytes; TX-100 extraction of the membrane pellet vs membrane-depleted homogenate; MudPIT, <1% FDR	Method read from: Lee 2020 Sci Data (PMC7708497) Results para 1 and Data Records (PXD017732); Supplementary Table 2/4 headers of Sharma 2015.	cationic colloidal silica	not stated	LTQ Orbitrap		Instrument as listed in the ProteomeXchange record PXD017732.	Human fetal ventricular cardiomyocytes (primary)	Supplementary Table 4 of Sharma 2015 (41467_2015_BFncomms9391_MOESM88_ESM.xlsx, re-deposited in PXD017732): per-replicate spectral counts for 2,763 protein rows (2,762 human + porcine trypsin) in three biological replicates of the homogenate (HS_H.1-3) and the TX-100 membrane fraction (HS_TX.1-3), with QSpec scores. Membership = spectral count > 0 in >= 2 of 3 TX replicates (1,346 accessions; any TX replicate gives 1,525, equal to the TX column of Supplementary Table 2). Homogenate columns kept as non-membership measurements. QSpec enrichment and the 555-protein enriched list are not used to select rows.	41467_2015_BFncomms9391_MOESM88_ESM.xlsx: swiss_prot_id		Human fetal ventricular cardiomyocytes / baseline, Triton X-100 extracted silica-coated membrane fraction: HS_TX.1, HS_TX.2, HS_TX.3 (min_observed 2) | Human fetal ventricular cardiomyocytes / membrane-depleted homogenate (not used for membership): HS_H.1, HS_H.2, HS_H.3 (min_observed 2)	1343	141	0.10498883097542815	0.2	Homo sapiens		1	0	1343
vildhede-liver-2015	Human liver tissue and isolated hepatocyte crude membrane fractions	Vildhede et al. 2015	Vildhede A	2015	26167961	10.1021/acs.jproteome.5b00334	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Total crude membrane fraction (salt/carbonate/urea-washed or 200,000 g pellet) of lysed tissue and cells, not a surface label; complementary evidence of liver membrane expression only.	PRIDE	PXD002235	proteinGroups.txt	Crude membrane fractions by consecutive 2 M NaCl / 0.01 M Na2CO3 / 4 M urea extraction of liver homogenate; hepatocyte crude membranes by 200,000 g ultracentrifugation of a 2,000 g supernatant; FASP; MaxQuant 1.2.6.20.	Method read from: PRIDE PXD002235 sample and data processing protocols (paper is not open access; abstract from PubMed).	none	not applicable	LTQ Orbitrap Velos		Instrument as listed in the ProteomeXchange record PXD002235.	Human liver tissue (12 donors) and freshly isolated primary human hepatocytes (8 preparations)	PRIDE PXD002235 txt.zip MaxQuant proteinGroups.txt (5,289 groups). Reverse, contaminant and only-identified-by-site groups removed (5,081 remain; paper: 5,144 unique proteins). Membership = Intensity > 0 in at least one sample of that donor/preparation (L1-L12 liver tissue, one run each; HA-HH hepatocyte preparations, three runs each). No protein FDR column is present (MaxQuant 1.2 output already 1% FDR). Matching between runs was enabled, so some per-sample intensities are transferred identifications.	proteinGroups.txt: Majority protein IDs	drop rows flagged Reverse, Contaminant, Only identified by site	Human liver tissue, donor L1 / baseline crude membrane fraction: Intensity L1 (min_observed 1) | Human liver tissue, donor L2 / baseline crude membrane fraction: Intensity L2 (min_observed 1) | Human liver tissue, donor L3 / baseline crude membrane fraction: Intensity L3 (min_observed 1) | Human liver tissue, donor L4 / baseline crude membrane fraction: Intensity L4 (min_observed 1) | Human liver tissue, donor L5 / baseline crude membrane fraction: Intensity L5 (min_observed 1) | Human liver tissue, donor L6 / baseline crude membrane fraction: Intensity L6 (min_observed 1) | Human liver tissue, donor L7 / baseline crude membrane fraction: Intensity L7 (min_observed 1) | Human liver tissue, donor L8 / baseline crude membrane fraction: Intensity L8 (min_observed 1) | Human liver tissue, donor L9 / baseline crude membrane fraction: Intensity L9 (min_observed 1) | Human liver tissue, donor L10 / baseline crude membrane fraction: Intensity L10 (min_observed 1) | Human liver tissue, donor L11 / baseline crude membrane fraction: Intensity L11 (min_observed 1) | Human liver tissue, donor L12 / baseline crude membrane fraction: Intensity L12 (min_observed 1) | Freshly isolated human hepatocytes, preparation HA / baseline crude membrane fraction: Intensity HA1, Intensity HA2, Intensity HA3 (min_observed 1) | Freshly isolated human hepatocytes, preparation HB / baseline crude membrane fraction: Intensity HB1, Intensity HB2, Intensity HB3 (min_observed 1) | Freshly isolated human hepatocytes, preparation HC / baseline crude membrane fraction: Intensity HC1, Intensity HC2, Intensity HC3 (min_observed 1) | Freshly isolated human hepatocytes, preparation HD / baseline crude membrane fraction: Intensity HD1, Intensity HD2, Intensity HD3 (min_observed 1) | Freshly isolated human hepatocytes, preparation HE / baseline crude membrane fraction: Intensity HE1, Intensity HE2, Intensity HE3 (min_observed 1) | Freshly isolated human hepatocytes, preparation HF / baseline crude membrane fraction: Intensity HF1, Intensity HF2, Intensity HF3 (min_observed 1) | Freshly isolated human hepatocytes, preparation HG / baseline crude membrane fraction: Intensity HG1, Intensity HG2, Intensity HG3 (min_observed 1) | Freshly isolated human hepatocytes, preparation HH / baseline crude membrane fraction: Intensity HH1, Intensity HH2, Intensity HH3 (min_observed 1)	4827	560	0.1160140874249016	0.2	Homo sapiens		0	162	4827
chen-breast-sialo-2015	MDA-MB-231 and MCF-7 metabolic-azide click surface N-sialoglycosites, SILAC	Chen et al. 2015	Chen W	2015	29142707	10.1039/c5sc01124h	core		Intact-cell click tagging (same method as the HEK293T surface arm, whose unlabeled control gave no sites) on two untreated breast lines; per-line identification flags let membership be stated per cell type.	none (supplementary tables only)		table_s4_detection.tsv	SILAC-labeled MDA-MB-231 and MCF-7 grown with Ac4ManNAz, surface azido-sialoglycans tagged with DBCO-sulfo-biotin on living cells, cells combined, lysed and digested; NeutrAvidin enrichment, PNGase F/18O; per-line identification.	Method as described in the paper's Results ('The principle...', Fig. 1; gel and imaging controls Fig. 2-3; identification Fig. 4; SILAC Fig. 5); detailed protocol is in ESI PDF (s001), not opened beyond the main text (full text PMC5667505).	NeutrAvidin (peptide-level enrichment)	not reported	not stated in accessible text		Where we looked for the instrument: PMC5667505 main text names no instrument; methods in ESI supplement not accessible.	MDA-MB-231 and MCF-7 breast cancer cell lines	Table S4 (s009, sheet 'Glycosylation-site-identified'): all 541 N-sialoglycosites on breast cancer cell surfaces with per-line Yes/No identification (paper: 439 sites in MDA-MB-231, 237 in MCF-7). Derived table converts Yes/No to 1/0; membership = site identified in that line. No further filter.	table_s4_detection.tsv: UniProt name		MDA-MB-231 / baseline, surface click-tagged (SILAC): detected_MDA-MB-231 (min_observed 1) | MCF-7 / baseline, surface click-tagged (SILAC): detected_MCF-7 (min_observed 1)	274	220	0.8029197080291971	0.2	Homo sapiens		0	0	274
kitata-nsclc-membrane-2015	NSCLC tumor tissue and cell line membrane fractions	Kitata et al. 2015	Kitata RB	2015	26202522	10.1021/acs.jproteome.5b00477	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis-then-centrifugation membrane enrichment from tissue and cell lines: membrane fractionation, complementary only. 'T' prefixes are read as tumor specimens (the raw files distinguish e.g. Lungmem172N for normal); confirm against the paper's sample table if the distinction matters.	PRIDE	PXD002224	T172_Protein.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2015/07/PXD002224/T172_Protein.txt> | T203_Protein.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2015/07/PXD002224/T203_Protein.txt> | T232_Protein.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2015/07/PXD002224/T232_Protein.txt> | T256_Protein.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2015/07/PXD002224/T256_Protein.txt> | T259_Protein.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2015/07/PXD002224/T259_Protein.txt> | T268_Protein.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2015/07/PXD002224/T268_Protein.txt> | T275_Protein.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2015/07/PXD002224/T275_Protein.txt> | T284_Protein.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2015/07/PXD002224/T284_Protein.txt> | T285_Protein.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2015/07/PXD002224/T285_Protein.txt> | CL25_Protein.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2015/07/PXD002224/CL25_Protein.txt> | CL83_1_Protein.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2015/07/PXD002224/CL83_1_Protein.txt> | H3255_Protein.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2015/07/PXD002224/H3255_Protein.txt> | PCIR_desalt_Protein.txt <https://ftp.pride.ebi.ac.uk/pride/data/archive/2015/07/PXD002224/PCIR_desalt_Protein.txt>	two-step centrifugation membrane enrichment, gel-assisted digestion, Hp-RP StageTip	Method read from: PXD002224 sample processing protocol; PubMed abstract.	none	n/a	TripleTOF 5600; Synapt MS		Instrument as listed in the ProteomeXchange record PXD002224.	Non-small cell lung cancer: 9 resected tumor tissues and 4 cell lines (CL25, CL83, H3255, PC9-IR)	The 13 PeptideShaker protein reports deposited in PXD002224 (*_Protein.txt; every row is a validated protein group at 1% FDR): T172, T203, T232, T256, T259, T268, T275, T284, T285 (tumor tissue) and CL25, CL83_1, H3255, PCIR_desalt (cell lines). Membership = protein listed with >= 1 validated spectrum in that sample; each sample is its own group. The paper analysed 11 lines and 20 tumor/adjacent-normal pairs, but only these 13 reports are deposited (no adjacent-normal protein reports).	T172_Protein.txt: Accession | T203_Protein.txt: Accession | T232_Protein.txt: Accession | T256_Protein.txt: Accession | T259_Protein.txt: Accession | T268_Protein.txt: Accession | T275_Protein.txt: Accession | T284_Protein.txt: Accession | T285_Protein.txt: Accession | CL25_Protein.txt: Accession | CL83_1_Protein.txt: Accession | H3255_Protein.txt: Accession | PCIR_desalt_Protein.txt: Accession		NSCLC tumor tissue, patient 172 / membrane-enriched fraction (two-step centrifugation), baseline: #Validated Spectra (min_observed 1) | NSCLC tumor tissue, patient 203 / membrane-enriched fraction (two-step centrifugation), baseline: #Validated Spectra (min_observed 1) | NSCLC tumor tissue, patient 232 / membrane-enriched fraction (two-step centrifugation), baseline: #Validated Spectra (min_observed 1) | NSCLC tumor tissue, patient 256 / membrane-enriched fraction (two-step centrifugation), baseline: #Validated Spectra (min_observed 1) | NSCLC tumor tissue, patient 259 / membrane-enriched fraction (two-step centrifugation), baseline: #Validated Spectra (min_observed 1) | NSCLC tumor tissue, patient 268 / membrane-enriched fraction (two-step centrifugation), baseline: #Validated Spectra (min_observed 1) | NSCLC tumor tissue, patient 275 / membrane-enriched fraction (two-step centrifugation), baseline: #Validated Spectra (min_observed 1) | NSCLC tumor tissue, patient 284 / membrane-enriched fraction (two-step centrifugation), baseline: #Validated Spectra (min_observed 1) | NSCLC tumor tissue, patient 285 / membrane-enriched fraction (two-step centrifugation), baseline: #Validated Spectra (min_observed 1) | NSCLC cell line CL25 / membrane-enriched fraction (two-step centrifugation), baseline: #Validated Spectra (min_observed 1) | NSCLC cell line CL83 (run 1) / membrane-enriched fraction (two-step centrifugation), baseline: #Validated Spectra (min_observed 1) | NSCLC cell line H3255 / membrane-enriched fraction (two-step centrifugation), baseline: #Validated Spectra (min_observed 1) | NSCLC cell line PC9-IR (gefitinib-resistant PC9) / membrane-enriched fraction (two-step centrifugation), baseline: #Validated Spectra (min_observed 1)	4599	859	0.1867797347249402	0.2	Homo sapiens		0	0	4599
jung-colonorg-2015	Normal colon organoid plasma-membrane kit fraction	Jung et al. 2015	Jung P	2015	26549850	10.1016/j.stemcr.2015.10.003	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Kit-based plasma-membrane enrichment (no surface label) from normal primary colon epithelium; per-sample detection cannot be recovered because missing values were imputed.	none		mmc2.xlsx sheet LCMSMS experiment in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4682088/supplementaryFiles>	Qiagen Qproteome Plasma Membrane Isolation Kit (lectin affinity on lysed cells) on 3D organoids from normal human colonic crypts, stem (WREN) vs 72 h differentiation (EN) media; Q Exactive Plus, MaxQuant 1.5.1.2 LFQ, Perseus.	Method summarized from the paper (PMC4682088) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	Q Exactive Plus			Organoids derived from normal human colonic mucosa (stem-enriched and differentiated cultures)	mmc2 'LCMSMS experiment' main table (2,006 protein groups that passed the authors' >= 3 of 6 quantified filter); the appended small-scale experiment below it is excluded by requiring summed Intensity >= 1000. Membership = present in the main table (summed raw intensity > 0); the six LFQ columns are Perseus-imputed and kept as measurements only.	mmc2.xlsx: Majority protein IDs	Intensity ≥ 1000	normal colon organoids / pooled stem + differentiated membrane fractions (summed MaxQuant intensity): Intensity (min_observed 1) | normal colon organoids (stem, WREN) / plasma-membrane kit fraction: STEM1, STEM2, STEM3 (min_observed 2) | normal colon organoids (differentiated, EN) / plasma-membrane kit fraction: Diff1, Diff2, Diff3 (min_observed 2)	1890	185	0.09788359788359788	0.2	Homo sapiens		0	108	1890
ducret-liver-csc-2015	Primary hepatocyte, lung fibroblast, airway epithelium, A549 and HepG2 hydrazide CSC with no-biocytin controls	Ducret et al. 2015	Ducret A	2015	26097162	10.1002/prca.201400194	core		Intact-cell hydrazide CSC with per-preparation eluate tables and a matched no-biocytin control for every preparation; the controls recover few proteins (19-63 vs 141-260 per labeled eluate), so the capture is specific. Membership is per cell type with >= 2 labeled preparations. Eluate tables include non-glycosylated co-purifying proteins (keratins etc.); deamidated-NxS/T evidence is not applied.	PRIDE	PXD001988	ducret_eluate_differentpeps.tsv	periodate + biocytin hydrazide on intact cells, PNGase F glycopeptide elution	Method read from: PRIDE PXD001988 sample/data processing protocol; PubMed abstract (paper not open access).	streptavidin-coated resin (not named)	not stated	LTQ Orbitrap		Instrument as listed in the ProteomeXchange record PXD001988.	Freshly isolated primary human hepatocytes (5 preparations), primary lung fibroblasts (4), small airway epithelial cells (3), A549 (3), HepG2 (2)	All 34 per-sample *_ELUAT_* protein tables in PXD001988 merged by accession; first row of each protein group, DifferentPeps kept where the group's cumulative FDrate <= 1%. Membership = DifferentPeps > 0 in >= 2 biocytin-labeled eluates of the same cell type. No-biocytin control eluates kept as non-membership measurements. Flow-through and combined files not used. Not the paper's 32-candidate selected list.	ducret_eluate_differentpeps.tsv: accession		primary human hepatocytes (freshly isolated) / baseline, biocytin hydrazide CSC eluate: HUHEP_biocytin_rep1, HUHEP_biocytin_rep2, HUHEP_biocytin_rep3, HUHEP_biocytin_rep4, HUHEP_biocytin_rep5 (min_observed 2) | primary human lung fibroblasts / baseline, biocytin hydrazide CSC eluate: LUFI_biocytin_rep1, LUFI_biocytin_rep2, LUFI_biocytin_rep3, LUFI_biocytin_rep4 (min_observed 2) | primary small airway epithelial cells / baseline, biocytin hydrazide CSC eluate: SAEC_biocytin_rep1, SAEC_biocytin_rep2, SAEC_biocytin_rep3 (min_observed 2) | A549 lung adenocarcinoma / baseline, biocytin hydrazide CSC eluate: A549_biocytin_rep1, A549_biocytin_rep2, A549_biocytin_rep3 (min_observed 2) | HepG2 hepatoblastoma / baseline, biocytin hydrazide CSC eluate: HEPG2_biocytin_rep1, HEPG2_biocytin_rep2 (min_observed 2) | primary human hepatocytes (freshly isolated) / no-biocytin control eluate (not used for membership): HUHEP_nobiocytin_rep1, HUHEP_nobiocytin_rep2, HUHEP_nobiocytin_rep3, HUHEP_nobiocytin_rep4, HUHEP_nobiocytin_rep5 (min_observed 2) | primary human lung fibroblasts / no-biocytin control eluate (not used for membership): LUFI_nobiocytin_rep1, LUFI_nobiocytin_rep2, LUFI_nobiocytin_rep3, LUFI_nobiocytin_rep4 (min_observed 2) | primary small airway epithelial cells / no-biocytin control eluate (not used for membership): SAEC_nobiocytin_rep1, SAEC_nobiocytin_rep2, SAEC_nobiocytin_rep3 (min_observed 2) | A549 lung adenocarcinoma / no-biocytin control eluate (not used for membership): A549_nobiocytin_rep1, A549_nobiocytin_rep2, A549_nobiocytin_rep3 (min_observed 2) | HepG2 hepatoblastoma / no-biocytin control eluate (not used for membership): HEPG2_nobiocytin_rep1, HEPG2_nobiocytin_rep2 (min_observed 2)	535	281	0.525233644859813	0.2	Homo sapiens		0	0	535
graessel-cd4t-pal-2015--cd3-cd28-stimulated-12h-pal-pngase-f-released-n	Primary human naive CD4+ T cell PAL surface glycoproteome · CD3/CD28 stimulated 12h, PNGase F-released glycopeptides	Graessel et al. 2015	Graessel A	2015	25991687	10.1074/mcp.m114.045690	perturbed	differentiation or activation: CD3/CD28 stimulated 12h, PAL PNGase F-released N-glycopeptides	differentiation or activation arm of graessel-cd4t-pal-2015; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD001432	graessel_trypsin_psms_by_sample.tsv | graessel_pngasef_psms_by_sample.tsv	PAL (periodate + aniline-catalysed aminooxy-biotin) on live cells	Method read from: PubMed abstract; PRIDE PXD001432 Description_of_Raw_files.txt and mzIdentML metadata.	streptavidin (not verified; full text not retrievable from Europe PMC)	not stated	LTQ Orbitrap XL		Instrument as listed in the ProteomeXchange record PXD001432.	naive CD4+ T cells	naive CD4+ T cells, CD3/CD28 stimulated 12h, PAL PNGase F-released N-glycopeptides: a non-baseline state of graessel-cd4t-pal-2015, listed when observed in at least 2 of its 4 samples				31	25	0.8064516129032258		Homo sapiens		0	0	31
graessel-cd4t-pal-2015--cd3-cd28-stimulated-12h-pal-on-bead-trypsin-digest	Primary human naive CD4+ T cell PAL surface glycoproteome · CD3/CD28 stimulated 12h, on-bead trypsin digest	Graessel et al. 2015	Graessel A	2015	25991687	10.1074/mcp.m114.045690	perturbed	differentiation or activation: CD3/CD28 stimulated 12h	differentiation or activation arm of graessel-cd4t-pal-2015; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD001432	graessel_trypsin_psms_by_sample.tsv | graessel_pngasef_psms_by_sample.tsv	PAL (periodate + aniline-catalysed aminooxy-biotin) on live cells	Method read from: PubMed abstract; PRIDE PXD001432 Description_of_Raw_files.txt and mzIdentML metadata.	streptavidin (not verified; full text not retrievable from Europe PMC)	not stated	LTQ Orbitrap XL		Instrument as listed in the ProteomeXchange record PXD001432.	naive CD4+ T cells	naive CD4+ T cells, CD3/CD28 stimulated 12h, PAL on-bead trypsin digest: a non-baseline state of graessel-cd4t-pal-2015, listed when observed in at least 2 of its 4 samples				70	50	0.7142857142857143		Homo sapiens		0	0	70
graessel-cd4t-pal-2015--cd3-cd28-stimulated-24h-pal-pngase-f-released-n	Primary human naive CD4+ T cell PAL surface glycoproteome · CD3/CD28 stimulated 24h, PNGase F-released glycopeptides	Graessel et al. 2015	Graessel A	2015	25991687	10.1074/mcp.m114.045690	perturbed	differentiation or activation: CD3/CD28 stimulated 24h, PAL PNGase F-released N-glycopeptides	differentiation or activation arm of graessel-cd4t-pal-2015; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD001432	graessel_trypsin_psms_by_sample.tsv | graessel_pngasef_psms_by_sample.tsv	PAL (periodate + aniline-catalysed aminooxy-biotin) on live cells	Method read from: PubMed abstract; PRIDE PXD001432 Description_of_Raw_files.txt and mzIdentML metadata.	streptavidin (not verified; full text not retrievable from Europe PMC)	not stated	LTQ Orbitrap XL		Instrument as listed in the ProteomeXchange record PXD001432.	naive CD4+ T cells	naive CD4+ T cells, CD3/CD28 stimulated 24h, PAL PNGase F-released N-glycopeptides: a non-baseline state of graessel-cd4t-pal-2015, listed when observed in at least 2 of its 4 samples				44	37	0.8409090909090909		Homo sapiens		0	0	44
graessel-cd4t-pal-2015--cd3-cd28-stimulated-24h-pal-on-bead-trypsin-digest	Primary human naive CD4+ T cell PAL surface glycoproteome · CD3/CD28 stimulated 24h, on-bead trypsin digest	Graessel et al. 2015	Graessel A	2015	25991687	10.1074/mcp.m114.045690	perturbed	differentiation or activation: CD3/CD28 stimulated 24h	differentiation or activation arm of graessel-cd4t-pal-2015; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD001432	graessel_trypsin_psms_by_sample.tsv | graessel_pngasef_psms_by_sample.tsv	PAL (periodate + aniline-catalysed aminooxy-biotin) on live cells	Method read from: PubMed abstract; PRIDE PXD001432 Description_of_Raw_files.txt and mzIdentML metadata.	streptavidin (not verified; full text not retrievable from Europe PMC)	not stated	LTQ Orbitrap XL		Instrument as listed in the ProteomeXchange record PXD001432.	naive CD4+ T cells	naive CD4+ T cells, CD3/CD28 stimulated 24h, PAL on-bead trypsin digest: a non-baseline state of graessel-cd4t-pal-2015, listed when observed in at least 2 of its 4 samples				92	69	0.75		Homo sapiens		0	0	92
graessel-cd4t-pal-2015--cd3-cd28-stimulated-3h-pal-pngase-f-released-n	Primary human naive CD4+ T cell PAL surface glycoproteome · CD3/CD28 stimulated 3h, PNGase F-released glycopeptides	Graessel et al. 2015	Graessel A	2015	25991687	10.1074/mcp.m114.045690	perturbed	differentiation or activation: CD3/CD28 stimulated 3h, PAL PNGase F-released N-glycopeptides	differentiation or activation arm of graessel-cd4t-pal-2015; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD001432	graessel_trypsin_psms_by_sample.tsv | graessel_pngasef_psms_by_sample.tsv	PAL (periodate + aniline-catalysed aminooxy-biotin) on live cells	Method read from: PubMed abstract; PRIDE PXD001432 Description_of_Raw_files.txt and mzIdentML metadata.	streptavidin (not verified; full text not retrievable from Europe PMC)	not stated	LTQ Orbitrap XL		Instrument as listed in the ProteomeXchange record PXD001432.	naive CD4+ T cells	naive CD4+ T cells, CD3/CD28 stimulated 3h, PAL PNGase F-released N-glycopeptides: a non-baseline state of graessel-cd4t-pal-2015, listed when observed in at least 2 of its 4 samples				22	18	0.8181818181818182		Homo sapiens		0	0	22
graessel-cd4t-pal-2015--cd3-cd28-stimulated-3h-pal-on-bead-trypsin-digest	Primary human naive CD4+ T cell PAL surface glycoproteome · CD3/CD28 stimulated 3h, on-bead trypsin digest	Graessel et al. 2015	Graessel A	2015	25991687	10.1074/mcp.m114.045690	perturbed	differentiation or activation: CD3/CD28 stimulated 3h	differentiation or activation arm of graessel-cd4t-pal-2015; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD001432	graessel_trypsin_psms_by_sample.tsv | graessel_pngasef_psms_by_sample.tsv	PAL (periodate + aniline-catalysed aminooxy-biotin) on live cells	Method read from: PubMed abstract; PRIDE PXD001432 Description_of_Raw_files.txt and mzIdentML metadata.	streptavidin (not verified; full text not retrievable from Europe PMC)	not stated	LTQ Orbitrap XL		Instrument as listed in the ProteomeXchange record PXD001432.	naive CD4+ T cells	naive CD4+ T cells, CD3/CD28 stimulated 3h, PAL on-bead trypsin digest: a non-baseline state of graessel-cd4t-pal-2015, listed when observed in at least 2 of its 4 samples				41	32	0.7804878048780488		Homo sapiens		0	0	41
graessel-cd4t-pal-2015--cd3-cd28-stimulated-48h-pal-pngase-f-released-n	Primary human naive CD4+ T cell PAL surface glycoproteome · CD3/CD28 stimulated 48h, PNGase F-released glycopeptides	Graessel et al. 2015	Graessel A	2015	25991687	10.1074/mcp.m114.045690	perturbed	differentiation or activation: CD3/CD28 stimulated 48h, PAL PNGase F-released N-glycopeptides	differentiation or activation arm of graessel-cd4t-pal-2015; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD001432	graessel_trypsin_psms_by_sample.tsv | graessel_pngasef_psms_by_sample.tsv	PAL (periodate + aniline-catalysed aminooxy-biotin) on live cells	Method read from: PubMed abstract; PRIDE PXD001432 Description_of_Raw_files.txt and mzIdentML metadata.	streptavidin (not verified; full text not retrievable from Europe PMC)	not stated	LTQ Orbitrap XL		Instrument as listed in the ProteomeXchange record PXD001432.	naive CD4+ T cells	naive CD4+ T cells, CD3/CD28 stimulated 48h, PAL PNGase F-released N-glycopeptides: a non-baseline state of graessel-cd4t-pal-2015, listed when observed in at least 2 of its 4 samples				92	78	0.8478260869565217		Homo sapiens		0	0	92
graessel-cd4t-pal-2015--cd3-cd28-stimulated-48h-pal-on-bead-trypsin-digest	Primary human naive CD4+ T cell PAL surface glycoproteome · CD3/CD28 stimulated 48h, on-bead trypsin digest	Graessel et al. 2015	Graessel A	2015	25991687	10.1074/mcp.m114.045690	perturbed	differentiation or activation: CD3/CD28 stimulated 48h	differentiation or activation arm of graessel-cd4t-pal-2015; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD001432	graessel_trypsin_psms_by_sample.tsv | graessel_pngasef_psms_by_sample.tsv	PAL (periodate + aniline-catalysed aminooxy-biotin) on live cells	Method read from: PubMed abstract; PRIDE PXD001432 Description_of_Raw_files.txt and mzIdentML metadata.	streptavidin (not verified; full text not retrievable from Europe PMC)	not stated	LTQ Orbitrap XL		Instrument as listed in the ProteomeXchange record PXD001432.	naive CD4+ T cells	naive CD4+ T cells, CD3/CD28 stimulated 48h, PAL on-bead trypsin digest: a non-baseline state of graessel-cd4t-pal-2015, listed when observed in at least 2 of its 4 samples				175	115	0.6571428571428571		Homo sapiens		0	0	175
graessel-cd4t-pal-2015--cd3-cd28-stimulated-6h-pal-pngase-f-released-n	Primary human naive CD4+ T cell PAL surface glycoproteome · CD3/CD28 stimulated 6h, PNGase F-released glycopeptides	Graessel et al. 2015	Graessel A	2015	25991687	10.1074/mcp.m114.045690	perturbed	differentiation or activation: CD3/CD28 stimulated 6h, PAL PNGase F-released N-glycopeptides	differentiation or activation arm of graessel-cd4t-pal-2015; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD001432	graessel_trypsin_psms_by_sample.tsv | graessel_pngasef_psms_by_sample.tsv	PAL (periodate + aniline-catalysed aminooxy-biotin) on live cells	Method read from: PubMed abstract; PRIDE PXD001432 Description_of_Raw_files.txt and mzIdentML metadata.	streptavidin (not verified; full text not retrievable from Europe PMC)	not stated	LTQ Orbitrap XL		Instrument as listed in the ProteomeXchange record PXD001432.	naive CD4+ T cells	naive CD4+ T cells, CD3/CD28 stimulated 6h, PAL PNGase F-released N-glycopeptides: a non-baseline state of graessel-cd4t-pal-2015, listed when observed in at least 2 of its 4 samples				23	19	0.8260869565217391		Homo sapiens		0	0	23
graessel-cd4t-pal-2015--cd3-cd28-stimulated-6h-pal-on-bead-trypsin-digest	Primary human naive CD4+ T cell PAL surface glycoproteome · CD3/CD28 stimulated 6h, on-bead trypsin digest	Graessel et al. 2015	Graessel A	2015	25991687	10.1074/mcp.m114.045690	perturbed	differentiation or activation: CD3/CD28 stimulated 6h	differentiation or activation arm of graessel-cd4t-pal-2015; shown, not counted. Membership follows the parent recipe's rule for this sample group.	PRIDE	PXD001432	graessel_trypsin_psms_by_sample.tsv | graessel_pngasef_psms_by_sample.tsv	PAL (periodate + aniline-catalysed aminooxy-biotin) on live cells	Method read from: PubMed abstract; PRIDE PXD001432 Description_of_Raw_files.txt and mzIdentML metadata.	streptavidin (not verified; full text not retrievable from Europe PMC)	not stated	LTQ Orbitrap XL		Instrument as listed in the ProteomeXchange record PXD001432.	naive CD4+ T cells	naive CD4+ T cells, CD3/CD28 stimulated 6h, PAL on-bead trypsin digest: a non-baseline state of graessel-cd4t-pal-2015, listed when observed in at least 2 of its 4 samples				46	29	0.6304347826086957		Homo sapiens		0	0	46
graessel-cd4t-pal-2015	Primary human naive CD4+ T cell PAL surface glycoproteome · unstimulated (0 h), on-bead trypsin digest (baseline)	Graessel et al. 2015	Graessel A	2015	25991687	10.1074/mcp.m114.045690	core		Intact-cell PAL capture on primary cells with per-donor runs; membership rests on unstimulated cells replicated in >= 2 of 4 donors. Per-run evidence is PSM counts from one merged search across all 24 runs (protein inference pooled); no no-label control.	PRIDE	PXD001432	graessel_trypsin_psms_by_sample.tsv | graessel_pngasef_psms_by_sample.tsv	PAL (periodate + aniline-catalysed aminooxy-biotin) on live cells	Method read from: PubMed abstract; PRIDE PXD001432 Description_of_Raw_files.txt and mzIdentML metadata.	streptavidin (not verified; full text not retrievable from Europe PMC)	not stated	LTQ Orbitrap XL		Instrument as listed in the ProteomeXchange record PXD001432.	Primary human naive CD4+ T cells (4 donors)	Deposited Mascot mzIdentML for the trypsin and PNGase F fractions (293 and 149 ambiguity groups passing threshold). Per-run PSM counts recovered from spectrum titles. Membership = >= 2 PSM-positive donors of 4 at 0 h (unstimulated) in either fraction; stimulated time points kept as non-membership measurements. Ensembl IDs mapped to UniProt; 24 trypsin / 16 PNGase F groups unmapped and dropped. Not the paper's 173-protein annotated surface list.	graessel_trypsin_psms_by_sample.tsv: uniprot_mapped | graessel_pngasef_psms_by_sample.tsv: uniprot_mapped		naive CD4+ T cells / baseline unstimulated (0 h medium control), PAL on-bead trypsin digest: psms_donor1_0h, psms_donor2_0h, psms_donor3_0h, psms_donor4_0h (min_observed 2) | naive CD4+ T cells / CD3/CD28 stimulated 3h, PAL on-bead trypsin digest (not used for membership): psms_donor1_3h, psms_donor2_3h, psms_donor3_3h, psms_donor4_3h (min_observed 2) | naive CD4+ T cells / CD3/CD28 stimulated 6h, PAL on-bead trypsin digest (not used for membership): psms_donor1_6h, psms_donor2_6h, psms_donor3_6h, psms_donor4_6h (min_observed 2) | naive CD4+ T cells / CD3/CD28 stimulated 12h, PAL on-bead trypsin digest (not used for membership): psms_donor1_12h, psms_donor2_12h, psms_donor3_12h, psms_donor4_12h (min_observed 2) | naive CD4+ T cells / CD3/CD28 stimulated 24h, PAL on-bead trypsin digest (not used for membership): psms_donor1_24h, psms_donor2_24h, psms_donor3_24h, psms_donor4_24h (min_observed 2) | naive CD4+ T cells / CD3/CD28 stimulated 48h, PAL on-bead trypsin digest (not used for membership): psms_donor1_48h, psms_donor2_48h, psms_donor3_48h, psms_donor4_48h (min_observed 2) | naive CD4+ T cells / baseline unstimulated (0 h medium control), PAL PNGase F-released N-glycopeptides: psms_donor1_0h, psms_donor2_0h, psms_donor3_0h, psms_donor4_0h (min_observed 2) | naive CD4+ T cells / CD3/CD28 stimulated 3h, PAL PNGase F-released N-glycopeptides (not used for membership): psms_donor1_3h, psms_donor2_3h, psms_donor3_3h, psms_donor4_3h (min_observed 2) | naive CD4+ T cells / CD3/CD28 stimulated 6h, PAL PNGase F-released N-glycopeptides (not used for membership): psms_donor1_6h, psms_donor2_6h, psms_donor3_6h, psms_donor4_6h (min_observed 2) | naive CD4+ T cells / CD3/CD28 stimulated 12h, PAL PNGase F-released N-glycopeptides (not used for membership): psms_donor1_12h, psms_donor2_12h, psms_donor3_12h, psms_donor4_12h (min_observed 2) | naive CD4+ T cells / CD3/CD28 stimulated 24h, PAL PNGase F-released N-glycopeptides (not used for membership): psms_donor1_24h, psms_donor2_24h, psms_donor3_24h, psms_donor4_24h (min_observed 2) | naive CD4+ T cells / CD3/CD28 stimulated 48h, PAL PNGase F-released N-glycopeptides (not used for membership): psms_donor1_48h, psms_donor2_48h, psms_donor3_48h, psms_donor4_48h (min_observed 2)	72	51	0.7083333333333334	0.2	Homo sapiens		0	0	72
autelitano-gbm-sialo-2014	Primary GBM cultures, astrocytes and NPCs, metabolic-azide surface sialoglycoproteome	Autelitano et al. 2014	Autelitano F	2014	25360666	10.1371/journal.pone.0110316	core		Live-cell metabolic sialic-acid labeling with a cell-surface Staudinger ligation, streptavidin capture; untreated cultures, each measured separately, so membership is per culture from observed (non-ND) intensities. No no-label MS control (flow cytometry showed negligible background in vehicle-treated cells). Gene symbols only.	none (supplementary tables only)		pone.0110316.s002.xlsx sheet Table S1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4216004/supplementaryFiles> | pone.0110316.s002.uniprot_mapped.tsv	Cells incubated 2 days in medium with 25 uM Ac4ManNAz, then 50 uM biotin-phosphine in PBS 1 h at room temperature (live cells); cell lysates incubated 2 h RT with streptavidin beads; on-bead trypsin digestion; LC-MS/MS, DIFFTAL label-free quantification; DanteR effect sizes.	Method as described in the paper's Methods 'Sialoglycoprotein labeling and enrichment', Fig. 1 workflow, Results (843 proteins) (full text PMC4216004).	streptavidin-conjugated beads (product named in Methods/File S1)	not reported	LTQ Orbitrap	hybrid LTQ Orbitrap (Thermo) with Dionex Ultimate/Famos/Switchos nano-LC	Instrument as named in the paper's Methods peptide analysis (full text PMC4216004).	Short-term primary cultures of 4 GBM patient tumors; fetal neural progenitor cells; fetal and adult human astrocytes	Table S1 (pone.0110316.s002.xlsx, sheet 'Table S1'): all 843 sialoglycoproteins identified and quantified (paper: 843). Membership per culture = a numeric log2 intensity in that culture's column ('ND'/'1ND' = not detected). The table's GO, glycosylation, SignalP/TM and location columns are annotations added to the full list, not a selection; Table S3 (top-65 overexpressed) not used. HUGO symbols only, mapped through gene_resolver.	pone.0110316.s002.uniprot_mapped.tsv: uniprot_mapped		Fetal human neural progenitor cells / baseline, surface sialoglycan labeled (Ac4ManNAz + biotin-phosphine): Log2 protein intensity in NPCs (min_observed 1) | Fetal human astrocytes / baseline, surface sialoglycan labeled (Ac4ManNAz + biotin-phosphine): Log2 protein intensity in fetal astrocytes (min_observed 1) | Adult human astrocytes / baseline, surface sialoglycan labeled (Ac4ManNAz + biotin-phosphine): Log2 protein intensity in adult astrocytes (min_observed 1) | GBM primary culture SID238 (proneural) / baseline, surface sialoglycan labeled (Ac4ManNAz + biotin-phosphine): Log2 protein intensity in SID238 (min_observed 1) | GBM primary culture SID233 (classical) / baseline, surface sialoglycan labeled (Ac4ManNAz + biotin-phosphine): Log2 protein intensity in SID233 (min_observed 1) | GBM primary culture SID227 (proneural) / baseline, surface sialoglycan labeled (Ac4ManNAz + biotin-phosphine): Log2 protein intensity in SID227 (min_observed 1) | GBM primary culture SID186 (mesenchymal) / baseline, surface sialoglycan labeled (Ac4ManNAz + biotin-phosphine): Log2 protein intensity in SID186 (min_observed 1)	838	563	0.6718377088305489	0.2	Homo sapiens		0	0	838
weekes-hfff-qtv-2014--hcmv-infected-or-irradiated-hcmv-pmp-repeat-pm2	Primary HFFF fibroblast plasma membrane profiling · HCMV-infected or irradiated HCMV, repeat PM2	Weekes et al. 2014	Weekes MP	2014	24906157	10.1016/j.cell.2014.04.028	perturbed	infection: HCMV-infected or irradiated HCMV, repeat PM2	infection arm of weekes-hfff-qtv-2014; shown, not counted. Membership follows the parent recipe's rule for this sample group.	none (supplementary tables only)		mmc3.xlsx sheet Data in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4048463/supplementaryFiles>	One 150 cm2 flask of HCMV-infected HFFFs per condition washed twice in ice-cold PBS; sialic acids oxidised with sodium meta-periodate (Thermo), biotinylated with aminooxy-biotin (Biotium), quenched, scraped into 1% Triton X-100; biotinylated glycoproteins enriched on high-affinity streptavidin agarose (Pierce), washed, on-bead digestion; TMT 8-plex (PM1) and 10-plex (PM2), MS3.	Method as described in the paper's Experimental Procedures, 'Plasma Membrane Profiling'; Results 'Validation of Quantitative Temporal Viromics'; Figure S1D (full text PMC4048463).	high-affinity streptavidin agarose (Pierce)	not reported	Orbitrap Elite; Orbitrap Fusion	Elite for PM1, PM2, WCL1, WCL2; Fusion for WCL3 (whole-cell lysate only)	Instrument as named in the paper's Methods, LC and tandem MS (full text PMC4048463).	HFFF primary fibroblasts	HFFF primary fibroblasts, HCMV-infected or irradiated HCMV, PMP repeat PM2: a non-baseline state of weekes-hfff-qtv-2014, listed when observed in at least 1 of its 8 samples				2317	719	0.3103150625809236		Homo sapiens		0	1	2317
weekes-hfff-qtv-2014--hcmv-infected-pmp-repeat-pm1	Primary HFFF fibroblast plasma membrane profiling · HCMV-infected, repeat PM1	Weekes et al. 2014	Weekes MP	2014	24906157	10.1016/j.cell.2014.04.028	perturbed	infection: HCMV-infected, repeat PM1	infection arm of weekes-hfff-qtv-2014; shown, not counted. Membership follows the parent recipe's rule for this sample group.	none (supplementary tables only)		mmc3.xlsx sheet Data in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4048463/supplementaryFiles>	One 150 cm2 flask of HCMV-infected HFFFs per condition washed twice in ice-cold PBS; sialic acids oxidised with sodium meta-periodate (Thermo), biotinylated with aminooxy-biotin (Biotium), quenched, scraped into 1% Triton X-100; biotinylated glycoproteins enriched on high-affinity streptavidin agarose (Pierce), washed, on-bead digestion; TMT 8-plex (PM1) and 10-plex (PM2), MS3.	Method as described in the paper's Experimental Procedures, 'Plasma Membrane Profiling'; Results 'Validation of Quantitative Temporal Viromics'; Figure S1D (full text PMC4048463).	high-affinity streptavidin agarose (Pierce)	not reported	Orbitrap Elite; Orbitrap Fusion	Elite for PM1, PM2, WCL1, WCL2; Fusion for WCL3 (whole-cell lysate only)	Instrument as named in the paper's Methods, LC and tandem MS (full text PMC4048463).	HFFF primary fibroblasts	HFFF primary fibroblasts, HCMV-infected, PMP repeat PM1: a non-baseline state of weekes-hfff-qtv-2014, listed when observed in at least 1 of its 6 samples				1716	613	0.3572261072261072		Homo sapiens		0	1	1716
weekes-hfff-qtv-2014	Primary HFFF fibroblast plasma membrane profiling · mock-infected (repeat PM1) (baseline)	Weekes et al. 2014	Weekes MP	2014	24906157	10.1016/j.cell.2014.04.028	core		Weekes-lab PMP on primary fibroblasts (same method as Depierreux, Hunter, Soh). Two independent TMT time courses each carry duplicate mock channels, so membership rests on uninfected cells. Whole-cell-lysate rows share the sheet; requiring a non-zero PM mock reporter excludes them.	none (supplementary tables only)		mmc3.xlsx sheet Data in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC4048463/supplementaryFiles>	One 150 cm2 flask of HCMV-infected HFFFs per condition washed twice in ice-cold PBS; sialic acids oxidised with sodium meta-periodate (Thermo), biotinylated with aminooxy-biotin (Biotium), quenched, scraped into 1% Triton X-100; biotinylated glycoproteins enriched on high-affinity streptavidin agarose (Pierce), washed, on-bead digestion; TMT 8-plex (PM1) and 10-plex (PM2), MS3.	Method as described in the paper's Experimental Procedures, 'Plasma Membrane Profiling'; Results 'Validation of Quantitative Temporal Viromics'; Figure S1D (full text PMC4048463).	high-affinity streptavidin agarose (Pierce)	not reported	Orbitrap Elite; Orbitrap Fusion	Elite for PM1, PM2, WCL1, WCL2; Fusion for WCL3 (whole-cell lysate only)	Instrument as named in the paper's Methods, LC and tandem MS (full text PMC4048463).	Primary human fetal foreskin fibroblasts (HFFF)	Table S2 (mmc3.xlsx) sheet 'Data', which merges PM1, PM2 and whole-cell-lysate (WCL1-3) rows. Species = HUMAN only (153 HCMV rows dropped). Membership = mock channel > 0 in repeat PM1 (Mock_1/Mock_2) or in repeat PM2 (Mock_1/Mock_2); infected and irradiated-virus PM channels kept as non-membership measurements; WCL channels not read. The table's GO columns (PM/CS/XC/ShG) are not used; the paper's 927 (PM1) and 1,184 (PM2) 'PM proteins' are the GO-annotated subset of the rows used here.	mmc3.xlsx: Uniprot	Species = HUMAN	HFFF primary fibroblasts / baseline mock-infected, PMP (repeat PM1): PM1_Mock_1, PM1_Mock_2 (min_observed 1) | HFFF primary fibroblasts / baseline mock-infected, PMP (repeat PM2): PM2_Mock_1, PM2_Mock_2 (min_observed 1) | HFFF primary fibroblasts / HCMV-infected, PMP repeat PM1 (not used for membership): PM1_24h_1, PM1_24h_2, PM1_48h_1, PM1_48h_2, PM1_72h_1, PM1_72h_2 (min_observed 1) | HFFF primary fibroblasts / HCMV-infected or irradiated HCMV, PMP repeat PM2 (not used for membership): PM2_6h, PM2_12h, PM2_18h, PM2_24h, PM2_48h, PM2_72h, PM2_96h, PM2_12h_irradiated (min_observed 1)	2539	746	0.2938164631744781	0.2	Homo sapiens		0	2	2539
vanderpost-colon-2014	Primary human colonic epithelial cell membrane fraction along four colon segments	van der Post and Hansson 2014	van der Post S	2014	24889196	10.1074/mcp.M114.040204	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis-then-ultracentrifugation membrane fraction with carbonate/high-pH stripping, so complementary evidence only. First primary human colonic epithelium membrane data in the compendium, resolved by colon segment.	PRIDE	PXD000987	proteinGroups.txt	Na2CO3 / EDTA pH 11.3 / 5 M urea washed 130,000 g membrane pellet from isolated epithelial cells	Method as described in the paper's Experimental Procedures (membrane protein extraction, ref 24) (full text PMC4159649).	none	not applicable	LTQ Orbitrap		Instrument as listed in the ProteomeXchange record PXD000987.	Primary human colonic epithelial cells from four colon segments	MaxQuant proteinGroups.txt from the deposited MaxQuantOutput.zip (2,815 protein groups; 16 samples = 4 individuals x 4 segments). Reverse, contaminant and only-by-site groups removed. Membership per segment = Intensity > 0 in >= 2 of the 4 individuals. No annotation filter (the paper's TMHMM split is not used).	proteinGroups.txt: Protein IDs	drop rows flagged Reverse, Contaminant, Only identified by site	Colonic epithelial cells, ascending colon (primary, biopsy-isolated) / baseline carbonate-washed membrane fraction: Intensity 548A, Intensity 549A, Intensity 550A, Intensity 551A (min_observed 2) | Colonic epithelial cells, transverse colon (primary, biopsy-isolated) / baseline carbonate-washed membrane fraction: Intensity 548T, Intensity 549T, Intensity 550T, Intensity 551T (min_observed 2) | Colonic epithelial cells, descending colon (primary, biopsy-isolated) / baseline carbonate-washed membrane fraction: Intensity 548D, Intensity 549D, Intensity 550D, Intensity 551D (min_observed 2) | Colonic epithelial cells, sigmoid colon (primary, biopsy-isolated) / baseline carbonate-washed membrane fraction: Intensity 548S, Intensity 549S, Intensity 550S, Intensity 551S (min_observed 2)	2602	465	0.1787086856264412	0.2	Homo sapiens		0	0	2602
boheler-2014	hPSC surface map	Boheler et al. 2014	Boheler KR	2014	25068131	10.1016/j.stemcr.2014.05.002	core		Original identification and specimen caveats retained in previous_reason.	supplement		control_surface_proteins.tsv	Gundry/Wollscheid Cell Surface Capture on live cells: approximately 0.6 to 1e8 cells per biological replicate (n >= 3) of H9 hESCs, KB3 hiPSCs and human fibroblasts; extracellular glycans biotinylated on intact cells (periodate oxidation + biocytin hydrazide; immunofluorescence confirmed surface-restricted biotin), lysis, tryptic digestion, biotinylated glycopeptides captured on immobilized streptavidin, PNGase F release; high-mass-accuracy LC-MS/MS with three search algorithms; every reported protein required a deamidated Asn within an N-X-S/T sequon. 496 N-glycoproteins at <=5% FDR; the inventory table is the author-curated hPSC surface list (Table S1). Reagent concentrations and bead product are in the Supplemental Information.	Method as described in the paper's Experimental Procedures 'Cell-Surface Capture: CSC Technology' (Stem Cell Reports 2014; full text PMC4110789).	immobilized streptavidin (product per Gundry-lab CSC protocol; in Supplemental Information)	not reported	not stated in accessible text		Where we looked for the instrument: PMC4110789 full text lacks LC-MS/MS methods (in Supplemental Information, not accessible); no repository ID; publisher blocked.	Embryonic and induced pluripotent stem cells (hESC/iPSC)	human ESC / iPSC / foreskin fibroblasts	control_surface_proteins.tsv: uniprot_accession			496	416	0.8387096774193549	0.2	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			496
ramya-bjab-gal-2013	BJA-B K20 B-cell GAL oxime-ligation glycan biotinylation, asialo and sialo	Ramya et al. 2013	Ramya TN	2013	23070960	10.1093/glycob/cws144	core		Living-cell glycan oxidation and aminooxy-biotin ligation with matched unlabeled controls; the authors' table is filtered on the label-vs-control spectral-count contrast (fixed thresholds, not tuned on annotation), with per-sample counts. The asialo and sialo states differ only in sialic-acid supply, so both are treated as baseline cultures of one line; the GAL arm is one of two complementary chemistries (the other is ramya-bjab-pal-2013).	none (supplementary tables only)		supp_cws144_cws144supp1.xlsx <https://academic.oup.com/glycob/article/23/2/211/1988614> | ramya_bjab_gal_counts.uniprot_mapped.tsv	GAL oxime ligation with aminooxy-biotin on living cells, streptavidin enrichment, on-bead digest (abstract and Table S2a legend)	Method read from: Europe PMC abstract and the Supplementary Data workbook legends; PMC full text not open.	immobilized streptavidin	not stated	LTQ ion trap (ThermoFisher)	LC-MS of tryptic peptides, Agilent 1100 HPLC; also PNGase-F samples	Instrument as named in the paper's Methods, LC-MS analysis (full text PMC3531297).	BJA-B K20 human B-lymphoma cell line, asialo and sialo states	Supplementary Table S2a (249 IPI rows): proteins with score > 4 and ratio > 15 (GAL minus / over control spectral counts) in at least one cell state, as filtered by the authors (no annotation used). IPI mapped to UniProt by sequence. Membership = >= 1 spectral count in either GAL-labeled sample within a cell state; unlabeled controls kept as non-membership measurements. Table S2b (looser GAL thresholds) and Tables S3-S5 (PNGase-released N-glycopeptides) not used.	ramya_bjab_gal_counts.uniprot_mapped.tsv: uniprot_accession		BJA-B K20 asialo (sialic-acid deficient) / baseline GAL aminooxy-biotin labeling of living cells, streptavidin capture: asialo_gal_1, asialo_gal_2 (min_observed 1) | BJA-B K20 asialo (sialic-acid deficient) / unlabeled streptavidin control (not used for membership): asialo_control_1, asialo_control_2 (min_observed 1) | BJA-B K20 sialo (sialylated) / baseline GAL aminooxy-biotin labeling of living cells, streptavidin capture: sialo_gal_1, sialo_gal_2 (min_observed 1) | BJA-B K20 sialo (sialylated) / unlabeled streptavidin control (not used for membership): sialo_control_1, sialo_control_2 (min_observed 1)	213	115	0.539906103286385	0.2	Homo sapiens		0	0	213
ramya-bjab-pal-2013	BJA-B K20 B-cell PAL oxime-ligation glycan biotinylation, asialo and sialo	Ramya et al. 2013	Ramya TN	2013	23070960	10.1093/glycob/cws144	core		Living-cell glycan oxidation and aminooxy-biotin ligation with matched unlabeled controls; the authors' table is filtered on the label-vs-control spectral-count contrast (fixed thresholds, not tuned on annotation), with per-sample counts. The asialo and sialo states differ only in sialic-acid supply, so both are treated as baseline cultures of one line; the PAL arm is one of two complementary chemistries (the other is ramya-bjab-gal-2013).	none (supplementary tables only)		supp_cws144_cws144supp1.xlsx <https://academic.oup.com/glycob/article/23/2/211/1988614> | ramya_bjab_pal_counts.uniprot_mapped.tsv	PAL oxime ligation with aminooxy-biotin on living cells, streptavidin enrichment, on-bead digest (abstract and Table S1 legend)	Method read from: Europe PMC abstract and the Supplementary Data workbook legends; PMC full text not open.	immobilized streptavidin	not stated	LTQ ion trap (ThermoFisher)	LC-MS of tryptic peptides, Agilent 1100 HPLC; also PNGase-F samples	Instrument as named in the paper's Methods, LC-MS analysis (full text PMC3531297).	BJA-B K20 human B-lymphoma cell line, asialo and sialo states	Supplementary Table S1 (492 IPI rows): proteins with score > 4 and ratio > 15 (PAL minus / over control spectral counts) in at least one cell state, as filtered by the authors (no annotation used). IPI mapped to UniProt by sequence. Membership = >= 1 spectral count in either PAL-labeled sample within a cell state; unlabeled controls kept as non-membership measurements. Tables S3-S5 (PNGase-released N-glycopeptides) not used.	ramya_bjab_pal_counts.uniprot_mapped.tsv: uniprot_accession		BJA-B K20 asialo (sialic-acid deficient) / baseline PAL aminooxy-biotin labeling of living cells, streptavidin capture: asialo_pal_1, asialo_pal_2 (min_observed 1) | BJA-B K20 asialo (sialic-acid deficient) / unlabeled streptavidin control (not used for membership): asialo_control_1, asialo_control_2 (min_observed 1) | BJA-B K20 sialo (sialylated) / baseline PAL aminooxy-biotin labeling of living cells, streptavidin capture: sialo_pal_1, sialo_pal_2 (min_observed 1) | BJA-B K20 sialo (sialylated) / unlabeled streptavidin control (not used for membership): sialo_control_1, sialo_control_2 (min_observed 1)	438	134	0.3059360730593607	0.2	Homo sapiens		0	0	438
yokoyama-endometrial-2013	Endometrial cancer and normal endometrial lines, cell-surface biotinylation iTRAQ	Yokoyama et al. 2013	Yokoyama T	2013	22729361	10.1002/ijc.27679	held	conditions are pooled in one list, with no separable baseline	Cell-surface biotinylation of intact cultured lines (abstract), but the identification list is pooled across eight lines in one iTRAQ plex: a protein's membership cannot be attributed to any line, the ratio columns are relative to the normal line and absent whenever either reporter is missing, and the line identities and labeling reagent could not be read (Wiley full text not accessible).	none (supporting information only)		ijc_27679_sm_supptabs2.xls sheet Supplementary Table S2 <https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fijc.27679&file=IJC_27679_sm_SuppTabS2.xls>	cell-surface biotinylation, iTRAQ, nano-LC-MS/MS	Method read from: PubMed abstract (biotinylation-based cell-surface protein enrichment; reagent not read); Table S2 header.	not read	not stated	not stated in accessible text		Where we looked for the instrument: Europe PMC abstract only (no free full text); publisher page via DOI blocked (refused automated access) or served no readable text; abstract says nano LC-MS/MS iTRAQ only.	seven endometrial cancer cell lines and one normal endometrial cell line (lines not named in the accessible text)	Supplementary Table S2 'List of all the proteins identified in iTRAQ analysis': 272 proteins (paper: 272). Membership = listed (identified in the pooled 8-line iTRAQ run). The localization column selects nothing; reporter ratios are kept in the source only. Tables S3 (single-peptide PSMs) and S4 (BSA ratio) not used.	ijc_27679_sm_supptabs2.xls: Accession			249	133	0.5341365461847389	0.2	Homo sapiens		2	0	249
yan-hnscc-spheres-2013	HNSCC tumor spheres and adherent cells, pooled four lines, sulfo-NHS surfaceome	Yan et al. 2013	Yan M	2013	23903875	10.1074/mcp.M112.025460	held	each sample mixes several cell lines, so membership can't be stated per line	Intact-cell sulfo-NHS-SS-biotin capture, full identification list (includes many intracellular proteins), but each sample is an equal-protein mix of four HNSCC lines, so membership cannot be stated per cell line; held rather than admitted as primary. Neither culture format is a drug/genetic perturbation.	none (supplementary tables only)		mcp.M112.025460-8.pdf <https://doi.org/10.1074/mcp.M112.025460> | yan_table_s4.tsv	Pierce cell surface protein isolation kit, EZ-Link sulfo-NHS-SS-biotin on cells before lysis, NeutrAvidin agarose; captures of four lines mixed equally per culture format before SDS-PAGE (Experimental Procedures, 'Isolation and Preparation of Membrane Proteins', 'One-dimensional SDS-PAGE')	Method read from: PMC3820938 article page read; supplemental Fig. S3 legend; Table S4.	NeutrAvidin agarose (kit)	not reported	Agilent 1200 Series LC/MSD Trap XCT Ultra ion trap	HPLC-Chip Cube interface	Instrument as named in the paper's Methods (full text PMC3820938).	four HNSCC lines pooled in equal protein amounts (CAL27, WSU-HN6, WSU-HN12, WSU-HN13)	Supplemental Table S4 (mcp.M112.025460-8.pdf): all 376 identified proteins (= paper's 376), with distinct peptide counts in the sphere pool (320 proteins > 0) and the adherent pool (255 > 0). Membership = >= 1 distinct peptide in the pool. Each pool mixes four lines, so membership is pooled across lines. Membrane-prediction score and type columns are annotation only.	yan_table_s4.tsv: uniprot_accession		four HNSCC lines pooled in equal protein amounts (CAL27, WSU-HN6, WSU-HN12, WSU-HN13) / tumor sphere culture (serum-free, EGF/bFGF), sulfo-NHS-SS-biotin labeled: peptides_spheres (min_observed 1) | four HNSCC lines pooled in equal protein amounts (CAL27, WSU-HN6, WSU-HN12, WSU-HN13) / adherent culture (10% FBS), sulfo-NHS-SS-biotin labeled: peptides_adherent (min_observed 1)	372	64	0.17204301075268819	0.2	Homo sapiens		0	0	372
petrareanu-heparg-2013	HepaRG undifferentiated and differentiated plasma-membrane fraction	Petrareanu et al. 2013	Petrareanu C	2013	23977166	10.1371/journal.pone.0071859	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Centrifugation-based plasma-membrane isolation from lysed cells, not a surface label: membrane-fractionation family, complementary. Undifferentiated and differentiated HepaRG are both unperturbed culture states, so each is its own membership group. Tables report GI numbers, mapped to UniProt by a pinned, conservative mapping; 56 of 474 GIs stay unmapped.	none (supplementary tables only)		petrareanu_heparg_pm_uniprot_mapped.tsv	Optimized subcellular fractionation (ref 22) to a PM ring, 2/3 collected; purity checked by organelle-marker westerns	Method as described in the paper's Methods 'Preparation of PM from HepaRG Cells' and 'Protein Digestion'; Results (307/112 and 210/78 hits) (PMC3748114).	none	not applicable	Q-TOF Micro (Micromass/Waters)	NanoAcuity UPLC LC-MS/MS	Instrument as named in the paper's Methods (full text PMC3748114).	HepaRG hepatic progenitor line, undifferentiated (ND) and DMSO-differentiated hepatocyte/biliary-like (D) cells	Tables S1 and S2 (experiments 1 and 2): every Mascot hit listed per state (ND 112 and 75, D 307 and 210 GIs; paper text says 78 ND hits in experiment 2). GI numbers mapped to UniProt through a pinned mapping (NCBI esummary accession, then UniProt ID mapping; one reviewed or one total entry only, else blank). Membership = listed in either experiment for that state. Mascot score > 25 as published; no further filter.	petrareanu_heparg_pm_uniprot_mapped.tsv: uniprot_mapped		HepaRG undifferentiated / plasma-membrane fraction: peptides_ND_exp1, peptides_ND_exp2 (min_observed 1) | HepaRG differentiated / plasma-membrane fraction: peptides_D_exp1, peptides_D_exp2 (min_observed 1)	323	30	0.09287925696594428	0.2	Homo sapiens		9	0	323
kang-mda453-csc-2013	MDA-MB-453 parental and CSC-like in-situ cell-surface biotinylation	Kang et al. 2013	Kang MJ	2013	23554123	10.1002/pmic.201200511	below_screen	12% Canonical or Likely proteins, under 20%	Intact-cell (in situ) biotinylation with avidin capture; both lines are unperturbed baseline cultures and the Scaffold report is the full identification list before any IPA plasma-membrane selection (that subset is Table S3, not used). No no-label control was reported, so intracellular carry-over cannot be read from the table.	none (supplementary tables only)		pmic7424-sup-0001-tables1.pdf <https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/pmic.201200511> | kang_mda453_surface_runs.uniprot_mapped.tsv	in-situ cell-surface biotinylation followed by MS (abstract); capture by avidin per the supplement design	Method read from: Europe PMC abstract and Supplemental Table 1 header; Wiley full text not read.	avidin/streptavidin (not read)	not stated	not stated in accessible text		Where we looked for the instrument: Wiley page, Europe PMC abstract.	MDA-MB-453 breast carcinoma cell line and its CD44+/CD24- CSC-like derivative	Supplemental Table 1 (PDF Scaffold report, parsed to a derived table): every protein reported in 54 runs (27 per cell type). Decoy (REVERSE_) lines dropped; first IPI of each group mapped to UniProt by sequence. Membership = reported in >= 1 injection of >= 1 of the nine samples within a cell type. Table S2 (peptide report) and Table S3 (IPA plasma-membrane subset) not used. No annotation filter.	kang_mda453_surface_runs.uniprot_mapped.tsv: uniprot_accession		MDA-MB-453 parental (non-CSC-like) / baseline in-situ cell-surface biotinylation, avidin capture: nonCSC_s1, nonCSC_s2, nonCSC_s3, nonCSC_s4, nonCSC_s5, nonCSC_s6, nonCSC_s7, nonCSC_s8, nonCSC_s9 (min_observed 1) | MDA-MB-453 CSC-like (CD44+/CD24-) derivative / baseline in-situ cell-surface biotinylation, avidin capture: CSC_s1, CSC_s2, CSC_s3, CSC_s4, CSC_s5, CSC_s6, CSC_s7, CSC_s8, CSC_s9 (min_observed 1)	2698	326	0.12083024462564863	0.2	Homo sapiens		0	0	2698
posthumadeboer-os-2013	Osteosarcoma and osteoblast sulfo-NHS surfaceome	Posthumadeboer et al. 2013	Posthumadeboer J	2013	24064975	10.1038/bjc.2013.578	core		Live-cell sulfo-NHS-SS-biotin capture of the full identification list (no annotation gate in Table S1). IPI accessions are retired, so proteins are joined through their reported gene symbol; unmapped or ambiguous symbols are quarantined. No no-label control.	none		bjc2013578x3.xls sheet Blad1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC3798973/supplementaryFiles> | bjc2013578x3.uniprot_mapped.tsv	Sulfo-NHS-SS-biotin on live cells, NeutrAvidin capture, GeLC-MS/MS; Sequest/Scaffold against IPI human 3.62; normalised spectral counts per cell line.	Method summarized from the paper (PMC3798973) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	LTQ-FT hybrid mass spectrometer	LC-MS/MS of peptides (details in Supplementary File S1)	Instrument as named in the paper's Methods (full text PMC3798973).	5 osteosarcoma lines (SaOS-2, MG-63, U2OS, Cal-72, SaOS-LM7) and 3 primary human osteoblast cultures (Hum54, Hum31, ORT-1)	Supplementary Table S1, complete surface proteomic dataset (2,841 IPI entries) with normalised spectral counts per line; detected = count > 0 in a line	bjc2013578x3.uniprot_mapped.tsv: uniprot_mapped		SaOS-2 / baseline intact-cell surface biotinylation: SaOS-2 (min_observed 1) | MG-63 / baseline intact-cell surface biotinylation: MG-63 (min_observed 1) | U2OS / baseline intact-cell surface biotinylation: U2OS (min_observed 1) | Cal-72 / baseline intact-cell surface biotinylation: Cal-72 (min_observed 1) | LM7 / baseline intact-cell surface biotinylation: LM7 (min_observed 1) | Hum54 / baseline intact-cell surface biotinylation: Hum54 (min_observed 1) | Hum31 / baseline intact-cell surface biotinylation: Hum31 (min_observed 1) | ORT-1 / baseline intact-cell surface biotinylation: ORT-1 (min_observed 1)	2740	530	0.19343065693430658	0.2	Homo sapiens		0	0	2740
wang-placenta-2013	Placental plasma membrane N-glycosites, sucrose-gradient PM then lectin capture	Wang et al. 2013	Wang F	2013	24260401	10.1371/journal.pone.0080480	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Tissue homogenate taken to a sucrose-gradient plasma-membrane fraction, then lectin glycopeptide capture after lysis: membrane-fractionation family, complementary. Neither step shows extracellular access, and the lectin step selects glycoproteins of every secretory compartment that co-sediment with the PM. Normal and preeclamptic placenta are pooled in the identifications because the light/heavy channel assignment is not stated.	none (supplementary tables only)		pone.0080480.s002.xls sheet phospho-sites in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC3829899/supplementaryFiles>	Placental tissue homogenate, 600 g and 24,000 g spins, 0.25 M/1.35 M sucrose step gradient (100,000 g, 2.5 h) PM band; SDS/urea solubilization, trypsin, dimethyl labeling, ConA/WGA/RCA120 lectin glycopeptide capture on a 1 kDa filter, PNGase F	Method as described in the paper's Methods 'Plasma Membrane Preparation' and 'Glycoprotein Digestion, Dimethyl Labeling, Glycopeptide Enrichment' (PMC3829899); Results para 1 (1,027 N-glyco and 2,094 phospho sites, Table S2).	none (lectin solution on MWCO filter)	not stated	LTQ-Orbitrap (Thermo); Results text says LTQ-Orbitrap-Velos	Waters nanoACQUITY UPLC; Methods say 'LTQ-Orbitrap instrument', Velos named once in Results	Instrument as named in the paper's Methods and Results (full text PMC3829899).	Human term placenta, maternal side (20 normal and 20 preeclamptic pregnancies, pooled into 3 + 3 groups)	Table S2 N-glycosite sheet (1,027 deamidated-N sites on 570 protein accessions; the sheet is labeled 'phospho-sites' in the file, the labels are swapped). Every listed site row is kept (MaxQuant site/peptide/protein FDR < 1%, as published); no quantification filter, because 158 of 1,027 sites have no dimethyl quantification. Identifications are pooled across normal and preeclamptic placenta, which were dimethyl-labeled and mixed before enrichment; the paper does not state which channel is which. The phosphosite sheet (2,094 S/T/Y sites, labeled 'N-glyco-sites') is not used.	pone.0080480.s002.xls: Protein	Amino acid = N		538	248	0.46096654275092935	0.2	Homo sapiens		0	22	538
muraoka-breast-membrane-2013	Pooled breast cancer tissue membrane fraction, iTRAQ	Muraoka et al. 2013	Muraoka S	2013	23153008	10.1021/pr300824m	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Tissue membrane fraction after homogenization: complementary by the membrane-fractionation family policy. Tissue pools from 18 patients; tumor tissue only (no normal comparator), so both iTRAQ pools are baseline tissue.	PRIDE	PXD000066;PXD005163	pride_xml_protein_identifications.tsv	membrane fraction from homogenized tumor tissue, iTRAQ	Method read from: Europe PMC abstract (JPR full text closed); PRIDE PXD000066 metadata and XML.	none	not applicable	LTQ Orbitrap Velos		Instrument as listed in the ProteomeXchange records PXD000066 and PXD005163.	Primary breast cancer tissue (18 patients, pooled into high- and low-risk pools)	Derived from PRIDE BreastCancerMembrane.xml: one row per <Identification> (15,376). Membership = accession with >= 1 peptide evidence in the export and not listed as 'Other member of protein ambiguity group' under another identification (one row per ambiguity group). Pooled iTRAQ run: both patient pools contribute to every identification; no per-channel values in the export.	pride_xml_protein_identifications.tsv: accession	listed_as_other_group_member = no | n_peptide_evidence ≥ 1		7607	1128	0.14828447482581833	0.2	Homo sapiens		0	0	7607
bonardi-aml-pm-2013	Primary AML CD34+/CD34- blast membrane fraction	Bonardi et al. 2013	Bonardi F	2013	23233446	10.1074/mcp.M112.021931	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis then sucrose-cushion membrane enrichment of sorted primary AML cells: membrane-fractionation family, complementary evidence only. The unfiltered protein reports (not the GO-selected PM sheets) are used, so membership reflects every identification in the membrane fraction, including the large intracellular-membrane background the authors note.	ProteomeCommons Tranche (hash in paper; service retired)		mcp.M112.021931-1.xlsx <https://doi.org/10.1074/mcp.M112.021931> | bonardi_protein_reports_by_sample.tsv | bonardi_protein_reports_by_sample.uniprot_mapped.tsv	needle lysis, 1000 g nuclear depletion, 60% sucrose cushion 100,000 g, membrane pellet 80,000 g (Experimental Procedures, 'Membrane Protein Purification')	Method as described in the paper's Experimental Procedures and Results ; Supplemental File S1 (full text PMC3591656).	none	n/a	LTQ-Orbitrap (Thermo; exact model not given)		Instrument as named in the paper's Methods (full text PMC3591656).	primary AML blasts (two patients), CD34+ and CD34- sorted fractions	Supplemental File S1, the four unfiltered Scaffold 'Protein Report' sheets (AML1 CD34+ 3,504 rows, AML1 CD34- 1,162, AML2 CD34+ 2,580, AML2 CD34- 4,085 = paper's 3504/1162/2580/4058 proteins with >= 1 unique peptide), rolled up to one row per reported gene symbol (max unique spectra per sample). Membership = present (>= 1 unique spectrum) in a patient x fraction report; no probability filter beyond the authors' Scaffold report. The GO-selected 'PM only' and 'PM&Associated' sheets (867/610 in the abstract) are not used. Gene symbols mapped through gene_resolver (first symbol of a ';'-joined list); 969 rows without a symbol and 11 symbols the source file stores as Excel dates are left unmapped.	bonardi_protein_reports_by_sample.uniprot_mapped.tsv: uniprot_mapped		AML1 CD34+ blasts / baseline sorted primary cells, sucrose-cushion membrane fraction: unique_spectra_AML1_CD34pos (min_observed 1) | AML1 CD34- blasts / baseline sorted primary cells, sucrose-cushion membrane fraction: unique_spectra_AML1_CD34neg (min_observed 1) | AML2 CD34+ blasts / baseline sorted primary cells, sucrose-cushion membrane fraction: unique_spectra_AML2_CD34pos (min_observed 1) | AML2 CD34- blasts / baseline sorted primary cells, sucrose-cushion membrane fraction: unique_spectra_AML2_CD34neg (min_observed 1)	6336	840	0.13257575757575757	0.2	Homo sapiens		0	0	6336
rorvig-neutrophil-2013	Primary neutrophil plasma membrane fraction from Percoll subcellular fractionation	Rørvig et al. 2013	Rørvig S	2013	23650620	10.1189/jlb.1212619	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Density-gradient plasma membrane fraction of lysed (cavitated) neutrophils, not a surface label; complementary. The HLA fraction detects 1,450 of 1,497 groups, so with matching and sensitive detection it is close to a whole-cell list; the per-fraction intensities, not membership, carry the localisation signal.	PRIDE	PXD005559	proteinGroups.uniprot_mapped.tsv	Nitrogen cavitation and four-layer Percoll density centrifugation of freshly isolated neutrophils; six fractions (four granule pools, secretory vesicles, plasma membrane) each run on SDS-PAGE, 10 slices, in-gel digestion, LTQ Orbitrap XL; MaxQuant 1.1.1.36.	Method read from: PubMed abstract; PRIDE PXD005559 protocols and Experimental_Design.xlsx (fraction names FICO, GELA, MPO, NGAL, HSA, HLA; replicate series A/B); paper not open access.	none	not applicable	LTQ Orbitrap XL			Primary human peripheral blood neutrophils	PRIDE PXD005559 MaxQuant proteinGroups.txt (1,601 IPI-keyed groups; only that member of MaxQuant_Result_Files.zip is read). Reverse, contaminant and only-identified-by-site groups removed (1,497 remain; paper: 1,292 unique proteins after its own grouping). Membership = Intensity HLA (plasma membrane fraction) > 0; the five granule and secretory-vesicle fractions are kept as non-membership measurements. IPI groups mapped to UniProt through the group's MaxQuant 'Uniprot' cross-reference column, kept only when exactly one reviewed human entry is listed (1,347 of 1,497); 150 groups with zero or several reviewed entries left unmapped.	proteinGroups.uniprot_mapped.tsv: uniprot_mapped	drop rows flagged Reverse, Contaminant, Only identified by site	Primary human blood neutrophils / plasma membrane fraction (HLA-marker gamma fraction), baseline unstimulated: Intensity HLA (min_observed 1) | Primary human blood neutrophils / secretory vesicle fraction (not used for membership): Intensity HSA (min_observed 1) | Primary human blood neutrophils / ficolin-1-rich granule fraction (not used for membership): Intensity FICO (min_observed 1) | Primary human blood neutrophils / gelatinase granule fraction (not used for membership): Intensity GELA (min_observed 1) | Primary human blood neutrophils / specific granule fraction (not used for membership): Intensity NGAL (min_observed 1) | Primary human blood neutrophils / azurophil granule fraction (not used for membership): Intensity MPO (min_observed 1)	1298	201	0.15485362095531588	0.2	Homo sapiens		0	0	1298
choksawangkarn-rpmi8226-pellicle-2013	RPMI 8226 myeloma cationic nanoparticle pellicle plasma-membrane fractions	Choksawangkarn et al. 2013	Choksawangkarn W	2013	23289353	10.1021/pr301107x	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Cationic-nanoparticle pellicle coating is applied to intact cells, but the readout is a density-sedimented membrane-sheet fraction after lysis with no surface label, so it is membrane fractionation (same family as sharma-fetal-cm-2015): complementary by policy, never votes. Each pellicle was a single preparation from a separate harvest.	none (supplementary tables only)		NIHMS435111-supplement-2_si_002.xls sheet Protein Summary <https://pmc.ncbi.nlm.nih.gov/articles/PMC3586300/>	cationic nanoparticle coating of intact cells + poly(acrylic acid) cross-link, N2 cavitation lysis, 100 g sedimentation of pellicle-bound PM sheets, carbonate/KCl washes	Method as described in the paper's Materials and Methods (Cell Culture and Pellicle Coating; Bioinformatics) (full text PMC3586300).	cationic nanoparticles (three types)	not stated	LTQ Orbitrap XL	Shimadzu nanoHPLC; six technical replicate injections per pellicle	Instrument as named in the paper's Methods (full text PMC3586300).	RPMI 8226 multiple myeloma cell line	Supplementary Table 2 'Protein Summary' (1,336 retained proteins, columns renamed by position). Membership = spectral count > 0 in any of the three pellicle preparations (aluminosilicate 761, Fe3O4/Al2O3 716, SiO2/Al2O3 1,001); whole-cell lysate (990) kept as a non-membership measurement. Retention (>= 2 unshared peptides) was applied by the authors across all samples, so a protein can be counted in one pellicle from fewer peptides. Supplementary Table 3 (peptides) not used. No annotation filter.	NIHMS435111-supplement-2_si_002.xls: Protein		RPMI 8226 / baseline LUDOX-CL aluminosilicate nanoparticle pellicle plasma-membrane fraction: aluminosilicate_spectral_count (min_observed 1) | RPMI 8226 / baseline Fe3O4/Al2O3 nanoparticle pellicle plasma-membrane fraction: fe3o4_al2o3_spectral_count (min_observed 1) | RPMI 8226 / baseline SiO2/Al2O3 nanoparticle pellicle plasma-membrane fraction: sio2_al2o3_spectral_count (min_observed 1) | RPMI 8226 / whole-cell lysate, uncoated (not used for membership): cell_lysate_spectral_count (min_observed 1)	1130	93	0.08230088495575222	0.2	Homo sapiens		0	49	1130
weekes-thp1-ul138-2013	THP-1 monocytic cell plasma membrane profiling, vector vs HCMV UL138 SILAC	Weekes et al. 2013	Weekes MP	2013	23580527	10.1126/science.1235047	core		Weekes-lab intact-cell periodate/aminooxy-biotin PMP (same method as Depierreux, Soh, Hoare). Identification comes from the SILAC mix of control and UL138-expressing THP-1, but every row has a UL138/control ratio and so was quantified in the control channel, the same rule as hoare-imr90-pmp-2016. The table is the full >2-peptide list, not the authors' 592 PM-annotated subset.	none (supplementary tables only)		NIHMS53510-supplement-supp_table_S2.xlsx sheet Table S2 <https://pmc.ncbi.nlm.nih.gov/articles/PMC3683642/>	'plasma membrane profiling (PMP) (13)' with SILAC; chemistry by reference to Weekes 2010 J Biomol Tech (periodate/aminooxy-biotin on live cells); details in the Science SOM (supporting_info.doc), not opened	Method read from: PMC3683642 main text (PMP paragraph, Fig. 1 legend) and the Table S2 footer ('Of all 620 proteins identified by >2 peptides, 470 (76%) were annotated PM or CS or XC or ShG').	streptavidin (per PMP protocol)	not stated	not stated in accessible text		Where we looked for the instrument: PMC3683642 main text has no instrument; methods in supplement not accessible.	THP-1 monocytic leukemia cell line (control vector and UL138-expressing)	Table S2 (NIHMS53510-supplement-supp_table_S2.xlsx): all 620 proteins identified by > 2 unique peptides in the SILAC PMP experiment (616 distinct base accessions), before any annotation; the GO squares (M, PM, CS, XC, ShG) are empty in the published file and never filter rows. Membership = unique peptides > 0 (every row; each row carries a UL138/control fold change, i.e. was quantified in the control channel). The signed fold change is not read as a measurement. Footer legend rows drop on the accession pattern.	NIHMS53510-supplement-supp_table_S2.xlsx: Uniprot		THP-1 / control and UL138-expressing cells SILAC-mixed; control channel quantified (UL138/control fold change present): Unique peptides (min_observed 1)	612	423	0.6911764705882353	0.2	Homo sapiens		0	1	612
kani-a431-gefitinib-2012	A431 epidermoid carcinoma cell-surface biotin capture, SILAC untreated vs gefitinib	Kani et al. 2012	Kani K	2012	22411897	10.1158/1535-7163.MCT-11-0852	below_screen	16% Canonical or Likely proteins, under 20%	Intact-cell biotin capture of A431 surface proteins. Identification comes from the SILAC mix of untreated and gefitinib-treated cells, but every member carries a surface H/L ratio and so was quantified in the untreated (light) channel, the same rule as hoare-imr90-pmp-2016. The labeling chemistry is described only by reference to the lab's earlier protocol.	none (supplementary tables only)		NIHMS363546-supplement-3.xls sheet PROTEIN QUANTITATION <https://pmc.ncbi.nlm.nih.gov/articles/PMC3959865/> | NIHMS363546-supplement-3.uniprot_mapped.tsv	'Cell-surface proteins were isolated by biotin labeling and subsequently captured by avidin chromatography' (Fig. 1 legend); protocol by reference (ref. 24, Hanash lab); reagent not named in this paper	Method as described in the paper's Materials and Methods (Cell culture/SILAC; Protein identification by LC-MS/MS), Fig. 1 legend, Table S2 header ('ALL RATIOS ARE REPORTED HEAVY / LIGHT', '16h_SURFACE H+/L') (full text PMC3959865).	avidin chromatography	not stated	LTQ-FTICR or LTQ-Orbitrap (Thermo-Finnigan); model not resolved per sample	LC-MS/MS of pooled fractions	Instrument as named in the paper's Methods (full text PMC3959865).	A431 epidermoid carcinoma cell line	Table S2 'PROTEIN QUANTITATION' (file NIHMS363546-supplement-3.xls; 3,994 IPI rows across compartments). Membership = a '16h_SURFACE H+/L' ratio quantified from >= 1 peptide (821 proteins): the light, untreated channel was measured for each. The 16 h surface H/L ratio (gefitinib/untreated) is kept as a non-membership measurement. Whole-cell-lysate (2H/16H_TE) and secreted columns not read. IPI-only accessions, so rows are mapped from the reported gene symbol (GN). No annotation filter.	NIHMS363546-supplement-3.uniprot_mapped.tsv: uniprot_mapped		A431 / untreated and gefitinib cells SILAC-mixed; untreated (light) channel quantified (surface H/L ratio present): surface_16h_ratio_peptides (min_observed 1) | A431 / gefitinib 16 h / untreated SILAC ratio (not used for membership): surface_16h_mean_H_over_L (min_observed 1)	693	110	0.15873015873015872	0.2	Homo sapiens		0	0	693
mi-hcc-csc-2012	Hepatocellular carcinoma cell surface N-glycopeptide capture, modified CSC	Mi et al. 2012	Mi W	2012	22752401	10.1007/s10719-012-9420-3	held	the cell line, and whether runs were pooled, aren't stated	Intact-cell CSC chemistry and an observed identification list, but the cell line(s) and whether lines/runs were pooled into this one list are not stated in the abstract or supplement (full text not read), so membership cannot be tied to one cell type. Promote to primary if the paper names a single unperturbed line.	none (supplementary tables only)		10719_2012_9420_MOESM1_ESM.pdf <https://static-content.springer.com/esm/art%3A10.1007%2Fs10719-012-9420-3/MediaObjects/10719_2012_9420_MOESM1_ESM.pdf> | mi_hcc_table2_accessions.tsv	glycan biotinylation on intact cell surfaces (CSC), modified (abstract)	Method read from: PubMed abstract; ESM Supplementary Table 2 header.	not stated	not stated	not stated in accessible text		Where we looked for the instrument: Europe PMC abstract only (no free full text); no model given.	hepatocellular carcinoma cells (line(s) not named in the abstract or supplement)	ESM Supplementary Table 2 (PDF pp. 4-10): every identified N-glycopeptide with its protein (79 IPI identifiers; paper: 79 protein species, 116 glycopeptides, 119 sites). Membership = protein listed: 78 distinct UniProt accessions (one row carries an IPI without a printed UniProt accession). Supplementary Table 1 (RNase B/ovalbumin standards) excluded. Location/TMH/CD columns are annotation only. No annotation filter.	mi_hcc_table2_accessions.tsv: uniprot_accession		HCC cells / baseline intact-cell CSC glycopeptide capture: listed (min_observed 1)	78	49	0.6282051282051282	0.2	Homo sapiens		0	0	78
zhang-luad-pm-2012	Lung adenocarcinoma and paired normal lung tissue plasma-membrane fraction, iTRAQ	Zhang et al. 2012	Zhang PF	2012	22982323	10.1016/j.jprot.2012.08.021	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Plasma-membrane fraction of lysed tissue: total-membrane enrichment, complementary only. Proteins reported in both iTRAQ runs (a reproducibility filter, not annotation); tumor and normal channels pooled into one list.	none (supplementary tables only)		1-s2.0-S1874391912006392-mmc1.xls sheet Protein quantification data <https://ars.els-cdn.com/content/image/1-s2.0-S1874391912006392-mmc1.xls>	tissue plasma-membrane fraction + iTRAQ 2D LC-MS/MS (from abstract and supplementary-table notes; full text not open)	Method read from: PubMed abstract; mmc1.xls notes (ProteinPilot 3, 114:115/116:117 AdC vs PNLT ratios, 'repeatedly identified by the two 2D LC-MS/MS analyses').	none	n/a	not stated in accessible text		Where we looked for the instrument: Europe PMC abstract only (no free full text); publisher page via DOI blocked (refused automated access) or served no readable text; abstract says iTRAQ 2D LC-MS/MS only.	Primary lung adenocarcinoma and paired paraneoplastic normal lung tissue	Supplementary data mmc1.xls sheet 'Protein quantification data': the 277 nonredundant proteins identified in both 2D LC-MS/MS iTRAQ analyses (authors' reproducibility filter; ProteinPilot Unused/coverage and per-channel ratios). Membership = every listed protein. Only ratios are reported, so tumor and normal channels cannot be separated; one pooled list. The PM-characteristic annotation on the identification sheet is not used.	1-s2.0-S1874391912006392-mmc1.xls: Accession #			270	86	0.31851851851851853	0.2	Homo sapiens		0	0	270
karhemo-mda435-2012	MDA-MB-435 isogenic metastatic/non-metastatic sublines, sulfo-NHS-SS-biotin surfaceome	Karhemo et al. 2012	Karhemo PR	2012	22813880	10.1016/j.jprot.2012.07.009	core		Intact-cell sulfo-NHS-SS-biotin capture of two unperturbed isogenic sublines with a non-biotinylated control per line; the authors removed control-shared peptides before protein assembly, and Table S1 is the full protein list before any localisation annotation. Small list (86 proteins).	none (supplementary tables only)		1-s2.0-S1874391912005398-mmc2.xls sheet Proteins <https://ars.els-cdn.com/content/image/1-s2.0-S1874391912005398-mmc2.xls>	Sulfo-NHS-SS-biotin on intact cells on ice, NeutrAvidin capture, DTT elution	Method as described in the paper's Methods 2.2-2.4 (three biological replicates + one non-biotinylated control per line; control peptides marked 'not included') (full text PMC3508169).	NeutrAvidin	not stated	LTQ Orbitrap XL	nano-LC with Advion ESI Chip interface	Instrument as named in the paper's Methods (full text PMC3508169).	MDA-MB-435 cancer cell line, isogenic sublines GD8 (metastatic) and BD12 (non-metastatic)	Supplemental Table S1 (mmc2.xls) sheet 'Proteins': 86 proteins (>= 2 peptides; peptides also present in the non-biotinylated control runs excluded by the authors). Membership per subline = MS/MS spectral count > 0 in >= 2 of 3 biological replicates (runs 01200/01201/01203 = GD8, 01205/01206/01209 = BD12). Progenesis normalised abundances carried as measurements only (feature alignment fills every run). Sheet 'Spectra for single hits' (11 one-peptide proteins) not used.	1-s2.0-S1874391912005398-mmc2.xls: Accession		MDA-MB-435 GD8 (metastatic subline) / baseline sulfo-NHS-SS-biotin labeled: spectral_count_01200, spectral_count_01201, spectral_count_01203 (min_observed 2) | MDA-MB-435 BD12 (non-metastatic subline) / baseline sulfo-NHS-SS-biotin labeled: spectral_count_01205, spectral_count_01206, spectral_count_01209 (min_observed 2)	61	46	0.7540983606557377	0.2	Homo sapiens		0	0	61
english-brain-2012	Post-mortem insular cortex Triton X-114 detergent phase	English et al. 2012	English JA	2012	22745773	10.1371/journal.pone.0039509	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Detergent-phase partitioning of whole tissue; total membrane, complementary only. Only adult human brain tissue membrane list in the family.	none		english_tableS3_S4_uniprot_mapped.tsv	Triton X-114 phase separation of post-mortem human insular cortex (Stanley Foundation); detergent-phase proteins by LC-MS/MS, Mascot.	Method summarized from the paper (PMC3382145) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	LTQ-Orbitrap (Thermo; exact model not given)		Instrument as named in the paper's Methods (full text PMC3382145).	Post-mortem human insular cortex	Tables S3 (DT1, 661 proteins) and S4 (DT2, 790), union 1,154 entry names; membership = listed in either detergent-phase sample (Mascot peptide matches > 0).	english_tableS3_S4_uniprot_mapped.tsv: uniprot_accession_mapped		insular cortex (post-mortem) / Triton X-114 detergent phase: prot_matches_DT1, prot_matches_DT2 (min_observed 1)	1130	135	0.11946902654867257	0.2	Homo sapiens		1	0	1130
ponnusamy-fnrbc-membrane-2012	Primary human fetal nucleated red blood cell membrane fraction	Ponnusamy et al. 2012	Ponnusamy S	2012	22842289	10.1016/j.jprot.2012.07.020	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Membrane fraction of lysed primary cells: membrane-fractionation family, complementary evidence only. The full identification list (Table 1) is used, not the annotation-split Tables 2-4.	none (supplementary tables only)		1-s2.0-S1874391912005507-mmc2.xls sheet Suppl Tables 1-5 <https://doi.org/10.1016/j.jprot.2012.07.020> | 1-s2.0-S1874391912005507-mmc3.xls sheet Peptide sequences for proteins  <https://doi.org/10.1016/j.jprot.2012.07.020> | ponnusamy_table1.uniprot_mapped.tsv	membrane protein fraction, 2D-LC-MS/MS with TFE and methanol arms (abstract and Supplemental Table 1 headers; full methods not readable: ScienceDirect full text not accessible, no PMC copy)	Method read from: PubMed abstract; Supplemental Datasets I and II.	none	n/a	not stated in accessible text		Where we looked for the instrument: Europe PMC abstract only (no free full text); publisher page via DOI blocked (refused automated access) or served no readable text; abstract says 2D-LCMS/MS only.	primary human fetal primitive nucleated red blood cells (FNRBCs)	Supplemental Table 1 'Total proteins identified in FNRBCs' (273 IPI hits = abstract's 273; 199 in the TFE arm, 144 in the MeOH arm). Membership = peptide count >= 1 in either arm (one group: same membrane preparation, two digestion chemistries). IPI mapped to UniProt through the hit's own reported peptides (mmc3): 236 hits mapped to exactly one reviewed entry, 36 left blank (several or no matching entries, or no peptides). Subcellular-location/TMHMM columns are annotation only.	ponnusamy_table1.uniprot_mapped.tsv: uniprot_accession		fetal nucleated red blood cells / baseline membrane fraction (TFE and MeOH digestion arms): tfe_peptide_count, meoh_peptide_count (min_observed 1)	226	24	0.10619469026548672	0.2	Homo sapiens		0	0	226
msc-hoflack-2011	MSC surfaceome	Niehage et al. 2011	Niehage C	2011	21637820	10.1371/journal.pone.0020399	annotation_selected	author pre-filtered to transmembrane or signal-peptide proteins	pre-filtered by surface annotation (annotation-selected); shown, not counted. Was provisional. provisional: threshold 47.0851%; borderline allowance 2.0%. TM/signal/lipid proxy does not reproduce the historical localization classifier.	supplement		control_surface_proteins.tsv	Cell-surface biotinylation of intact plastic-adherent bone-marrow hMSCs (~1e7 cells per donor) with 0.5 mg/mL cleavable EZ-Link Sulfo-NHS-SS-biotin (Thermo Fisher) in Ca/Mg-PBS for 1 h at 4 C, quenched with 20 mM glycine; lysis in PBS / 0.1% SDS / 1% Triton X-100 with protease inhibitors; biotinylated proteins bound 2 h at 4 C to streptavidin-agarose beads, washed with Triton buffers, released by reduction with 50 mM MESNA (so non-specifically adsorbed proteins stay on the beads); TCA precipitation, 1D-PAGE into 24 slices, in-gel trypsin and LC-MS/MS; proteins required >=2 peptides. 888 proteins identified, ~200 classified as bona fide plasma-membrane proteins.	Method as described in the paper's Methods 'Biotinylation of cell surface proteins' (PLoS One 2011; full text PMC3102717).	streptavidin-agarose beads (vendor/catalog not stated)	not reported	LTQ Orbitrap XL		Instrument as named in the paper's Methods (full text PMC3102717).	Healthy-donor bone-marrow mesenchymal stromal cells	Bone-marrow-derived mesenchymal stromal cells (hMSC), plastic-adherent, isolated by Percoll density-gradient from bone-marrow aspirates of healthy donors (TU Dresden ethics board EK263122004), expanded in DMEM-low-glucose + 10% FCS, biotinylated at passages up to 8; hMSC preparations pooled across multiple donors for the biotinylation/MS pipeline.	control_surface_proteins.tsv: uniprot_accession			201	121	0.6019900497512438	0.47085130205355774	Homo sapiens	Human cell/tissue arm selected; protein-ID taxonomy checked separately.			175
yang-pc3-sialo-2011	PC3-derived N2 and ML2 prostate cancer lines, metabolic-azide surface sialoglycoproteome	Yang et al. 2011	Yang L	2011	21447706	10.1074/mcp.M110.007294	below_screen	10% Canonical or Likely proteins, under 20%	Azido-sialic acid labeled metabolically, then biotin-alkyne clicked on intact live cells before lysis (Experimental Procedures), so capture is surface-directed. Baseline ManNAz lists define membership per line; ManNAc control-sugar lists are not used. The authors annotate only 26-29% of hits as extracellular/membrane glycoproteins, so expect a sizeable intracellular background.	none (supplementary tables only)		mcp.M110.007294-2.xls | mcp.M110.007294-2.xls sheet 1 | mcp.M110.007294-2.xls sheet 2 | mcp.M110.007294-2.xls sheet 3	Ac4ManNAz 3 days, then 'chemoselective conjugation of azide sugars with a biotinylated alkyne capture reagent via Cu(I) catalyzed click chemistry in live cells'; cells washed then lysed in 1% NP-40	Method read from: PMC3108840 full text (Europe PMC fullTextXML), Experimental Procedures and Results.	high-capacity streptavidin agarose (Thermo)	not stated	LTQ linear ion trap (ThermoFinnigan)	LC-MS/MS data-dependent acquisition	Instrument as named in the paper's Methods (full text PMC3108840).	PC3-derived syngeneic prostate cancer lines N2 (non-metastatic) and ML2 (highly metastatic)	Supplemental Table 1 (mcp.M110.007294-2.xls), sheets 1A-1D: all proteins identified in each line x sugar list (N2 ManNAz 324, ML2 ManNAz 372 = paper's 324 and 372; ManNAc controls 132 and 75). Membership = presence (Mascot protein score) in the line's ManNAz list; ManNAc control lists kept as measurements only. UniProtKB location, SOSUI/TMHMM and NetNGlyc columns annotate the full list and were not used to select rows. Lysate lists (Table 4) not used.	mcp.M110.007294-2.xls: Access # | mcp.M110.007294-2.xls: Access # | mcp.M110.007294-2.xls: Access # | mcp.M110.007294-2.xls: Access #		PC3-N2 (non-metastatic) / baseline, Ac4ManNAz + live-cell CuAAC biotin-alkyne: Protein score (min_observed 1) | PC3-N2 (non-metastatic) / ManNAc control sugar, same click and capture (not used for membership): Protein score (min_observed 1) | PC3-ML2 (highly metastatic) / baseline, Ac4ManNAz + live-cell CuAAC biotin-alkyne: Protein score (min_observed 1) | PC3-ML2 (highly metastatic) / ManNAc control sugar, same click and capture (not used for membership): Protein score (min_observed 1)	511	51	0.09980430528375733	0.2	Homo sapiens		0	0	511
qattan-mcf7-sucrose-2010	MCF-7 sucrose-gradient plasma-membrane fraction	Qattan et al. 2010	Qattan AT	2010	19911851	10.1021/pr9008332	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis-then-sucrose-gradient organelle fractionation of untreated MCF-7; the PM fraction is a density fraction, not a surface-labeled population, so it is complementary by family policy and never votes. The fraction carries abundant cytosolic, ER and mitochondrial proteins (the paper reports 57% of proteins in multiple fractions).	none (supplementary tables only)		NIHMS61387-supplement-STable3.xls sheet Supp Table 2 <https://pmc.ncbi.nlm.nih.gov/articles/PMC4261601/> | qattan_table2_fraction_spectral_counts.tsv	Dounce homogenisation, 800 g clearing, sucrose density gradient; F13 = plasma-membrane fraction	Method as described in the paper's Experimental Procedures (cell culture and subcellular fractionation; mass spectrometric analysis; Scaffold); Table 1; Supplementary Table 2 footnotes (full text PMC4261601).	none	not stated	LTQ-Orbitrap (Thermo; exact model not given)		Instrument as named in the paper's Methods (full text PMC4261601).	MCF-7 breast carcinoma cell line	Supplementary Table 2 (file NIHMS61387-supplement-STable3.xls; 2,184 proteins, 'initial data set'), derived to one row per GI with the marker-stripped UniProtKB AC. Membership = unweighted spectral count > 0 in the plasma-membrane fraction F13 (1,611 proteins, matching the paper's Table 1 'Total Proteins per Fraction'). Cytosol (F9), ER (F16) and mitochondrial (F20) fractions kept as non-membership measurements. 'not_found' rows (5, incl. porcine trypsin) have no accession and drop. No annotation filter; the Location columns of the sheet are not used.	qattan_table2_fraction_spectral_counts.tsv: uniprot_accession		MCF-7 / baseline sucrose-gradient plasma-membrane fraction (F13): F13_plasma_membrane_spectral_counts (min_observed 1) | MCF-7 / sucrose-gradient cytosol fraction F9 (not used for membership): F9_cytosol_spectral_counts (min_observed 1) | MCF-7 / sucrose-gradient endoplasmic-reticulum fraction F16 (not used for membership): F16_er_spectral_counts (min_observed 1) | MCF-7 / sucrose-gradient mitochondrial fraction F20 (not used for membership): F20_mitochondrion_spectral_counts (min_observed 1)	1451	180	0.12405237767057202	0.2	Homo sapiens		0	0	1451
zhang-os-2010	Osteosarcoma vs osteoblast plasma membrane, two-phase partition	Zhang et al. 2010	Zhang Z	2010	20470422	10.1186/1471-2407-10-206	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Aqueous two-phase plasma-membrane partition, not a surface label. IPI accessions are retired and the table carries the gene symbol only as the first word of the protein name, which is used for the join.	none		1471-2407-10-206-S1.XLS in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC2880991/supplementaryFiles> | 1471-2407-10-206-S1.uniprot_mapped.tsv	Aqueous two-phase (dextran/PEG) plasma-membrane partition, iTRAQ, ProteinPilot against IPI human.	Method summarized from the paper (PMC2880991) during our 2026-10-28/29 literature search; not yet checked against the full text.	not recorded (capture matrix not yet audited)	not reported	QSTAR Pulsar (Applied Biosystems-MDS Sciex)	LC-MS of SCX fractions	Instrument as named in the paper's Methods, LC-MS Analysis (full text PMC2880991).	MG-63 osteosarcoma cells and hFOB 1.19 osteoblastic cells	Additional file 1, all proteins identified in two iTRAQ experiments (identifications pooled across MG-63 and hFOB 1.19)	1471-2407-10-206-S1.uniprot_mapped.tsv: uniprot_mapped			287	104	0.3623693379790941	0.2	Homo sapiens		0	0	287
zhang-placenta-stb-2010	Term placenta syncytiotrophoblast light apical plasma-membrane fraction	Zhang et al. 2010	Zhang Q	2010	21137071	10.1002/prca.200900048	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Sucrose-gradient apical membrane fraction from homogenised tissue, no surface label: complementary membrane-family evidence from a primary human tissue barrier. Table is the authors' full identification list.	none (supplementary tables only)		Supplemental_table_I_161209.xls <https://analyticalsciencejournals.onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Fprca.200900048&file=prca_200900048_sm_SupplInfo.zip> | 20210127_human_rew_uni.fasta <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/07/PXD031828/20210127_human_rew_uni.fasta> | zhang_stb_la_mascot.uniprot_mapped.tsv	differential centrifugation, MgCl2 apical/basolateral separation, sucrose step gradient light apical fraction	Method read from: Supporting information PDF 'Supplemental_method_+figure_151209.pdf' (Methods; Supplemental figure 1).	none	not stated	Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD031828.	human term placenta, syncytiotrophoblast apical plasma membrane	Supplemental Table I (sheet 'Zusammenfassung'; 296 IPI proteins, = the paper's 296) with Mascot scores in three light-apical preparations LA1-LA3. Membership = Mascot score reported in >= 1 of the 3 preparations (every row has >= 2). IPI rows mapped to reviewed UniProt by the printed Swiss-Prot entry name (264), else by a gene symbol carried by exactly one reviewed entry (19, mostly TrEMBL entry names); 13 left blank (renamed entries, multi-gene rows such as CSH1;CSH2;GH1, CALM1-3, HSPA1A/B, IGL) and drop. Localisation/TMD columns are annotation only. No annotation filter.	zhang_stb_la_mascot.uniprot_mapped.tsv: uniprot_accession		term placenta syncytiotrophoblast / baseline light apical plasma-membrane fraction: LA1_mascot_score, LA2_mascot_score, LA3_mascot_score (min_observed 1)	280	86	0.30714285714285716	0.2	Homo sapiens		0	0	280
mcquade-hesc-membrane-2009	Human embryonic stem cell membrane-enriched fraction, peptide IPG-IEF	McQuade et al. 2009	McQuade LR	2009	19899800	10.1021/pr900597s	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis-then-fractionation membrane preparation with no surface label: complementary membrane-family evidence. The table is the authors' full non-redundant identification list before any GO/TMHMM selection.	none (supplementary tables only)		pr900597s_si_001.xls <https://pubs.acs.org/jprobs/article-supplement/1638896/xls/pr900597s_si_001/> | mcquade_hesc_nonredundant.uniprot_mapped.tsv	membrane-enriched fraction (abstract); exact enrichment steps not read (ACS full text not accessible)	Method read from: PubMed abstract; Supporting Information si_001.xls.	none	not stated	not stated in accessible text		Where we looked for the instrument: No free full text; abstract has no instrument; ACS page refused automated access.	human embryonic stem cells	Supporting Information si_001.xls 'hESC Non-Redundant List' (2,851 Ensembl proteins incl. 558 single-peptide hits). Membership = >= 2 peptides (rI), the paper's criterion: 2,292 ENSP rows (paper: 2,292). UniProt accession read from the Ensembl description's Source/Acc tag; 22 of those rows have no UniProt tag (RefSeq or none) and drop. TMHMM table (si_002) and commonly-reported-protein table (si_003) are annotation selections and not used. No annotation filter.	mcquade_hesc_nonredundant.uniprot_mapped.tsv: uniprot_accession	peptides_rI ≥ 2	hESC / baseline membrane-enriched fraction: peptides_rI (min_observed 1)	2236	294	0.13148479427549195	0.2	Homo sapiens		0	7	2236
lethlarsen-mda-pm-2009	MDA-MB-435 isogenic sublines SILAC plasma-membrane purifications	Leth-Larsen et al. 2009	Leth-Larsen R	2009	19321434	10.1074/mcp.m800061-mcp200	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis-then-fractionate plasma-membrane purification; complementary by family policy. Each sample is a SILAC mix of two isogenic sublines of one parental line, so the list is one pooled membership for the MDA-MB-435 lineage.	none (supplementary tables only)		lethlarsen_sd3_proteins.uniprot_mapped.tsv	Abstract: membrane purification and comparative quantitative LC-MS/MS of SILAC-labeled isogenic lines; Supplementary Data 2 part 2 description: fractions 'enriched for cell surface proteins and with minimal mitochondrial contamination derived of the density fractionation'. Supplementary Data 1: VEMS normalisation to beta-actin and Na/K-ATPase.	Method read from: Europe PMC abstract; Elsevier mmc1.zip (Supplementary Data 1 PDF, Data 2 and 3 description sheets). MCP full text (mcponline.org) not accessible to us, so the detailed purification protocol for each sample letter was not read.	none	not applicable	not stated in accessible text		Where we looked for the instrument: PMC2690497 not available: Europe PMC fullText 500, PMC page PoW-blocked, efetch no body, MCP refused automated access.	MDA-MB-435-derived isogenic sublines M-4A4 and NM-2C5 (SILAC-mixed)	Supplementary Data 3: every protein identification of membrane purifications A-I and L-P (4,709 protein-sample rows), rolled up to 1,920 IPI entries (paper: 1,919 protein entries). UniProt accession taken from each IPI header's own SWISS-PROT (1,047) or first TREMBL (401) cross-reference; 472 IPI entries with only ENSEMBL/REFSEQ/H-INV/VEGA cross-references left unmapped. Membership = identified in any purification; each sample is a SILAC mix of the two isogenic sublines, so identifications cannot be split by line. No other filter.	lethlarsen_sd3_proteins.uniprot_mapped.tsv: uniprot_mapped			913	127	0.13910186199342825	0.2	Homo sapiens		0	100	913
garcia-shsy5y-2009	SH-SY5Y neuroblastoma sulfo-NHS biotin surface proteome, avidin column	Garcia et al. 2009	Garcia J	2009	19505085	10.1021/pr800964v	below_screen	14.8% of its length-corrected amount in Canonical or Likely proteins, under 25%	Intact-cell sulfo-NHS biotinylation with avidin capture on unperturbed SH-SY5Y; the supplement is the complete group list before any annotation. Deep fractionation makes it large and intracellular-heavy; there is no no-label control. Second SH-SY5Y dataset after gangras-shsy5y-2022.	none (supplementary tables only; search results cited at the FHCRC CPAS server)		pr800964v_si_001.xls <https://pubs.acs.org/doi/10.1021/pr800964v> | 20210127_human_rew_uni.fasta <https://ftp.pride.ebi.ac.uk/pride/data/archive/2023/07/PXD031828/20210127_human_rew_uni.fasta> | garcia_shsy5y_groups.uniprot_mapped.tsv	biotinylated cell-surface proteins captured on an avidin affinity column, RP-fractionated, LC-MS/MS (abstract)	Method read from: Europe PMC abstract and the supplementary sheet title; ACS full text not read.	avidin affinity column	not stated	Orbitrap Fusion		Instrument as listed in the ProteomeXchange record PXD031828.	SH-SY5Y neuroblastoma cell line (MYCN non-amplified)	Supplementary Table 1 (sheet TableS1, peptide rows collapsed to 2,542 protein groups, ProteinProphet probability 0.80-1.00 as published). Each group mapped to UniProt through its own peptides (all peptides in exactly one reviewed human entry); unmapped groups and the bovine trypsin group drop out. Membership = listed group with >= 1 spectral count. The 'Cellular Location' and 'Transm. Helices' annotation columns are carried along, never used to select. No further filter.	garcia_shsy5y_groups.uniprot_mapped.tsv: uniprot_accession		SH-SY5Y / baseline sulfo-NHS biotinylation, avidin column: spectral_counts (min_observed 1)	2316	236	0.10189982728842832	0.2	Homo sapiens		0	0	2316
adam-lncap-drm-2008	LNCaP/MyrAkt1 prostate cancer detergent-resistant membranes, two extraction methods	Adam et al. 2008	Adam RM	2008	18534013	10.1186/1471-2121-9-30	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lipid-raft/DRM preparation after lysis: membrane fractionation, complementary by family policy. A methods paper with one high-confidence run per extraction method; the authors state the analysis was not meant to be exhaustive.	none (supplementary table only)		adam_drm_proteins.uniprot_mapped.tsv	Differential detergent extraction (Triton X-100 then octylglucoside) of DRMs from LNCaP/MyrAkt1 cells, conventional vs nuclei-depleted modified protocol	Method as described in the paper's Methods (DRM isolation; mass spectrometry and database searching) and Additional file 1 (full text PMC2440737).	none	not applicable	LTQ Orbitrap	nanoLC-MS/MS of DRM fraction digests	Instrument as named in the paper's Methods (full text PMC2440737).	LNCaP prostate cancer cells stably expressing myristoylated Akt1 (MyrAkt1)	Additional file 1 (Sheet4): Mascot high-confidence protein hits (>= 2 peptides, peptide score >= 33, p < 0.01; keratins and trypsin removed by the authors) of the conventional and modified DRM fractions, one run each, rolled up to one row per IPI accession (543 IPI hits: 389 conventional, 371 modified). IPI mapped to UniProt through the hit's own peptides (single reviewed human entry containing all peptides; 513 of 543 mapped, 30 left unmapped). Membership = Mascot protein score present in either fraction (min_observed 1 per fraction, single runs).	adam_drm_proteins.uniprot_mapped.tsv: uniprot_mapped		LNCaP/MyrAkt1 / detergent-resistant membrane fraction, conventional extraction: conventional_protein_score (min_observed 1) | LNCaP/MyrAkt1 / detergent-resistant membrane fraction, modified nuclei-depleted extraction: modified_protein_score (min_observed 1)	503	46	0.09145129224652088	0.2	Homo sapiens		0	0	503
faca-ovarian-2008	Ovarian cancer lines and ascites tumor cells sulfo-NHS-SS-biotin surfaceome	Faça et al. 2008	Faça VM	2008	18560578	10.1371/journal.pone.0002425	below_screen	19.3% of its length-corrected amount in Canonical or Likely proteins, under 25%	Intact-cell sulfo-NHS-SS-biotin capture with the full identification table (no annotation gate). Each line and the ascites sample is one pooled surface fraction, so detection is a single observation, and there is no no-biotin control; the paired whole-cell extract counts allow a surface/total enrichment reading. IPI accessions are retired, so proteins are joined through the reported gene symbol; unmapped or ambiguous symbols are quarantined.	none (supplementary tables only)		pone.0002425.s002.xls sheet TABLE S1 in supplementaryFiles <https://www.ebi.ac.uk/europepmc/webservices/rest/PMC2409963/supplementaryFiles> | pone.0002425.s002.uniprot_mapped.tsv	Sulfo-NHS-SS-biotin (0.25 mg/mL, 10 min RT on adherent lines; 0.48 mg/mL, 30 min RT on ascites cells in suspension), 10 mM lysine quench, NP-40 lysis, NeutrAvidin affinity chromatography, DTT elution	Method as described in the paper's Methods 'Capture of cell surface proteins' and 'Mass spectrometry analysis' (PMC2409963).	UltraLink Immobilized NeutrAvidin (Pierce), 1 mL column; DTT elution	not stated	LTQ-Orbitrap	Thermo-Finnigan LTQ-Orbitrap with Eksigent nanoflow LC, pooled fractions	Instrument as named in the paper's Methods (full text PMC2409963).	OVCAR3, CaOV3 and ES2 ovarian cancer lines; primary serous ovarian tumor cells enriched from the ascites of one patient	Table S1 (6,462 IPI protein groups across all specimens and compartments, ProteinProphet 1% error rate). Proteins joined through the reported gene symbol (IPI retired). Membership = cell-surface spectral count > 0 in that line or sample (one pooled surface fraction each; paper reports 1,093 OVCAR3, 1,556 CaOV3, 1,690 ES2 and 1,727 ascites surface proteins). Whole-cell extract and conditioned-medium counts kept as measurements only. Annotation columns (cellular location, TMHMM, SignalP, plasma) in the table select no rows.	pone.0002425.s002.uniprot_mapped.tsv: uniprot_mapped		OVCAR3 / baseline intact-cell surface biotinylation: OVCAR3 Cell Surface Counts (min_observed 1) | CaOV3 / baseline intact-cell surface biotinylation: CaOV3 Cell Surface Counts (min_observed 1) | ES2 / baseline intact-cell surface biotinylation: ES2 Cell Surface Counts (min_observed 1) | primary ovarian serous carcinoma cells enriched from ascites (one patient) / baseline intact-cell surface biotinylation: ascites Cell Surface Counts (min_observed 1) | OVCAR3 / whole-cell extract (not used for membership): OVCAR3 Total Extract Counts (min_observed 1) | OVCAR3 / conditioned medium (not used for membership): OVCAR3 Secreted Counts (min_observed 1) | CaOV3 / whole-cell extract (not used for membership): CaOV3 Total Extract Counts (min_observed 1) | CaOV3 / conditioned medium (not used for membership): CaOV3 Secreted Counts (min_observed 1) | ES2 / whole-cell extract (not used for membership): ES2 Total Extract Counts (min_observed 1) | ES2 / conditioned medium (not used for membership): ES2 Secreted Counts (min_observed 1) | primary ovarian serous carcinoma cells enriched from ascites (one patient) / whole-cell extract (not used for membership): ascites Total Extract Counts (min_observed 1) | primary ovarian serous carcinoma cells enriched from ascites (one patient) / conditioned medium (not used for membership): ascites Secreted Counts (min_observed 1)	3009	467	0.15520106347623797	0.2	Homo sapiens		0	0	3009
dormeyer-hesc-hecc-pm-2008	hESC HUES-7 and hECC NT2/D1 plasma-membrane-enriched preparations	Dormeyer et al. 2008	Dormeyer W	2008	18489135	10.1021/pr800056j	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis-based membrane enrichment with no surface label: membrane fractionation, complementary by policy, never votes. Most of each list is non-membrane by the authors' own GO count (447/1,077 and 695/1,261).	none (supplementary tables only)		pr800056j_si_002.pdf <https://pubs.acs.org/doi/10.1021/pr800056j> | dormeyer_hesc_hecc_pm.uniprot_mapped.tsv	membrane enrichment without tedious cell fractionation (abstract); triple digest +/- deglycosylation (Supplemental Table 1)	Method read from: Europe PMC abstract, Supplemental Tables 1-2 and the si_007 reproducibility workbook; ACS full text not read, so the exact enrichment step is not stated here.	none	not stated	not stated in accessible text		Where we looked for the instrument: ACS refused automated access; Europe PMC abstract only; no free full text in PubMed Central.	HUES-7 human embryonic stem cell line and NT2/D1 human embryonal carcinoma cell line	Supplemental Table 2 (PDF): the complete identification lists, 1,077 proteins in HUES-7 and 1,261 in NT2/D1 (the totals on its summary page), parsed from the accession blocks to one row per IPI with each line's Mascot score; mapped to UniProt through the table's own Entrez Gene id (one reviewed human entry), or the IPI sequence where the gene id is #N/A. Membership = listed in that line. The GO 'Protein localization' block (from which the paper's 237/219 plasma-membrane counts come) is not used; Table 3 (membrane-only unique/common split) not used. No annotation filter.	dormeyer_hesc_hecc_pm.uniprot_mapped.tsv: uniprot_accession		HUES-7 hESC / baseline plasma-membrane-enriched preparation: HUES7_mascot_score (min_observed 1) | NT2/D1 hECC / baseline plasma-membrane-enriched preparation: NT2D1_mascot_score (min_observed 1)	1572	364	0.23155216284987276	0.2	Homo sapiens		0	0	1572
pshezhetsky-caco2-pm-2007	Caco-2 plasma and apical membrane fractions, proliferating and differentiated	Pshezhetsky et al. 2007	Pshezhetsky AV	2007	17549793	10.1002/pmic.200600956	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis-then-fractionation membrane preparations (complementary family). The two Caco-2 states are unperturbed culture stages (spontaneous differentiation), but the table does not resolve per-state detection for proteins without a ratio, so the list is used whole as one pooled Caco-2 membrane catalog.	none (supporting information PDF only)		pro200600956_s.pdf <http://www.wiley-vch.de/contents/jc_2120/2007/pro200600956_s.pdf> | pshezhetsky_table_s1.tsv	plasma membrane (PC) and apical membrane (DC) isolation by subcellular fractionation (abstract); fractionation protocol not read (Wiley full text paywalled, not in PMC)	Method read from: Europe PMC abstract; supporting-information table header and legend.	none	n/a	not stated in accessible text		Where we looked for the instrument: No free full text; abstract has no instrument; Wiley page blocked.	Caco-2 colorectal adenocarcinoma cell line (proliferating and enterocyte-differentiated)	Supplemental Table 1 of the supporting information PDF: 1,124 UniProt records (the abstract states 1,125 proteins) identified in the membranes of proliferating (PC) and differentiated (DC) Caco-2 by any of the three MS workflows. Membership = listed; identifications are pooled across the PC plasma-membrane and DC apical-membrane preparations because the table cannot say which preparation detected a protein when no DC/PC ratio is given (blank = not detected or ratio not calculable). GO columns select nothing; Supplemental Table 2 (significantly changed subset) is not used.	pshezhetsky_table_s1.tsv: uniprot_id			1085	143	0.13179723502304147	0.2	Homo sapiens		0	36	1085
yanagida-hl60-raft-2007--dmso-induced-neutrophilic-differentiation	HL-60 plasma-membrane lipid rafts · DMSO-induced neutrophilic differentiation	Yanagida et al. 2007	Yanagida M	2007	17623299	10.1002/pmic.200700056	perturbed	differentiation or activation: DMSO-induced neutrophilic differentiation	differentiation or activation arm of yanagida-hl60-raft-2007; shown, not counted. Membership follows the parent recipe's rule for this sample group.	none (supporting information PDF only)		pro200700056_s.pdf <http://www.wiley-vch.de/contents/jc_2120/2007/pro200700056_s.pdf> | yanagida_table_s1.uniprot_mapped.tsv	plasma membrane lipid raft isolation, nano-LC-MS/MS (abstract); raft protocol not read (Wiley full text paywalled, not in PMC)	Method read from: Europe PMC abstract; supporting-information Table 1 header and legend.	none	n/a	not stated in accessible text		Where we looked for the instrument: Europe PMC abstract only (no free full text); mentions nano-LC-MS/MS, no model.	HL-60	HL-60, DMSO-induced neutrophilic differentiation: a non-baseline state of yanagida-hl60-raft-2007, listed when observed in at least 1 of its 1 samples				115	37	0.3217391304347826		Homo sapiens		0	0	115
yanagida-hl60-raft-2007	HL-60 plasma-membrane lipid rafts · untreated (baseline)	Yanagida et al. 2007	Yanagida M	2007	17623299	10.1002/pmic.200700056	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lipid-raft fractionation after lysis (complementary family). Untreated HL-60 defines membership; DMSO differentiation is a chemical perturbation and is kept as measurements only.	none (supporting information PDF only)		pro200700056_s.pdf <http://www.wiley-vch.de/contents/jc_2120/2007/pro200700056_s.pdf> | yanagida_table_s1.uniprot_mapped.tsv	plasma membrane lipid raft isolation, nano-LC-MS/MS (abstract); raft protocol not read (Wiley full text paywalled, not in PMC)	Method read from: Europe PMC abstract; supporting-information Table 1 header and legend.	none	n/a	not stated in accessible text		Where we looked for the instrument: Europe PMC abstract only (no free full text); mentions nano-LC-MS/MS, no model.	HL-60 promyelocytic leukemia cell line	Supplementary Table 1: all 147 proteins identified (matches the abstract), RefSeq ids with number of peptides in untreated and DMSO-treated raft preparations. Membership = untreated HL-60 with >= 1 peptide (129 RefSeq proteins); DMSO-differentiated arm (117) kept as measurements only. RefSeq ids mapped to UniProt by sequence identity through UniParc (144 mapped, 3 unmapped: NP_000564, XP_058611, XP_497670).	yanagida_table_s1.uniprot_mapped.tsv: uniprot_accession		HL-60 / baseline untreated, plasma-membrane lipid rafts: peptides_untreated (min_observed 1) | HL-60 / DMSO-induced neutrophilic differentiation (not used for membership): peptides_dmso (min_observed 1)	127	32	0.25196850393700787	0.2	Homo sapiens		0	0	127
he-liver-pm-2007	Human liver tissue plasma membrane, original and carbonate-washed, shotgun	He et al. 2007	He J	2007	21136673	10.1002/prca.200600004	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Lysis-then-fractionation liver plasma membrane (complementary family). The two shotgun preparations of the same tissue PM define membership; peptide-mass-fingerprint 2-DE spot identifications are lower-specificity and kept as measurements only.	none (supporting information PDF only)		pca200600004_s.pdf <http://www.wiley-vch.de/contents/jc_2456/2007/pca200600004_s.pdf> | he_liver_pm_tables.uniprot_mapped.tsv	subcellular fractionation of human liver PM, carbonate wash (abstract); donor details and fractionation protocol not read (Wiley full text paywalled, not in PMC)	Method read from: Europe PMC abstract; supporting-information table captions.	none	n/a	not stated in accessible text		Where we looked for the instrument: Europe PMC abstract only (no free full text); publisher page via DOI blocked (refused automated access) or served no readable text; abstract mentions 2-DE MALDI-TOF-MS and shotgun, model not stated.	Human liver tissue	Supporting-information Tables 2-5: PM_2DE 228, EPM_2DE 63, PM_Shotgun 248, EPM_Shotgun 260 (= the abstract's 260 high-confidence proteins) IPI records; Table 6 (139 integral membrane proteins, TMD-selected) recorded as a flag only. Membership = listed in either shotgun table (unique peptides >= 2 as published); the 2-DE PMF tables are kept as measurements only. 522 distinct IPI ids, 494 mapped to UniProt by UniParc sequence identity, 28 blank (26 no active human entry, 2 ambiguous).	he_liver_pm_tables.uniprot_mapped.tsv: uniprot_accession		liver tissue / plasma membrane fraction, shotgun LC-MS/MS: PM_Shotgun_unique_peptides (min_observed 1) | liver tissue / carbonate-washed plasma membrane fraction, shotgun LC-MS/MS: EPM_Shotgun_unique_peptides (min_observed 1) | liver tissue / plasma membrane fraction, 2-DE MALDI-TOF PMF (not used for membership): PM_2DE_mascot_score (min_observed 1) | liver tissue / carbonate-washed plasma membrane fraction, 2-DE MALDI-TOF PMF (not used for membership): EPM_2DE_mascot_score (min_observed 1)	370	67	0.1810810810810811	0.2	Homo sapiens		0	0	370
everberg-pbmc-atps-2006	Peripheral blood mononuclear cell plasma membranes by aqueous two-phase partitioning	Everberg et al. 2006	Everberg H	2006	16674106	10.1021/pr050469z	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Two-phase partitioning of homogenised cells with no surface label: complementary membrane-family evidence. Table 4 is the full identification list across localisation classes.	none (supplementary tables only)		pr050469z_si_001.pdf <https://pubs.acs.org/jprobs/article-supplement/3504706/pdf/pr050469z_si_001/> | everberg_table4_proteins.tsv	aqueous two-phase partitioning, alkaline stripping (abstract and Table 4 caption)	Method read from: PubMed abstract; supporting Table 4 caption.	none	not stated	not stated in accessible text		Where we looked for the instrument: Europe PMC abstract only (no free full text); publisher page via DOI blocked (refused automated access) or served no readable text; abstract says 1DE LC-MS/MS only.	primary human peripheral blood mononuclear cells (one donor)	Supporting Table 4 (PDF): every protein identified in the two-phase plasma-membrane preparation, 239 Swiss-Prot accessions across all localisation classes (105 'plasma membrane', 134 other). Membership = listed in Table 4. The localisation and TMHMM columns are the authors' annotation and never filter rows. No annotation filter.	everberg_table4_proteins.tsv: uniprot_accession		PBMC / baseline two-phase partitioned plasma-membrane fraction: listed (min_observed 1)	224	52	0.23214285714285715	0.2	Homo sapiens		0	0	224
rahbar-mcf7mxr-pellicle-2005	Mitoxantrone-resistant MCF-7 (MXR) colloidal-silica pellicle plasma-membrane fraction	Rahbar and Fenselau 2005	Rahbar AM	2005	16335961	10.1021/pr0502370	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Colloidal-silica pellicle coats intact attached cells but labels no protein; the readout is a membrane-sheet fraction after lysis (same family as choksawangkarn-rpmi8226-pellicle-2013 from the same lab and sharma-fetal-cm-2015): complementary by policy, never votes. The list comes from the drug-selected MXR subline, a stable line in its own right rather than an acute perturbation.	none (supplementary tables only)		pr0502370_si_001.pdf <https://pubs.acs.org/doi/10.1021/pr0502370> | rahbar_mxr_pm_table1.tsv	colloidal silica pellicle coating, lysis, density sedimentation of PM sheets (abstract); metabolic differential labeling of the two lines	Method read from: Europe PMC abstract and the Supporting Information Table 1 caption; ACS full text not read.	cationic colloidal silica	not stated	not stated in accessible text		Where we looked for the instrument: ACS page, Europe PMC abstract.	MCF-7/MXR mitoxantrone-resistant breast adenocarcinoma subline	Supporting Information Table 1 (PDF, parsed to a derived table): all 540 proteins identified in the basolateral plasma-membrane pellicle fraction of MXR MCF-7 cells, with SwissProt/TrEMBL accession and number of peptides (>= 1). Membership = listed. The authors' location labels (PM, Cytoplasm, Mitochondria, ...) are kept as a column and not used to select rows. No per-sample columns; the parental-vs-MXR ratios are not in the table.	rahbar_mxr_pm_table1.tsv: accession		MCF-7/MXR / baseline silica pellicle basolateral plasma-membrane fraction: peptides (min_observed 1)	526	150	0.28517110266159695	0.2	Homo sapiens		0	3	526
zhao-lung-bdap-2004	Human lung cancer cell line biotin-directed affinity purification of integral plasma-membrane proteins	Zhao et al. 2004	Zhao Y	2004	15053638	10.1021/ac0354037	provisional	within 2 points of the 20% screen (19.9%)	Intact viable-cell biotinylation with streptavidin capture; the table is the full identification list from all 49 bands before the authors' localisation annotation. Old GI-based identifications: 14% of records cannot be mapped to UniProt and stay blank.	none (supplementary tables only)		ac0354037_si_001.pdf <https://pubs.acs.org/ancham/article-supplement/3445832/pdf/ac0354037_si_001/> | zhao_bdap_band_proteins.uniprot_mapped.tsv	biotinylation of cell-surface proteins in viable cells, streptavidin beads, high-salt/high-pH washes (abstract)	Method read from: PubMed abstract; supporting table header.	streptavidin beads	not stated	not stated in accessible text		Where we looked for the instrument: ACS page, Europe PMC abstract.	human lung cancer cell line (line not named in the abstract or supplement)	Supporting table 'protein IDs from 49 gel bands' (PDF): 897 GI records, one per protein (paper: 898 unique proteins), with Mascot score and peptide count. Membership = listed (>= 1 peptide; 328 single-peptide identifications included, as in the authors' count). GI -> UniProt by a mapping pinned in the derive (NCBI esummary then UniProt ID mapping; single reviewed or single total entry): 769 GIs mapped (663 distinct accessions), 128 blank (52 PIR, 5 PRF, 50 retired RefSeq without UniProt hit, ambiguous PDB/RefSeq, EMBL without hit). ~20 GIs are non-human records (mouse/rat/rabbit, nr search) left for the species filter. TMD and localisation annotations never filter rows.	zhao_bdap_band_proteins.uniprot_mapped.tsv: uniprot_accession		human lung cancer cell line / baseline intact-cell biotinylation, streptavidin capture with high-salt/high-pH washes: peptides_min (min_observed 1)	644	128	0.19875776397515527	0.2	Homo sapiens	Mascot search against NCBI nr; 20 GI records are non-human orthologue entries (mostly mouse) and are dropped by the pipeline's taxonomy filter when they map to nonhuman UniProt entries.	17	0	644
blonder-epidermis-pm-2004	Human neonatal epidermis plasma membrane, sucrose-gradient purification	Blonder et al. 2004	Blonder J	2004	15373774	10.1111/j.0022-202X.2004.23421.x	comparator	cells broken open and membranes purified, so it can't show a protein faces outward	Sucrose-gradient plasma-membrane purification after tissue homogenisation: membrane fractionation, complementary by family policy. Primary human tissue (unperturbed); SEQUEST-era identifications with 1-peptide hits included, as published.	none (supplementary tables only)		blonder_table_I_proteins.tsv	abstract: 'A highly enriched plasma membrane fraction was prepared from newborn foreskins using sucrose gradient centrifugation, followed by a single-tube solubilization and tryptic digestion'	Method read from: Europe PMC abstract; Supplementary Table I-IV headers (Elsevier CDN .doc files); JID full text not opened (publisher landing page only).	none	n/a	not stated in accessible text		Where we looked for the instrument: Europe PMC abstract only; jidonline page had no text.	Human neonatal foreskin epidermis (keratinocytes)	Supplementary Table I (Elsevier mmc3.doc, 'Comprehensive list of 1305 identified proteins'): every peptide row (Xcorr, charge, peptide, count, Swiss-Prot accession) rolled up to 1,305 accessions (= the table title's 1,305); one accession printed truncated ('Q9UM6') is flagged and dropped. Supplementary Tables II-IV (receptor, caveolar and lipid-raft subsets) are annotation-selected and not used. One pooled identification list; no replicate columns.	blonder_table_I_proteins.tsv: accession	accession_status = uniprot_format		1258	255	0.20270270270270271	0.2	Homo sapiens		0	15	1258
zhao-pm-affinity-2003	Human cell line affinity-purified plasma membrane, surface biotinylation	Zhao et al. 2003	Zhao Y	2003	14572040	10.1021/ac034184m	below_screen	13% Canonical or Likely proteins, under 20%	Intact-cell surface biotinylation with streptavidin purification; the table is the full identification list before the authors' location coding. Old GI-based identifications: 20% of records cannot be mapped to UniProt and stay blank. The cell line is not named in the accessible text.	none (supporting information only)		ac034184msi20030305_020009.xls <https://pubs.acs.org/ancham/article-supplement/3780531/xls/ac034184msi20030305_020009/> | zhao_pm_affinity_proteins.uniprot_mapped.tsv	biotinylation of cell-surface proteins, streptavidin-bead affinity enrichment of plasma membrane (abstract)	Method read from: PubMed abstract; supporting table header.	streptavidin beads	not stated	not stated in accessible text		Where we looked for the instrument: No free full text; abstract says capillary-HPLC/MS only; ACS page refused automated access.	human cell line (line not named in the abstract or supplement; MeSH: Cell Line, Humans)	Supporting table 'total proteins list': 917 protein records (paper: 918 unique proteins), one per GI, with peptide count as printed (1, 2 or m = multiple; 437 single-peptide identifications included, as in the authors' count). Membership = listed. GI -> UniProt by a mapping pinned in the derive (NCBI esummary then UniProt ID mapping; single reviewed or single total entry): 734 records mapped (663 distinct accessions), 183 blank (61 PIR, 3 PRF, retired RefSeq/EMBL without UniProt hit, ambiguous PDB, 1 record without a GI). The authors' location and note codes never filter rows.	zhao_pm_affinity_proteins.uniprot_mapped.tsv: uniprot_accession			662	83	0.12537764350453173	0.2	Homo sapiens		0	0	662
